[
{
"id":"mk19_a_np_q001",
"number":1,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 1",
"stimulus":[
{
"type":"p",
"hlId":"a99327",
"children":[
"An 18-year-old man is evaluated in the emergency department for a severe asthma exacerbation unresponsive to intensification of his home program of albuterol and fluticasone-salmeterol inhalers. Intravenous magnesium sulfate, prednisone, and inhaled albuterol are initiated."
]
},
{
"type":"p",
"hlId":"00b6fe",
"children":[
"On physical examination, the patient is in respiratory distress. Blood pressure is 145/88 mm Hg, respiratory rate is 32/min, pulse is 108/min, and ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"oxygen saturation"
]
},
" is 95% with the patient breathing ambient air. Pulmonary examination reveals diffuse wheezes. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"167259",
"class":"cell text l",
"children":[
"140 mEq/L (140 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28b9c6",
"class":"cell text l",
"children":[
"3.2 mEq/L (3.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"80ce87",
"class":"cell text l",
"children":[
"110 mEq/L (110 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"93f0c1",
"class":"cell text l",
"children":[
"124 mg/dL (6.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"18044b",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, arterial (ambient air)",
"children":[
"Arterial blood gases"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"397dff",
"class":"cell text li",
"children":[
"pH"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4ad131",
"class":"cell text l",
"children":[
"7.50"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"dd372e",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Pco2, arterial (ambient air)",
"children":[
"P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f1bf4d",
"class":"cell text l",
"children":[
"32 mm Hg (4.2 kPa)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"acab5a",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Po2, arterial (ambient air)",
"children":[
"P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"O"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"02a781",
"class":"cell text l",
"children":[
"77 mm Hg (10.2 kPa)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"9a3394",
"children":[
"Which of the following is the most likely cause of this patient's hypokalemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Albuterol"
}
},
{
"letter":"B",
"text":{
"__html":"Hyperglycemia"
}
},
{
"letter":"C",
"text":{
"__html":"Hypermagnesemia"
}
},
{
"letter":"D",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"E",
"text":{
"__html":"Respiratory alkalosis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"71e583",
"children":[
"β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Agonists can cause hypokalemia by facilitating intercellular shifts of potassium."
]
},
{
"type":"keypoint",
"hlId":"db05b4",
"children":[
"When hypokalemia is secondary to acute transcellular shifts, total body potassium is normal and potassium replacement may cause rebound hyperkalemia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"5ca8e7",
"children":[
"The most likely cause of this patient's hypokalemia is albuterol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Hypokalemia is defined as a serum potassium level <3.5 mEq/L (3.5 mmol/L). It can be divided into disorders of internal balance (movement of potassium between the intracellular and extracellular compartments) and disorders of external balance (potassium intake and output). β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Agonists such as albuterol that are administered intravenously or by inhalation increase the activity of the Na",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"/K",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"-ATPase, which drives potassium into cells. This causes a transient decline in the extracellular potassium concentration. The decline in serum potassium is dose dependent and related to the potency of the drug, averaging approximately 0.5 mEq/L (0.5 mmol/L) but can be much greater. In patients with underlying heart disease, the rapid decline in serum potassium can cause fatal arrhythmias. When significant hypokalemia is secondary to acute transcellular shifts, such as in this case, total body potassium is normal and excessive potassium replacement may cause rebound hyperkalemia."
]
},
{
"type":"p",
"hlId":"745ab1",
"children":[
"Similar to β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists, insulin increases Na",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"/K",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"-ATPase activity and will acutely lower the extracellular potassium concentration. This effect of insulin on potassium homeostasis is separate from its effect on glucose metabolism. In this patient, however, it is unlikely that his hyperglycemia with a serum glucose level of 124 mg/dL (6.9 mmol/L) is high enough (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") to stimulate significant insulin release to cause hypokalemia."
]
},
{
"type":"p",
"hlId":"37ade0",
"children":[
"Blockage of the cellular potassium channel by the divalent cation barium can cause acute decreases in serum potassium. Although magnesium is a divalent cation, it does not affect the potassium channel in cell membranes, and thus hypermagnesemia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") cannot cause hypokalemia."
]
},
{
"type":"p",
"hlId":"8b8184",
"children":[
"Although prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") has mineralocorticoid activity, any mineralocorticoid increase in potassium excretion would not occur rapidly and would therefore not explain this patient's hypokalemia. In addition, hyperaldosteronism is associated with hypertension and a metabolic alkalosis."
]
},
{
"type":"p",
"hlId":"d96b37",
"children":[
"Respiratory disturbances have minimal effect on potassium distribution, and thus respiratory alkalosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") would not be expected to cause a significant decrease in potassium in this patient."
]
}
],
"relatedSection":"mk19_a_np_s2_3_1_1",
"objective":{
"__html":"Diagnose β<sub>2</sub>-agonist–related hypokalemia."
},
"references":[
[
"Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ. 2016;40:480-490. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27756725",
"target":"_blank"
},
"children":[
"PMID: 27756725"
]
}
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":55,
"B":0,
"C":3,
"D":2,
"E":40
},
"hlIds":[
"a99327",
"00b6fe",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"167259",
"e92687",
"28b9c6",
"a207b1",
"80ce87",
"6827e3",
"075484",
"847136",
"93f0c1",
"18044b",
"d41d8c",
"397dff",
"4ad131",
"dd372e",
"f1bf4d",
"acab5a",
"02a781",
"9a3394",
"71e583",
"db05b4",
"5ca8e7",
"745ab1",
"37ade0",
"8b8184",
"d96b37"
]
},
{
"id":"mk19_a_np_q002",
"number":2,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 2",
"stimulus":[
{
"type":"p",
"hlId":"9487fa",
"children":[
"A 63-year-old woman is hospitalized for cardiac catheterization for unstable angina. History is significant for stage G3 chronic kidney disease attributed to diabetic nephropathy. Medications are heparin, metoprolol, losartan, amlodipine, atorvastatin, basal insulin, and prandial insulin."
]
},
{
"type":"p",
"hlId":"dc0e10",
"children":[
"On physical examination, vital signs are normal. There is no jugular venous distension or lower extremity edema. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"3fbff3",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 2.4 mg/dL (212.2 µmol/L) and an ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" of 24 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"eeb944",
"children":[
"Which of the following is the most appropriate periprocedure measure to prevent acute kidney injury?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hemodialysis, postprocedure"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous isotonic bicarbonate, pre- and postprocedure"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous 0.9% saline, pre- and postprocedure"
}
},
{
"letter":"D",
"text":{
"__html":"Oral N-acetylcysteine, preprocedure"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9bdbbc",
"children":[
"Contrast-associated nephropathy prophylaxis with intravenous 0.9% saline pre- and postprocedure is indicated for patients who have an estimated glomerular filtration rate <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" or acute kidney injury."
]
},
{
"type":"keypoint",
"hlId":"839057",
"children":[
"Contrast-associated nephropathy prophylaxis is not indicated for patients with a stable estimated glomerular filtration rate ≥45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b73cf6",
"children":[
"The most appropriate periprocedure measure to prevent contrast-associated nephropathy (CAN) is to administer intravenous 0.9% saline pre- and postprocedure (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") for this patient undergoing cardiac catheterization. Multiple patient-related risk factors have been associated with CAN. The primary risk factor is a reduced estimated glomerular filtration rate (eGFR). Some studies find an added risk of CAN from diabetes mellitus. Well-established additional risk factors include nephrotoxic agents and exposures, hypotension, hypovolemia, albuminuria, and impaired kidney perfusion (e.g., as occurs in heart failure). Although multiple myeloma has historically been considered a risk factor for CAN, this is not supported by more recent literature. A 2020 guideline from the American College of Radiology and the National Kidney Foundation recommends that the risk for CAN be determined primarily by using the chronic kidney disease stage and associated eGFR measurement. Patients at highest risk for CAN include those with recent acute kidney injury and those with an eGFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Prophylaxis with intravenous 0.9% saline pre- and postprocedure is indicated for patients not undergoing dialysis who have an eGFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" or acute kidney injury. In individual high-risk circumstances, prophylaxis may be considered in patients with eGFR of 30 to 44 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" at the discretion of the ordering clinician. Prophylaxis is not indicated for patients with stable eGFR ≥45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". The presence of a solitary kidney should not independently influence decision-making regarding the risk for CAN."
]
},
{
"type":"p",
"hlId":"87b64c",
"children":[
"Renal replacement therapy should neither be initiated nor have a schedule adjustment solely based on contrast media administration. Postprocedure initiation of hemodialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") directed at removal of contrast from the blood has been attempted in a few small studies with mixed results."
]
},
{
"type":"p",
"hlId":"a2f6e3",
"children":[
"Neither infusion of sodium bicarbonate pre- and postprocedure (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") nor use of oral N-acetylcysteine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is recommended to prevent CAN due to a lack of consistent evidence demonstrating efficacy."
]
}
],
"relatedSection":"mk19_a_np_s9_6_1",
"objective":{
"__html":"Prevent contrast-associated nephropathy."
},
"references":[
[
"Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020;294:660. doi.org/10.1148/radiol.2019192094"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":1,
"B":4,
"C":88,
"D":7,
"E":0
},
"hlIds":[
"9487fa",
"dc0e10",
"3fbff3",
"eeb944",
"9bdbbc",
"839057",
"b73cf6",
"87b64c",
"a2f6e3"
]
},
{
"id":"mk19_a_np_q003",
"number":3,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 3",
"stimulus":[
{
"type":"p",
"hlId":"c38c93",
"children":[
"A 69-year-old man is evaluated for a 4-week history of lower extremity edema. He has a 45-pack-year history of smoking but quit 3 years ago. A screening colonoscopy performed 1 year ago was normal. He has no other medical history and takes no medications."
]
},
{
"type":"p",
"hlId":"56761d",
"children":[
"On physical examination, vital signs are normal. There is 2-mm pitting edema of the lower extremities through the ankles, equal on both sides. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"613818",
"class":"cell text l",
"children":[
"2.9 g/dL (29 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"714406",
"class":"cell text l",
"children":[
"311 mg/dL (8.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"23f624",
"class":"cell text l",
"children":[
"1.0 mg/dL (88.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b01639",
"class":"cell text l",
"children":[
"24-Hour urine protein excretion"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e7c9ea",
"class":"cell text l",
"children":[
"6300 mg/24 h"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"82ebab",
"children":[
"Kidney biopsy shows membranous nephropathy with negative staining for the phospholipase A2 receptor antigen."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"983777",
"children":[
"Which of the following is the most appropriate test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Kidney and renal vein Doppler ultrasonography"
}
},
{
"letter":"B",
"text":{
"__html":"Lower extremity Doppler ultrasonography"
}
},
{
"letter":"C",
"text":{
"__html":"Noncontrast CT of the chest"
}
},
{
"letter":"D",
"text":{
"__html":"Random (spot) urine protein-creatinine ratio"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"8a9c27",
"children":[
"The initial step in the management of newly diagnosed membranous nephropathy (MN) is to evaluate for secondary forms of the disease, and cancer screening is particularly important in evaluating for secondary forms of MN in patients >65 years of age."
]
},
{
"type":"keypoint",
"hlId":"e72c52",
"children":[
"Testing for phospholipase A2 receptor (PLA2R) antigen is used to help distinguish primary (PLA2R antigen–positive) from secondary (PLA2R antigen–negative) forms of membranous nephropathy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a79332",
"children":[
"A noncontrast CT of the chest (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") should be performed to screen for lung cancer in this patient newly diagnosed with phospholipase A2 receptor (PLA2R)-negative membranous nephropathy (MN) and a history of heavy tobacco use. Testing for PLA2R antigen is used to help distinguish primary from secondary forms of MN. This distinction is crucial because secondary (PLA2R antigen–negative) forms are expected to remit if the underlying systemic disease responsible for the lesion is successfully treated. Therefore, age- and sex-appropriate cancer screening is recommended for all patients at the time of diagnosis, even those with PLA2R positivity. Thus, the initial step in management of newly diagnosed MN is to evaluate for secondary forms of the disease, which account for approximately 25% of MN cases and include lupus-, hepatitis-, drug-, and malignancy-associated forms of MN. Cancer screening is particularly important in evaluating for secondary forms of MN in patients >65 years of age. Up to 25% of such patients will have a malignancy discovered within 1 year of diagnosis. This 69-year-old man with a 45-pack-year history of smoking has not undergone risk factor–appropriate cancer screening, which would include a noncontrast CT of the chest."
]
},
{
"type":"p",
"hlId":"a3e97f",
"children":[
"Renal vein thrombosis is found in up to 20% of patients with MN. Doppler ultrasonography screening for renal vein thrombosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is reserved for when acute kidney injury, flank pain, and/or gross hematuria raise suspicion for this complication."
]
},
{
"type":"p",
"hlId":"cffeef",
"children":[
"MN is associated with a higher risk for clotting when serum albumin is <2.8 g/dL (28 g/L); this patient's serum albumin is 2.9 g/dL (29 g/L). The symmetric lower extremity edema in this patient is more consistent with the nephrotic syndrome than a lower extremity clot; therefore, Doppler ultrasonography of his legs (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") would not be required."
]
},
{
"type":"p",
"hlId":"80e0b6",
"children":[
"Random (spot) urine protein-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), particularly when collected on first morning void, can serve as a surrogate for 24-hour urine protein quantification. This test is unnecessary in this case, as the more accurate quantification of proteinuria via 24-hour urine protein excretion has already been performed."
]
}
],
"relatedSection":"mk19_a_np_s6_3_3_3",
"objective":{
"__html":"Screen for malignancy in an older patient with membranous nephropathy."
},
"references":[
[
"Khairallah P, Bomback AS. Membranous nephropathy and cancer in the era of PLA",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"R testing. J Onco-Nephrol. 2018;2:50-55. doi/10.1177/2399369318816333"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":27,
"B":8,
"C":61,
"D":4,
"E":0
},
"hlIds":[
"c38c93",
"56761d",
"a462a3",
"4590ed",
"613818",
"182194",
"714406",
"f461b2",
"23f624",
"b01639",
"e7c9ea",
"82ebab",
"983777",
"8a9c27",
"e72c52",
"a79332",
"a3e97f",
"cffeef",
"80e0b6"
]
},
{
"id":"mk19_a_np_q004",
"number":4,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 4",
"stimulus":[
{
"type":"p",
"hlId":"7262cb",
"children":[
"A 54-year-old woman is evaluated during a follow-up visit after beginning lisinopril for hypertension 2weeks ago. History is also significant for chronic kidney disease. Her only other medication is amlodipine."
]
},
{
"type":"p",
"hlId":"051c6f",
"children":[
"On physical examination, blood pressure is 128/78 mm Hg; other vital signs are normal. There is 1+ pitting pretibial edema bilaterally. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"03567b",
"class":"cell text l",
"children":[
"1.7 mg/dL (150.3 µmol/L); 2 weeks ago: 1.2 mg/dL (106.1 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cee8b8",
"class":"cell text l",
"children":[
"5.7 mEq/L (5.7 mmol/L); 2 weeks ago: 4.4 mEq/L (4.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a7abaa",
"class":"cell text l",
"children":[
"33 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"; 2 weeks ago, 50 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"25eeda",
"children":[
"Two weeks ago, laboratory studies showed a urine ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"albumin-creatinine ratio"
]
},
" of 1600 mg/g."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Continue lisinopril; add furosemide"
}
},
{
"letter":"B",
"text":{
"__html":"Continue lisinopril; recheck laboratory studies in 2 weeks"
}
},
{
"letter":"C",
"text":{
"__html":"Discontinue lisinopril; add furosemide"
}
},
{
"letter":"D",
"text":{
"__html":"Discontinue lisinopril; add losartan"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"6f5b0e",
"children":[
"In patients with chronic kidney disease, kidney function and serum potassium levels should be reassessed 2 to 3 weeks after initiation of an ACE inhibitor or angiotensin receptor blocker."
]
},
{
"type":"keypoint",
"hlId":"081178",
"children":[
"Following initiation of an ACE inhibitor or angiotensin receptor blocker, a >30% increase in serum creatinine levels necessitates decreasing the dose of or discontinuing these agents."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"8b9386",
"children":[
"The most appropriate treatment for this patient is to discontinue lisinopril and add furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Treatment of hypertension with a renin-angiotensin system inhibitor, such as an ACE inhibitor (e.g., lisinopril) or an angiotensin receptor blocker (ARB) (e.g., losartan), is indicated in patients with stage G3 chronic kidney disease (CKD) or higher or for those with stage G1 or G2 CKD with albuminuria (urine albumin-creatinine ratio ≥300 mg/g). However, kidney function and serum potassium levels should be reassessed 2 to 3 weeks after initiation of an ACE inhibitor or ARB. A 25% to 30% increase in serum creatinine is acceptable, but the dose may need to be lowered or the medication discontinued if a more severe decline in kidney function is observed, such as in this patient. A decrease of the glomerular filtration rate of this magnitude is usually the result of renovascular hypertension. In patients with significant hyperkalemia, a loop diuretic such as furosemide can be added to promote kaliuresis."
]
},
{
"type":"p",
"hlId":"c7c3f1",
"children":[
"Continuing lisinopril, with or without the addition of furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, B"
]
},
"), or replacing lisinopril with losartan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), places the patient at increased risk for progressive kidney injury and hyperkalemia. However, discontinuation of lisinopril in this case is a temporary solution. This patient's laboratory tests can be repeated in 2 to 3 weeks after the discontinuation of lisinopril and addition of furosemide. If the laboratory tests have normalized, reinitiation of lisinopril at a lower dose can be considered with careful monitoring of serum creatinine and potassium levels."
]
}
],
"relatedSection":"mk19_a_np_s4_11_1_4",
"objective":{
"__html":"Manage a patient following initiation of a renin-angiotensin system inhibitor."
},
"references":[
[
"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29146535",
"target":"_blank"
},
"children":[
"PMID: 29146535"
]
},
" doi:10.1016/j.jacc.2017.11.006"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":22,
"B":29,
"C":45,
"D":4,
"E":0
},
"hlIds":[
"7262cb",
"051c6f",
"a462a3",
"f461b2",
"03567b",
"e92687",
"cee8b8",
"77db81",
"a7abaa",
"25eeda",
"cb2b54",
"6f5b0e",
"081178",
"8b9386",
"c7c3f1"
]
},
{
"id":"mk19_a_np_q005",
"number":5,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 5",
"stimulus":[
{
"type":"p",
"hlId":"6d1322",
"children":[
"A 32-year-old man is evaluated for end-stage kidney disease due to congenital reflux nephropathy. He began hemodialysis at age 21 years. He is on the kidney transplant list. He also has hypertension. Medications are amlodipine, calcitriol, lisinopril, and sevelamer carbonate."
]
},
{
"type":"p",
"hlId":"01e4db",
"children":[
"On physical examination, vital signs are normal. There is a left upper extremity arteriovenous fistula with strong thrill. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"a00e18",
"children":[
"Kidney ultrasound shows small kidneys with multiple cysts bilaterally. A few cysts have internal septations. There are no solid components or evidence of vascular flow within the cysts."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"45fdbd",
"children":[
"Which of the following is the most appropriate management of this patient's acquired kidney cysts?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Annual kidney ultrasonography"
}
},
{
"letter":"B",
"text":{
"__html":"Bilateral nephrectomy"
}
},
{
"letter":"C",
"text":{
"__html":"Tolvaptan therapy"
}
},
{
"letter":"D",
"text":{
"__html":"No intervention"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9d360a",
"children":[
"Patients with end-stage kidney disease are at increased risk for renal cell carcinoma."
]
},
{
"type":"keypoint",
"hlId":"dab6a2",
"children":[
"Screening for renal cell carcinoma in patients with end-stage kidney disease and acquired cystic kidney disease may be reasonable in patients with a longer life expectancy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"31d99d",
"children":[
"The most appropriate management of this patient's acquired kidney cysts is annual kidney ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Patients with end-stage kidney disease (ESKD) are at increased risk for renal cell carcinoma compared with the general population. Acquired cystic changes of the kidney are common in patients with severe chronic kidney disease (CKD) and ESKD and are at risk for malignant transformation. Risk factors for acquired cystic kidney disease include longer duration of ESKD and dialysis and male sex. For patients with ESKD and acquired kidney cysts, decisions about screening must be individualized based on the competing issues of risk for renal cell carcinoma versus a shortened overall life expectancy. This young patient is a kidney transplant candidate with extended life expectancy. His kidney ultrasound confirms the presence of acquired cysts, a few of which are complex with internal septations; however, there is no evidence of malignant change with no solid components or neovascularization. This patient should have annual ultrasonography of the kidneys to monitor for malignant conversion and undergo nephrectomy if a suspicious mass develops."
]
},
{
"type":"p",
"hlId":"173437",
"children":[
"Preemptive nephrectomy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is an invasive intervention that would put this patient at risk for surgical complications with no clear benefit; he has no evidence of renal cell carcinoma or other indications for nephrectomy, such as recurrent infections related to the kidney."
]
},
{
"type":"p",
"hlId":"49f8d0",
"children":[
"Tolvaptan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has been FDA approved for treatment of patients with autosomal dominant polycystic kidney disease. However, there is no role for tolvaptan in patients with acquired kidney cysts."
]
},
{
"type":"p",
"hlId":"4c8bbd",
"children":[
"For older patients with ESKD and those who are not transplant candidates, screening is not recommended (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), even in the presence of known acquired cystic kidney disease. The American Society of Nephrology's Choosing Wisely Campaign recommends not screening for malignancy in patients with reduced life expectancy. However, because of the increased risk for renal cell carcinoma in this patient population, development of symptoms or signs consistent with renal cell carcinoma should be investigated. For example, spontaneous improvement in hemoglobin is suspicious for renal cell carcinoma–related erythropoietin production."
]
}
],
"relatedSection":"mk19_a_np_s12_9_3_3",
"objective":{
"__html":"Screen for renal cell carcinoma in a patient with acquired cystic kidney disease."
},
"references":[
[
"Tsuzuki T, Iwata H, Murase Y, et al. Renal tumors in end-stage renal disease: a comprehensive review. Int J Urol. 2018;25:780-786. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30066367",
"target":"_blank"
},
"children":[
"PMID: 30066367"
]
},
" doi:10.1111/iju.13759"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":40,
"B":3,
"C":1,
"D":56,
"E":0
},
"hlIds":[
"6d1322",
"01e4db",
"a00e18",
"45fdbd",
"9d360a",
"dab6a2",
"31d99d",
"173437",
"49f8d0",
"4c8bbd"
]
},
{
"id":"mk19_a_np_q006",
"number":6,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 6",
"stimulus":[
{
"type":"p",
"hlId":"34428f",
"children":[
"A 69-year-old woman is evaluated for a 2-month history of worsening fatigue, weight loss, and anorexia. She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"63fa79",
"children":[
"On physical examination, the patient is afebrile. Blood pressure is 160/95 mm Hg, pulse rate is 88/min, respiration rate is 16/min, and ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"oxygen saturation"
]
},
" is 100% breathing ambient air. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d5fe2",
"children":[
"Laboratory studies: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f1fae6",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hematocrit",
"children":[
"Hematocrit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c79d06",
"class":"cell text l",
"children":[
"25.5%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e038fc",
"class":"cell text l",
"children":[
"3.7 g/dL (37 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"621dbd",
"class":"cell text l",
"children":[
"10.9 mg/dL (2.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f20f2e",
"class":"cell text l",
"children":[
"4.2 mg/dL (371.3 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"eec76b",
"class":"cell text l",
"children":[
"Free κ light chains"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"705e67",
"class":"cell text l",
"children":[
"Elevated"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"894097",
"class":"cell text l",
"children":[
"Free λ light chains"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"705e67",
"class":"cell text l",
"children":[
"Elevated"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"90c709",
"class":"cell text l",
"children":[
"κ/λ Free light chain ratio"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2931b3",
"class":"cell text l",
"children":[
"4.1 (normal, 0.26-1.65)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a5fc4d",
"class":"cell text l",
"children":[
"No blood; 1+ protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4b421c",
"class":"cell text l",
"children":[
"2500 mg/g"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e4c879",
"class":"cell text l",
"children":[
"Urine output"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"668b17",
"class":"cell text l",
"children":[
"2.3 L/24 h"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"cc9fae",
"children":[
"Kidney biopsy confirms the presence of myeloma cast nephropathy."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Chemotherapy"
}
},
{
"letter":"B",
"text":{
"__html":"Hemodialysis"
}
},
{
"letter":"C",
"text":{
"__html":"Hospice referral"
}
},
{
"letter":"D",
"text":{
"__html":"Plasmapheresis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"fea267",
"children":[
"Initiation of chemotherapy is the most appropriate treatment for myeloma cast nephropathy and is aimed at reducing the concentration of free light chains."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"dc1766",
"children":[
"The most appropriate treatment is chemotherapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient presents with acute kidney injury (AKI), anemia, hypercalcemia, and a biopsy confirming the presence of myeloma cast nephropathy. Myeloma cast nephropathy is caused by the interaction and aggregation of filtered free light chains and Tamm-Horsfall protein causing intratubular obstruction and damage. Rapid lowering of free light chains with bortezomib-based chemotherapy with high-dose dexamethasone correlates with kidney recovery and is more effective than plasmapheresis or hemodialysis."
]
},
{
"type":"p",
"hlId":"6e1597",
"children":[
"In this patient with preserved urine output, hemodialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") with either a high-cutoff or regular dialyzer would not be recommended. Extended high-cutoff hemodialysis uses a high-cutoff dialyzer with very large membrane pores and high permeability to immunoglobulin light chains to remove free light chains. This high-cutoff hemodialysis has proven better than conventional hemodialysis in lowering light chain burden, but in a randomized trial of patients with myeloma cast nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysis did not result in improved kidney survival compared with conventional hemodialysis. These data suggest that the use of chemotherapy is the most important factor in reduction of light chain burden. Fluid overload, hyperkalemia, and uremia remain indications for hemodialysis in all patients with AKI."
]
},
{
"type":"p",
"hlId":"4a381d",
"children":[
"Hospice referral (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is premature for this patient. Nearly 50% of all patients with multiple myeloma develop kidney disease, most commonly AKI caused by cast nephropathy, and this complication does lead to reduced 1-year survival rates. However, advances in chemotherapy regimens are improving both mortality rates and kidney survival rates, and this patient with a normal functional status and no comorbidities would benefit from chemotherapy."
]
},
{
"type":"p",
"hlId":"53d88c",
"children":[
"Small trials initially showed that therapeutic plasmapheresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") improved renal outcomes in myeloma cast nephropathy, but a large randomized trial of therapeutic plasmapheresis failed to show benefit. If used, plasmapheresis is combined with chemotherapy to reduce the rate of light chain production rather than as monotherapy."
]
}
],
"relatedSection":"mk19_a_np_s7_3",
"objective":{
"__html":"Treat myeloma cast nephropathy."
},
"references":[
[
"Finkel KW, Cohen EP, Shirali A, et al; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy. Clin J Am Soc Nephrol. 2016;11:2273-2279. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27526708",
"target":"_blank"
},
"children":[
"PMID: 27526708"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":74,
"B":9,
"C":1,
"D":17,
"E":0
},
"hlIds":[
"34428f",
"63fa79",
"9d5fe2",
"f1fae6",
"c79d06",
"4590ed",
"e038fc",
"1a4da4",
"621dbd",
"f461b2",
"f20f2e",
"eec76b",
"705e67",
"894097",
"705e67",
"90c709",
"2931b3",
"747c2a",
"a5fc4d",
"d17af8",
"4b421c",
"e4c879",
"668b17",
"cc9fae",
"cb2b54",
"fea267",
"dc1766",
"6e1597",
"4a381d",
"53d88c"
]
},
{
"id":"mk19_a_np_q007",
"number":7,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 7",
"stimulus":[
{
"type":"p",
"hlId":"4e79a3",
"children":[
"A 52-year-old man is evaluated during a follow-up visit for membranous nephropathy diagnosed by kidney biopsy 1 month ago. His medical history is otherwise unremarkable. Medications are lisinopril, furosemide, and atorvastatin."
]
},
{
"type":"p",
"hlId":"dd8c7b",
"children":[
"On physical examination, vital signs are normal. There is symmetric 2+ pitting edema of the lower extremities. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"780602",
"class":"cell text l",
"children":[
"2.1 g/dL (21 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9e6a3d",
"class":"cell text l",
"children":[
"359 mg/dL (9.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"38947c",
"class":"cell text l",
"children":[
"0.8 mg/dL (70.7 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2e9fdc",
"class":"cell text l",
"children":[
"5500 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"162104",
"children":[
"Which of the following is the most likely complication to develop in this patient during the next 12 months?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Diabetes mellitus"
}
},
{
"letter":"B",
"text":{
"__html":"End-stage kidney disease"
}
},
{
"letter":"C",
"text":{
"__html":"Pulmonary hemorrhage"
}
},
{
"letter":"D",
"text":{
"__html":"Venous thromboembolism"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"e7655a",
"children":[
"Patients with the nephrotic syndrome and hypoalbuminemia are at increased risk for venous thromboembolism (VTE); VTE is most often seen in patients with membranous nephropathy."
]
},
{
"type":"keypoint",
"hlId":"153601",
"children":[
"Prophylactic anticoagulation of asymptomatic patients with the nephrotic syndrome and hypoalbuminemia is controversial."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b4025c",
"children":[
"The most likely complication to develop in this patient during the next 12 months is venous thromboembolism (VTE) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). The nephrotic syndrome is a hypercoagulable state due to urinary losses of anticoagulant proteins (antithrombin III, protein S) and fibrinolytics as well as hepatic overproduction of procoagulant proteins (factor V, factor VIII, fibrinogen). A very low serum albumin level seems to be a surrogate measure for abnormalities in antithrombin and fibrinogen. As a result, patients with the nephrotic syndrome are at increased risk for lower extremity, pulmonary, and renal vein thrombosis. Clots are most often seen in patients with membranous nephropathy, such as this patient, in which VTE risk appears to begin at a serum albumin level <2.8 g/dL (28 g/L) and increases proportionately with declining albumin levels. Therefore, any patient with nephrotic-range proteinuria and significant hypoalbuminemia (typically <2.5 g/dL [25 g/L]) should be considered at risk. Most VTE events occur in the first 6 months after a diagnosis of the nephrotic syndrome is made. Prophylactic anticoagulation of asymptomatic patients with the nephrotic syndrome and hypoalbuminemia is controversial, and no randomized clinical trials are available to help guide clinical decision-making."
]
},
{
"type":"p",
"hlId":"c87065",
"children":[
"Diabetes mellitus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is the most common cause of the nephrotic syndrome. Other causes of the nephrotic syndrome do not predispose the development of diabetes mellitus, independent of the role that glucocorticoid therapy may play in predisposing a patient to hyperglycemia."
]
},
{
"type":"p",
"hlId":"503da1",
"children":[
"Approximately one third of patients with membranous nephropathy achieve spontaneous remission in the first year following diagnosis. Of those who do not achieve remission, 75% will respond to immunosuppression with glucocorticoids plus alkylator agents, calcineurin inhibitors, or rituximab. Progression to end-stage kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") requiring dialysis is unlikely, especially in the first year of the diagnosis."
]
},
{
"type":"p",
"hlId":"c47ba5",
"children":[
"Pulmonary hemorrhage (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is a complication associated with glomerulonephritis caused by anti–glomerular basement membrane antibody disease or possibly with ANCA-associated glomerulonephritis; however, it is not expected in a patient with membranous nephropathy."
]
}
],
"relatedSection":"mk19_a_np_s6_2_1",
"objective":{
"__html":"Identify hypercoagulability as a complication of the nephrotic syndrome."
},
"references":[
[
"Gyamlani G, Molnar MZ, Lu JL, et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32:157-164. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28391310",
"target":"_blank"
},
"children":[
"PMID: 28391310"
]
},
" doi:10.1093/ndt/gfw227"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":2,
"B":9,
"C":1,
"D":88,
"E":0
},
"hlIds":[
"4e79a3",
"dd8c7b",
"a462a3",
"4590ed",
"780602",
"182194",
"9e6a3d",
"f461b2",
"38947c",
"d17af8",
"2e9fdc",
"162104",
"e7655a",
"153601",
"b4025c",
"c87065",
"503da1",
"c47ba5"
]
},
{
"id":"mk19_a_np_q008",
"number":8,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 8",
"stimulus":[
{
"type":"p",
"hlId":"aa8e36",
"children":[
"A 53-year-old woman is evaluated for an increase in her serum creatinine level. History is significant for long-standing hypertension treated with lisinopril. She reports no changes to her medication regimen during the past year."
]
},
{
"type":"p",
"hlId":"b14447",
"children":[
"On physical examination, blood pressure is 145/92 mm Hg, and pulse rate is 84/min; other vital signs are normal. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"afe495",
"class":"cell text l",
"children":[
"1.2 mg/dL (106.1 µmol/L); 6 months ago: 0.7 mg/dL (61.9 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"18c2da",
"class":"cell text l",
"children":[
">52 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3492fb",
"class":"cell text l",
"children":[
"Specific gravity 1.014; pH 5.7; no blood; trace protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"170ade",
"class":"cell text l",
"children":[
"290 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"8fc399",
"children":[
"Ultrasound reveals normal-sized kidneys with increased echogenicity; no hydronephrosis or abnormalities of the collecting system are seen."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Obtain kidney biopsy"
}
},
{
"letter":"B",
"text":{
"__html":"Obtain random urine protein-creatinine ratio"
}
},
{
"letter":"C",
"text":{
"__html":"Recheck serum creatinine in 3 months"
}
},
{
"letter":"D",
"text":{
"__html":"Substitute hydrochlorothiazide for lisinopril"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"fb3988",
"children":[
"Indications for kidney biopsy include glomerular hematuria, severely increased albuminuria, acute or chronic kidney disease of unclear cause, and kidney transplant dysfunction or monitoring."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"f8b03b",
"children":[
"The most appropriate management is kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") for this patient with a significant decline in kidney function. In addition, this patient has unexplained moderately increased albuminuria and an increase in echogenicity on kidney ultrasound, suggesting a chronic condition. Clinical and laboratory features are often insufficient for definitive diagnosis of kidney disease. Therefore, kidney biopsy may be essential for diagnosis and management. Indications include glomerular hematuria, severely increased albuminuria, acute or chronic kidney disease of unclear cause, and kidney transplant dysfunction or monitoring. In this case, the patient has an elevated serum creatinine level with albuminuria and possible chronic kidney disease without a clear cause. Although further urine and serologic testing will be performed to guide diagnosis, a kidney biopsy will provide definitive diagnosis."
]
},
{
"type":"p",
"hlId":"a78ce8",
"children":[
"The patient has moderately increased albuminuria (albumin-creatinine ratio of 30-300 mg/g). The urine protein-creatinine ratio will be greater than the urine albumin-creatinine ratio due to the presence of nonalbumin protein and therefore will be in the pathologic range. Therefore, random urine protein-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") will not add new information in this case."
]
},
{
"type":"p",
"hlId":"f87d69",
"children":[
"Because the patient has a significant loss of kidney function, a reassessment of serum creatinine in 3 months (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") would not be appropriate and would result in potentially harmful delay in the diagnosis of a treatable disease."
]
},
{
"type":"p",
"hlId":"31aac9",
"children":[
"Discontinuation of lisinopril for hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not indicated. Due to preferential dilation of the efferent arteriole, the ACE inhibitor lisinopril may reduce glomerular filtration rate and increase serum creatinine; however, this change in serum creatinine will occur within days of drug initiation and then will stabilize. In this case, the serum creatinine increased without a change in dose, suggesting that lisinopril is not the cause of the rising serum creatinine and will not be resolved by discontinuing the drug. In addition, treatment with lisinopril cannot account for the presence of albuminuria."
]
}
],
"relatedSection":"mk19_a_np_s1_4",
"objective":{
"__html":"Evaluate progressive kidney disease."
},
"references":[
[
"Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. Am J Kidney Dis. 2019;73:404-415. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30661724",
"target":"_blank"
},
"children":[
"PMID: 30661724"
]
},
" doi:10.1053/j.ajkd.2018.10.011"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":24,
"B":11,
"C":52,
"D":13,
"E":0
},
"hlIds":[
"aa8e36",
"b14447",
"a462a3",
"f461b2",
"afe495",
"77db81",
"18c2da",
"747c2a",
"3492fb",
"58e613",
"170ade",
"8fc399",
"cb2b54",
"fb3988",
"f8b03b",
"a78ce8",
"f87d69",
"31aac9"
]
},
{
"id":"mk19_a_np_q009",
"number":9,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 9",
"stimulus":[
{
"type":"p",
"hlId":"c88d25",
"children":[
"A 24-year-old woman is evaluated in the hospital 24 hours after being admitted for severe preeclampsia. On admission, antihypertensive therapy and intravenous magnesium sulfate were initiated followed by cesarean section. She continues to receive hydralazine, nifedipine, and intravenous magnesium sulfate."
]
},
{
"type":"p",
"hlId":"b1731f",
"children":[
"On physical examination, temperature is 37.1 °C (98.8 °F), blood pressure is 142/90 mm Hg, and pulse rate is 84/min. Abdominal examination reveals a clean, sutured cesarean section incision without bleeding. There is no oozing from venipuncture sites. There is 1+ lower extremity edema. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d12432",
"children":[
"Current laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"97c659",
"class":"cell text l",
"children":[
"7.5 g/dL (75 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f00ff6",
"class":"cell text l",
"children":[
"84,000/µL (84 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"62ea29",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Aminotransferase, alanine (ALT)",
"children":[
"Alanine aminotransferase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2eae6a",
"class":"cell text l",
"children":[
"383 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c7d329",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Aminotransferase, aspartate (AST)",
"children":[
"Aspartate aminotransferase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a3689c",
"class":"cell text l",
"children":[
"187 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28ecb5",
"class":"cell text l",
"children":[
"1.3 mg/dL (114.9 µmol/L)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"7f697c",
"children":[
"A peripheral blood smear shows schistocytes."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Continue current therapy"
}
},
{
"letter":"B",
"text":{
"__html":"Start intravenous dexamethasone"
}
},
{
"letter":"C",
"text":{
"__html":"Start intravenous eculizumab"
}
},
{
"letter":"D",
"text":{
"__html":"Transfuse fresh frozen plasma"
}
},
{
"letter":"E",
"text":{
"__html":"Transfuse packed red blood cells and platelets"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"3bb2ab",
"children":[
"Severe preeclampsia is identified by persistent systolic blood pressure >160 mm Hg or diastolic blood pressure >110 mm Hg and end-organ damage."
]
},
{
"type":"keypoint",
"hlId":"2869e4",
"children":[
"Initial therapy for severe preeclampsia is magnesium, antihypertensive medication, and immediate delivery of the fetus."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"6d3363",
"children":[
"The most appropriate treatment is to continue current therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Severe preeclampsia is identified by persistent systolic blood pressure (BP) >160 mm Hg or diastolic BP >110 mm Hg and end-organ damage. The HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome may represent a severe form of preeclampsia. In the HELLP syndrome, the hemolytic anemia, thrombocytopenia, and liver dysfunction are more prominent, whereas severe preeclampsia has greater BP elevations. This patient has severe preeclampsia with features of the HELLP syndrome. The appropriate initial therapy is rapid stabilization of severely elevated BP and intravenous magnesium followed by immediate delivery of the fetus. Magnesium sulfate is the drug of choice for seizure prophylaxis for women with acute-onset severe hypertension during pregnancy and the postpartum period. Starting magnesium should not be delayed in the setting of acute severe hypertension; it is recommended regardless of whether the patient has gestational hypertension with severe features, preeclampsia with severe features, or eclampsia. Acute kidney injury may persist for up to 48 hours following delivery; proteinuria may take months to resolve."
]
},
{
"type":"p",
"hlId":"05690a",
"children":[
"In large studies, intravenous dexamethasone therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") has not been shown to be efficacious in treatment of severe preeclampsia or the HELLP syndrome."
]
},
{
"type":"p",
"hlId":"1cf29a",
"children":[
"Intravenous eculizumab (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is indicated for patients with atypical hemolytic uremic syndrome with deficiencies in the complement cascade. Atypical hemolytic uremic syndrome does not cause liver dysfunction as seen in this patient."
]
},
{
"type":"p",
"hlId":"58beb2",
"children":[
"Distinguishing the HELLP syndrome from thrombotic thrombocytopenic purpura (TTP) is important, as patients with TTP require fresh frozen plasma exchange (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") and glucocorticoids. TTP is very uncommon in pregnancy, typically presents earlier in gestation, and is marked by an even more profound decrease in hemoglobin and platelet count than seen in this patient."
]
},
{
"type":"p",
"hlId":"22ad2f",
"children":[
"Transfusion of packed red blood cells and platelets (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") is generally not recommended for patients in the absence of overt bleeding unless hemoglobin levels decrease to <7 g/dL (70 g/L) or platelet count decreases to <20,000/µL (20 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_4",
"objective":{
"__html":"Treat severe preeclampsia."
},
"references":[
[
"ACOG committee opinion no. 767 summary: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period [editorial]. Obstet Gynecol. 2019;133:409-412. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30681541",
"target":"_blank"
},
"children":[
"PMID: 30681541"
]
},
" doi:10.1097/AOG.0000000000003082"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":61,
"B":14,
"C":11,
"D":8,
"E":6
},
"hlIds":[
"c88d25",
"b1731f",
"d12432",
"f9867c",
"97c659",
"fcac73",
"f00ff6",
"62ea29",
"2eae6a",
"c7d329",
"a3689c",
"f461b2",
"28ecb5",
"7f697c",
"1054f1",
"3bb2ab",
"2869e4",
"6d3363",
"05690a",
"1cf29a",
"58beb2",
"22ad2f"
]
},
{
"id":"mk19_a_np_q010",
"number":10,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 10",
"stimulus":[
{
"type":"p",
"hlId":"082eda",
"children":[
"A 63-year-old man is evaluated during a follow-up visit for gastroesophageal reflux disease and heartburn. His symptoms are worse after large meals and when lying down and have significantly decreased the quality of his life and disrupted his sleep. He also has stage G4 chronic kidney disease, obesity, and hypertension. Medications are atenolol, lisinopril, and nifedipine."
]
},
{
"type":"p",
"hlId":"d1cb96",
"children":[
"On physical examination, vital signs are normal. BMI is 38. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"2cd905",
"children":[
"Laboratory studies show an ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" of 29 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"f897f3",
"children":[
"Weight loss and other lifestyle management modifications for gastroesophageal reflux disease are discussed."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"907369",
"children":[
"Which of the following is the most appropriate additional therapy?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Famotidine"
}
},
{
"letter":"B",
"text":{
"__html":"Omeprazole"
}
},
{
"letter":"C",
"text":{
"__html":"Oral calcium carbonate and magnesium hydroxide"
}
},
{
"letter":"D",
"text":{
"__html":"Sucralfate"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"6f3e9e",
"hvc":true,
"children":[
"Proton pump inhibitors may contribute to the development and progression of chronic kidney disease and should be avoided."
]
},
{
"type":"keypoint",
"hlId":"63fd55",
"hvc":true,
"children":[
"H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blocker therapy can be considered for patients with advanced chronic kidney disease provided appropriate dosing is used."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"5cea3c",
"children":[
"The most appropriate additional therapy is famotidine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has stage G4 chronic kidney disease (CKD) and symptoms of his gastroesophageal reflux disease (GERD). In patients with CKD, the nephrotoxic risk of medication or treatment used for comorbid medical conditions must be considered. As with all patients with GERD, first-line treatment should focus on lifestyle and diet modifications. Pharmacologic therapy includes antacids, H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blockers, and proton pump inhibitor (PPI) therapy. In this patient with significant symptoms, an H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blocker such as famotidine should be added to lifestyle modifications as treatment for GERD. In patients with advanced CKD, the dosing of H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blockers should be decreased or the dosing interval increased as guided by labeling instruction."
]
},
{
"type":"p",
"hlId":"8f43f3",
"children":[
"In addition to their classic association with acute interstitial nephritis/acute kidney injury, PPIs such as omeprazole (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") may contribute to the development and progression of CKD. The association has been observed in case-control studies and affirmed in a systematic review and meta-analysis. Although the evidence comes from observational studies, caution is still advised when considering PPI use in patients with advanced CKD, particularly when alternative therapies are available."
]
},
{
"type":"p",
"hlId":"e60b41",
"children":[
"Over-the-counter oral antacids containing calcium carbonate and magnesium hydroxide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") are commonly used to treat symptoms of GERD. However, patients with advanced CKD are at risk for magnesium toxicity with the use of these antacids and therefore should be avoided."
]
},
{
"type":"p",
"hlId":"6266ae",
"children":[
"Sucralfate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a sulfated polysaccharide complexed with aluminum hydroxide used in the treatment of peptic ulcer disease. Sucralfate binds to injured mucosal surface, promotes healing, and provides a barrier to peptic injury. Sucralfate is less effective than PPI therapy for peptic ulcer disease. Sucralfate has no role in the treatment of GERD due to its short duration of action and reduced effectiveness compared with other therapies, including PPIs and H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blockers. Finally, sucralfate contains aluminum, which may accumulate in patients with advanced CKD and is thus not recommended."
]
}
],
"relatedSection":"mk19_a_np_s12_6_5",
"objective":{
"__html":"Treat gastroesophageal reflux disease in a patient with advanced chronic kidney disease."
},
"references":[
[
"Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33:331-342. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28339835",
"target":"_blank"
},
"children":[
"PMID: 28339835"
]
},
" doi:10.1093/ndt/gfw470"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":43,
"B":42,
"C":4,
"D":11,
"E":0
},
"hlIds":[
"082eda",
"d1cb96",
"2cd905",
"f897f3",
"907369",
"6f3e9e",
"63fd55",
"5cea3c",
"8f43f3",
"e60b41",
"6266ae"
]
},
{
"id":"mk19_a_np_q011",
"number":11,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 11",
"stimulus":[
{
"type":"p",
"hlId":"b9329c",
"children":[
"A 38-year-old woman is evaluated in the emergency department for a 4-hour history of left flank pain that radiates to the groin. She is otherwise well and takes no medications."
]
},
{
"type":"p",
"hlId":"42450c",
"children":[
"A noncontrast helical CT scan of the abdomen shows an 11-mm stone in the proximal ureter. There is dilation of the renal calyces."
]
},
{
"type":"p",
"hlId":"b6e3e7",
"children":[
"Analgesics are initiated."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Intravenous 0.9% saline"
}
},
{
"letter":"B",
"text":{
"__html":"Lithotripsy"
}
},
{
"letter":"C",
"text":{
"__html":"Tamsulosin"
}
},
{
"letter":"D",
"text":{
"__html":"Observation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"31f148",
"children":[
"Stone passage decreases with increasing size; only 50% of stones >6 mm will pass, and stones >10 mm are extremely unlikely to pass spontaneously."
]
},
{
"type":"keypoint",
"hlId":"f70e62",
"children":[
"Urologic intervention is required in all patients with evidence of infection, acute kidney injury, intractable pain, stones that fail to pass, or large stones that are unlikely to pass."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"49e4ec",
"children":[
"The most appropriate treatment is lithotripsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). A kidney stone >10 mm, as seen in this patient, is unlikely to pass into the bladder and must be removed promptly because there are signs of ureteral obstruction, which can result in kidney damage. Acute management of symptomatic nephrolithiasis is aimed at pain management and facilitation of stone passage. Pain can be relieved by NSAIDs and opioids as needed. Stone passage decreases with increasing size. Only 50% of stones >6 mm will pass, generally within 2 weeks, and stones >10 mm are extremely unlikely to pass spontaneously. Urologic intervention is required in all patients with evidence of infection, acute kidney injury, intractable pain, and stones that fail to pass. The most effective method for removal of this patient's stone is to break it up using either shock wave or laser lithotripsy. The former is noninvasive, whereas the latter is accomplished using an ureteroscope and requires anesthesia. Both methods have similar rates of stone clearance. Laser lithotripsy is more expensive but is associated with less postlithotripsy discomfort."
]
},
{
"type":"p",
"hlId":"48e6ae",
"children":[
"Administering intravenous 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") would not be beneficial. There is no evidence that increasing urinary flow with the use of intravenous hydration results in a more rapid transit of kidney stones or decreased use of pain medication but may add to discomfort and patient inconvenience."
]
},
{
"type":"p",
"hlId":"86f40e",
"children":[
"Although tamsulosin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has been used to facilitate stone passage, data suggest it may be less effective than previously believed reported. The data, however, remain controversial and, because risk is minimal, use of tamsulosin to aid in stone passage can still be considered. Trials of assisted passage may last up to 4 weeks. Regardless, this patient's stone is too large to pass into the ureter with or without tamsulosin therapy."
]
},
{
"type":"p",
"hlId":"44cd3c",
"children":[
"Observation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") with frequent reevaluation may be an acceptable strategy for select patients with small stones and mild, easily managed pain, no evidence of infection, and no evidence of impending kidney damage. This patient has a stone that is too large to pass spontaneously and has evidence of hydroureter. Treatment with lithotripsy is a better option in this patient."
]
}
],
"relatedSection":"mk19_a_np_s10_5",
"objective":{
"__html":"Treat a kidney stone with lithotripsy."
},
"references":[
[
"Preminger GM, Tiselius HG, Assimos DG, et al; EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. J Urol. 2007;178:2418-2434. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/17993340",
"target":"_blank"
},
"children":[
"PMID: 17993340"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":26,
"B":59,
"C":12,
"D":3,
"E":0
},
"hlIds":[
"b9329c",
"42450c",
"b6e3e7",
"78ff87",
"31f148",
"f70e62",
"49e4ec",
"48e6ae",
"86f40e",
"44cd3c"
]
},
{
"id":"mk19_a_np_q012",
"number":12,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 12",
"stimulus":[
{
"type":"p",
"hlId":"9f3fff",
"children":[
"A 45-year-old woman is evaluated in the emergency department for a 3-day history of lower extremity weakness. Medical history is significant for hypertension, type 2 diabetes mellitus, and gastroesophageal reflux disease. Medications are lisinopril, metformin, canagliflozin, and pantoprazole."
]
},
{
"type":"p",
"hlId":"6acf4f",
"children":[
"On physical examination, vital signs are normal. Knee and ankle reflexes are decreased. Muscle strength is 4/5 in the lower extremities. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0f19a0",
"class":"cell text l",
"children":[
"1.1 mg/dL (97.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d956f7",
"class":"cell text l",
"children":[
"3.0 mEq/L (3.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5adbf9",
"class":"cell text l",
"children":[
"23 mEq/L (23 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fad908",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Magnesium, serum",
"children":[
"Magnesium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d8a046",
"class":"cell text l",
"children":[
"1.1 mg/dL (0.45 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"73618d",
"children":[
"Which of the follow is the most likely cause of this patient's hypokalemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Canagliflozin"
}
},
{
"letter":"B",
"text":{
"__html":"Lisinopril"
}
},
{
"letter":"C",
"text":{
"__html":"Pantoprazole"
}
},
{
"letter":"D",
"text":{
"__html":"Surreptitious diuretic use"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"87766c",
"children":[
"Proton pump inhibitors are a cause of hypomagnesemia, which typically occurs after long-term use."
]
},
{
"type":"keypoint",
"hlId":"0f62e1",
"children":[
"Magnesium deficiency is an important cause of hypokalemia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"03222c",
"children":[
"This most likely cause of this patient's hypokalemia is secondary hypomagnesemia caused by pantoprazole (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). The potassium channel in the distal nephron is gated by magnesium and, in states of hypomagnesemia, remains open with subsequent renal losses of potassium. Hypomagnesemia has become increasingly recognized in patients taking proton pump inhibitors (PPIs) and is listed as a potential adverse effect in package inserts. The longer duration a person has been taking PPIs, the greater the likelihood of developing hypomagnesemia. Because urine magnesium levels are low in patients with hypomagnesemia, the presumed mechanism is believed to be inhibition of the magnesium transporters in the gastrointestinal tract. Recent genomic analysis has identified a genetic polymorphism in the TRMP 6 magnesium transporter in patients with PPI-induced hypomagnesemia. Until the hypomagnesemia is corrected, the kidney will continue to waste potassium, making correction of hypokalemia difficult."
]
},
{
"type":"p",
"hlId":"a876be",
"children":[
"Sodium-glucose transporter 2 (SGLT2) inhibitors such as canagliflozin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") have been associated with a small increase in magnesium levels and would not be associated with this patient's hypomagnesemia. Patients with type 2 diabetes mellitus frequently have mild hypomagnesemia, which has been postulated to be secondary to insulin resistance. The cause of the increase in magnesium noted with SGLT2 inhibitors is unclear but may be related to improvement in insulin resistance or possibly a direct effect on magnesium transporters in the kidney."
]
},
{
"type":"p",
"hlId":"3b78cc",
"children":[
"Lisinopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), an ACE inhibitor, has minimal if any effect on magnesium levels. By decreasing aldosterone levels, these medications are associated with hyperkalemia."
]
},
{
"type":"p",
"hlId":"3411b4",
"children":[
"Although diuretic use can cause both hypokalemia and hypomagnesemia, this is usually associated with a metabolic alkalosis. Because this patient's serum bicarbonate is not increased, surreptitious diuretic use (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a less likely cause of her hypokalemia."
]
}
],
"relatedSection":"mk19_a_np_s2_5_1_1",
"objective":{
"__html":"Diagnose drug-induced hypomagnesemia as a cause of hypokalemia."
},
"references":[
[
"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237-1241. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26108134",
"target":"_blank"
},
"children":[
"PMID: 26108134"
]
},
" doi:10.3109/0886022X.2015.1057800"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":20,
"B":2,
"C":30,
"D":48,
"E":0
},
"hlIds":[
"9f3fff",
"6acf4f",
"a462a3",
"f461b2",
"0f19a0",
"89662a",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"d956f7",
"a207b1",
"21724f",
"6827e3",
"5adbf9",
"fad908",
"d8a046",
"73618d",
"87766c",
"0f62e1",
"03222c",
"a876be",
"3b78cc",
"3411b4"
]
},
{
"id":"mk19_a_np_q013",
"number":13,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 13",
"stimulus":[
{
"type":"p",
"hlId":"d024ac",
"children":[
"A 32-year-old woman is referred by the public health department for elevated blood pressure measurements during pregnancy. She is at 24 weeks' gestation of her first pregnancy. Records document blood pressure measurements averaging 140/90 mm Hg before pregnancy. She did not have routine medical care before her pregnancy. Her only medication is a prenatal vitamin."
]
},
{
"type":"p",
"hlId":"8b9cef",
"children":[
"On physical examination, blood pressure is 154/92 mm Hg; other vital signs are normal. The patient has a gravid uterus consistent with her stage of pregnancy. There is trace ankle edema bilaterally. Funduscopic, cardiac, and neurologic examinations are normal."
]
},
{
"type":"p",
"hlId":"607fa2",
"children":[
"Laboratory studies are normal; urinalysis shows no proteinuria."
]
},
{
"type":"p",
"hlId":"96ef5f",
"children":[
"ECG is normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"19a609",
"children":[
"Which of the following is the most appropriate management for this patient's hypertension?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Early delivery of the fetus"
}
},
{
"letter":"B",
"text":{
"__html":"Start hydrochlorothiazide"
}
},
{
"letter":"C",
"text":{
"__html":"Start labetalol"
}
},
{
"letter":"D",
"text":{
"__html":"Clinical monitoring"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"d641cd",
"hvc":true,
"children":[
"For pregnant women with chronic hypertension, guidelines recommend only treating persistent systolic ≥160 mm Hg or diastolic ≥110 mm Hg blood pressure in the absence of end-organ damage to avoid overtreatment of hypertension and associated fetal risk."
]
},
{
"type":"keypoint",
"hlId":"954697",
"hvc":true,
"children":[
"Treatment of chronic hypertension (<160/110 mm Hg) during pregnancy is not associated with improved fetal outcomes."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"119522",
"children":[
"No further management other than clinical monitoring (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is needed for this pregnant patient with chronic hypertension. Chronic hypertension is defined as hypertension starting before pregnancy or before 20 weeks of gestation. According to the American College of Cardiology/American Heart Association guidelines, and adopted by the American College of Obstetricians and Gynecologists (ACOG), the diagnosis of hypertension before pregnancy is based on systolic blood pressure >130 mm Hg and diastolic blood pressure >80 mm Hg. This patient is at 24 weeks' gestation and has no proteinuria or other evidence of end-organ damage; the diagnosis is most consistent with chronic hypertension. A 2014 Cochrane systematic review of 49 trials (4723 women) concluded that treatment of mild-to-moderate hypertension reduced the risk for developing severe hypertension but had no effect on the incidence of preeclampsia, preterm birth, fetal death, fetal growth restriction, or any other measured outcome. Antihypertensive treatment is not necessary at this time. For pregnant women with chronic hypertension, the 2019 ACOG Taskforce on Hypertension in Pregnancy recommends only treating persistent systolic blood pressure ≥160 mm Hg or diastolic ≥110 mm Hg to avoid overtreatment of hypertension and associated fetal risk. In the setting of comorbidities or underlying impaired kidney function, treating at lower blood pressure thresholds may be appropriate. Blood pressure goals with medications are 120-159/80-109 mm Hg. First-line agents are labetalol, nifedipine, and methyldopa."
]
},
{
"type":"p",
"hlId":"d732bb",
"children":[
"Early delivery of the fetus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") would be recommended if the patient had preeclampsia, which is defined by new-onset hypertension that occurs after 20 weeks' gestation associated proteinuria or end-organ damage. The absence of proteinuria and end-organ involvement in this patient is not consistent with preeclampsia."
]
},
{
"type":"p",
"hlId":"8b3c32",
"children":[
"Although thiazide diuretics such as hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") can be used in pregnancy, this patient's blood pressure does not warrant treatment at this time. Furthermore, diuretics are considered second-line antihypertensive agents during pregnancy and should be used with caution in pregnant patients, as they may induce oligohydramnios."
]
},
{
"type":"p",
"hlId":"40531c",
"children":[
"Labetalol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") and other antihypertensive agents are not indicated, as treatment of chronic hypertension in pregnancy is not needed if the patient's blood pressure is <160/110 mm Hg and there is no evidence of end-organ damage, as seen in this patient."
]
}
],
"relatedSection":"mk19_a_np_s11_2_1",
"objective":{
"__html":"Manage chronic hypertension in a pregnant patient."
},
"references":[
[
"ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133:e26-e50. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30575676",
"target":"_blank"
},
"children":[
"PMID: 30575676"
]
},
" doi:10.1097/AOG.0000000000003020"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":1,
"B":4,
"C":67,
"D":28,
"E":0
},
"hlIds":[
"d024ac",
"8b9cef",
"607fa2",
"96ef5f",
"19a609",
"d641cd",
"954697",
"119522",
"d732bb",
"8b3c32",
"40531c"
]
},
{
"id":"mk19_a_np_q014",
"number":14,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 14",
"stimulus":[
{
"type":"p",
"hlId":"ff2194",
"children":[
"A 34-year-old woman is evaluated for hypertension. During the past 3 months, two blood pressure measurements in health care settings averaged 150/90 mm Hg. During the same time period, three blood pressure measurements obtained outside of health care settings averaged 128/78 mm Hg. She has no other pertinent personal or family history. She takes no medications."
]
},
{
"type":"p",
"hlId":"d35e3d",
"children":[
"On physical examination, blood pressure is 144/92 mm Hg in both arms, pulse rate is 80/min, and respiration rate is 18/min. BMI is 22. The remainder of the examination is normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Begin chlorthalidone"
}
},
{
"letter":"B",
"text":{
"__html":"Obtain renal artery imaging"
}
},
{
"letter":"C",
"text":{
"__html":"Perform ambulatory blood pressure monitoring"
}
},
{
"letter":"D",
"text":{
"__html":"Recheck blood pressure in the office in 3 months"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"b7e1b9",
"children":[
"White coat hypertension refers to elevated blood pressure measured in the office, but normal out-of-office measurements."
]
},
{
"type":"keypoint",
"hlId":"0a99f5",
"children":[
"In adults with untreated systolic blood pressure >130 mm Hg but <160 mm Hg or diastolic blood pressure >80 mm Hg but <100 mm Hg, it is reasonable to screen for white coat hypertension using either ambulatory blood pressure monitoring or home blood pressure monitoring."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"09f531",
"children":[
"The most appropriate management is to perform ambulatory blood pressure monitoring (ABPM) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") to evaluate for white coat hypertension. White coat hypertension, also termed isolated clinic or office hypertension, refers to elevated blood pressure (BP) measured in the office, but normal out-of-office BP averages. According to guideline recommendations, in adults with untreated systolic BP >130 mm Hg but <160 mm Hg or diastolic BP >80 mm Hg but <100 mm Hg, it is reasonable to screen for white coat hypertension using either ABPM or home BP monitoring measurements obtained by the patient. Before white coat hypertension is diagnosed, the reliability of out-of-office measurements must be confirmed; for example, the patient's home BP monitor should be calibrated against the office sphygmomanometer or, preferably, BP should be measured by an ABPM device. In patients with white coat hypertension, annual follow-up with out-of-office BP measurements should be considered to determine if conversion to sustained hypertension has occurred."
]
},
{
"type":"p",
"hlId":"1bbd7f",
"children":[
"Initiating chlorthalidone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), a thiazide diuretic, is a reasonable initial therapy in patients with documented hypertension. Chlorthalidone is not indicated in this patient unless hypertension is confirmed using ABPM or home BP monitoring."
]
},
{
"type":"p",
"hlId":"311932",
"children":[
"CT angiography, MR angiography, and duplex Doppler ultrasonography are imaging modalities used to diagnose renovascular hypertension. Routine testing for renovascular disease may not change management for patients with atherosclerotic renovascular disease, because data suggest that medical therapy may be as beneficial as invasive procedures. However, in young patients with resistant hypertension and a high clinical suspicion for fibromuscular dysplasia (e.g., sudden onset of resistant hypertension at a young age, presence of an abdominal bruit), renal artery imaging may be considered. This patient has no indication for renal artery imaging (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
")."
]
},
{
"type":"p",
"hlId":"75c54f",
"children":[
"Rechecking this patient's BP in the office in 3 months (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not appropriate management, as elevated office BP should be confirmed using out-of-office measurements."
]
}
],
"relatedSection":"mk19_a_np_s4_8",
"objective":{
"__html":"Diagnose white coat hypertension using ambulatory blood pressure monitoring."
},
"references":[
[
"Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:351-362. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30715088",
"target":"_blank"
},
"children":[
"PMID: 30715088"
]
},
" doi:10.1001/jamainternmed.2018.6551"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":2,
"C":93,
"D":4,
"E":0
},
"hlIds":[
"ff2194",
"d35e3d",
"cb2b54",
"b7e1b9",
"0a99f5",
"09f531",
"1bbd7f",
"311932",
"75c54f"
]
},
{
"id":"mk19_a_np_q015",
"number":15,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 15",
"stimulus":[
{
"type":"p",
"hlId":"bfe39e",
"children":[
"A 68-year-old man is evaluated in the emergency department for generalized weakness that began 12 hours ago after ingesting a bottle of magnesium citrate for constipation. He has hypertension, hyperlipidemia, and stage G4 chronic kidney disease. Medications are furosemide, nifedipine, and simvastatin."
]
},
{
"type":"p",
"hlId":"c1161f",
"children":[
"On physical examination, blood pressure is 102/64 mm Hg, and pulse rate is 50/min; other vital signs are normal. Muscle strength is 4/5 diffusely. Reflexes are absent throughout. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b47e6a",
"class":"cell text l",
"children":[
"8.4 mg/dL (2.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"06bd48",
"class":"cell text l",
"children":[
"5.5 mg/dL (486.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fad908",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Magnesium, serum",
"children":[
"Magnesium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"233c7f",
"class":"cell text l",
"children":[
"6.8 mg/dL (2.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4db880",
"class":"cell text l",
"children":[
"5.5 mg/dL (1.8 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"c4ff97",
"children":[
"Which of the following is the most appropriate immediate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Intravenous calcium gluconate"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous furosemide"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous sodium bicarbonate"
}
},
{
"letter":"D",
"text":{
"__html":"Oral patiromer"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"5291b1",
"children":[
"Hypermagnesemia decreases neural transmission, resulting in weakness, and blocks both calcium and potassium channels, resulting in hypotension and bradycardia."
]
},
{
"type":"keypoint",
"hlId":"052402",
"children":[
"Symptomatic hypermagnesemia (serum magnesium level >4.8 mg/dL [2.0 mmol/L]) is immediately treated with intravenous calcium gluconate while awaiting hemodialysis."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"e68a63",
"children":[
"The most appropriate immediate treatment is intravenous calcium gluconate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Hypermagnesemia is defined by a serum magnesium level of >2.4 mg/dL (0.99 mmol/L). Hypermagnesemia occurs infrequently and most commonly results from excessive intake in the setting of decreased kidney function. Laboratory analysis often shows hypocalcemia. In patients with significant kidney disease, use of magnesium laxatives can cause significant elevation of serum magnesium levels and should be avoided in these patients. Many medications such as antacids and magnesium sulfate used in the treatment of refractory asthma and preeclampsia are other sources of magnesium. Hypermagnesemia decreases neural transmission, resulting in weakness, as seen in this patient, which can progress to paralysis. Hypermagnesemia also blocks calcium and potassium channels, resulting in hypotension and bradycardia. These effects become apparent when the serum magnesium level is >4.8 mg/dL (2.0 mmol/L). Prevention is the key to management of hypermagnesemia by avoiding magnesium-containing medications in patients with reduced kidney function. The immediate treatment for symptomatic hypermagnesemia is intravenous calcium gluconate. Calcium rapidly antagonizes the cardiovascular and neuromuscular effects of hypermagnesemia. This will allow time to set up and initiate hemodialysis, which is the definitive treatment to lower magnesium levels in patients with severe hypermagnesemia."
]
},
{
"type":"p",
"hlId":"c02338",
"children":[
"In patients with normal kidney function, intravenous furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), a loop diuretic, will increase kidney magnesium excretion; treatment would not be beneficial in this patient with late-stage chronic kidney disease."
]
},
{
"type":"p",
"hlId":"617456",
"children":[
"Intravenous sodium bicarbonate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is associated with a decrease in ionized calcium. Although in vitro studies suggest a similar effect on ionized magnesium, human studies have not been done to support the use of sodium bicarbonate in the treatment of hypermagnesemia."
]
},
{
"type":"p",
"hlId":"33b713",
"children":[
"Patiromer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a cation exchanger that is used to manage chronic elevations of serum potassium. Although patiromer has been associated with hypomagnesemia, this agent has a relative slow onset of action (1 to 4 hours) and would not be effective acutely and thus not an appropriate treatment for this patient."
]
}
],
"relatedSection":"mk19_a_np_s2_5_2_2",
"objective":{
"__html":"Treat hypermagnesemia in a patient with chronic kidney disease."
},
"references":[
[
"Reddy ST, Soman SS, Yee J. Magnesium balance and measurement. Adv Chronic Kidney Dis. 2018;25:224-229. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29793660",
"target":"_blank"
},
"children":[
"PMID: 29793660"
]
},
" doi:10.1053/j.ackd.2018.03.002"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":71,
"B":17,
"C":7,
"D":4,
"E":0
},
"hlIds":[
"bfe39e",
"c1161f",
"a462a3",
"1a4da4",
"b47e6a",
"f461b2",
"06bd48",
"fad908",
"233c7f",
"a4922e",
"4db880",
"c4ff97",
"5291b1",
"052402",
"e68a63",
"c02338",
"617456",
"33b713"
]
},
{
"id":"mk19_a_np_q016",
"number":16,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 16",
"stimulus":[
{
"type":"p",
"hlId":"d3ef12",
"children":[
"A 77-year-old woman is evaluated in the ICU for acute kidney injury after being hospitalized 2 days ago for septic shock and acute respiratory distress syndrome secondary to community-acquired pneumonia. She was intubated and vasopressor support was initiated. Over the first 18 hours of hospitalization, she received 3600 mL of Ringer's lactate solution. Current medications are norepinephrine, ceftaroline, levofloxacin, and dexmedetomidine."
]
},
{
"type":"p",
"hlId":"987c37",
"children":[
"On physical examination, the patient is mechanically ventilated. Temperature is 38.4 °C (101.1 °F), blood pressure is 88/52 mm Hg, pulse rate is 105/min, respiration rate is 16/min, and ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"oxygen saturation"
]
},
" is 90% with the patient breathing 50% F",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"IO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
". Diffusely coarse breath sounds are heard on pulmonary examination. A central venous catheter is in place; central venous pressure measurement is 14 mm Hg."
]
},
{
"type":"p",
"hlId":"0dfa01",
"children":[
"Urine output is 30 mL/h and unresponsive to escalating doses of intravenous furosemide."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d12432",
"children":[
"Current laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ea504e",
"class":"cell text l",
"children":[
"3.4 mg/dL (300.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"dbbe15",
"class":"cell text l",
"children":[
"134 mEq/L (134 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"444712",
"class":"cell text l",
"children":[
"6.4 mEq/L (6.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"658b18",
"class":"cell text l",
"children":[
"100 mEq/L (100 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"20d759",
"class":"cell text l",
"children":[
"12 mEq/L (12 mmol/L)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"52e55d",
"children":[
"Chest radiograph shows diffuse bilateral infiltrates and vascular cephalization."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"fff861",
"children":[
"Which of the following is the most appropriate therapy?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Begin continuous renal replacement therapy"
}
},
{
"letter":"B",
"text":{
"__html":"Begin peritoneal dialysis"
}
},
{
"letter":"C",
"text":{
"__html":"Continue current management"
}
},
{
"letter":"D",
"text":{
"__html":"Switch to intravenous bumetanide"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bb5108",
"children":[
"Continuous renal replacement therapy is a preferred modality of renal replacement therapy in patients with acute kidney injury and hemodynamic instability."
]
},
{
"type":"keypoint",
"hlId":"481fad",
"children":[
"Randomized clinical trials have not shown a survival benefit of continuous renal replacement therapy over intermittent hemodialysis or prolonged intermittent renal replacement therapy for critically ill patients with acute kidney injury."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"92cce4",
"children":[
"The most appropriate renal replacement therapy (RRT) is continuous RRT (CRRT) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). RRT is used to manage the urgent complications of severe acute kidney injury (AKI), including hyperkalemia, metabolic acidosis, volume overload refractory to diuretics, uremic manifestations, and dialyzable toxins. In patients with AKI, RRT options include intermittent hemodialysis (IHD); CRRT; “hybrid” therapies such as prolonged intermittent RRT (PIRRT); and peritoneal dialysis. This patient has AKI, metabolic acidosis, hyperkalemia, and volume overload. In patients who are hemodynamically unstable, CRRT is preferred because it is administered 24 hours per day, removing solutes and fluid much more slowly than IHD and resulting in better hemodynamic tolerance. However, randomized clinical trials have not shown a survival benefit of CRRT over IHD or PIRRT for critically ill patients with AKI."
]
},
{
"type":"p",
"hlId":"9575b8",
"children":[
"Peritoneal dialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not as effective as the other types of RRT but may be useful when other types are unavailable or vascular access cannot be obtained."
]
},
{
"type":"p",
"hlId":"489f08",
"children":[
"This patient has life-threatening electrolyte abnormalities and no immediate prospect of kidney function recovery. Therefore, continuation of current management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is unacceptable."
]
},
{
"type":"p",
"hlId":"e3025d",
"children":[
"All of the loop diuretics produce the same diuresis when given at equipotent doses. The patient has been unresponsive to escalating doses of furosemide; therefore, switching to another loop diuretic such as intravenous bumetanide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is unlikely to result in a significant diuresis and will not address this patient's acidemia."
]
}
],
"relatedSection":"mk19_a_np_s9_7_2",
"objective":{
"__html":"Treat acute kidney injury with renal replacement therapy."
},
"references":[
[
"Gaudry S, Hajage D, Dreyfuss D. Initiation of renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:1901-1902. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27959653",
"target":"_blank"
},
"children":[
"PMID: 27959653"
]
}
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":84,
"B":8,
"C":1,
"D":7,
"E":0
},
"hlIds":[
"d3ef12",
"987c37",
"0dfa01",
"d12432",
"f461b2",
"ea504e",
"89662a",
"d41d8c",
"b99276",
"dbbe15",
"e92687",
"444712",
"a207b1",
"658b18",
"6827e3",
"20d759",
"52e55d",
"fff861",
"bb5108",
"481fad",
"92cce4",
"9575b8",
"489f08",
"e3025d"
]
},
{
"id":"mk19_a_np_q017",
"number":17,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 17",
"stimulus":[
{
"type":"p",
"hlId":"02e2d8",
"children":[
"A 23-year-old woman is evaluated for a 1-week history of muscle weakness. Medical history is significant for chronic migraine headaches. Medications are topiramate, sumatriptan, naproxen, and aspirin."
]
},
{
"type":"p",
"hlId":"3c4b08",
"children":[
"On physical examination, vital signs are normal. BMI is 19. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21b71a",
"class":"cell text l",
"children":[
"142 mEq/L (142 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"115bcd",
"class":"cell text l",
"children":[
"3.1 mEq/L (3.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"219319",
"class":"cell text l",
"children":[
"120 mEq/L (120 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"788ef7",
"class":"cell text l",
"children":[
"15 mEq/L (15 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a54671",
"class":"cell text l",
"children":[
"Urine potassium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c6094b",
"class":"cell text l",
"children":[
"8.0 mEq/L (8.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c1bef6",
"class":"cell text l",
"children":[
"Urine chloride"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b9fe11",
"class":"cell text l",
"children":[
"32 mEq/L (32 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"27f4b7",
"children":[
"Which of the following is the most likely cause of this patient's metabolic acidosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Salicylate toxicity"
}
},
{
"letter":"B",
"text":{
"__html":"Surreptitious furosemide use"
}
},
{
"letter":"C",
"text":{
"__html":"Surreptitious laxative use"
}
},
{
"letter":"D",
"text":{
"__html":"Topiramate"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"fee671",
"children":[
"Normal anion gap metabolic acidosis can be caused by gastrointestinal bicarbonate loss, renal loss of bicarbonate, or the inability of the kidney to excrete acid."
]
},
{
"type":"keypoint",
"hlId":"098bf4",
"children":[
"A negative urine anion gap suggests appropriate kidney excretion of acid and therefore gastrointestinal bicarbonate loss as the cause of normal anion gap metabolic acidosis."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"083436",
"children":[
"Laxative abuse (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is the most likely cause of this patient's normal anion gap metabolic acidosis. Normal anion gap metabolic acidosis can be caused by gastrointestinal bicarbonate loss, renal loss of bicarbonate, or the inability of the kidney to excrete acid. The normal physiologic response to systemic acidosis is an increase in urine acid excretion. Therefore, an initial diagnostic step in normal anion gap metabolic acidosis is to determine whether the kidney is appropriately excreting acid. Increased acid excretion by the kidney is reflected as a marked increase in urine ammonium. However, urine ammonium measurement is difficult to obtain. Because ammonium carries a positive charge, chloride is excreted as the corresponding anion. Therefore, the amount of excreted chloride increases as urine ammonium levels increase. The urine anion gap can be used as an indicator of the ability of the kidney to excrete acid. The urine anion gap is calculated as follows:"
]
},
{
"type":"p",
"hlId":"3a2e16",
"class":"equation",
"children":[
"Urine Anion Gap = (Urine Sodium + Urine Potassium) – Urine Chloride"
]
},
{
"type":"p",
"hlId":"3a2ca6",
"children":[
"In the context of increased urinary ammonium excretion, therefore, the urine anion gap will be negative. The negative urine anion gap in this patient (-6.0 mEq/L [-6.0 mmol/L]) suggests appropriate renal excretion of acid and therefore a gastrointestinal cause of the normal anion gap metabolic acidosis. In this patient, laxative abuse is a possible, even likely, explanation. In addition, the low urine potassium indicates appropriate renal compensation in context of laxative-induced hypokalemia."
]
},
{
"type":"p",
"hlId":"ec6cb2",
"children":[
"Salicylate toxicity (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") would be associated with an anion gap, which is not present in this patient."
]
},
{
"type":"p",
"hlId":"c65062",
"children":[
"Surreptitious furosemide use (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") would be expected to result in a metabolic alkalosis, not metabolic acidosis."
]
},
{
"type":"p",
"hlId":"5a0e81",
"children":[
"Renal causes of normal anion gap metabolic acidosis are due to specific defects in bicarbonate reclamation (type 2 renal tubular acidosis [RTA]) or in hydrogen ion secretion (type 1 RTA). Topiramate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") can cause both type 1 and type 2 RTA. The urine anion gap due to type 1 RTA is positive, which is not the case in this patient."
]
}
],
"relatedSection":"mk19_a_np_s3_2_3",
"objective":{
"__html":"Identify laxative abuse as a cause of normal anion gap metabolic acidosis."
},
"references":[
[
"Rastegar M, Nagami GT. Non-anion gap metabolic acidosis: a clinical approach to evaluation. Am J Kidney Dis. 2017;69:296-301. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28029394",
"target":"_blank"
},
"children":[
"PMID: 28029394"
]
},
" doi:10.1053/j.ajkd.2016.09.01"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":20,
"B":6,
"C":37,
"D":37,
"E":0
},
"hlIds":[
"02e2d8",
"3c4b08",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"21b71a",
"e92687",
"115bcd",
"a207b1",
"219319",
"6827e3",
"788ef7",
"e331de",
"653d7c",
"a54671",
"c6094b",
"c1bef6",
"b9fe11",
"27f4b7",
"fee671",
"098bf4",
"083436",
"3a2e16",
"3a2ca6",
"ec6cb2",
"c65062",
"5a0e81"
]
},
{
"id":"mk19_a_np_q018",
"number":18,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 18",
"stimulus":[
{
"type":"p",
"hlId":"6aa57a",
"children":[
"A 57-year-old man is evaluated during a follow-up visit for stable chronic kidney disease diagnosed 1 year ago. Renal duplex Doppler ultrasound at that time showed a 7-cm right kidney and 11-cm left kidney with a >75% midstenotic lesion of the left renal artery. He also has type 2 diabetes mellitus, hyperlipidemia, and peripheral artery disease. Medications are low-dose aspirin, furosemide, lisinopril, amlodipine, carvedilol, metformin, empagliflozin, and atorvastatin."
]
},
{
"type":"p",
"hlId":"eff2d7",
"children":[
"On physical examination, blood pressure is 128/74 mm Hg, pulse rate is 65/min, and respiration rate is 18/min. Bilateral carotid and lower abdominal quadrant bruits are heard. Peripheral extremity pulses are diminished. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d34d5",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"06bcde",
"class":"cell text l",
"children":[
"Electrolytes"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"83dfd7",
"class":"cell text l",
"children":[
"45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d9648a",
"class":"cell text l",
"children":[
"1100 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Left renal artery angioplasty"
}
},
{
"letter":"B",
"text":{
"__html":"Renal artery CT angiography"
}
},
{
"letter":"C",
"text":{
"__html":"Renal artery MR angiography"
}
},
{
"letter":"D",
"text":{
"__html":"No additional diagnostic testing"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7bd379",
"hvc":true,
"children":[
"In most patients with renal artery stenosis, the primary therapeutic intervention is medical management, including correction of modifiable cardiovascular risk factors."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"1427af",
"children":[
"No additional diagnostic testing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is needed for this patient with stable renovascular hypertension. Clinical suspicion for renovascular hypertension is raised when patients >55 years of age present with onset of severe hypertension and develop acute kidney injury (AKI) after initiation of an ACE inhibitor or angiotensin receptor blocker (ARB), or after control of blood pressure (BP) to target goal. In addition, asymmetry >1.5 cm in kidney sizes on imaging or the presence of a kidney ≤9 cm can also increase the probability. Patients such as this one with evidence of atherosclerotic cardiovascular disease should receive medical therapy, including lifestyle interventions, low-dose aspirin, BP control, guideline-directed diabetes management, and high-intensity statin therapy. In patients with hypertension and chronic kidney disease (CKD) stage G3 or higher or stage G1 or G2 with albuminuria, treatment with an ACE inhibitor or ARB is recommended to slow kidney disease progression."
]
},
{
"type":"p",
"hlId":"8d6006",
"children":[
"Three randomized trials (STAR, ASTRAL, and CORAL) failed to show that renal artery angioplasty (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") confers additional benefit above optimal medical therapy in patients with renovascular hypertension and stable kidney function. Patients who may benefit from percutaneous angioplasty or surgical intervention include those with a short duration of hypertension; atherosclerotic renovascular disease refractory to optimal medical therapy; severe hypertension or recurrent acute flash pulmonary edema; AKI following treatment with an ACE inhibitor or ARB; progressive impaired kidney function believed to be caused by bilateral renovascular disease; or unilateral stenosis affecting a solitary functioning kidney. This patient has none of these indications. Finally, patients with advanced CKD or with proteinuria >1000 mg/g, such as this patient, are less likely to benefit from revascularization."
]
},
{
"type":"p",
"hlId":"280183",
"children":[
"Although CT angiography and MR angiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, C"
]
},
") have higher diagnostic utility than ultrasonography, these imaging studies may be potentially harmful in patients with severe CKD, given the risk for contrast nephropathy and gadolinium-induced nephrogenic systemic fibrosis (with group 1 but not group 2 gadolinium-based contras media). Renal duplex Doppler ultrasonography is a reasonable imaging modality in these patients if performed by experienced sonographers. Additional testing for renal vascular disease is not required in this patient and is not cost-effective, given that no interventions other than continuing the current medical management will be undertaken."
]
}
],
"relatedSection":"mk19_a_np_s4_11_2_3",
"objective":{
"__html":"Manage stable renovascular hypertension."
},
"references":[
[
"Cooper CJ, Murphy TP, Cutlip DE, et al; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13-22. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24245566",
"target":"_blank"
},
"children":[
"PMID: 24245566"
]
},
" doi:10.1056/NEJMoa1310753"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":17,
"B":8,
"C":17,
"D":58,
"E":0
},
"hlIds":[
"6aa57a",
"eff2d7",
"a462a3",
"f461b2",
"0d34d5",
"06bcde",
"960b44",
"77db81",
"83dfd7",
"58e613",
"d9648a",
"cb2b54",
"7bd379",
"1427af",
"8d6006",
"280183"
]
},
{
"id":"mk19_a_np_q019",
"number":19,
"bookId":"np",
"correctAnswer":"E",
"title":"Question 19",
"stimulus":[
{
"type":"p",
"hlId":"4d9167",
"children":[
"A 46-year-old woman is evaluated for a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 2.6 mg/dL (229.8 µmol/L). Her baseline ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level 3 months ago was 0.9 mg/dL (79.6 µmol/L). She has no symptoms. Two years ago, she started losartan and amlodipine for hypertension. One year ago, she started omeprazole for gastroesophageal reflux disease and naproxen for knee osteoarthritis. Eight months ago, she began atorvastatin for hyperlipidemia."
]
},
{
"type":"p",
"hlId":"32322e",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), and blood pressure is 138/86 mm Hg. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"a6bf5c",
"children":[
"Urinalysis shows the following: specific gravity 1.015; pH 5.5; 1+ erythrocytes; 3+ leukocytes; 1+ leukocyte esterase; no nitrates; and >100 leukocytes/hpf with leukocyte and granular casts."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"b16968",
"children":[
"Which of the following drugs should be discontinued in this patient?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Atorvastatin and amlodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Losartan and amlodipine"
}
},
{
"letter":"C",
"text":{
"__html":"Losartan and omeprazole"
}
},
{
"letter":"D",
"text":{
"__html":"Naproxen and atorvastatin"
}
},
{
"letter":"E",
"text":{
"__html":"Naproxen and omeprazole"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"00fc2d",
"children":[
"Medications, especially antibiotics, are the most common cause of acute interstitial nephritis."
]
},
{
"type":"keypoint",
"hlId":"321171",
"children":[
"Acute interstitial nephritis can be caused by NSAIDs and proton pump inhibitors in the absence of fever, rash, or eosinophilia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"86b8ed",
"children":[
"Naproxen and omeprazole should be discontinued (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"). Acute interstitial nephritis (AIN) is a common cause of acute kidney injury (AKI) and is characterized by inflammation and edema of the interstitium. The classic clinical presentation of fever, rash, and peripheral eosinophilia occurs in only 10% to 30% of patients with AIN. Urinary findings can include eosinophiluria, leukocytes, erythrocytes, and leukocyte casts. Urine eosinophils are neither sensitive nor specific for AIN. Drug-induced AIN, especially due to antibiotics, is the most common cause of AIN. Other causes include infection, systemic disease, and autoimmune disorders. Typically, the serum creatinine level gradually increases 7 to 10 days after drug exposure. Drug-induced AIN from NSAIDs, including selective cyclooxygenase-2 inhibitors, is usually not associated with fever, rash, or eosinophilia and develops 6 to 18 months after drug exposure. AIN from NSAIDs can be associated with the nephrotic syndrome due to minimal change glomerulopathy or membranous nephropathy. Proton pump inhibitors are also associated with AIN without fever, rash, and eosinophilia. The onset of AIN with proton pump inhibitors is variable but typically occurs 10 to 11 weeks after exposure. Proton pump inhibitors are believed to be a risk factor for the development of chronic kidney disease."
]
},
{
"type":"p",
"hlId":"cf03b9",
"children":[
"Kidney recovery from drug-induced AIN is usually complete if the drug is discontinued immediately after the onset of kidney injury; however, recovery may take weeks to several months. Kidney biopsy should be considered if there is no improvement in kidney function after 5 to 7 days of drug discontinuation. Early glucocorticoid administration may limit damage associated with drug-induced AIN. When there are no obvious signs and symptoms of infection or toxic exposures, the most appropriate management is to discontinue high-probability medications and consider initiating a course of oral glucocorticoids. In patients taking multiple medications, it is reasonable to selectively discontinue the medications most likely causative of AIN. In this patient, the most appropriate course is to discontinue the naproxen and omeprazole."
]
},
{
"type":"p",
"hlId":"552d6b",
"children":[
"Calcium channel blockers (amlodipine), statins (atorvastatin), and angiotensin receptor blockers (losartan) are rarely associated with AIN (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A-D"
]
},
")."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_2",
"objective":{
"__html":"Manage acute interstitial nephritis in a patient taking multiple medications."
},
"references":[
[
"Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis. 2017;24:57-63. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28284380",
"target":"_blank"
},
"children":[
"PMID: 28284380"
]
},
" doi:10.1053/j.ackd.2016.08.003"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":0,
"C":5,
"D":6,
"E":88
},
"hlIds":[
"4d9167",
"32322e",
"a6bf5c",
"b16968",
"00fc2d",
"321171",
"86b8ed",
"cf03b9",
"552d6b"
]
},
{
"id":"mk19_a_np_q020",
"number":20,
"bookId":"np",
"correctAnswer":"E",
"title":"Question 20",
"stimulus":[
{
"type":"p",
"hlId":"3a6ff1",
"children":[
"A 56-year-old man is evaluated for weakness after completing a second cycle of chemotherapy for a soft-tissue sarcoma recently excised from the right thigh. Medications are ifosfamide, doxorubicin, and mesna."
]
},
{
"type":"p",
"hlId":"73e9b1",
"children":[
"On physical examination, vital signs are normal. The patient appears well. Generalized weakness is noted. There is a healing surgical scar on the upper right thigh. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1fd2c7",
"class":"cell text l",
"children":[
"136 mEq/L (136 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"81b8c4",
"class":"cell text l",
"children":[
"3.5 mEq/L (3.5 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"715f55",
"class":"cell text l",
"children":[
"106 mEq/L (106 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"daf5c9",
"class":"cell text l",
"children":[
"88 mg/dL (4.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"be4aca",
"class":"cell text l",
"children":[
"1.2 mg/dL (0.39 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f212ab",
"class":"cell text l",
"children":[
"Fractional excretion of phosphorus"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"bb1a5a",
"class":"cell text l",
"children":[
"10%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"57bdde",
"class":"cell text l",
"children":[
"pH 7.0; no blood; 3+ protein; 2+ glucose; no leukocyte esterase"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"6403ae",
"children":[
"Which of the following is the most likely cause of this patient's hypophosphatemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Chronic kidney disease"
}
},
{
"letter":"B",
"text":{
"__html":"Increased fibroblast growth factor 23 production"
}
},
{
"letter":"C",
"text":{
"__html":"Intracellular shift of phosphorus"
}
},
{
"letter":"D",
"text":{
"__html":"Osmotic diuresis"
}
},
{
"letter":"E",
"text":{
"__html":"Proximal renal tubular dysfunction"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ea71c9",
"children":[
"In patients with hypophosphatemia, proximal renal tubular phosphate dysfunction can be identified by a fractional excretion of phosphorus >5%."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b26728",
"children":[
"The most likely cause of this patient's hypophosphatemia is proximal renal tubular dysfunction (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"). This patient has ifosfamide-induced Fanconi syndrome. Ifosfamide metabolites are toxic to the proximal tubule, resulting in a generalized decrease in cell energetics and a decrease in transport of various substances across the luminal membrane, including phosphorus, glucose, amino acids, and protons. In addition to phosphate wasting, as identified by the fractional excretion of phosphorus >5%, this patient also has glycosuria despite having a normal serum glucose; this is commonly seen in patients with ifosfamide-induced Fanconi syndrome. The urinalysis finding of proteinuria is most likely secondary to the loss of amino acids in the urine. Mesna is a thiol compound that, when delivered intravenously, inactivates acrolein in the urine to reduce the risk for bladder toxicity from cyclophosphamide and ifosfamide. Although mesna can prevent the hemorrhagic cystitis, it has not been demonstrated to prevent the tubular toxicity. The treatment of the hypophosphatemia in this disorder requires large quantities of phosphorus, typically intravenously."
]
},
{
"type":"p",
"hlId":"c751e9",
"children":[
"Chronic kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is associated with an increase in the serum phosphorus caused by a decrease in filtered phosphorus; this patient has a decrease in serum phosphorus, which is inconsistent with chronic kidney disease as a cause for hypophosphatemia."
]
},
{
"type":"p",
"hlId":"911946",
"children":[
"Three hormones are largely responsible for regulating calcium and phosphorus homeostasis: parathyroid hormone, vitamin D, and fibroblast growth factor 23 (FGF-23) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). FGF-23 is a peptide secreted by various types of bone cells. It acts on the kidney to induce phosphaturia and downregulates 1α-hydroxylase to inhibit synthesis of 1,25-dihydroxyvitamin D. Although sarcomas have been associated with increased secretion of FGF-23 and severe phosphate wasting due to tumor-induced osteomalacia, this is extremely rare and would not explain the patient's glycosuria and proteinuria."
]
},
{
"type":"p",
"hlId":"d2bfa8",
"children":[
"Intracellular shifts of phosphorus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") can occur with administration of insulin, refeeding in individuals with starvation, or secondary to respiratory alkalosis; none of these factors is present in this patient."
]
},
{
"type":"p",
"hlId":"5e14ce",
"children":[
"Patients with diabetes mellitus and hyperglycemia may have hypophosphatemia caused by osmotic diuresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). However, this patient has no evidence of hyperglycemia or evidence of an ongoing osmotic diuresis such as hypotension or hypernatremia."
]
}
],
"relatedSection":"mk19_a_np_s2_4_1_1",
"objective":{
"__html":"Diagnose proximal renal tubule dysfunction as a cause of hypophosphatemia."
},
"references":[
[
"Panezai MA, Owen C, Szerlip HM. Partial Fanconi syndrome induced by ifosfamide. Proc (Bayl Univ Med Cent). 2019;32:73-74. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30956588",
"target":"_blank"
},
"children":[
"PMID: 30956588"
]
},
" doi:10.1080/08998280.2018.1536020"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":4,
"B":11,
"C":20,
"D":6,
"E":58
},
"hlIds":[
"3a6ff1",
"73e9b1",
"a462a3",
"f461b2",
"3a34ea",
"89662a",
"d41d8c",
"b99276",
"1fd2c7",
"e92687",
"81b8c4",
"a207b1",
"715f55",
"6827e3",
"653d7c",
"847136",
"daf5c9",
"a4922e",
"be4aca",
"f212ab",
"bb1a5a",
"747c2a",
"57bdde",
"6403ae",
"ea71c9",
"b26728",
"c751e9",
"911946",
"d2bfa8",
"5e14ce"
]
},
{
"id":"mk19_a_np_q021",
"number":21,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 21",
"stimulus":[
{
"type":"p",
"hlId":"5eab4c",
"children":[
"A 25-year-old woman is evaluated for a 6-month history of fatigue, joint pain, sun sensitivity, and pleuritic chest pain. Medications are an oral contraceptive pill and as-needed naproxen."
]
},
{
"type":"p",
"hlId":"1a56e7",
"children":[
"On physical examination, temperature is 38.2 °C (100.8 °F), blood pressure is 142/90 mm Hg, and pulse rate is 100/min. The fingers and wrist joints are tender, but there is no synovitis. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"49dd19",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 1.4 mg/dL (123.8 µmol/L); dipstick urinalysis shows 2+ blood, 3+ protein, positive leukocyte esterase, and no nitrites."
]
},
{
"type":"p",
"hlId":"57876a",
"children":[
"Urine microscopy is ",
{
"type":"figure-link",
"target":"mk19_a_np_mcq_f021",
"wrapId":"1",
"children":[
"shown"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_np_mcq_f021"
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"c5165c",
"children":[
"Which of the following is the most appropriate test?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Cystoscopy"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney biopsy"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney ultrasonography"
}
},
{
"letter":"D",
"text":{
"__html":"Urine culture"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ad1317",
"children":[
"Glomerular hematuria typically features dysmorphic erythrocytes (or acanthocytes) and/or erythrocyte casts on urine sediment examination and is associated with proteinuria."
]
},
{
"type":"keypoint",
"hlId":"2e41ad",
"children":[
"Undiagnosed glomerular hematuria is an indication for a kidney biopsy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a9b1ab",
"children":[
"The most appropriate test is kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient likely has glomerulonephritis. Glomerular hematuria typically features tea- or brown-colored urine with dysmorphic erythrocytes (or acanthocytes) and/or erythrocyte casts on urine sediment examination. Leukocyturia and leukocyte casts can be seen in patients, such as this one, with glomerulonephritis. Dysmorphic urinary erythrocytes are defined by their irregular (nonspherical) shape; acanthocytes are one type of dysmorphic erythrocyte. Erythrocyte casts are recognized by their cylindrical or tubular structure and inclusion of small, agranular spherocytes and, when present, are specific for hematuria of glomerular origin. Indications for kidney biopsy include glomerular hematuria, severely increased albuminuria, acute or chronic kidney disease of unclear cause (in the absence of atrophic kidneys), and kidney transplant dysfunction or monitoring. This patient with undiagnosed glomerular hematuria should have a kidney biopsy."
]
},
{
"type":"p",
"hlId":"d64a3a",
"children":[
"Cystoscopy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is indicated in the evaluation of gross or microscopic hematuria of nonglomerular origin. The presence of erythrocyte casts, proteinuria, and clinical features suggesting an underlying rheumatologic or autoimmune disease signifies glomerular bleeding and precludes the need for cystoscopy."
]
},
{
"type":"p",
"hlId":"4a452c",
"children":[
"Ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is the most commonly used kidney imaging modality. It is easily available, safe, and relatively inexpensive. Ultrasonography can demonstrate hydronephrosis, kidney size and cortical thickness, echogenicity, and presence of cysts and tumors. Absence of hydronephrosis quickly rules out obstruction in most cases. Echogenicity is the ability of a tissue to “bounce back” or return the ultrasound signal and is recognized as brighter shades on the sonogram image. Echogenicity is nonspecific but implies acute or chronic parenchymal disease. Ultrasonography is very useful in the evaluation of patients with undifferentiated acute kidney injury but is of limited usefulness in the evaluation of glomerulonephritis."
]
},
{
"type":"p",
"hlId":"da4a69",
"children":[
"Leukocyte esterase is an enzyme present in leukocytes. A positive test suggests pyuria (≥5 leukocytes/hpf). A positive nitrite test signifies the presence of gram-negative bacteria capable of converting urine nitrates into nitrites. Dipstick analysis for urinary tract infection is most helpful when both the leukocyte esterase and nitrite tests are concordant. This patient's microscopic urinalysis reveals pyuria and accounts for the positive leukocyte esterase test. In this case, pyuria would be an expected finding in a patient with the nephritic syndrome. A urine culture (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") therefore is not needed."
]
}
],
"relatedSection":"mk19_a_np_s1_4",
"objective":{
"__html":"Diagnose glomerulonephritis."
},
"references":[
[
"Willis GC, Tewelde SZ. The approach to the patient with hematuria. Emerg Med Clin North Am. 2019;37:755-769. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31563206",
"target":"_blank"
},
"children":[
"PMID: 31563206"
]
},
" doi:10.1016/j.emc.2019.07.011"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":83,
"C":6,
"D":10,
"E":0
},
"figuresContent":{
"mk19_a_np_mcq_f021":{
"id":"mk19_a_np_mcq_f021",
"number":21,
"bookId":"np",
"legend":"",
"footnotes":[

],
"imageInfo":{
"hash":"0a2ee7c6dcfe98014dc5181bd4c3279b",
"height":1199,
"width":900,
"extension":"jpg"
}
}
},
"hlIds":[
"5eab4c",
"1a56e7",
"49dd19",
"57876a",
"c5165c",
"ad1317",
"2e41ad",
"a9b1ab",
"d64a3a",
"4a452c",
"da4a69"
]
},
{
"id":"mk19_a_np_q022",
"number":22,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 22",
"stimulus":[
{
"type":"p",
"hlId":"91054a",
"class":"updated",
"children":[
"This question has been updated as a result of postpublication analysis and/or new data that are relevant to the question."
]
},
{
"type":"p",
"hlId":"ad9f4a",
"children":[
"A 42-year-old man is evaluated during a follow-up visit for recently confirmed primary hypertension. Hypertension was confirmed with multiple home blood pressure monitoring readings that averaged 148/98 mm Hg. Chlorthalidone was initiated 1 month ago, and home blood pressure monitoring showed readings above target despite adherence to lifestyle interventions and medication. He has no other medical problems and takes no other medication."
]
},
{
"type":"p",
"hlId":"c78a1f",
"children":[
"On physical examination, blood pressure is 144/94 mm Hg, and pulse rate is 72/min; other vital signs are normal. BMI is 22. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"3b7f87",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 1.0 mg/dL (88.4 µmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"serum potassium"
]
},
" level of 3.5 mEq/L (3.5 mmol/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Amlodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Doxazosin"
}
},
{
"letter":"C",
"text":{
"__html":"Hydralazine"
}
},
{
"letter":"D",
"text":{
"__html":"Metoprolol"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"d5297a",
"children":[
"Except for the combination of ACE inhibitors and angiotensin receptor blockers (ARBs), regimens containing a combination of thiazide diuretics, calcium channel blockers, ACE inhibitors, and ARBs are preferred to achieve blood pressure goals in patients requiring dual antihypertensive therapy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b35c49",
"children":[
"The most appropriate additional treatment is amlodipine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). In this patient, a blood pressure (BP) target <130/80 mm Hg is reasonable. Two or more antihypertensive medications are recommended to achieve a BP target of <130/80 mm Hg in most adults with hypertension. According to the American College of Cardiology/American Heart Association guideline, four drug classes (thiazide diuretics, CCBs, ACE inhibitors, or ARBs) lower BP and reduce cardiovascular or renal outcomes. Except for the combination of ACE inhibitors and ARBs, regimens containing a combination of these classes are reasonable to achieve the BP target."
]
},
{
"type":"p",
"hlId":"f08097",
"children":[
"Doxazosin, hydralazine, and metoprolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B-D"
]
},
") are not recommended drugs for either initial therapy or as add-on therapy in patients with hypertension without the presence of compelling indications. Doxazosin might be considered in male patients with bothersome lower urinary symptoms due to benign prostatic hyperplasia; hydralazine and metoprolol in selected patients with heart failure; or metoprolol in patients with a recent myocardial infarction. None of these indications is present in this patient."
]
}
],
"relatedSection":"mk19_a_np_s4_7_2_3_4",
"objective":{
"__html":"Treat hypertension in a patient who is unresponsive to initial therapy."
},
"references":[
[
"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29146535",
"target":"_blank"
},
"children":[
"PMID: 29146535"
]
},
" doi:10.1016/j.jacc.2017.11.006"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":87,
"B":0,
"C":6,
"D":7,
"E":0
},
"hlIds":[
"91054a",
"ad9f4a",
"c78a1f",
"3b7f87",
"78ff87",
"d5297a",
"b35c49",
"f08097"
]
},
{
"id":"mk19_a_np_q023",
"number":23,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 23",
"stimulus":[
{
"type":"p",
"hlId":"89fba7",
"children":[
"A 73-year-old woman is evaluated during a follow-up visit for stage G4 chronic kidney disease. She reports no uremic symptoms. Medical history is also significant for hypertension. Medications are atenolol, chlorthalidone, cholecalciferol, hydralazine, and nifedipine."
]
},
{
"type":"p",
"hlId":"9ce0f2",
"children":[
"The physical examination, including vital signs, is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a8b027",
"class":"cell text l",
"children":[
"8.7 mg/dL (2.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2bfd48",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"39ae6a",
"class":"cell text l",
"children":[
"5.4 mg/dL (1.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"ca2815",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Parathyroid hormone, serum",
"children":[
"Parathyroid hormone"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"02008f",
"class":"cell text l",
"children":[
"97 pg/mL (97 ng/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3370f5",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Vitamin D",
"children":[
"25-hydroxyvitamin D"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"30f099",
"class":"cell text l",
"children":[
"60 ng/mL (150 nmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"20d29c",
"class":"cell text l",
"children":[
"24 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Calcitriol"
}
},
{
"letter":"B",
"text":{
"__html":"Calcium acetate"
}
},
{
"letter":"C",
"text":{
"__html":"Cinacalcet"
}
},
{
"letter":"D",
"text":{
"__html":"Low phosphate diet"
}
},
{
"letter":"E",
"text":{
"__html":"Sevelamer"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7c1e2f",
"hvc":true,
"children":[
"In patients with chronic kidney disease and hyperphosphatemia, the initial step in management is a low phosphate diet."
]
},
{
"type":"keypoint",
"hlId":"15846f",
"hvc":true,
"children":[
"In patients with chronic kidney disease who remain hyperphosphatemic following dietary optimization, the next step is addition of a phosphate binder."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"7a14f7",
"children":[
"The most appropriate management is dietary restriction of phosphorus through a low phosphate diet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). As kidney function declines, the normal homeostasis of calcium and phosphorus levels by the kidney becomes compromised, resulting in alterations in bone mineralization. The term chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses these changes. Parathyroid hormone (PTH) is the most important regulator of calcium and phosphorus concentrations. PTH stimulates osteoclasts to resorb bone, stimulates hydroxylation of 25-hydroxyvitamin D in the kidneys, and stimulates tubular reabsorption of calcium and induces renal phosphorus excretion. As CKD progresses, rising fibroblast growth factor 23 levels inhibit the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, resulting in lower intestinal absorption of calcium and phosphorus in the gut, contributing to hypocalcemia. Hypocalcemia is a potent stimulus for further increases in PTH levels. Increased PTH levels result in reduced calcium excretion, increased calcium absorption from the gut, increased phosphorus excretion by the kidneys, and activation of osteoclast bone resorption. As CKD progresses, the kidney is unable to compensate for the increased release of phosphorus from bone, and phosphorus levels rise. Disordered calcium and phosphate metabolism lead to several adverse pathologic effects, including vascular calcification, increased risk for cardiovascular events, and the altered-bone physiology of renal osteodystrophy. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that, in patients with CKD stages G3a to G5, elevated phosphorus levels should be lowered toward the normal range. Treatment options include dietary modifications (phosphorus restriction) alone or in combination with the administration of phosphate binders."
]
},
{
"type":"p",
"hlId":"3cf2df",
"children":[
"KDIGO guidelines recommend against the use of activated vitamin D analogues such as calcitriol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") in non-dialysis–dependent patients with CKD to avoid the risk of calcium overload; therefore, calcitriol should be avoided in this non-dialysis–dependent patient. These agents are routinely used in dialysis-dependent patients with end-stage kidney disease as CKD-MBD worsens."
]
},
{
"type":"p",
"hlId":"2eafcf",
"children":[
"For patients who remain hyperphosphatemic following dietary optimization, the next step is addition of a phosphate binder. The choice of a phosphate binder, calcium- or non-calcium–based, must be individualized for each patient. Calcium-based binders include calcium carbonate and calcium acetate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"); non-calcium–based binders include sevelamer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") and lanthanum. However, data are lacking to guide clinicians in choosing calcium-based binders."
]
},
{
"type":"p",
"hlId":"323cbc",
"children":[
"Cinacalcet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a calcimimetic that decreases PTH levels, is FDA approved for use in patients who are undergoing dialysis but not for use in patients with CKD."
]
}
],
"relatedSection":"mk19_a_np_s12_6_2_5",
"objective":{
"__html":"Manage hyperphosphatemia in chronic kidney disease-mineral and bone disorder."
},
"references":[
[
"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59."
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":10,
"B":10,
"C":5,
"D":34,
"E":42
},
"hlIds":[
"89fba7",
"9ce0f2",
"a462a3",
"1a4da4",
"a8b027",
"f461b2",
"2bfd48",
"a4922e",
"39ae6a",
"ca2815",
"02008f",
"3370f5",
"30f099",
"77db81",
"20d29c",
"cb2b54",
"7c1e2f",
"15846f",
"7a14f7",
"3cf2df",
"2eafcf",
"323cbc"
]
},
{
"id":"mk19_a_np_q024",
"number":24,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 24",
"stimulus":[
{
"type":"p",
"hlId":"46b925",
"children":[
"A 35-year-old man is evaluated during a follow-up visit for an elevated serum creatinine level. The elevated serum creatinine was discovered during a recent hospitalization for cellulitis of the right lower leg that was treated with intravenous cephazolin followed by oral cephalexin for a total of 7 days of antibiotic therapy. He is a migratory agricultural worker. He works in the northeastern United States during summer months and returns to Guatemala for the remainder of the year performing similar work. The patient has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"de72b4",
"children":[
"On physical examination, blood pressure is 138/90 mm Hg; other vital signs are normal. BMI is 27. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2bfd48",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"167259",
"class":"cell text l",
"children":[
"140 mEq/L (140 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a94844",
"class":"cell text l",
"children":[
"5.0 mEq/L (5.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"627ee2",
"class":"cell text l",
"children":[
"112 mEq/L (112 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"623643",
"class":"cell text l",
"children":[
"Specific gravity 1.015; pH 6.5; no blood; 1+ protein; 1+ leukocytes; 2-5 leukocytes/hpf; 0-2 erythrocytes/hpf; no casts"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b5217d",
"class":"cell text l",
"children":[
"400 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"353c4e",
"children":[
"Kidney ultrasound shows a 9.9-cm right kidney and a 10.3-cm left kidney with increased cortical echogenicity and mild thinning; there is no hydronephrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acute interstitial nephritis"
}
},
{
"letter":"B",
"text":{
"__html":"Acute tubular necrosis"
}
},
{
"letter":"C",
"text":{
"__html":"Chronic interstitial nephritis"
}
},
{
"letter":"D",
"text":{
"__html":"IgA nephropathy"
}
},
{
"letter":"E",
"text":{
"__html":"Infection-related glomerulonephritis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2aa09e",
"children":[
"Chronic interstitial nephritis in agricultural communities is most commonly observed in young- to middle-aged male agricultural workers and often progresses to end-stage kidney disease."
]
},
{
"type":"keypoint",
"hlId":"c7216e",
"children":[
"Patients with chronic interstitial nephritis in agricultural communities may be hypertensive, and urinalysis may be normal or demonstrate pyuria and low-grade proteinuria."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ff8432",
"children":[
"Chronic interstitial nephritis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is the most likely diagnosis. Chronic interstitial nephritis in agricultural communities (CINAC; also known as Mesoamerican nephropathy) is an emerging public health problem in many Central American and Asian countries. It is observed most commonly in young- to middle-aged male migratory agricultural workers and often progresses to end-stage kidney disease. This patient has many findings associated with chronic tubulointerstitial kidney disease. He is hypertensive and has a normal anion gap metabolic acidosis. Furthermore, his urinalysis demonstrates pyuria and low-grade proteinuria, and his kidney ultrasound shows nonspecific chronic kidney injury changes (increased cortical echogenicity and mild thinning). These findings, in the context of a patient who is a migratory agricultural worker in Central America, suggest that he has developed CINAC. Kidney biopsy may establish a definitive diagnosis."
]
},
{
"type":"p",
"hlId":"d8b342",
"children":[
"Acute interstitial nephritis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is characterized by urine sediment containing leukocytes and leukocyte casts, unlike this patient's relatively bland urine sediment."
]
},
{
"type":"p",
"hlId":"86feb9",
"children":[
"Although patients with acute bacterial infection may occasionally present with acute tubular necrosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), these patients typically have features of a systemic inflammatory response syndrome at the time of presentation and urine sediment showing granular casts."
]
},
{
"type":"p",
"hlId":"520ea4",
"children":[
"IgA nephropathy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a chronic glomerular disease typically characterized by microhematuria and occasional episodes of gross hematuria. This patient has a chronic tubulointerstitial disorder, not a glomerular disorder."
]
},
{
"type":"p",
"hlId":"1ee879",
"children":[
"Infection-related glomerulonephritis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"), which may be seen concurrent with or following cellulitis, is accompanied by erythrocytes and erythrocyte casts in the urine sediment and often resolves after the acute infection resolves."
]
}
],
"relatedSection":"mk19_a_np_s5_3_7",
"objective":{
"__html":"Diagnose chronic interstitial nephritis in agricultural communities."
},
"references":[
[
"Orantes-Navarro CM, Herrera-Valdés R, Almaguer-López M, et al. Toward a comprehensive hypothesis of chronic interstitial nephritis in agricultural communities. Adv Chronic Kidney Dis. 2017;24:101-106. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28284375",
"target":"_blank"
},
"children":[
"PMID: 28284375"
]
},
" doi:10.1053/j.ackd.2017.01.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":38,
"B":3,
"C":29,
"D":12,
"E":18
},
"hlIds":[
"46b925",
"de72b4",
"a462a3",
"f461b2",
"2bfd48",
"89662a",
"d41d8c",
"b99276",
"167259",
"e92687",
"a94844",
"a207b1",
"627ee2",
"6827e3",
"653d7c",
"747c2a",
"623643",
"d17af8",
"b5217d",
"353c4e",
"413696",
"2aa09e",
"c7216e",
"ff8432",
"d8b342",
"86feb9",
"520ea4",
"1ee879"
]
},
{
"id":"mk19_a_np_q025",
"number":25,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 25",
"stimulus":[
{
"type":"p",
"hlId":"8d40a9",
"children":[
"A 48-year-old woman is evaluated in the ICU for increasing serum creatinine and oliguria; she has cirrhosis. She was hospitalized 24 hours ago and treated for a bleeding esophageal varix. Outpatient medications are furosemide, spironolactone, nadolol, and norfloxacin. On admission, her ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level was 1.5 mg/dL (132.6 µmol/L)."
]
},
{
"type":"p",
"hlId":"608197",
"children":[
"On physical examination, blood pressure is 102/63 mm Hg, and pulse rate is 66/min; other vital signs are normal. Ascites and jaundice are present. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"69e4d1",
"children":[
"Urine output is 190 mL over the past 24 hours."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d12432",
"children":[
"Current laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"846f94",
"class":"cell text l",
"children":[
"2.3 g/dL (23 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e6438c",
"class":"cell text l",
"children":[
"2.3 mg/dL (203.3 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9eaf68",
"class":"cell text l",
"children":[
"Electrolytes:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"178a22",
"class":"cell text l",
"children":[
"126 mEq/L (126 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"841805",
"class":"cell text l",
"children":[
"3.9 mEq/L (3.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d4cfef",
"class":"cell text l",
"children":[
"95 mEq/L (95 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"feec07",
"class":"cell text l",
"children":[
"<10 mEq/L (10 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fffa58",
"class":"cell text l",
"children":[
"Specific gravity 1.030; pH 5.0; trace protein; 2+ bilirubin; bilirubin staining; no erythrocytes or leukocytes"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"f6a227",
"children":[
"Kidney ultrasound shows normal-appearing kidneys without hydronephrosis."
]
},
{
"type":"p",
"hlId":"cf99fa",
"children":[
"Diuretics are withheld, and norepinephrine infusion is initiated."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hemodialysis"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous albumin"
}
},
{
"letter":"C",
"text":{
"__html":"Oral midodrine and intravenous octreotide"
}
},
{
"letter":"D",
"text":{
"__html":"Transjugular intrahepatic portosystemic shunt"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0eaef6",
"children":[
"Type 1 hepatorenal syndrome is characterized by an increase in the serum creatinine level of at least 0.3 mg/dL (26.5 µmol/L) and/or ≥50% from baseline within 48 hours; bland urinalysis; and normal findings on kidney ultrasound."
]
},
{
"type":"keypoint",
"hlId":"97f416",
"children":[
"Treatment of type 1 hepatorenal syndrome includes vasoconstrictors and intravenous albumin."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"3a96f7",
"children":[
"The most appropriate additional treatment is intravenous albumin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient exhibits acute kidney injury (AKI) in the context of advanced cirrhosis. At this stage in her hospitalization, it is uncertain if she could have prerenal AKI, acute tubular necrosis, or hepatorenal syndrome (HRS). Type 1 HRS is a clinical diagnosis made after exclusion of other causes of kidney dysfunction. It is characterized by an increase in the serum creatinine level of at least 0.3 mg/dL (26.5 µmol/L) and/or ≥50% from baseline within 48 hours; bland urinalysis; and normal findings on kidney ultrasound. It is also supported by a lack of improvement in kidney function after withdrawal of diuretics and 2 days of volume expansion with intravenous albumin. Often, patients also have low urine sodium, low fractional excretion of sodium, and oliguria. Type 2 HRS is defined as a more gradual decline in kidney function associated with refractory ascites. General management includes discontinuing diuretics, restricting sodium, restricting water in hyponatremic patients, and searching for precipitating factors. Therapeutic interventions include treatment with vasoconstrictors and albumin."
]
},
{
"type":"p",
"hlId":"1a504f",
"children":[
"Patients with HRS have an overall poor prognosis without liver transplantation. Hemodialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is typically not the best therapeutic option unless the patient is a liver transplant candidate."
]
},
{
"type":"p",
"hlId":"227545",
"children":[
"Treatment of hepatorenal syndrome may also include the vasoconstrictors midodrine and octreotide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") along with intravenous albumin to raise mean arterial pressure and improve kidney perfusion. However, midodrine and octreotide are not necessary in a patient such as this one who is receiving intravenous norepinephrine."
]
},
{
"type":"p",
"hlId":"07c7c9",
"children":[
"Although transjugular intrahepatic portosystemic shunt (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is an effective therapy for some cases of refractory HRS, it is an invasive therapy with numerous potential complications that should not preempt the administration of albumin."
]
}
],
"relatedSection":"mk19_a_np_s9_6_3",
"objective":{
"__html":"Treat hepatorenal syndrome."
},
"references":[
[
"Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9:CD013103. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31513287",
"target":"_blank"
},
"children":[
"PMID: 31513287"
]
},
" doi:10.1002/14651858.CD013103.pub2"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":4,
"B":57,
"C":25,
"D":14,
"E":0
},
"hlIds":[
"8d40a9",
"608197",
"69e4d1",
"d12432",
"4590ed",
"846f94",
"f461b2",
"e6438c",
"9eaf68",
"d41d8c",
"b99276",
"178a22",
"e92687",
"841805",
"a207b1",
"d4cfef",
"6827e3",
"653d7c",
"e331de",
"feec07",
"747c2a",
"fffa58",
"f6a227",
"cf99fa",
"78ff87",
"0eaef6",
"97f416",
"3a96f7",
"1a504f",
"227545",
"07c7c9"
]
},
{
"id":"mk19_a_np_q026",
"number":26,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 26",
"stimulus":[
{
"type":"p",
"hlId":"ecfa00",
"children":[
"A 43-year-old man is evaluated during a routine follow-up visit for end-stage kidney disease due to IgA nephropathy. He received a living-donor related kidney transplant 5 years ago. He is asymptomatic. Medical history is also significant for hypertension. Medications are prednisone, mycophenolate mofetil, tacrolimus, lisinopril, metoprolol, and atorvastatin."
]
},
{
"type":"p",
"hlId":"cb6bca",
"children":[
"All physical examination findings, including vital signs, are normal."
]
},
{
"type":"p",
"hlId":"73f197",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.8 mg/dL (70.7 µmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"fasting blood glucose"
]
},
" level of 99 mg/dL (5.5 mmol/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"f5e940",
"children":[
"Which of the following is the most appropriate screening test at this time?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Colonoscopy"
}
},
{
"letter":"B",
"text":{
"__html":"Low-dose chest CT"
}
},
{
"letter":"C",
"text":{
"__html":"Oral glucose tolerance test"
}
},
{
"letter":"D",
"text":{
"__html":"Skin examination"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"5e3a3c",
"children":[
"Kidney transplant recipients are at increased risk for multiple types of skin cancer and should undergo annual skin examination."
]
},
{
"type":"keypoint",
"hlId":"88186a",
"children":[
"Although patients on immunosuppressive medications are at increased risk for various cancers, screening for non-skin cancers should follow guidelines for the general population."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"974797",
"children":[
"The most appropriate screening test to perform next is a skin examination (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient, who is at increased risk for multiple types of skin cancer, should be referred to a dermatologist or a clinician with special expertise for annual screening; screening frequency is increased for patients who have a history of skin cancer. Kidney transplant recipients are at increased risk for various complications due to their original underlying end-stage kidney disease and the use of chronic immunosuppressive medications, which may be related to risks for altered immune surveillance or idiosyncratic medication side effects. Kidney transplant recipients are at increased risk for several other malignancies, including renal cell carcinoma, colon cancer, lung cancer, thyroid cancer, anogenital cancers, and posttransplant lymphoproliferative disease. These patients are also at increased risk for cardiovascular disease, and those treated with glucocorticoids, calcineurin inhibitors, and mTOR inhibitors are at increased risk for new-onset diabetes after transplant (NODAT)."
]
},
{
"type":"p",
"hlId":"11baa5",
"children":[
"The U.S. Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer in asymptomatic adults aged 50 to 75 years. The USPSTF supports using the test that is most likely to result in completion of screening. Options include colonoscopy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), flexible sigmoidoscopy, CT colonography, stool-based testing, and combination of stool-based testing and flexible sigmoidoscopy. This patient should be screened for colon cancer beginning at 50 years of age."
]
},
{
"type":"p",
"hlId":"7255ee",
"children":[
"A low-dose chest CT (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") to screen for lung cancer is not indicated. Although patients on immunosuppressive medications are at increased risk for various cancers, screening for non-skin cancers should follow guidelines for the general population. The criteria for screening include those who are aged 55 to 74-80 years (guidelines differ on ages to discontinue screening), have at least a 30-pack-year smoking history, and are current smokers or have quit within the last 15 years."
]
},
{
"type":"p",
"hlId":"08e9be",
"children":[
"Kidney transplant recipients are at risk for NODAT. Posttransplant fasting glucose and symptoms should be monitored. Fasting glucose is monitored more frequently in the first year after transplant and then annually in the absence of symptoms to suggest hyperglycemia. The diagnosis of NODAT is made based on the same criteria as that for the general population. An oral glucose tolerance test (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated for this patient with a normal fasting blood glucose."
]
}
],
"relatedSection":"mk19_a_np_s12_9_2_3_2",
"objective":{
"__html":"Screen for skin cancer in a kidney transplant recipient."
},
"references":[
[
"Voora S, Adey DB. Management of kidney transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73:866-879. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30981567",
"target":"_blank"
},
"children":[
"PMID: 30981567"
]
},
" doi:10.1053/j.ajkd.2019.01.031"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":6,
"B":5,
"C":24,
"D":65,
"E":0
},
"hlIds":[
"ecfa00",
"cb6bca",
"73f197",
"f5e940",
"5e3a3c",
"88186a",
"974797",
"11baa5",
"7255ee",
"08e9be"
]
},
{
"id":"mk19_a_np_q027",
"number":27,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 27",
"stimulus":[
{
"type":"p",
"hlId":"c2436d",
"children":[
"A 43-year-old man is evaluated during a follow-up visit for a recent biopsy-confirmed diagnosis of IgA nephropathy. He is asymptomatic. He has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"96790f",
"class":"cell text l",
"children":[
"4.0 g/dL (40 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9db8fb",
"class":"cell text l",
"children":[
"0.95 mg/dL (84 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"98ac4a",
"class":"cell text l",
"children":[
"3+ blood; 2+ protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b01639",
"class":"cell text l",
"children":[
"24-Hour urine protein excretion"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fd7572",
"class":"cell text l",
"children":[
"725 mg/24 h"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Lisinopril"
}
},
{
"letter":"B",
"text":{
"__html":"Mycophenolate mofetil"
}
},
{
"letter":"C",
"text":{
"__html":"Omega-3 fatty acids"
}
},
{
"letter":"D",
"text":{
"__html":"Prednisone"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0aa465",
"children":[
"First-line therapy for IgA nephropathy is either an ACE inhibitor or an angiotensin receptor blocker."
]
},
{
"type":"keypoint",
"hlId":"91cfa6",
"children":[
"Treatment of IgA nephropathy with high-dose glucocorticoids is associated with an increased risk for adverse events and may not improve kidney function."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"001cf5",
"children":[
"First-line therapy for IgA nephropathy (IgAN) is initiation of antiproteinuric therapy with blockade of the renin-angiotensin system using either an ACE inhibitor, such as lisinopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), or an angiotensin receptor blocker (ARB) and is the most appropriate management for this patient. In patients with proteinuria, treatment with ACE inhibitors or ARBs lowers intraglomerular pressure resulting in decreased protein excretion and often slows the rate of declining kidney function. Acute decline in glomerular filtration rate and hyperkalemia are well-recognized potential adverse effects of these drugs, mandating monitoring of serum creatinine and potassium levels. Antiproteinuric therapy is usually coupled with lipid-lowering therapy and fish oil, although the efficacy of the latter two as specific IgAN therapies is unproven."
]
},
{
"type":"p",
"hlId":"6afb63",
"children":[
"Mycophenolate mofetil (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is reserved as a second- or third-line therapy for patients with IgAN who decline despite glucocorticoid or other immunosuppression. This treatment has only shown benefit in patients of Asian descent."
]
},
{
"type":"p",
"hlId":"608e3c",
"children":[
"Despite its purported anti-inflammatory properties, the benefit of treating IgAN with omega-3 fatty acids (fish oil) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is unclear. Because of its safety, it can be used in conjunction with other therapies but should not be the exclusive treatment of IgAN."
]
},
{
"type":"p",
"hlId":"19ade3",
"children":[
"Immunosuppressive therapy, such as prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), would not be used for this patient. Although two thirds of patients with IgAN will have progressive loss of kidney function, the use of immunosuppressive therapy remains controversial. Small studies have shown that a 6-month course of prednisone reduces proteinuria and slows decline in glomerular filtration rate in patients with IgAN and >1000 mg/24 h proteinuria despite maximal therapy with an ACE inhibitor or ARB. However, two large randomized controlled trials (STOP-IgAN and TESTING) called into question this management. The STOP-IgAN study showed no difference in changes in kidney function between those patients with IgAN treated with or without immunosuppression over a 3-year period. The TESTING study was terminated early due to significantly higher rates of adverse events in patients with IgAN who were treated with prednisone. As a result, treatment efficacy could not be determined. Because this patient has not yet been treated with an ACE inhibitor or ARB, consideration of immunosuppressive therapy with prednisone is premature."
]
}
],
"relatedSection":"mk19_a_np_s6_4_4_1_4",
"objective":{
"__html":"Treat IgA nephropathy with blockade of the renin-angiotensin system."
},
"references":[
[
"Barratt J, Tang SCW. Treatment of IgA nephropathy: evolution over half a century. Semin Nephrol. 2018;38:531-540. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30177025",
"target":"_blank"
},
"children":[
"PMID: 30177025"
]
},
" doi:10.1016/j.semnephrol.2018.05.023"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":66,
"B":6,
"C":6,
"D":23,
"E":0
},
"hlIds":[
"c2436d",
"f8786b",
"a462a3",
"4590ed",
"96790f",
"f461b2",
"9db8fb",
"747c2a",
"98ac4a",
"b01639",
"fd7572",
"cb2b54",
"0aa465",
"91cfa6",
"001cf5",
"6afb63",
"608e3c",
"19ade3"
]
},
{
"id":"mk19_a_np_q028",
"number":28,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 28",
"stimulus":[
{
"type":"p",
"hlId":"91e5dd",
"children":[
"A 22-year-old woman participating in a marathon is evaluated in the medical tent for headache, confusion, and disorientation after she stopped running at mile 20. This is her first marathon."
]
},
{
"type":"p",
"hlId":"3439e3",
"children":[
"On physical examination, temperature is 38.0 °C (100.4 °F), blood pressure is 110/72 mm Hg, pulse rate is 110/min, and respiration rate is 20/min. The patient is confused. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"084287",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"serum sodium"
]
},
" level of 130 mEq/L (130 mmol/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Fluid restriction"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous 0.9% saline"
}
},
{
"letter":"C",
"text":{
"__html":"100-mL bolus of 3% saline"
}
},
{
"letter":"D",
"text":{
"__html":"No treatment"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"1b56f2",
"children":[
"Acute hyponatremia developing in less than 48 hours can cause headaches, seizures, or death."
]
},
{
"type":"keypoint",
"hlId":"6f9271",
"children":[
"Acute hyponatremia should be treated with a 100-mL bolus of 3% saline."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"f19cd0",
"children":[
"The most appropriate management is a 100-mL bolus of 3% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Symptoms caused by hyponatremia depend on both the rapidity and degree of decline in serum sodium. A sudden drop in serum sodium causes water to move into the brain, producing cerebral edema and possibly causing headaches, seizures, or death. Hyponatremia has been reported in inexperienced marathon runners who overhydrate. A systematic study of hyponatremia in runners finishing a marathon revealed that 13% had a serum sodium concentration of ≤135 mEq/L (135 mmol/L) and 0.6% had critical hyponatremia of ≤120 mEq/L (120 mmol/L). Hyponatremia was associated with consumption of more than 3 liters of fluids during the race, consumption of fluids every mile, and a racing time of more than 4 hours, which is a possible indication of less training. Female runners remain a readily identifiable risk group in many studies, but this may represent the impact of body size and longer racing time rather than the sex of the athlete. The other major factor causing hyponatremia in endurance athletes is persistent secretion of antidiuretic hormone (ADH). Because hyponatremia is not uncommon with extreme exercise and overhydration, it is important that medical personnel are able to measure sodium rapidly. If the patient's sodium cannot be measured, treatment should be held until the patient can be transported to a facility where sodium measurements can be made. Individuals with severe symptoms (e.g., confusion, coma, seizures) secondary to acute hyponatremia should be treated with a 100-mL bolus of 3% saline. If symptoms do not improve and the sodium remains low, an additional bolus can be given."
]
},
{
"type":"p",
"hlId":"362c2c",
"children":[
"Although fluid restriction (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") may allow for correction of serum sodium in persons with minimal symptoms, it should never be the sole treatment when severe symptoms such as confusion are present, as they are in this patient."
]
},
{
"type":"p",
"hlId":"c733ac",
"children":[
"Intravenous 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") should not be administered in this patient. If her ADH levels are extremely elevated, her urine osmolality will exceed the osmolality of normal saline. Intravenous 0.9% saline could potentially lower the patient's sodium further. The use of 0.9% saline should be limited to those patients with evidence of volume depletion and minimal symptoms."
]
},
{
"type":"p",
"hlId":"70faed",
"children":[
"It is inappropriate to not treat this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient's serum sodium is 130 mEq/L (130 mmol/L), and serious neurologic symptoms may occur when the sodium decreases acutely to <132 mEq/L (132 mmol/L). Therefore, this patient needs prompt treatment."
]
}
],
"relatedSection":"mk19_a_np_s2_2_1_2",
"objective":{
"__html":"Treat acute hyponatremia."
},
"references":[
[
"Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28:1340-1349. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28174217",
"target":"_blank"
},
"children":[
"PMID: 28174217"
]
},
" doi:10.1681/ASN.2016101139"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":4,
"B":60,
"C":36,
"D":1,
"E":0
},
"hlIds":[
"91e5dd",
"3439e3",
"084287",
"cb2b54",
"1b56f2",
"6f9271",
"f19cd0",
"362c2c",
"c733ac",
"70faed"
]
},
{
"id":"mk19_a_np_q029",
"number":29,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 29",
"stimulus":[
{
"type":"p",
"hlId":"bdc300",
"children":[
"A 54-year-old man is evaluated during a new patient visit. He has a 30-year history of type 2 diabetes mellitus and 10-year history of hypertension. Medical history is also significant for obesity and hypercholesterolemia. Medications are amlodipine, atorvastatin, canagliflozin, metformin, and lisinopril-hydrochlorothiazide. At his last visit to his previous physician, ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level was 1.4 mg/dL (123.8 µmol/L), and ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" was 58 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"c537d5",
"children":[
"On physical examination, blood pressure is 158/82 mm Hg, and pulse rate is 62/min; other vital signs are normal. BMI is 38. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1f0320",
"class":"cell text l",
"children":[
"3.5 g/dL (35 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"06bcde",
"class":"cell text l",
"children":[
"Electrolytes"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ce4c56",
"class":"cell text l",
"children":[
"50 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"bd78e9",
"class":"cell text l",
"children":[
"No blood; 2+ protein"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"c88264",
"children":[
"Results of kidney ultrasonography and referral to an ophthalmologist for a dilated retinal examination are pending."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"2a5978",
"children":[
"Which of the following is the most appropriate test to assess the prognosis of this patient's chronic kidney disease?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hemoglobin A<sub>1c</sub> measurement"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney biopsy"
}
},
{
"letter":"C",
"text":{
"__html":"Serum parathyroid hormone measurement"
}
},
{
"letter":"D",
"text":{
"__html":"Spot urine albumin-creatinine ratio"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a5ff77",
"children":[
"Chronic kidney disease is defined as abnormal kidney structure or function present for >3 months."
]
},
{
"type":"keypoint",
"hlId":"a8c014",
"children":[
"In patients with chronic kidney disease, albuminuria is associated with increased renal and cardiovascular morbidity and mortality."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"253cae",
"children":[
"The most appropriate test to help diagnose the cause and assess the prognosis of this patient's chronic kidney disease (CKD) is a spot urine albumin-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). CKD is defined as abnormal kidney structure or function present for >3 months. CKD is stratified into stages 1 to 5 based on the level of estimated glomerular filtration rate (eGFR). Because albuminuria is associated with increased renal and cardiovascular morbidity and mortality, eGFR-based kidney stages are modified by the degree of albuminuria. This dual eGFR and albuminuria-staging matrix provides a means for predicting which patients are at highest risk for developing end-stage kidney disease. This patient has CKD confirmed by a persistently low eGFR for at least 6 months. A spot urine albumin-creatinine ratio should be obtained to determine the degree of proteinuria. In addition to prognostication, this test will help categorize his CKD as nephrotic or non-nephrotic, which will inform diagnostic testing."
]
},
{
"type":"p",
"hlId":"e4f926",
"children":[
"Controlling hyperglycemia in patients with diabetes mellitus will slow the progression of CKD. Although a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" measurement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is important in the management of diabetes, it is not the most appropriate test to determine the cause and prognosis of CKD."
]
},
{
"type":"p",
"hlId":"35fbd8",
"children":[
"Kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is used to determine the cause of CKD when a glomerulonephritis or unexplained tubulointerstitial disease is likely. Kidney biopsy is not indicated in the presence of shrunken kidneys (<9 cm), which generally indicate chronic irreversible disease. Consideration of a kidney biopsy is premature for this patient, pending results of kidney ultrasonography, urine albumin-creatinine ratio, and ophthalmology examination. If retinopathy is confirmed by a dilated retinal examination and the patient has albuminuria, the most likely diagnosis in this patient with long-standing diabetes is diabetic kidney disease."
]
},
{
"type":"p",
"hlId":"833d3b",
"children":[
"Serum parathyroid hormone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), calcium, phosphorus, and 25-hydroxyvitamin D levels are indicated for management of CKD-mineral and bone disorder. Although these laboratory studies are indicated for all patients with CKD, they are not used as tests to help determine the prognosis of CKD."
]
}
],
"relatedSection":"mk19_a_np_s12_5",
"objective":{
"__html":"Evaluate chronic kidney disease."
},
"references":[
[
"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294-1304. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31573641",
"target":"_blank"
},
"children":[
"PMID: 31573641"
]
},
" doi:10.1001/jama.2019.14745"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":17,
"B":6,
"C":0,
"D":77,
"E":0
},
"hlIds":[
"bdc300",
"c537d5",
"a462a3",
"4590ed",
"1f0320",
"f461b2",
"3a34ea",
"06bcde",
"960b44",
"77db81",
"ce4c56",
"747c2a",
"bd78e9",
"c88264",
"2a5978",
"a5ff77",
"a8c014",
"253cae",
"e4f926",
"35fbd8",
"833d3b"
]
},
{
"id":"mk19_a_np_q030",
"number":30,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 30",
"stimulus":[
{
"type":"p",
"hlId":"b97562",
"children":[
"A 62-year-old man is evaluated in the emergency department for abrupt onset of sharp chest pain radiating to his upper back that started 90 minutes ago. Medical history includes difficult-to-control hypertension, hyperlipidemia, and type 2 diabetes mellitus. Medications are metformin, empagliflozin, rosuvastatin, amlodipine, hydrochlorothiazide, and lisinopril."
]
},
{
"type":"p",
"hlId":"0acd43",
"children":[
"On physical examination, blood pressure is 210/120 mm Hg in the right arm and 180/100 mm Hg in the left arm, pulse rate is 118/min, respiration rate is 20/min, and ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"oxygen saturation"
]
},
" is 97% with the patient breathing ambient air. The patient is diaphoretic and in distress. Cardiac examination reveals tachycardia with a 3/6 diastolic murmur heard along the upper left sternal border. Lungs are clear to auscultation. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"493c87",
"children":[
"Emergency CT imaging confirms the diagnosis of ascending aortic dissection."
]
},
{
"type":"p",
"hlId":"9d63eb",
"children":[
"Referral for emergency surgical consultation is obtained."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78e525",
"children":[
"Which of the following is the most appropriate initial intravenous treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Esmolol"
}
},
{
"letter":"B",
"text":{
"__html":"Hydralazine"
}
},
{
"letter":"C",
"text":{
"__html":"Nicardipine"
}
},
{
"letter":"D",
"text":{
"__html":"Nitroprusside"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"95cffd",
"children":[
"Intravenous short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-selective adrenergic receptor blockers are an initial first-line treatment to rapidly lower blood pressure in patients with hypertensive emergency and aortic dissection."
]
},
{
"type":"keypoint",
"hlId":"b7ca86",
"children":[
"In adults with a compelling condition (such as aortic dissection, severe preeclampsia or eclampsia, or pheochromocytoma crisis), systolic blood pressure should be reduced to <140 mm Hg during the first hour and to <120 mm Hg in aortic dissection."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a5e9f4",
"children":[
"The most appropriate initial treatment is to administer intravenous (IV) esmolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has a hypertensive emergency with a type A aortic dissection involving the ascending aorta. For hypertensive emergency with evidence of end-organ damage, blood pressure (BP) should be rapidly lowered using IV short-acting agents. Esmolol is a β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-selective adrenergic receptor blocker with a 1- to 2-minute onset of action. Esmolol can rapidly reduce heart rate and BP, thereby reducing aortic wall sheer stress and limiting the propagation of the dissection. The 2017 American College of Cardiology/American Heart Association BP guideline recommends that for adults with a compelling condition (such as aortic dissection, severe preeclampsia or eclampsia, or pheochromocytoma crisis), systolic BP should be reduced to <140 mm Hg during the first hour and to <120 mm Hg in aortic dissection. Referral for emergency surgery should be considered in all patients with type A aortic dissection given the very high mortality rate associated with this condition."
]
},
{
"type":"p",
"hlId":"c5894e",
"children":[
"Hydralazine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") can increase myocardial contractility and is not the first-line treatment in this case."
]
},
{
"type":"p",
"hlId":"28a066",
"children":[
"Treatment with an IV rapidly acting calcium channel blocker such as nicardipine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") or with a vasodilator such as nitroprusside (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") should not be initiated before β-blockade. In the absence of β–blockade, vasodilator therapy induces reflex activation of the sympathetic nervous system, resulting in tachycardia and enhanced ventricular contraction, which increases aortic wall sheer stress. Following effective β-blockade, vasodilator therapy can be initiated to reduce the systolic BP to <120 mm Hg."
]
}
],
"relatedSection":"mk19_a_np_s4_13",
"objective":{
"__html":"Treat a hypertensive emergency with aortic dissection."
},
"references":[
[
"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29146535",
"target":"_blank"
},
"children":[
"PMID: 29146535"
]
},
" doi:10.1016/j.jacc.2017.11.006."
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":67,
"B":1,
"C":11,
"D":20,
"E":0
},
"hlIds":[
"b97562",
"0acd43",
"493c87",
"9d63eb",
"78e525",
"95cffd",
"b7ca86",
"a5e9f4",
"c5894e",
"28a066"
]
},
{
"id":"mk19_a_np_q031",
"number":31,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 31",
"stimulus":[
{
"type":"p",
"hlId":"42c7c5",
"children":[
"A 65-year-old man is evaluated for fatigue and weakness progressing over the last 3 months. His medical history is otherwise unremarkable, and he takes no medications."
]
},
{
"type":"p",
"hlId":"6cbba7",
"children":[
"Findings on physical examination, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9d311a",
"class":"cell text l",
"children":[
"9 g/dL (90 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6d5102",
"class":"cell text l",
"children":[
"3.0 g/dL (30 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfe04",
"class":"cell text l",
"children":[
"0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5e0d7b",
"class":"cell text l",
"children":[
"3.4 mEq/L (3.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e88973",
"class":"cell text l",
"children":[
"118 mEq/L (118 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a84a64",
"class":"cell text l",
"children":[
"14 mEq/L (14 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d5ad00",
"class":"cell text l",
"children":[
"74 mg/dL (4.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7ec267",
"class":"cell text l",
"children":[
"2.1 mg/dL (0.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"386431",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Total, serum",
"children":[
"Total protein"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"752956",
"class":"cell text l",
"children":[
"8.0 g/dL (80 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d5dec0",
"class":"cell text l",
"children":[
"pH 5.0; no blood; no protein; no erythrocytes; 1+ leukocytes; trace glucose"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"33ebc7",
"children":[
"Which of the following is the most likely cause of this patient's laboratory findings?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bartter syndrome"
}
},
{
"letter":"B",
"text":{
"__html":"Liddle syndrome"
}
},
{
"letter":"C",
"text":{
"__html":"Type 1 (hypokalemic distal) renal tubular acidosis"
}
},
{
"letter":"D",
"text":{
"__html":"Type 2 (proximal) renal tubular acidosis"
}
},
{
"letter":"E",
"text":{
"__html":"Type 4 (hyperkalemic distal) renal tubular acidosis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"48941d",
"children":[
"Type 2 (proximal) renal tubular acidosis is characterized by a normal anion gap metabolic acidosis, hypokalemia, glycosuria (without hyperglycemia), low-molecular-weight proteinuria, and renal phosphate wasting."
]
},
{
"type":"keypoint",
"hlId":"f3745c",
"children":[
"Type 1 (hypokalemic distal) renal tubular acidosis is characterized by a normal anion gap metabolic acidosis, hypokalemia, urine pH >6.0, and calcium phosphate kidney stones."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"189fa5",
"children":[
"The most likely cause of this patient's laboratory findings is type 2 (proximal) renal tubular acidosis (RTA) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Type 2 RTA involves a proximal tubular defect in reclaiming bicarbonate and is characterized by a normal anion gap metabolic acidosis, hypokalemia, glycosuria (without hyperglycemia), low-molecular-weight proteinuria, and renal phosphate wasting (known as Fanconi syndrome when all features are present). Because distal urine acidification remains intact, the urine pH is usually <5.5 without alkali therapy, and the urine anion gap ([Urine Sodium + Urine Potassium] – Urine Chloride) would be negative, reflecting increased excretion of acid in the form of ammonium and chloride. This patient's normal anion gap metabolic acidosis, low urine pH, hypokalemia, and hypophosphatemia makes type 2 RTA most likely. Type 2 RTA in this case is likely due to multiple myeloma–associated light chain proximal tubulopathy. Multiple myeloma is suggested by the presence of anemia and high gamma globulin fraction (elevated total protein and low albumin concentrations)."
]
},
{
"type":"p",
"hlId":"3af83f",
"children":[
"Bartter syndrome (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") can cause hypokalemia and hypophosphatemia but is also associated with metabolic alkalosis and most often presents in childhood. Liddle syndrome (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") causes increased sodium reabsorption in the distal nephron with resulting hypertension, metabolic alkalosis, and potassium wasting. This patient has a normal anion gap metabolic acidosis, which excludes Bartter and Liddle syndromes."
]
},
{
"type":"p",
"hlId":"732b91",
"children":[
"Type 1 (hypokalemic distal) RTA (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is due to a defect in urine acidification in the distal nephron. Because of the inability to excrete hydrogen ions, patients develop a metabolic acidosis with compensatory hyperchloremia, resulting in a normal anion gap and the inability to acidify urine below a pH of 6.0; this patient's urine pH is 5.0. The urine anion gap is positive, reflecting decreased acid excretion in the form of ammonium and chloride. The same defects also cause potassium wasting, and the increased proximal resorption of citrate that occurs with metabolic acidosis leads to hypocitraturia and increased risk for calcium phosphate kidney stones and nephrocalcinosis."
]
},
{
"type":"p",
"hlId":"ef7175",
"children":[
"Type 4 (hyperkalemic distal) RTA (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") due to aldosterone deficiency or resistance is associated with a mild normal anion gap metabolic acidosis and hyperkalemia, which are not seen in this patient."
]
}
],
"relatedSection":"mk19_a_np_s3_2_3_1",
"objective":{
"__html":"Diagnose type 2 (proximal) renal tubular acidosis."
},
"references":[
[
"Rastegar M, Nagami GT. Non-anion gap metabolic acidosis: a clinical approach to evaluation. Am J Kidney Dis. 2017;69:296-301. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28029394",
"target":"_blank"
},
"children":[
"PMID: 28029394"
]
},
" doi:10.1053/j.ajkd.2016.09.013"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":7,
"B":3,
"C":39,
"D":48,
"E":4
},
"hlIds":[
"42c7c5",
"6cbba7",
"a462a3",
"f9867c",
"9d311a",
"4590ed",
"6d5102",
"f461b2",
"9bfe04",
"89662a",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"5e0d7b",
"a207b1",
"e88973",
"6827e3",
"a84a64",
"847136",
"d5ad00",
"a4922e",
"7ec267",
"386431",
"752956",
"747c2a",
"d5dec0",
"33ebc7",
"48941d",
"f3745c",
"189fa5",
"3af83f",
"732b91",
"ef7175"
]
},
{
"id":"mk19_a_np_q032",
"number":32,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 32",
"stimulus":[
{
"type":"p",
"hlId":"32c88e",
"children":[
"A 46-year-old man is evaluated for confirmed primary hypertension. The patient is asymptomatic and takes no medications. He is a current smoker with a 20-pack-year history. Family history is significant for hypertension in his mother and father; his father had a stroke at age 55 years."
]
},
{
"type":"p",
"hlId":"698fbc",
"children":[
"On physical examination, blood pressure is 154/96 mm Hg in both arms, pulse rate is 74/min, and respiration rate is 18/min. BMI is 30. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"340fba",
"class":"cell text l",
"children":[
"Fasting lipid profile:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text li",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfc77",
"class":"cell text l",
"children":[
"220 mg/dL (5.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"0c2f10",
"class":"cell text li",
"children":[
"LDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f34cbd",
"class":"cell text l",
"children":[
"160 mg/dL (4.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"8a43cb",
"class":"cell text li",
"children":[
"HDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b1b995",
"class":"cell text l",
"children":[
"48 mg/dL (1.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"23f624",
"class":"cell text l",
"children":[
"1.0 mg/dL (88.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"06bcde",
"class":"cell text l",
"children":[
"Electrolytes"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d42e3c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose, fasting"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5f8c08",
"class":"cell text l",
"children":[
"80 mg/dL (4.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ec7a86",
"class":"cell text l",
"children":[
"No protein, erythrocytes, or leukocytes"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"bc1f37",
"children":[
"A 12-lead ECG is normal."
]
},
{
"type":"p",
"hlId":"a58740",
"children":[
"The patient is instructed in lifestyle modifications, including smoking cessation, exercise, and a low sodium diet. Moderate-intensity atorvastatin is initiated."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"907369",
"children":[
"Which of the following is the most appropriate additional therapy?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Amlodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Amlodipine-valsartan"
}
},
{
"letter":"C",
"text":{
"__html":"Chlorthalidone"
}
},
{
"letter":"D",
"text":{
"__html":"Valsartan"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2e5eff",
"children":[
"A blood pressure <130/80 mm Hg is recommended for adults with hypertension and cardiovascular disease or a 10-year atherosclerotic cardiovascular disease event risk ≥10%."
]
},
{
"type":"keypoint",
"hlId":"ecb044",
"children":[
"Combination therapy with two first-line antihypertensive medications of different classes is recommended for adults with stage 2 hypertension and an average blood pressure (BP) of >20/10 mm Hg above BP target."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ca6c86",
"children":[
"The most appropriate additional therapy is amlodipine-valsartan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient has stage 2 hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg). For patients with stage 2 hypertension with or without cardiovascular risk or disease, pharmacologic management in addition to therapeutic lifestyle interventions is recommended. The 2017 American College of Cardiology/American Heart Association blood pressure (BP) guideline recommends combination therapy with two first-line antihypertensive drugs of different classes for adults with stage 2 hypertension and an average BP that is 20/10 mm Hg above their BP target. Based on the presence of hypertension, dyslipidemia, and cigarette smoking, this patient has a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) event risk of 10%. The target BP for patients with established cardiovascular disease or for patients with an estimated ASCVD event risk ≥10% is 130/80 mm Hg. This patient has an elevated 10-year ASCVD event risk and his BP is >20/10 mm Hg above target; therefore, combination drug therapy is indicated. To maximize adherence, using a fixed-dose combination agent may be more effective than adding two separate antihypertensive agents."
]
},
{
"type":"p",
"hlId":"c12740",
"children":[
"Starting chlorthalidone, amlodipine, or valsartan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, C, D"
]
},
") as single-agent therapy would each be appropriate as first-line therapy for patients with stage 1 hypertension (systolic BP of 130-139 mm Hg or diastolic BP of 80–89 mm Hg). Combination therapy is recommended for patients with stage 2 hypertension and an average BP that is 20/10 mm Hg above their BP target."
]
}
],
"relatedSection":"mk19_a_np_s4_7_2_3_4",
"objective":{
"__html":"Treat stage 2 hypertension with combination drug therapy."
},
"references":[
[
"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29146535",
"target":"_blank"
},
"children":[
"PMID: 29146535"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":14,
"B":34,
"C":40,
"D":12,
"E":0
},
"hlIds":[
"32c88e",
"698fbc",
"a462a3",
"340fba",
"d41d8c",
"182194",
"9bfc77",
"0c2f10",
"f34cbd",
"8a43cb",
"b1b995",
"f461b2",
"23f624",
"06bcde",
"960b44",
"d42e3c",
"5f8c08",
"747c2a",
"ec7a86",
"bc1f37",
"a58740",
"907369",
"2e5eff",
"ecb044",
"ca6c86",
"c12740"
]
},
{
"id":"mk19_a_np_q033",
"number":33,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 33",
"stimulus":[
{
"type":"p",
"hlId":"7b5df9",
"children":[
"A 43-year-old man is evaluated for one episode of gross hematuria 3 days ago. He reports no flank pain and no associated trauma on exertion. Medical history is otherwise unremarkable. He does not smoke cigarettes and takes no medications."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"268ab1",
"class":"cell text l",
"children":[
"Blood urea nitrogen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e33337",
"class":"cell text l",
"children":[
"Creatinine"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ebd3ec",
"class":"cell text l",
"children":[
"No protein; 1+ heme pigment; 10-15 erythrocytes/hpf; 0-2 leukocytes/hpf; no nitrites; no leukocyte esterase"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b0c5a3",
"class":"cell text l",
"children":[
"Random ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ecb9a7",
"class":"cell text l",
"children":[
"20 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"d14355",
"children":[
"Contrast-enhanced CT urogram of the kidneys shows no stones, masses, or cysts."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Cystoscopy"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney biopsy"
}
},
{
"letter":"C",
"text":{
"__html":"Repeat urinalysis"
}
},
{
"letter":"D",
"text":{
"__html":"24-Hour urine protein measurement"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"32abdd",
"children":[
"Patients with gross hematuria who are >35 years of age or have risk factors for lower urinary tract malignancy should be evaluated for malignancy."
]
},
{
"type":"keypoint",
"hlId":"a99d5d",
"children":[
"Evaluation of gross hematuria includes imaging of the lower urinary tract followed by cystoscopy if imaging is negative."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"fd289c",
"children":[
"Cystoscopy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is the most appropriate diagnostic test to perform next in this patient. Hematuria is frequently encountered among adults in ambulatory care. Macroscopic hematuria should prompt urology referral even if self-limited. Hematuria is most often of nonglomerular origin. If a nephrologic cause of hematuria is not suggested, it may indicate a malignancy. Guidelines from the American Urological Association recommend that patients ≥40 years of age or of any age with risk factors for lower urinary tract malignancy (such as irritative voiding symptoms, smoking history, aniline dye exposure, or cyclophosphamide exposure) undergo evaluation for malignancy with imaging. If imaging is negative, cystoscopy should be performed. This patient is a 43-year-old man without evidence of glomerular disease (no proteinuria or increased serum creatinine level) or infection (no leukocyturia, negative nitrites, and no leukocyte esterase) and negative imaging of the upper genitourinary tract. Therefore, it is appropriate to assess for bladder pathology using cystoscopy."
]
},
{
"type":"p",
"hlId":"65c60b",
"children":[
"Kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") in a patient with hematuria is not indicated in the absence of evidence of glomerular disease. A glomerular origin is suggested by concurrent proteinuria, presence of dysmorphic erythrocytes, increased serum creatinine, or decrease in estimated glomerular filtration rate. This patient has no indication for a kidney biopsy."
]
},
{
"type":"p",
"hlId":"e5b5f1",
"children":[
"Repeat urinalysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated. This patient's macroscopic hematuria should prompt urologic investigation now. A single incident of hematuria warrants further investigation, even if the patient has a bleeding disorder or is receiving antiplatelet or anticoagulation therapy. If menstruation, viral illness, urinary tract infection, vigorous exercise, or another benign cause is suspected, urinalysis should be repeated after the cause is resolved. Otherwise, as in this case, further evaluation should ensue without additional urinalysis."
]
},
{
"type":"p",
"hlId":"34eecf",
"children":[
"The absence of proteinuria makes a glomerular cause of hematuria less likely. Although a 24-hour urine protein collection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is the gold standard for determining proteinuria, random urine albumin-creatinine ratio and protein-creatinine ratio correlate well with timed collections. This patient has a normal urine protein-creatinine ratio; therefore, a 24-hour collection is not indicated."
]
}
],
"relatedSection":"mk19_a_np_s1_2_4",
"objective":{
"__html":"Evaluate gross hematuria."
},
"references":[
[
"Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204:778-786. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32698717",
"target":"_blank"
},
"children":[
"PMID: 32698717"
]
},
" doi:10.1097/JU.0000000000001297"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":73,
"B":3,
"C":20,
"D":4,
"E":0
},
"hlIds":[
"7b5df9",
"f8786b",
"a462a3",
"268ab1",
"960b44",
"e33337",
"960b44",
"747c2a",
"ebd3ec",
"b0c5a3",
"ecb9a7",
"d14355",
"ab9d96",
"32abdd",
"a99d5d",
"fd289c",
"65c60b",
"e5b5f1",
"34eecf"
]
},
{
"id":"mk19_a_np_q034",
"number":34,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 34",
"stimulus":[
{
"type":"p",
"hlId":"a7ad9c",
"children":[
"A 62-year-old woman comes to the office for kidney transplantation evaluation. She has end-stage kidney disease. A peritoneal dialysis catheter was placed 2 weeks ago. She also has hypertension. Medications are amlodipine, benazepril, furosemide, metoprolol, and sodium bicarbonate."
]
},
{
"type":"p",
"hlId":"4b3a7a",
"children":[
"On physical examination, vital signs are normal. A peritoneal dialysis catheter is present. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a3a396",
"class":"cell text l",
"children":[
"Hepatitis B core antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"74fe78",
"class":"cell text l",
"children":[
"Hepatitis C antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"216558",
"class":"cell text l",
"children":[
"Hepatitis C viral load"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"35fc69",
"class":"cell text l",
"children":[
"2.8 million IU/mL"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Avoid antiviral treatment and transplantation"
}
},
{
"letter":"B",
"text":{
"__html":"Begin entecavir"
}
},
{
"letter":"C",
"text":{
"__html":"Begin pegylated interferon and ribavirin"
}
},
{
"letter":"D",
"text":{
"__html":"Discuss hepatitis C virus treatment and timing"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2b9a6d",
"children":[
"In patients with end-stage kidney disease, treatment for concurrent hepatitis C virus infection can be timed before kidney transplantation or after transplantation if receiving a hepatitis C–infected donor kidney."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c46607",
"children":[
"The most appropriate management is to discuss hepatitis C virus (HCV) treatment and timing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient has evidence of HCV infection and hepatitis B virus (HBV) immunity (negative hepatitis B surface antigen, positive hepatitis B surface antibody). Screening patients for both viruses on admission to a dialysis center is part of ongoing infection control surveillance within a dialysis center. Identification of infection is important because treatment can be offered. All patients with HCV infection should be considered for treatment unless there are significant life-limiting comorbidities. Treatment regimens for HCV infection include a combination of direct-acting antivirals, using different mechanisms to prevent viral reproduction. Regimens are chosen based on genotype, previous treatment experience and response, and fibrosis status. The timing of HCV treatment must be individualized in patients such as this one with end-stage kidney disease (ESKD) who are potential kidney transplant recipients. It is important to discuss treatment and treatment timing with this patient and the kidney transplant program. In patients with ESKD, treatment for concurrent HCV infection can be timed before kidney transplantation or after transplantation if receiving an HCV-infected donor kidney."
]
},
{
"type":"p",
"hlId":"d702d6",
"children":[
"Antiviral treatment is safe and generally well tolerated in patients with ESKD, and the presence of HCV infection is not a contraindication for kidney transplantation. Neither avoiding antiviral therapy nor transplantation is appropriate for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"d2cd6d",
"children":[
"First-line treatment for HBV infection is entecavir (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") or tenofovir. However, this patient is immune to hepatitis B, and treatment is not warranted."
]
},
{
"type":"p",
"hlId":"4bfb8c",
"children":[
"Pegylated interferon and ribavirin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") would not be indicated for this patient before a discussion about the timing of HCV therapy. In addition, many direct-acting antiviral regimens are available and are safe for use in patients with chronic kidney disease or ESKD with significantly less morbidity compared with interferon therapy."
]
}
],
"relatedSection":"mk19_a_np_s12_9_2_4_6",
"objective":{
"__html":"Manage hepatitis C virus infection in a patient with end-stage kidney disease."
},
"references":[
[
"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011). 2018;8:91-165. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30675443",
"target":"_blank"
},
"children":[
"PMID: 30675443"
]
},
" doi:10.1016/j.kisu.2018.06.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":0,
"B":4,
"C":7,
"D":89,
"E":0
},
"hlIds":[
"a7ad9c",
"4b3a7a",
"a462a3",
"a3a396",
"328929",
"3a242b",
"328929",
"2ff2e8",
"ffb935",
"74fe78",
"328929",
"216558",
"35fc69",
"cb2b54",
"2b9a6d",
"c46607",
"d702d6",
"d2cd6d",
"4bfb8c"
]
},
{
"id":"mk19_a_np_q035",
"number":35,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 35",
"stimulus":[
{
"type":"p",
"hlId":"9e199f",
"children":[
"An 87-year-old man is evaluated in the emergency department for a 36-hour history of lower abdominal discomfort, urinary frequency, and nocturia. He has no other symptoms. Medical history is significant for type 2 diabetes mellitus, hypertension, and IgG4-related autoimmune pancreatitis. Medications are metformin, hydrochlorothiazide, and rituximab. He began taking over-the-counter chlorpheniramine last week for symptoms related to seasonal allergies."
]
},
{
"type":"p",
"hlId":"4ec302",
"children":[
"On physical examination, he is afebrile. Blood pressure is 158/64 mm Hg, and pulse rate is 78/min. There is tenderness to palpation of the lower abdomen. The prostate is diffusely enlarged."
]
},
{
"type":"p",
"hlId":"2e7de9",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"blood urea nitrogen"
]
},
" level of 50 mg/dL (17.9 mmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 2.4 mg/dL (212.2 µmol/L). Urinalysis shows a specific gravity of 1.012, 1+ blood, 1+ protein, 1+ leukocytes, 3 nondysmorphic erythrocytes/hpf, 1-3 leukocytes/hpf, and no casts."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"573da9",
"children":[
"Which of the following is the most appropriate initial step in management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bladder ultrasonography"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney ultrasonography"
}
},
{
"letter":"C",
"text":{
"__html":"MRI of the abdomen and pelvis"
}
},
{
"letter":"D",
"text":{
"__html":"Noncontrast CT of the abdomen and pelvis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"6b18ee",
"children":[
"Postrenal acute kidney injury results from urinary tract obstruction that is readily reversible if recognized early and corrected promptly."
]
},
{
"type":"keypoint",
"hlId":"16f6eb",
"children":[
"Postrenal obstruction should be suspected in patients with a history of benign prostatic hyperplasia, diabetes mellitus, nephrolithiasis, abdominal or pelvic surgeries or radiation, pelvic malignancies, or retroperitoneal fibrosis or lymphadenopathy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"f46c1a",
"children":[
"The most appropriate initial step in management is bladder ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient most likely has postrenal obstructive uropathy secondary to benign prostatic hyperplasia (BPH) and the recent introduction of chlorpheniramine, a drug with anticholinergic properties. Postrenal acute kidney injury (AKI) results from urinary tract obstruction. If left uncorrected, the elevated tubular pressure can cause chronic and end-stage kidney disease. Postrenal obstruction due to bladder outlet obstruction should be suspected in patients with a history of BPH and diabetes mellitus (neurogenic bladder). Symptoms of bladder outlet obstruction may include abdominal fullness or pain; urinary frequency, urgency, and hesitancy; nocturia; and incomplete voiding. The diagnosis is supported by a distended bladder and prostate enlargement on physical examination. In postrenal obstruction, urine sediment is often unremarkable, but microscopic hematuria may be present. Bladder outlet obstruction is confirmed by an elevated postvoid residual bladder volume by ultrasonography. If the obstruction is relieved within 1 to 2 weeks, recovery of kidney function is excellent."
]
},
{
"type":"p",
"hlId":"b685e0",
"children":[
"Obstruction of the upper tract (ureters or renal pelvis) must be bilateral to cause AKI (unless obstruction occurs in a single kidney); causes may include nephrolithiasis, abdominal or pelvic surgeries or radiation, pelvic malignancies, or retroperitoneal fibrosis or lymphadenopathy. Kidney ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is the initial modality of choice for diagnosing upper tract obstruction. Although kidney ultrasonography may ultimately be performed, the next management step is bladder ultrasonography and possible bladder catheterization because bladder outlet obstruction is more likely to occur in a man with BPH recently exposed to a medication with anticholinergic effects."
]
},
{
"type":"p",
"hlId":"211a34",
"children":[
"IgG4-related autoimmune pancreatitis can be associated with other IgG4-related diseases, including retroperitoneal fibrosis and obstructive uropathy. CT with contrast or MRI of the abdomen and pelvis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") are the initial imaging studies. However, in this patient with BPH, the initial diagnostic modality is bladder ultrasonography. Failure to establish a diagnosis should prompt appropriate imaging tests."
]
},
{
"type":"p",
"hlId":"b4dfab",
"children":[
"Patients with acute ureteral obstruction caused by nephrolithiasis may present with ureteral colic. In this scenario, a noncontrast CT of the abdomen and pelvis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") may provide the correct diagnosis. However, there are no symptoms to support this diagnosis, and bladder ultrasonography will establish the most likely diagnosis."
]
}
],
"relatedSection":"mk19_a_np_s9_5_3",
"objective":{
"__html":"Diagnose postrenal obstructive uropathy."
},
"references":[
[
"Levey AS, James MT. Acute kidney injury. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201711070",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2017;167:ITC66-ITC80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29114754",
"target":"_blank"
},
"children":[
"PMID: 29114754"
]
}
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":60,
"B":16,
"C":2,
"D":22,
"E":0
},
"hlIds":[
"9e199f",
"4ec302",
"2e7de9",
"573da9",
"6b18ee",
"16f6eb",
"f46c1a",
"b685e0",
"211a34",
"b4dfab"
]
},
{
"id":"mk19_a_np_q036",
"number":36,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 36",
"stimulus":[
{
"type":"p",
"hlId":"c4e60d",
"children":[
"A 38-year-old man is evaluated during a follow-up visit for proteinuric chronic kidney disease. Family history is significant for end-stage kidney disease in two uncles and a female cousin. He has no other medical problems, and his only medication is lisinopril. The patient is of African descent."
]
},
{
"type":"p",
"hlId":"938af6",
"children":[
"On physical examination, vital signs are normal. There are features of generalized anasarca, with marked edema of the lower extremities. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b7d2e2",
"class":"cell text l",
"children":[
"2.2 g/dL (22 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4726bc",
"class":"cell text l",
"children":[
"264 mg/dL (6.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3ea104",
"class":"cell text l",
"children":[
"1.8 mg/dL (159.1 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ec9779",
"class":"cell text l",
"children":[
"No blood; 4+ protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"023ac6",
"class":"cell text l",
"children":[
"7850 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Focal segmental glomerulosclerosis"
}
},
{
"letter":"B",
"text":{
"__html":"Lupus nephritis"
}
},
{
"letter":"C",
"text":{
"__html":"Membranous nephropathy"
}
},
{
"letter":"D",
"text":{
"__html":"Minimal change glomerulopathy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bea2b8",
"children":[
"Focal segmental glomerulosclerosis is the most common form of the nephrotic syndrome in patients of African descent, likely mediated in part by variants in the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"APOL1"
]
},
" gene."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"96643b",
"children":[
"The most likely diagnosis is focal segmental glomerulosclerosis (FSGS) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). In the United States, FSGS currently accounts for up to 40% of primary nephrotic syndromes in adults. Individuals of African ancestry carry approximately a five times higher risk for FSGS than those of European descent, likely mediated in part by variants in the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"APOL1"
]
},
" gene, which is likely responsible for this patient's FSGS as well as the kidney disease found in other members of his family. Two risk alleles for kidney disease (G1 and G2) have been identified in the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"APOL1"
]
},
" gene. The transmission of disease risk is consistent with recessive inheritance. Approximately 12% to 15% of African Americans inherit a high-risk ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"APOL1"
]
},
" genotype; this accounts for a large fraction of nondiabetic kidney disease in African Americans that in the past has been attributed to hypertension but would appear as FSGS on biopsy. Persons with a high-risk ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"APOL1"
]
},
" genotype have an approximately 10-fold increased risk for FSGS and a 7-fold increased risk for hypertension-attributed end-stage kidney disease."
]
},
{
"type":"p",
"hlId":"8854c8",
"children":[
"Kidney involvement in systemic lupus erythematosus (SLE) is common, and lupus nephritis (LN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is a major source of morbidity. Patients typically present with extrarenal symptoms of SLE at the time of diagnosis of LN, with active lupus serologies and low complement levels. Occasionally, LN may be the initial manifestation. Patients with class I or II LN may have minimal or no kidney findings, and those with class III or IV present with varying degrees of the nephritic syndrome. Patients with class V LN typically present with proteinuria."
]
},
{
"type":"p",
"hlId":"c29607",
"children":[
"Membranous nephropathy (MN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is a common cause of idiopathic nephrotic syndrome. MN may also be associated with infections (hepatitis B and C, malaria, syphilis), SLE, medications (gold salts, NSAIDs), and malignancies (solid tumors, lymphomas). In most patients with idiopathic MN, circulating antibodies directed to podocyte surface antigens (phospholipase A2 receptor) activate complement and damage the glomerular basement membrane."
]
},
{
"type":"p",
"hlId":"d1c047",
"children":[
"Minimal change glomerulopathy (MCG) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is the most common cause of idiopathic nephrotic syndrome in children and accounts for approximately 10% of cases in adults. Secondary causes of MCG include medications (NSAIDs, lithium, pamidronate, the interferons) and malignancies (Hodgkin lymphoma and thymoma)."
]
}
],
"relatedSection":"mk19_a_np_s6_3_2_1",
"objective":{
"__html":"Diagnose focal segmental glomerulosclerosis."
},
"references":[
[
"Freedman BI, Limou S, Ma L, et al. APOL1-associated nephropathy: A key contributor to racial disparities in CKD. Am J Kidney Dis. 2018;72:S8-S16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30343724",
"target":"_blank"
},
"children":[
"PMID: 30343724"
]
},
" doi:10.1053/j.ajkd.2018.06.020"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":60,
"B":2,
"C":29,
"D":9,
"E":0
},
"hlIds":[
"c4e60d",
"938af6",
"a462a3",
"4590ed",
"b7d2e2",
"182194",
"4726bc",
"f461b2",
"3ea104",
"747c2a",
"ec9779",
"d17af8",
"023ac6",
"413696",
"bea2b8",
"96643b",
"8854c8",
"c29607",
"d1c047"
]
},
{
"id":"mk19_a_np_q037",
"number":37,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 37",
"stimulus":[
{
"type":"p",
"hlId":"afab2d",
"children":[
"A 52-year-old woman is evaluated during a follow-up visit for hypertension management. She has a 10-year history of type 2 diabetes mellitus. Diabetic retinopathy was diagnosed 1 year ago. She also has obesity and hyperlipidemia. Medications are hydrochlorothiazide, metformin, empagliflozin, and atorvastatin."
]
},
{
"type":"p",
"hlId":"1918b2",
"children":[
"On physical examination, blood pressure is 138/86 mm Hg; other vital signs are normal. BMI is 32. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfe04",
"class":"cell text l",
"children":[
"0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"06bcde",
"class":"cell text l",
"children":[
"Electrolytes"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7bfec6",
"class":"cell text l",
"children":[
"550 mg/g"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"97bfab",
"class":"cell text l",
"children":[
">60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Amlodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Atenolol"
}
},
{
"letter":"C",
"text":{
"__html":"Doxazosin"
}
},
{
"letter":"D",
"text":{
"__html":"Losartan"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"aa7a26",
"children":[
"In adults with diabetes mellitus and hypertension, diuretics, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers are all effective agents."
]
},
{
"type":"keypoint",
"hlId":"4684b0",
"children":[
"ACE inhibitors or angiotensin receptor blockers are the preferred drug classes for treatment of hypertension in patients with diabetes mellitus and albuminuria."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"557cf0",
"children":[
"The most appropriate treatment is to begin losartan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Blood pressure (BP) control is more difficult to achieve in patients with diabetes mellitus, necessitating use of combination therapy in most of these patients. The 2017 American College of Cardiology/American Heart Association guideline recommends a target BP of <130/80 mm Hg for patients with hypertension and diabetes. The American Diabetes Association (ADA) recommends that most patients with diabetes and hypertension should be treated to a target BP of 140/90 mm Hg; 130/80 mm Hg may be appropriate for individuals at higher risk (existing atherosclerotic cardiovascular disease [ASCVD] or 10-year ASCVD risk ≥15%), if it can be achieved safely. In adults with diabetes and hypertension, all first-line classes of antihypertensive agents (i.e., diuretics, ACE inhibitors, angiotensin receptor blockers [ARBs], and calcium channel blockers) are useful and effective. ACE inhibitors or ARBs are the preferred drug classes for treatment of hypertension for patients with diabetes and albuminuria (albumin-creatinine ratio ≥300 mg/g) and in adults with hypertension and chronic kidney disease (stage G3 or higher or stage G1 or G2 with albuminuria) to slow kidney disease progression. Among the drug classes, ACE inhibitors and ARBs have the best efficacy on urinary albumin excretion and demonstrate a significant reduction in disease progression. The ADA also recommends use of an ACE inhibitor or ARB at the maximum tolerated dose indicated as first-line treatment for hypertension in patients with diabetes and albuminuria."
]
},
{
"type":"p",
"hlId":"14c071",
"children":[
"Although first-line therapy in patients with diabetes can include a thiazide diuretic or a calcium channel blocker (e.g., amlodipine) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), the presence of albuminuria is an indication for the addition of a renin-angiotensin system inhibitor such as losartan."
]
},
{
"type":"p",
"hlId":"23f8b2",
"children":[
"Due to the absence of outcome data, β-blockers such as atenolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") are not usually recommended as initial antihypertensive medication therapy. However, they can be used in special populations, such as patients with a previous myocardial infarction or heart failure, in which outcome data exist."
]
},
{
"type":"p",
"hlId":"4203e5",
"children":[
"Doxazosin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not a typical second drug added to thiazide diuretic therapy because of its side-effect profile, which includes orthostatic hypotension. In addition, doxazosin is not as efficacious as ACE inhibitors or ARBs in preventing the progression of kidney disease."
]
}
],
"relatedSection":"mk19_a_np_s4_14_2",
"objective":{
"__html":"Treat hypertension in a patient with diabetes mellitus and albuminuria using an ACE inhibitor or angiotensin receptor blocker."
},
"references":[
[
"Byrd JB, Brook RD. Hypertension. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201905070",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC65-ITC80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31060074",
"target":"_blank"
},
"children":[
"PMID: 31060074"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":0,
"C":1,
"D":98,
"E":0
},
"hlIds":[
"afab2d",
"1918b2",
"a462a3",
"f461b2",
"9bfe04",
"06bcde",
"960b44",
"58e613",
"7bfec6",
"77db81",
"97bfab",
"1054f1",
"aa7a26",
"4684b0",
"557cf0",
"14c071",
"23f8b2",
"4203e5"
]
},
{
"id":"mk19_a_np_q038",
"number":38,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 38",
"stimulus":[
{
"type":"p",
"hlId":"8319f1",
"children":[
"A 70-year-old woman is evaluated for right flank pain and dysuria. She has a 20-year history of type 2 diabetes mellitus with neurogenic bladder and recurrent urinary tract infections. Medications are metformin and simvastatin."
]
},
{
"type":"p",
"hlId":"8d6268",
"children":[
"On physical examination, temperature is 38.3 °C (100.9 °F); other vital signs are normal. There is tenderness to palpation over the right flank. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"b5da0b",
"children":[
"Urinalysis shows cloudy urine with a specific gravity of 1.010, pH of 8.0, 1+ blood, trace protein, 3+ leukocyte esterase, and positive nitrites. Microscopic urinalysis reveals 1-2 erythrocytes/hpf, 20-25 leukocytes/hpf, and crystals ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"figure-link",
"target":"mk19_a_np_mcq_f038",
"wrapId":"1",
"children":[
"shown"
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_np_mcq_f038"
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"4cac7b",
"children":[
"Infection with which of the following organisms is most likely?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"\n          <i>Escherichia coli</i>\n        "
}
},
{
"letter":"B",
"text":{
"__html":"\n          <i>Proteus mirabilis</i>\n        "
}
},
{
"letter":"C",
"text":{
"__html":"\n          <i>Staphylococcus saprophyticus</i>\n        "
}
},
{
"letter":"D",
"text":{
"__html":"\n          <i>Streptococcus agalactiae</i>\n        "
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"f66fc5",
"children":[
"Infection with urea-splitting organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Proteus, Klebsiella,"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas"
]
},
" increases urine pH and results in the precipitation of magnesium ammonium phosphate, also known as struvite."
]
},
{
"type":"keypoint",
"hlId":"56dd88",
"children":[
"Struvite crystals in the urine are recognized by their characteristic coffin-lid appearance."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"0f99d4",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Proteus mirabilis"
]
},
" (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is the most likely organism responsible for this patient's infection. This patient most likely has a urinary tract infection (UTI) caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Proteus,"
]
},
" or other urea-splitting organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Klebsiella"
]
},
" or, less frequently, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas."
]
},
" These bacteria secrete urease, which enzymatically hydrolyzes urea into carbon dioxide and ammonium, which markedly increases urine pH and results in the precipitation of magnesium ammonium phosphate, also known as struvite. On urinalysis, the urine pH will be >7.5. Struvite crystals are recognized by their coffin-lid appearance. Struvite crystals can rapidly form large stones in the renal pelvis and are responsible for the creation of staghorn calculi, which are stones that bridge two or more renal calyces. Because struvite stones are large and grow rapidly, they do not pass into the ureter to cause pain typical of smaller stones. Struvite stones form most commonly in women, and women are more likely than men to develop upper UTI. Other predisposing conditions include urinary stasis from a neurogenic bladder, as seen in this patient. Patients with infection caused by urea-splitting organisms have the typical signs and symptoms of UTI. However, these stones may become persistently infected despite antibiotic therapy and are a source of significant morbidity and mortality due to sepsis. Percutaneous nephrolithotomy is the first-line treatment for most patients."
]
},
{
"type":"p",
"hlId":"7d877f",
"children":[
"In 95% of cases, UTIs are caused by a single bacterial species, mainly gram-negative aerobic bacilli originating from the bowel. Uropathogenic ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli"
]
},
" (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") accounts for 75% to 95% of UTIs in women. Less common urinary pathogens include other members of the Enterobacteriaceae family, staphylococci (most often ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus saprophyticus"
]
},
") (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), streptococci (in particular ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Streptococcus agalactiae"
]
},
") (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), and enterococci. UTIs occurring in hospitals and long-term care facilities frequently involve a more varied group of organisms (such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Enterobacter, Providencia, Morganella, Citrobacter, Serratia,"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas"
]
},
"). These bacteria are not associated with crystal formation."
]
}
],
"relatedSection":"mk19_a_np_s1_2_2_6",
"objective":{
"__html":"Diagnose urinary tract infection caused by a urea-splitting organism."
},
"references":[
[
"Daudon M, Frochot V. Crystalluria. Clin Chem Lab Med. 2015;53 Suppl 2:s1479-87. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26509782",
"target":"_blank"
},
"children":[
"PMID: 26509782"
]
},
" doi:10.1515/cclm-2015-0860"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":6,
"B":88,
"C":2,
"D":4,
"E":0
},
"figuresContent":{
"mk19_a_np_mcq_f038":{
"id":"mk19_a_np_mcq_f038",
"number":38,
"bookId":"np",
"legend":"",
"footnotes":[

],
"imageInfo":{
"hash":"3fb188abe0328fc1c64e846850d3d830",
"height":482,
"width":362,
"extension":"jpg"
}
}
},
"hlIds":[
"8319f1",
"8d6268",
"b5da0b",
"4cac7b",
"f66fc5",
"56dd88",
"0f99d4",
"7d877f"
]
},
{
"id":"mk19_a_np_q039",
"number":39,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 39",
"stimulus":[
{
"type":"p",
"hlId":"f49a29",
"children":[
"A 39-year-old woman is evaluated during a follow-up visit for recently diagnosed stage 2 hypertension confirmed with home blood pressure monitoring measurements taken over the past month. She also has a 12-year history of type 2 diabetes mellitus. Medications are metformin and empagliflozin."
]
},
{
"type":"p",
"hlId":"d37cd6",
"children":[
"On physical examination, blood pressure is 144/92 mm Hg, pulse rate is 88/min, and respiration rate is 18/min. BMI is 28. The remainder of the examination unremarkable."
]
},
{
"type":"p",
"hlId":"9cd1da",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.9 mg/dL (79.6 µmol/L), normal electrolyte levels, and a urine ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"albumin-creatinine ratio"
]
},
" of 330 mg/g."
]
},
{
"type":"p",
"hlId":"2fb268",
"children":[
"The patient is instructed in lifestyle modifications to control hypertension."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"6a41fc",
"children":[
"Which of the following is the most appropriate initial therapy?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Felodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Hydrochlorothiazide"
}
},
{
"letter":"C",
"text":{
"__html":"Hydrochlorothiazide and amlodipine"
}
},
{
"letter":"D",
"text":{
"__html":"Lisinopril"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bac06f",
"children":[
"An ACE inhibitor or angiotensin receptor blocker is the initial treatment of choice for hypertension in patients with diabetes mellitus and albuminuria."
]
},
{
"type":"keypoint",
"hlId":"b02f3f",
"children":[
"Use of an ACE inhibitor or angiotensin receptor blocker can result in decreased progression of albuminuria and chronic kidney disease in patients with diabetes mellitus and albuminuria."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"73886b",
"children":[
"The most appropriate initial therapy is lisinopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), an ACE inhibitor, to treat hypertension in this patient with type 2 diabetes mellitus and albuminuria. Although this patient's serum creatinine level is normal, she has evidence of chronic kidney disease (CKD) based on the presence of albuminuria (urine albumin-creatinine ratio ≥30 mg/g). Albuminuria and uncontrolled blood pressure increase her risk for progression of CKD. Several large randomized controlled trials showed that use of an ACE inhibitor or angiotensin receptor blocker (ARB) can result in decreased progression of albuminuria and CKD, which may include doubling of serum creatinine or progression to end-stage kidney disease, in patients with diabetes and albuminuria."
]
},
{
"type":"p",
"hlId":"5bde24",
"children":[
"The American Diabetes Association (ADA) recommends an ACE inhibitor or ARB at the maximum tolerated dose as first-line treatment for hypertension in patients with diabetes and urine albumin-creatinine ratio >300 mg/g; treatment with these drugs should be initiated when the urine albumin-creatinine ratio is ≥30 to 300 mg/g. For this reason, felodipine (a CCB) and hydrochlorothiazide (a thiazide diuretic) are not the most appropriate initial therapies for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A-C"
]
},
")."
]
},
{
"type":"p",
"hlId":"7a1c25",
"children":[
"Initial treatment with two antihypertensive drugs is recommended for patients with stage 2 hypertension and who are >20/10 mm Hg above their target blood pressure. According to the ADA, this patient's target blood pressure is <140/90 mm Hg or <130/80 mm Hg in the presence of atherosclerotic cardiovascular disease or if her 10-year atherosclerotic cardiovascular disease event risk is >15%. Regardless, the patient is not >20/10 mm Hg above her blood pressure target, and the initiation of two antihypertensive drugs is not indicated. However, if this patient's blood pressure is still not controlled to target while receiving the maximum dose of lisinopril, then another class of first-line antihypertensive agents, such as a thiazide diuretic or CCB, should be added."
]
}
],
"relatedSection":"mk19_a_np_s4_14_2",
"objective":{
"__html":"Treat hypertension in a patient with type 2 diabetes mellitus and albuminuria."
},
"references":[
[
"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S125-S150. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298421",
"target":"_blank"
},
"children":[
"PMID: 33298421"
]
},
" doi:10.2337/dc21-S010"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":4,
"C":1,
"D":94,
"E":0
},
"hlIds":[
"f49a29",
"d37cd6",
"9cd1da",
"2fb268",
"6a41fc",
"bac06f",
"b02f3f",
"73886b",
"5bde24",
"7a1c25"
]
},
{
"id":"mk19_a_np_q040",
"number":40,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 40",
"stimulus":[
{
"type":"p",
"hlId":"d7158d",
"children":[
"A 38-year-old woman seeks treatment for polyuria and nocturia that began 6 weeks ago after starting lithium for bipolar disorder. Medical history is otherwise unremarkable. Her only other medication is olanzapine."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"p",
"hlId":"64a270",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"serum sodium"
]
},
" level of 145 mEq/L (145 mmol/L) and a urine osmolality of 200 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add amiloride"
}
},
{
"letter":"B",
"text":{
"__html":"Add furosemide"
}
},
{
"letter":"C",
"text":{
"__html":"Decrease water intake"
}
},
{
"letter":"D",
"text":{
"__html":"Increase protein intake"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"047c5d",
"children":[
"Treatment of lithium-induced nephrogenic diabetes insipidus is best accomplished with amiloride, as it blocks the epithelial sodium channel in the collecting tubule and prevents the uptake of lithium by these cells."
]
},
{
"type":"keypoint",
"hlId":"c9ea0d",
"children":[
"If amiloride is ineffective in treating lithium-induced nephrogenic diabetes insipidus and lithium must be continued, treatment is aimed at limiting solute intake and causing mild volume depletion with the use of a thiazide diuretic."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c08770",
"children":[
"The most appropriate management is to add amiloride (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has polyuria, a serum sodium concentration at the upper limit of normal, and dilute urine, which establish the diagnosis of diabetes insipidus (DI). DI may be secondary to either an inadequate release of antidiuretic hormone (ADH) (central DI) or inadequate action of ADH (nephrogenic DI). Central DI can result from tumors that invade the hypothalamus, infiltrating diseases such as sarcoidosis, or surgical destruction. Nephrogenic DI is often caused by drugs such as lithium. The temporal association with the initiation of lithium in this patient establishes the diagnosis of lithium-induced nephrogenic DI. Up to 40% of patients treated with lithium will develop polydipsia secondary to lithium interfering with the action of ADH. Amiloride is the most appropriate management in this case, as it blocks the epithelial sodium channel in the collecting tubule and prevents the uptake of lithium by these cells. Intracellular lithium appears to decrease the number of aquaporin water channels inserted in the membrane, thereby decreasing water reabsorption causing increased excretion of dilute urine. If amiloride is ineffective and lithium must be continued, the treatment of nephrogenic DI is aimed at decreasing the amount of urine excreted and is best accomplished by limiting solute intake and causing mild volume depletion with the use of a thiazide diuretic. Because the amount of urine excreted daily is dependent on solute intake and minimum urine osmolality, decreasing solute will limit urine volume. By causing mild volume depletion with a thiazide diuretic, more salt and water will be reabsorbed in the proximal tubule and loop of Henle, further decreasing urine output."
]
},
{
"type":"p",
"hlId":"0e4f8f",
"children":[
"Although furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") will produce volume depletion, it is not helpful in the treatment of nephrogenic DI. Furosemide blocks the ability to concentrate the urine at the loop of Henle, creating a state of antidiuretic hormone resistance."
]
},
{
"type":"p",
"hlId":"9374ce",
"children":[
"Patients with nephrogenic DI will develop increased thirst as their serum sodium increases. Water intake should never be restricted (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") in patients with nephrogenic DI because it can lead to severe hypernatremia."
]
},
{
"type":"p",
"hlId":"4aa4b6",
"children":[
"Because the treatment of nephrogenic DI is aimed at decreasing solute intake, increasing protein intake (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not appropriate management."
]
}
],
"relatedSection":"mk19_a_np_s2_2_2_2",
"objective":{
"__html":"Manage nephrogenic diabetes insipidus."
},
"references":[
[
"Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015;11:576-588. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26077742",
"target":"_blank"
},
"children":[
"PMID: 26077742"
]
},
" doi:10.1038/nrneph.2015.89"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":59,
"B":7,
"C":30,
"D":4,
"E":0
},
"hlIds":[
"d7158d",
"f8786b",
"64a270",
"cb2b54",
"047c5d",
"c9ea0d",
"c08770",
"0e4f8f",
"9374ce",
"4aa4b6"
]
},
{
"id":"mk19_a_np_q041",
"number":41,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 41",
"stimulus":[
{
"type":"p",
"hlId":"249e8e",
"children":[
"A 28-year-old man is evaluated for hematuria that he noted on awakening and a 3-day history of fever, runny nose, and cough. One year ago, he had an episode of gross hematuria after running a half marathon. Evaluation at that time resulted in a biopsy diagnosis of IgA nephropathy. He has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"db89da",
"children":[
"On physical examination, temperature is 37.9 °C (100.2 °F), and blood pressure is 110/70 mm Hg; other vital signs are normal. The nasal mucosa is edematous, with serous discharge. Examination of the oropharynx reveals erythema without exudate. There is no lymphadenopathy. Lungs are clear to auscultation. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"6e5be6",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.9 mg/dL (79.6 µmol/L); urinalysis shows 3+ blood, trace protein, too numerous to count erythrocytes, and no casts. Streptococcal rapid antigen test is negative."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Amoxicillin"
}
},
{
"letter":"B",
"text":{
"__html":"CT of the abdomen and pelvis"
}
},
{
"letter":"C",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"D",
"text":{
"__html":"Clinical observation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"cac77f",
"hvc":true,
"children":[
"In younger patients with IgA nephropathy, recurrent hematuria in the absence of proteinuria usually portends a benign clinical course and treatment is conservative."
]
},
{
"type":"keypoint",
"hlId":"b082eb",
"hvc":true,
"children":[
"Recurrent gross hematuria, often occurring at the time of an upper respiratory infection or following strenuous exercise, is a common manifestation of IgA nephropathy in younger patients."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"75dddc",
"children":[
"The most appropriate management is clinical observation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient can be reassured that the gross hematuria is related to his underlying IgA nephropathy and will resolve spontaneously. Recurrent gross hematuria, in which the hematuria occurs in the setting of an upper respiratory infection (synpharyngitic hematuria) or after heavy exertion, is a common manifestation of IgA nephropathy in younger patients; it usually portends a benign clinical course with recurrent episodes of gross hematuria without progression to chronic kidney disease. Other predictors of a benign prognosis include a normal serum creatinine concentration and blood pressure as well as minimal proteinuria."
]
},
{
"type":"p",
"hlId":"57635a",
"children":[
"Amoxicillin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") would be indicated to treat streptococcal pharyngitis. However, this diagnosis is unlikely in the presence of cough, the absence of pharyngeal exudate and cervical lymphadenopathy, and a negative rapid antigen test."
]
},
{
"type":"p",
"hlId":"a27ce5",
"children":[
"CT of the abdomen and pelvis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is an appropriate screening test for unexplained gross hematuria, which may be due to the presence of a stone or mass in the kidney or bladder. However, this patient has a known diagnosis of IgA nephropathy and a classic presentation of synpharyngitic hematuria; the gross hematuria is well explained, and imaging is not required."
]
},
{
"type":"p",
"hlId":"4f5057",
"children":[
"Glucocorticoid therapy, such as with prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), is unnecessary in a mild form of nonprogressive IgA nephropathy. The use of immunosuppression in progressive IgA nephropathy remains controversial: The STOP-IgAN study showed no benefit of glucocorticoid therapy in slowing the decline of kidney function, and the TESTING study was terminated early due to significantly increased risk for adverse events in patients treated with glucocorticoids. Therefore, glucocorticoid therapy is reserved for severe forms of IgA nephropathy deemed high risk for rapid progression to end-stage kidney disease."
]
}
],
"relatedSection":"mk19_a_np_s6_4_4_1_4",
"objective":{
"__html":"Manage gross hematuria in IgA nephropathy."
},
"references":[
[
"Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38:435-42. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30177015",
"target":"_blank"
},
"children":[
"PMID: 30177015"
]
},
" doi:10.1016/j.semnephrol.2018.05.013"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":5,
"B":8,
"C":21,
"D":66,
"E":0
},
"hlIds":[
"249e8e",
"db89da",
"6e5be6",
"cb2b54",
"cac77f",
"b082eb",
"75dddc",
"57635a",
"a27ce5",
"4f5057"
]
},
{
"id":"mk19_a_np_q042",
"number":42,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 42",
"stimulus":[
{
"type":"p",
"hlId":"00740d",
"children":[
"A 45-year-old man is evaluated during a routine visit in September. He has advanced chronic kidney disease due to IgA nephropathy. Medical history is also significant for chickenpox but with no history of shingles. Medications are carvedilol, diltiazem, lisinopril, and sevelamer. His vaccination history includes completion of only required childhood vaccinations and recent COVID-19 immunization."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b626bf",
"class":"cell text l",
"children":[
"Hepatitis A virus IgM antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"67b35c",
"class":"cell text l",
"children":[
"Hepatitis C virus antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"7014ec",
"children":[
"Inactivated influenza vaccine is administered."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"fb497a",
"children":[
"Which of the following is the most appropriate additional vaccine to administer at this visit?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hepatitis A vaccine"
}
},
{
"letter":"B",
"text":{
"__html":"Hepatitis B vaccine"
}
},
{
"letter":"C",
"text":{
"__html":"Herpes zoster recombinant vaccine"
}
},
{
"letter":"D",
"text":{
"__html":"Pneumococcal conjugate vaccine"
}
},
{
"letter":"E",
"text":{
"__html":"Pneumococcal polysaccharide vaccine"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"795579",
"children":[
"Patients with chronic kidney disease and end-stage kidney disease or on hemodialysis should receive either the 20-valent pneumococcal conjugate vaccine or the 15-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal conjugate vaccine."
]
},
{
"type":"keypoint",
"hlId":"f6ec54",
"children":[
"Patients with chronic kidney disease and end-stage kidney disease are at increased risk for influenza-related morbidity and mortality and should receive the influenza vaccine annually."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"96467f",
"children":[
"The most appropriate additional vaccine to administer at this visit is the pneumococcal conjugate vaccine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Chronic kidney disease (CKD) is an indication for pneumococcal vaccination. Three pneumococcal vaccines are available: the 15-valent pneumococcal conjugate vaccine (PCV15), the 20-valent pneumococcal conjugate vaccine (PCV20), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23). In adults aged 19 to 64 years with CKD, pneumococcal vaccination with either PCV20 or both PCV15 and PPSV23 is indicated. If PCV15 and PPSV23 are administered, PCV15 should be administered first followed by PPSV23 (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E)"
]
},
" at least 8 weeks later. In addition, patients with CKD and end-stage kidney disease (ESKD) are at increased risk for influenza-related morbidity and mortality and should be strongly encouraged to receive the influenza vaccine annually. Influenza vaccination has been shown to decrease influenza-related mortality and decrease hospitalization for acute coronary syndrome and heart failure in patients who are vaccinated."
]
},
{
"type":"p",
"hlId":"9acc5f",
"children":[
"Patients with CKD and ESKD should receive vaccines for hepatitis A or herpes zoster (shingles) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, C"
]
},
") and others (for example, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) according to the same guidelines as the general population based on age (>50 years) for the herpes zoster vaccine and hepatitis A vaccine for upcoming travel to endemic areas, and for adults at risk for hepatitis A virus (HAV) infection or severe disease from HAV infection and for adults requesting protection against HAV without acknowledgment of a risk factor."
]
},
{
"type":"p",
"hlId":"31e51d",
"children":[
"Patients with ESKD who are receiving hemodialysis and blood transfusions are at increased risk for exposure to blood-borne viruses. Hepatitis B vaccination (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is indicated for patients with CKD who are not already immune. For patients on hemodialysis, the vaccine should be administered as part of the infection control program at the dialysis center. Patients with ESKD require a higher dose of vaccine to enhance the likelihood of immune response. Serology indicates that this patient is immune to hepatitis B; therefore, vaccination is not indicated."
]
}
],
"relatedSection":"mk19_a_np_s12_9_2_4_5",
"objective":{
"__html":"Manage vaccinations in a patient with chronic kidney disease."
},
"references":[
[
"Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75:417-425. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31585683",
"target":"_blank"
},
"children":[
"PMID: 31585683"
]
},
" doi:10.1053/j.ajkd.2019.06.014"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":9,
"B":2,
"C":9,
"D":40,
"E":40
},
"hlIds":[
"00740d",
"a462a3",
"b626bf",
"ffb935",
"2ff2e8",
"ffb935",
"3a242b",
"328929",
"67b35c",
"ffb935",
"7014ec",
"fb497a",
"795579",
"f6ec54",
"96467f",
"9acc5f",
"31e51d"
]
},
{
"id":"mk19_a_np_q043",
"number":43,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 43",
"stimulus":[
{
"type":"p",
"hlId":"17ede0",
"children":[
"A 66-year-old man is evaluated in the hospital for acute kidney injury following percutaneous coronary angiography and stent placement 48 hours ago. His medical history is also significant for hypertension, hyperlipidemia, type 2 diabetes mellitus, and diabetic kidney disease. Medications are lisinopril, hydrochlorothiazide, basal and prandial insulin, atorvastatin, metoprolol, clopidogrel, and aspirin."
]
},
{
"type":"p",
"hlId":"917537",
"children":[
"On physical examination, blood pressure is 132/88 mm Hg, and pulse rate is 58/min without postural changes. Skin is warm and dry. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f1fae6",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hematocrit",
"children":[
"Hematocrit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8b47ff",
"class":"cell text l",
"children":[
"36%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"56c72c",
"class":"cell text l",
"children":[
"127,000/µL (127 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1e3aa5",
"class":"cell text l",
"children":[
"54 mg/dL (19.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"51149d",
"class":"cell text l",
"children":[
"3.6 mg/dL (318.2 µmol/L); on admission, 3.3 mg/dL (291.7 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"169298",
"class":"cell text l",
"children":[
"Specific gravity 1.010; pH 5.5; trace protein; trace leukocytes; 1-3 erythrocytes/hpf; 1-3 leukocytes/hpf; 3-5 granular casts/hpf"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"e57e8b",
"children":[
"Kidney ultrasound shows a 10.5-cm right kidney, 11.3-cm left kidney, and normal cortical echogenicity; there is no hydronephrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acute tubular necrosis"
}
},
{
"letter":"B",
"text":{
"__html":"Atheroembolic-induced acute kidney injury"
}
},
{
"letter":"C",
"text":{
"__html":"Hemolytic uremic syndrome"
}
},
{
"letter":"D",
"text":{
"__html":"Prerenal acute kidney injury"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"e47d2d",
"children":[
"Contrast-associated nephropathy is a cause of acute tubular necrosis and is characterized by an increase in the serum creatinine 24 to 48 hours after contrast exposure."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"058753",
"children":[
"The most likely diagnosis is acute tubular necrosis (ATN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") due to contrast-associated nephropathy (CAN). CAN is characterized by an abrupt increase in the serum creatinine level 24 to 48 hours after contrast exposure. This patient's risk factors for CAN include chronic kidney injury, type 2 diabetes mellitus, and a presumptive large volume contrast exposure. Laboratory findings consistent with the diagnosis include a blood urea nitrogen (BUN)-creatinine ratio of 15:1, urine specific gravity of 1.010 (isosthenuria), urine sodium >40 mEq/L (40 mmol/L), and a urine sediment with a few granular casts; notably, pigmented granular casts do not have to be present to diagnose ATN."
]
},
{
"type":"p",
"hlId":"3892f6",
"children":[
"Atheroembolic-induced acute kidney injury (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") after a vascular intervention is characterized by a slow, stuttering rise in the serum creatinine level, often not apparent until several days or weeks after the procedure. It is often accompanied by stigmata of atheroemboli to the lower extremities, including livedo reticularis. In this patient, serum creatinine levels began rising 24 hours after the procedure and he has no skin findings."
]
},
{
"type":"p",
"hlId":"10f7c4",
"children":[
"Clopidogrel can be a cause of hemolytic uremic syndrome (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). However, this syndrome is typically characterized by a profound decrease in hemoglobin levels and platelet counts, and a longer exposure to the offending agent would be expected before the full manifestations develop. In this patient, the anemia and thrombocytopenia are modest and nonspecific."
]
},
{
"type":"p",
"hlId":"e96abb",
"children":[
"Prerenal acute kidney injury (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is unlikely in the absence of physical findings supporting hypovolemia or reduced cardiac output. Additionally, BUN-creatinine ratio >20:1, urine specific gravity >1.020, and a normal microscopic urinalysis or presence of hyaline casts are more typical."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_1_2",
"objective":{
"__html":"Diagnose contrast-associated acute tubular necrosis."
},
"references":[
[
"Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146-2155. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31141635",
"target":"_blank"
},
"children":[
"PMID: 31141635"
]
},
" doi:10.1056/NEJMra1805256"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":55,
"B":28,
"C":2,
"D":16,
"E":0
},
"hlIds":[
"17ede0",
"917537",
"a462a3",
"f1fae6",
"8b47ff",
"fcac73",
"56c72c",
"29d161",
"1e3aa5",
"f461b2",
"51149d",
"747c2a",
"169298",
"e57e8b",
"413696",
"e47d2d",
"058753",
"3892f6",
"10f7c4",
"e96abb"
]
},
{
"id":"mk19_a_np_q044",
"number":44,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 44",
"stimulus":[
{
"type":"p",
"hlId":"4fee59",
"children":[
"A 45-year-old woman is evaluated in the emergency department after ingesting 50 aspirin. She is alert and reports symptoms of nausea and tinnitus. Activated charcoal is administered."
]
},
{
"type":"p",
"hlId":"dd3535",
"children":[
"On physical examination, the patient is afebrile. Blood pressure is 130/70 mm Hg, pulse rate is 92/min, and respiration rate is 32/min. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfe04",
"class":"cell text l",
"children":[
"0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"db618e",
"class":"cell text l",
"children":[
"139 mEq/L (139 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"48cea7",
"class":"cell text l",
"children":[
"4.0 mEq/L (4.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9342ac",
"class":"cell text l",
"children":[
"91 mEq/L (91 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a84a64",
"class":"cell text l",
"children":[
"14 mEq/L (14 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"18044b",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, arterial (ambient air)",
"children":[
"Arterial blood gases"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"397dff",
"class":"cell text li",
"children":[
"pH"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cc060a",
"class":"cell text l",
"children":[
"7.45"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"dd372e",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Pco2, arterial (ambient air)",
"children":[
"P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ea6011",
"class":"cell text l",
"children":[
"21 mm Hg (2.8 kPa)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"890527",
"class":"cell text l",
"children":[
"Salicylate"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"314890",
"class":"cell text l",
"children":[
"65 µg/mL (470 µmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acetazolamide"
}
},
{
"letter":"B",
"text":{
"__html":"Hemodialysis"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous 0.9% saline"
}
},
{
"letter":"D",
"text":{
"__html":"Intravenous sodium bicarbonate"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"d3e94e",
"children":[
"Salicylate toxicity related to the ingestion of aspirin commonly manifests as a primary respiratory alkalosis or complex mixed acid-base disorders."
]
},
{
"type":"keypoint",
"hlId":"3ce70d",
"children":[
"Intravenous sodium bicarbonate administration is used to treat patients with salicylate toxicity, as it increases urinary elimination of salicylate (with a goal of a urine pH >7.5) and protects the patient from central nervous system toxicity."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"bcf86e",
"children":[
"The most appropriate treatment is intravenous sodium bicarbonate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient has salicylate toxicity related to the ingestion of aspirin and has developed a complex mixed acid-base disorder characterized by respiratory alkalosis, increased anion gap metabolic acidosis, and metabolic alkalosis. Intravenous sodium bicarbonate administration increases urinary elimination of salicylate (with a goal of a urine pH >7.5) and protects the patient from central nervous system (CNS) toxicity. Maintaining the serum pH at 7.50 to 7.55 is essential to avoid CNS accumulation of salicylic acid in the brain. Aspirin (acetylsalicylic acid) is rapidly converted to salicylic acid in the body. Acidosis promotes the influx of salicylic acid into the CNS. Increasing the systemic pH with alkali therapy favors the formation of the ionic form of salicylic acid where it is “trapped” in extracellular fluid. The formation of ionic salicylic acid in extracellular fluid creates a favorable concentration gradient for diffusion of salicylic acid from the CNS to the extracellular fluid. Alkalinization of the urine converts urinary salicylic acid to its ionic form, trapping it in the renal tubule and diminishing the diffusion from the renal tubule back into the systemic circulation."
]
},
{
"type":"p",
"hlId":"fb74a9",
"children":[
"Acetazolamide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not indicated in the treatment of salicylate toxicity. Although acetazolamide, a carbonic anhydrase inhibitor, can alkalinize the urine, it does so by reducing bicarbonate reabsorption. The alkaline urine will result in enhanced excretion of salicylic acid; however, the loss of bicarbonate will result in a mild systemic acidosis and will drive salicylate into the CNS."
]
},
{
"type":"p",
"hlId":"bf9eac",
"children":[
"Hemodialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not indicated for this patient. It is indicated for patients with serum salicylate levels >90 to 100 µg/mL (651-724 µmol/L) with acute intoxication and >60 µg/mL (434.4 µmol/L) in chronic administration, or if there is acute kidney injury, cerebral or pulmonary edema, refractory acidemia, or severe alteration of mental status."
]
},
{
"type":"p",
"hlId":"ca29ac",
"children":[
"Forced diuresis with administration of intravenous 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has no role in managing salicylate toxicity, as it will not increase elimination of salicylate in the absence of systemic and urinary alkalinization."
]
}
],
"relatedSection":"mk19_a_np_s3_2_2",
"objective":{
"__html":"Treat salicylate toxicity."
},
"references":[
[
"Palmer BF, Clegg DJ. Salicylate toxicity. N Engl J Med. 2020;382(26):2544-2555. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32579814",
"target":"_blank"
},
"children":[
"PMID: 32579814"
]
},
" doi:10.1056/NEJMra2010852"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":4,
"B":9,
"C":24,
"D":64,
"E":0
},
"hlIds":[
"4fee59",
"dd3535",
"a462a3",
"f461b2",
"9bfe04",
"89662a",
"d41d8c",
"b99276",
"db618e",
"e92687",
"48cea7",
"a207b1",
"9342ac",
"6827e3",
"a84a64",
"18044b",
"d41d8c",
"397dff",
"cc060a",
"dd372e",
"ea6011",
"890527",
"314890",
"1054f1",
"d3e94e",
"3ce70d",
"bcf86e",
"fb74a9",
"bf9eac",
"ca29ac"
]
},
{
"id":"mk19_a_np_q045",
"number":45,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 45",
"stimulus":[
{
"type":"p",
"hlId":"156ba3",
"children":[
"A 19-year-old woman is evaluated for a 2-week history of fatigue, poor appetite, arthralgia of the hands and knees, and a rash, all of which appeared 1 day after a trip to the beach. She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"16a525",
"children":[
"On physical examination, vital signs are normal. A malar rash characterized by pink-violet papules and plaques with sparing of the nasolabial folds is noted. The remainder of the examination, including joint examination, is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fa57a4",
"class":"cell text l",
"children":[
"3.1 g/dL (31 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"687cd3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C3, serum",
"children":[
"C3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ebe1cb",
"class":"cell text l",
"children":[
"50 mg/dL (500 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"dcfa5e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C4, serum",
"children":[
"C4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a0e488",
"class":"cell text l",
"children":[
"9 mg/dL (90 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0f19a0",
"class":"cell text l",
"children":[
"1.1 mg/dL (97.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f992e5",
"class":"cell text l",
"children":[
"Titer, 1:160"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"71b202",
"class":"cell text l",
"children":[
"3+ blood; 3+ protein; many erythrocytes; occasional dysmorphic erythrocytes; rare erythrocyte casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"d9342c",
"children":[
"Kidney ultrasound shows kidneys of normal size and echogenicity."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Erythrocyte sedimentation rate"
}
},
{
"letter":"B",
"text":{
"__html":"Extractable nuclear antigen panel"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney biopsy"
}
},
{
"letter":"D",
"text":{
"__html":"Skin biopsy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"121b6a",
"children":[
"Kidney biopsy is the definitive diagnostic test for lupus nephritis and, based on histologic findings, is crucial in determining treatment."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"8b77f7",
"children":[
"Kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is the most appropriate diagnostic test to perform next. The 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (SLE) include having antinuclear antibody (ANA) positivity at least once as obligatory entry criterion, followed by additive weighted criteria grouped into seven clinical and three immunologic domains. Patients with the entry criteria of a positive ANA, at least one clinical criterion, and having accumulated ≥10 points are classified as having SLE with a sensitivity of 96.1% and specificity of 93.4%. This patient has a positive ANA, acute cutaneous lupus erythematosus, and low serum complement levels (10 total points). The classic pattern of lupus nephritis is an immune complex–mediated glomerulonephritis with a varied pathology that includes six distinct classes of disease. The biopsy is crucial not only to establish the diagnosis but also to indicate which class of lupus nephritis she has, as the approach to treating lupus nephritis is guided by histologic class and the degree of kidney function impairment."
]
},
{
"type":"p",
"hlId":"ae2043",
"children":[
"Erythrocyte sedimentation rate (ESR) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") measurement can be checked serially alongside other clinical parameters to gauge disease activity. However, an ESR measurement would not help in determining the class of lupus nephritis needed to choose optimal therapy."
]
},
{
"type":"p",
"hlId":"cae251",
"children":[
"This patient may test positive for one or more antibodies on the extractable nuclear antigen (ENA) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") panel (e.g., anti-Smith, anti-U1-RNP, anti-Ro/SSA, anti-La/SSB), but this antibody panel test is not required to make a diagnosis of SLE. In addition, the results of an ENA panel are not expected to influence treatment plans compared with those of a kidney biopsy."
]
},
{
"type":"p",
"hlId":"ce5cc9",
"children":[
"The diagnosis of acute cutaneous lupus erythematosus is primarily clinical. A skin biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is indicated when the clinical diagnosis is in doubt. In this case, the appearance of the classic malar rash in the context of positive SLE-associated immunologic findings make a skin biopsy unnecessary. Finally, a skin biopsy would not shed any light on the patient's kidney manifestations or guide therapy for either the patient's skin or kidney disease."
]
}
],
"relatedSection":"mk19_a_np_s6_4_4_3_3",
"objective":{
"__html":"Diagnose lupus nephritis."
},
"references":[
[
"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12:825-35. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27821390",
"target":"_blank"
},
"children":[
"PMID: 27821390"
]
},
" doi:10.2215/CJN.05780616"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":3,
"B":22,
"C":69,
"D":6,
"E":0
},
"hlIds":[
"156ba3",
"16a525",
"a462a3",
"4590ed",
"fa57a4",
"687cd3",
"ebe1cb",
"dcfa5e",
"a0e488",
"f461b2",
"0f19a0",
"b534b1",
"f992e5",
"747c2a",
"71b202",
"d9342c",
"ab9d96",
"121b6a",
"8b77f7",
"ae2043",
"cae251",
"ce5cc9"
]
},
{
"id":"mk19_a_np_q046",
"number":46,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 46",
"stimulus":[
{
"type":"p",
"hlId":"471e4e",
"children":[
"A 74-year-old woman is evaluated during a follow-up visit for hypertension and slowly progressive chronic kidney disease. She reports that she feels well and has no symptoms. Medications are atenolol, cholecalciferol, hydralazine, nifedipine, simvastatin, and sodium bicarbonate."
]
},
{
"type":"p",
"hlId":"6e510c",
"children":[
"On physical examination, blood pressure is 130/70 mm Hg; other vital signs are normal. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"1b7d39",
"children":[
"Laboratory studies show an ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" of 28 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Arteriovenous fistula placement evaluation"
}
},
{
"letter":"B",
"text":{
"__html":"Dialysis initiation"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney transplant evaluation"
}
},
{
"letter":"D",
"text":{
"__html":"Renal replacement therapy education"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"795d86",
"children":[
"Patients with progressive chronic kidney disease and an estimated glomerular filtration rate <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" should be referred to a renal replacement therapy education program."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c9abf1",
"children":[
"This most appropriate management is renal replacement therapy (RRT) education (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient with slowly progressive chronic kidney disease (CKD) is at borderline stage G3/G4. When estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", the patient should be referred for RRT education. It is appropriate to begin the education process for the patient to learn about RRT options, including in-center and home hemodialysis, peritoneal dialysis, kidney transplantation, and non-dialytic medical management, to make an informed decision in the future. An RRT education session empowers the patient to make decisions regarding venous access or preemptive kidney transplant to ensure a controlled initiation of RRT. It also helps prevents the risk for initiating dialysis emergently. Patients who receive preparatory RRT education before they are diagnosed with end-stage kidney disease are more likely to select a home modality for RRT, be listed for a kidney transplant, or receive a preemptive kidney transplant and may have a mortality benefit compared with patients who do not receive similar education."
]
},
{
"type":"p",
"hlId":"49896c",
"children":[
"Evaluation for arteriovenous fistula (AVF) placement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is indicated after the patient has learned about RRT options and chooses to receive hemodialysis in the future. After this decision, the patient is referred for arm-access evaluation. Patients with suitable anatomy should have AVF placement well in advance of anticipated ESKD to allow adequate maturation of the vein to allow robust blood flow needed for hemodialysis."
]
},
{
"type":"p",
"hlId":"2469d9",
"children":[
"For patients amenable to dialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), studies demonstrate no benefit in starting it in asymptomatic patients or at a specific eGFR cutoff compared with watchful waiting and initiating dialysis for symptoms or metabolic abnormalities that are refractory to medical treatment."
]
},
{
"type":"p",
"hlId":"b46a69",
"children":[
"Patients should be referred to a kidney transplant center for evaluation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") when the eGFR is 15 to 29 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Early referral is important because preemptive kidney transplants (transplants before needing dialysis) are associated with improved clinical outcomes compared with receiving a transplant after starting dialysis. Early referral also allows adequate time to identify suitable living donors; if no living donor is available, early listing is essential to begin the waiting process for a deceased-donor kidney. Referral for evaluation will be appropriate if this patient selects this mode of RRT following RRT education."
]
}
],
"relatedSection":"mk19_a_np_s12_9",
"objective":{
"__html":"Prepare a patient for end-stage kidney disease by providing renal replacement therapy education."
},
"references":[
[
"Kurella Tamura M, Li S, Chen SC, et al. Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. Kidney Int. 2014;85:686-692. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24067435",
"target":"_blank"
},
"children":[
"PMID: 24067435"
]
},
" doi:10.1038/ki.2013.369"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":17,
"B":2,
"C":15,
"D":66,
"E":0
},
"hlIds":[
"471e4e",
"6e510c",
"1b7d39",
"cb2b54",
"795d86",
"c9abf1",
"49896c",
"2469d9",
"b46a69"
]
},
{
"id":"mk19_a_np_q047",
"number":47,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 47",
"stimulus":[
{
"type":"p",
"hlId":"3440ac",
"children":[
"A 72-year-old man is evaluated for an ulcerating, painful lesion on his left calf that began as a patch of red skin 2 to 3 weeks ago. He has dialysis-dependent end-stage kidney disease, atrial fibrillation, and hypertension. Medications are amlodipine, calcium acetate, calcitriol, insulin, and warfarin. There have been no recent changes in his medications."
]
},
{
"type":"p",
"hlId":"5dab55",
"children":[
"On physical examination, vital signs are normal. Skin findings are ",
{
"type":"figure-link",
"target":"mk19_a_np_mcq_f047",
"wrapId":"1",
"children":[
"shown"
]
},
". There are no other skin changes, lesions, or rash."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_np_mcq_f047"
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4ffae8",
"class":"cell text l",
"children":[
"INR"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"822143",
"class":"cell text l",
"children":[
"2.5"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d8afe5",
"class":"cell text l",
"children":[
"9.6 mg/dL (2.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"37c918",
"class":"cell text l",
"children":[
"3.1 mg/dL (1.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"ca2815",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Parathyroid hormone, serum",
"children":[
"Parathyroid hormone"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d332d9",
"class":"cell text l",
"children":[
"361 pg/mL (361 ng/L)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"6914cc",
"children":[
"A skin punch biopsy shows calcifications in the subcutaneous tissue within necrotic lipocytes and within the walls of small blood vessels. There is confluent epidermal necrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Calciphylaxis"
}
},
{
"letter":"B",
"text":{
"__html":"Leukocytoclastic vasculitis"
}
},
{
"letter":"C",
"text":{
"__html":"Venous stasis ulcer"
}
},
{
"letter":"D",
"text":{
"__html":"Warfarin skin necrosis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"5e0119",
"children":[
"Calciphylaxis (calcific uremic arteriolopathy) is characterized by calcifications in the dermal arterioles resulting in painful ischemic skin lesions and is an increasingly recognized complication of end-stage kidney disease."
]
},
{
"type":"keypoint",
"hlId":"cd50f0",
"children":[
"Many patients with calciphylaxis have severe secondary hyperparathyroidism and elevated calcium-phosphorous product."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"4743f4",
"children":[
"The most likely diagnosis is calciphylaxis (calcific uremic arteriolopathy) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient with dialysis-dependent end-stage kidney disease (ESKD) has developed a painful ulcer on the left calf with central necrosis and a skin biopsy showing vascular calcification. Calciphylaxis develops from pathologic calcifications in the dermal arterioles, leading to thrombosis, ischemia, and necrosis of the overlying skin. It is a painful and often life-threatening complication of ESKD and is associated with a high risk of mortality due to secondary infection and sepsis. Many patients with calciphylaxis have severe secondary hyperparathyroidism and elevated calcium-phosphorous product. However, patients such as this one with normalized serum calcium and phosphate levels are also at risk; calciphylaxis is an increasingly recognized complication of ESKD in the dialysis community. There are no FDA-approved treatments for calciphylaxis. However, calcimimetics are used to suppress parathyroid hormone, and data from a large study show fewer cases of calciphylaxis among treated patients. Sodium thiosulfate, an anti-inflammatory agent, is also routinely used for patients with calciphylaxis."
]
},
{
"type":"p",
"hlId":"1aab1b",
"children":[
"Leukocytoclastic vasculitis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") should be considered in the differential diagnosis of a nonhealing leg ulcer, but patients typically present with palpable purpura, not a rapidly advancing cutaneous ulcer, and the biopsy would show perivenular and intramural inflammatory infiltrates rather than the vascular calcifications seen in this patient."
]
},
{
"type":"p",
"hlId":"3f75f6",
"children":[
"Venous stasis ulcers (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a chronic skin condition associated with other signs of venous insufficiency (edema, varicosities, hyperpigmentation), are irregularly shaped, shallow, and often weep serous fluid. The ulcers are rarely necrotic. The sudden appearance of a necrotic ulcer is not indicative of a venous ulcer."
]
},
{
"type":"p",
"hlId":"5f0d4e",
"children":[
"Although warfarin-related necrosis could cause necrotic skin ulceration (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), it would be expected to occur when the agent was initiated, often with large loading doses, and would not show calcifications in the underlying vessel walls on biopsy but rather thrombosis."
]
}
],
"relatedSection":"mk19_a_np_s12_9_3_4",
"objective":{
"__html":"Diagnosis calciphylaxis in end-stage kidney disease."
},
"references":[
[
"Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378:1704-1714. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29719190",
"target":"_blank"
},
"children":[
"PMID: 29719190"
]
},
" doi:10.1056/NEJMra1505292"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":84,
"B":4,
"C":1,
"D":11,
"E":0
},
"figuresContent":{
"mk19_a_np_mcq_f047":{
"id":"mk19_a_np_mcq_f047",
"number":47,
"bookId":"np",
"legend":"",
"footnotes":[

],
"imageInfo":{
"hash":"1434fedd53a838e959ae97a1912c1816",
"height":562,
"width":900,
"extension":"jpg"
}
}
},
"hlIds":[
"3440ac",
"5dab55",
"a462a3",
"4ffae8",
"822143",
"1a4da4",
"d8afe5",
"a4922e",
"37c918",
"ca2815",
"d332d9",
"6914cc",
"413696",
"5e0119",
"cd50f0",
"4743f4",
"1aab1b",
"3f75f6",
"5f0d4e"
]
},
{
"id":"mk19_a_np_q048",
"number":48,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 48",
"stimulus":[
{
"type":"p",
"hlId":"700e0a",
"children":[
"A 27-year-old woman is evaluated for hypertension. At her routine visit 6 months ago, her blood pressure was 120/76 mm Hg. There is no family history of hypertension. She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"aac5a9",
"children":[
"On physical examination, blood pressure is 146/92 mm Hg in the right arm and 148/94 mm Hg in the left arm; pulse rate is 68/min. A systolic-diastolic abdominal bruit over the right lower quadrant is heard. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"38947c",
"class":"cell text l",
"children":[
"0.8 mg/dL (70.7 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8153ca",
"class":"cell text l",
"children":[
"4.2 mEq/L (4.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"167259",
"class":"cell text l",
"children":[
"140 mEq/L (140 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ad4a56",
"class":"cell text l",
"children":[
"No blood or protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a661de",
"class":"cell text l",
"children":[
"Pregnancy test"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Plasma aldosterone concentration/plasma renin activity ratio"
}
},
{
"letter":"B",
"text":{
"__html":"Plasma fractionated metanephrines"
}
},
{
"letter":"C",
"text":{
"__html":"Renal artery CT angiography"
}
},
{
"letter":"D",
"text":{
"__html":"Urine albumin-creatinine ratio"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"43f95f",
"children":[
"Fibromuscular dysplasia typically occurs in young persons, particularly women <35 years of age, with the abrupt onset of hypertension."
]
},
{
"type":"keypoint",
"hlId":"c70688",
"children":[
"Renal artery CT angiography is the most appropriate diagnostic test to evaluate for fibromuscular dysplasia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"f838b2",
"children":[
"The most appropriate diagnostic test to perform next is renal artery CT angiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Fibromuscular dysplasia should be considered in this young woman with new-onset hypertension and an abdominal bruit. Fibromuscular dysplasia is a noninflammatory, nonatherosclerotic form of renovascular disease of unknown etiology that affects medium-sized arteries. Fibromuscular dysplasia typically occurs in young persons, particularly women <35 years of age. The abrupt onset of hypertension in a young patient with a lateralizing abdominal bruit suggests the diagnosis. For patients with suspected renal artery fibromuscular dysplasia, CT angiography (CTA) is the initial imaging modality of choice. Contrast-enhanced magnetic resonance angiography (MRA) is an alternative when CTA is contraindicated. Duplex ultrasound may be used as the first diagnostic procedure in specialized centers with extensive expertise with this imaging modality. Patients with fibromuscular dysplasia are at risk for aneurysm formation and/or dissection, most commonly of the renal, carotid, and intracranial arteries. Patients with fibromuscular dysplasia should undergo at least one-time assessment for intracranial aneurysm with brain CTA or MRA."
]
},
{
"type":"p",
"hlId":"9333ed",
"children":[
"A plasma aldosterone concentration/plasma renin activity ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is obtained in patients with a clinical suspicion for primary hyperaldosteronism; this patient does not have hypokalemia or a metabolic alkalosis that would raise suspicion for hyperaldosteronism. Furthermore, primary hyperaldosteronism cannot explain the abdominal bruit."
]
},
{
"type":"p",
"hlId":"f998b8",
"children":[
"Plasma fractionated metanephrines (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") are obtained to screen for a pheochromocytoma. The absence of episodic palpitations, headaches, and tachycardia make pheochromocytoma a less likely diagnosis in this patient and it cannot explain the abdominal bruit."
]
},
{
"type":"p",
"hlId":"deb275",
"children":[
"There is no indication to obtain a urine albumin-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), as her urinalysis does not show blood that would raise suspicion for glomerulonephritis, which would be another cause of secondary hypertension."
]
}
],
"relatedSection":"mk19_a_np_s4_11_2_3",
"objective":{
"__html":"Diagnose fibromuscular dysplasia."
},
"references":[
[
"Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24:164-189. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30648921",
"target":"_blank"
},
"children":[
"PMID: 30648921"
]
},
" doi:10.1177/1358863X18821816"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":11,
"B":3,
"C":84,
"D":2,
"E":0
},
"hlIds":[
"700e0a",
"aac5a9",
"a462a3",
"6827e3",
"075484",
"f461b2",
"38947c",
"e92687",
"8153ca",
"b99276",
"167259",
"747c2a",
"ad4a56",
"a661de",
"ffb935",
"ab9d96",
"43f95f",
"c70688",
"f838b2",
"9333ed",
"f998b8",
"deb275"
]
},
{
"id":"mk19_a_np_q049",
"number":49,
"bookId":"np",
"correctAnswer":"E",
"title":"Question 49",
"stimulus":[
{
"type":"p",
"hlId":"a860d7",
"children":[
"A 55-year-old man is evaluated for a 4-month history of persistent hyperkalemia and intermittent diarrhea. Medical history is significant for long-standing type 2 diabetes mellitus and hypertension. Medications are metformin, atorvastatin, atenolol, and amlodipine."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"876016",
"class":"cell text l",
"children":[
"5.3 mEq/L (5.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"627ee2",
"class":"cell text l",
"children":[
"112 mEq/L (112 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2480ef",
"class":"cell text l",
"children":[
"56 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"417485",
"class":"cell text l",
"children":[
"Specific gravity 1.020; pH 5.0; no blood; no leukocytes; no ketones"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9b00f9",
"class":"cell text l",
"children":[
"45 mEq/L (45 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a54671",
"class":"cell text l",
"children":[
"Urine potassium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"522366",
"class":"cell text l",
"children":[
"10 mEq/L (10 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c1bef6",
"class":"cell text l",
"children":[
"Urine chloride"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c1cb9f",
"class":"cell text l",
"children":[
"40 mEq/L (40 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"5a8e02",
"children":[
"Which of the following is the most likely cause of this patient's hyperkalemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Atenolol"
}
},
{
"letter":"B",
"text":{
"__html":"Chronic kidney disease"
}
},
{
"letter":"C",
"text":{
"__html":"Diarrhea"
}
},
{
"letter":"D",
"text":{
"__html":"Type 1 (hypokalemic distal) renal tubular acidosis"
}
},
{
"letter":"E",
"text":{
"__html":"Type 4 (hyperkalemic distal) renal tubular acidosis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"d47d35",
"children":[
"Diabetes mellitus is a common cause of type 4 (hyperkalemic distal) renal tubular acidosis characterized by hyperkalemia, a normal anion gap metabolic acidosis, and a urine pH <5.5."
]
},
{
"type":"keypoint",
"hlId":"eacf92",
"children":[
"Drug-induced type 4 (hyperkalemic distal) renal tubular acidosis can be caused by ACE inhibitors, angiotensin receptor blockers, heparin, and NSAIDs."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"12ca97",
"children":[
"The most likely cause of this patient's hyperkalemia is type 4 (hyperkalemic distal) renal tubular acidosis (RTA) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"). Type 4 RTA results from either aldosterone deficiency or resistance. Primary adrenal insufficiency (Addison disease) or hyporeninemic hypoaldosteronism may cause aldosterone deficiency. Hyporeninemic hypoaldosteronism is a more common cause and may occur in the presence of various kidney diseases, most often diabetes mellitus. Aldosterone resistance is seen with tubulointerstitial disease, including urinary obstruction, sickle cell disease, medullary cystic kidney disease, and kidney transplant rejection. Drug-induced type 4 RTA can be caused by numerous drugs that reduce aldosterone production, including ACE inhibitors, angiotensin receptor blockers, heparin, and NSAIDs. Patients with type 4 RTA have a positive urine anion gap ([Urine Sodium + Urine Potassium] – Urine Chloride), indicating a reduced excretion of acid in the form of ammonium and chloride but a urine pH <5.5. Hyperkalemia decreases ammonia production with consequent lower ammonium excretion and therefore results in the positive urine anion gap. Due to the inadequate amount of ammonia available to buffer protons, the few protons that are secreted distally will result in the low urine pH (<5.5). Treatment is focused on correcting the underlying cause if possible."
]
},
{
"type":"p",
"hlId":"7fb22c",
"children":[
"Nonselective β-blockers such as atenolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") block the β-2-adrenergic facilitation of potassium uptake by the cells. The increase in serum potassium is usually very modest unless β-blockade occurs in the context of a potassium load. β-Blockers do not cause a metabolic acidosis."
]
},
{
"type":"p",
"hlId":"8db6bf",
"children":[
"Although chronic kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") may result in hyperkalemia and metabolic acidosis, the acidosis does not usually develop until the glomerular filtration rate (GFR) is <40 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", and hyperkalemia is usually not present until stage G4 disease (GFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
")."
]
},
{
"type":"p",
"hlId":"0a9a64",
"children":[
"Although diarrhea (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may be associated with normal anion gap metabolic acidosis, the urine anion gap would be negative; this patient has a positive urine anion gap."
]
},
{
"type":"p",
"hlId":"bdaf37",
"children":[
"The normal anion gap of type 1 (hypokalemic distal) RTA (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") results from a distal tubular defect and associated impaired excretion of hydrogen ions by the distal nephron. Although the urine anion gap is generally positive, type 1 RTA is usually associated with hypokalemia and urine pH >5.5, which are not present in this patient."
]
}
],
"relatedSection":"mk19_a_np_s3_2_3_3",
"objective":{
"__html":"Diagnose type 4 (hyperkalemic distal) renal tubular acidosis."
},
"references":[
[
"Yaxley J, Pirrone C. Review of the diagnostic evaluation of renal tubular acidosis. Ochsner J. 2016;16:525-530. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27999512",
"target":"_blank"
},
"children":[
"PMID: 27999512"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":3,
"C":3,
"D":6,
"E":86
},
"hlIds":[
"a860d7",
"f8786b",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"876016",
"a207b1",
"627ee2",
"6827e3",
"653d7c",
"77db81",
"2480ef",
"747c2a",
"417485",
"e331de",
"9b00f9",
"a54671",
"522366",
"c1bef6",
"c1cb9f",
"5a8e02",
"d47d35",
"eacf92",
"12ca97",
"7fb22c",
"8db6bf",
"0a9a64",
"bdaf37"
]
},
{
"id":"mk19_a_np_q050",
"number":50,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 50",
"stimulus":[
{
"type":"p",
"hlId":"28bc6a",
"class":"invalid",
"children":[
"This question has been invalidated as a result of postpublication analysis and/or new data that are relevant to the question. CME credit and ABIM MOC points will be honored for this invalidated question."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"4e9c50",
"children":[
"Please select option A for CME and MOC credit."
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Select this option"
}
},
{
"letter":"B",
"text":{
"__html":"Do not select"
}
},
{
"letter":"C",
"text":{
"__html":"Do not select"
}
},
{
"letter":"D",
"text":{
"__html":"Do not select"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2a2d0d",
"children":[
"Invalidated question"
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2a2d0d",
"children":[
"Invalidated question"
]
}
],
"invalidated":true,
"relatedSection":null,
"objective":{
"__html":"Invalidated question"
},
"references":[

],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":80,
"B":14,
"C":4,
"D":2,
"E":0
},
"hlIds":[
"28bc6a",
"4e9c50",
"2a2d0d",
"2a2d0d"
]
},
{
"id":"mk19_a_np_q051",
"number":51,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 51",
"stimulus":[
{
"type":"p",
"hlId":"29a6a2",
"children":[
"A 45-year-old man is evaluated in the emergency department for painful myalgia of his legs and difficulty walking after running in a 10-kilometer race. Since the race, he has had minimal output of dark brown urine. He has hyperlipidemia treated with high-intensity atorvastatin."
]
},
{
"type":"p",
"hlId":"0e87b4",
"children":[
"On physical examination, temperature is 37.7 °C (99.9 °F), blood pressure is 112/67 mm Hg, and pulse rate is 88/min. Mucosae are dry, and skin turgor is diminished. The muscles of the upper and lower extremities are tender to palpation. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ae0dd8",
"class":"cell text l",
"children":[
"7.5 mg/dL (1.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b58be9",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatine kinase, serum",
"children":[
"Creatine kinase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ea455d",
"class":"cell text l",
"children":[
"57,000 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"48f071",
"class":"cell text l",
"children":[
"1.5 mg/dL (132.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9eaf68",
"class":"cell text l",
"children":[
"Electrolytes:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3d979b",
"class":"cell text l",
"children":[
"137 mEq/L (137 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"876016",
"class":"cell text l",
"children":[
"5.3 mEq/L (5.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d95465",
"class":"cell text l",
"children":[
"19 mEq/L (19 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6116ee",
"class":"cell text l",
"children":[
"6.3 mg/dL (2.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"07e6a7",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Urate, serum",
"children":[
"Urate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"391a87",
"class":"cell text l",
"children":[
"9.4 mg/dL (0.55 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"91ee3d",
"class":"cell text l",
"children":[
"Specific gravity 1.012; pH 5.5; 3+ blood; trace protein; 1-2 erythrocytes/hpf and pigmented granular casts/hpf"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"bc5c0d",
"children":[
"Which of the following is the most likely cause of this patient's findings?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Immune-mediated necrotizing myopathy"
}
},
{
"letter":"B",
"text":{
"__html":"Inflammatory myopathy"
}
},
{
"letter":"C",
"text":{
"__html":"March hemoglobinuria"
}
},
{
"letter":"D",
"text":{
"__html":"Rhabdomyolysis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9d711d",
"children":[
"Rhabdomyolysis is associated with elevated serum creatinine and creatine kinase levels and may be associated with hyperkalemia, hypocalcemia, hyperphosphatemia, hyperuricemia, increased lactate dehydrogenase concentration, and metabolic acidosis."
]
},
{
"type":"keypoint",
"hlId":"e7a260",
"children":[
"In patients with acute tubular necrosis caused by rhabdomyolysis, urinary sediment is characterized by amorphous tubular debris, including heavily pigmented granular casts."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"37ca28",
"children":[
"The most likely cause of this patient's findings is rhabdomyolysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") caused by acute muscle injury in the setting of extreme physical exertion. Inadequately conditioned individuals who engage in extreme physical challenges under conditions promoting rapid fluid loss are at risk. Rhabdomyolysis causes acute tubular necrosis (ATN), which is believed to be mediated through a combination of direct toxic effects of myoglobin, associated oxygen-free radical production, and local renal vasoconstriction. Rhabdomyolysis-induced ATN is more likely to occur with serum creatine kinase (CK) levels >5000 U/L. In addition to elevated serum CK and creatinine levels, hyperkalemia, hypocalcemia, hyperphosphatemia, hyperuricemia, metabolic acidosis, increased lactate dehydrogenase concentration, and increased aspartate and alanine aminotransferase levels can occur. Urinary findings include fractional excretion of sodium <1% (caused by renal vasoconstriction), myoglobinuria, pigmented (red) granular casts, and a urine dipstick positive for blood with the absence of a significant number of erythrocytes on urine microscopy."
]
},
{
"type":"p",
"hlId":"725ff2",
"children":[
"Immune-mediated necrotizing myopathy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") typically presents with progressive proximal weakness and an elevated serum CK level; diagnosis is based on muscle biopsy findings of necrotic fibers with limited inflammation. Onset can be triggered by statins, or it may present as a paraneoplastic syndrome. The onset can be acute or slowly progressive but does not cause ATN."
]
},
{
"type":"p",
"hlId":"877310",
"children":[
"The inflammatory myopathies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") commonly present with symmetric proximal muscle weakness without substantial muscle pain or tenderness. Serum CK is almost universally elevated in the inflammatory myopathies and is a marker of muscle damage, but the urinalysis is normal. The onset tends to be insidious and presence of pain or tenderness should prompt considerations of other causes of myopathy."
]
},
{
"type":"p",
"hlId":"8b488e",
"children":[
"March hemoglobinuria (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") develops after physical erythrocyte destruction in the soles of the feet in response to long-distance running or marching. Both hematuria and hemoglobinuria due to hemolysis may result in reddish-brown urine. Serum CK levels in these patients will not be elevated."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_1_3",
"objective":{
"__html":"Diagnose acute tubular necrosis due to rhabdomyolysis."
},
"references":[
[
"Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20:135. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27301374",
"target":"_blank"
},
"children":[
"PMID: 27301374"
]
},
" doi:10.1186/s13054-016-1314-5"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":1,
"B":1,
"C":2,
"D":96,
"E":0
},
"hlIds":[
"29a6a2",
"0e87b4",
"a462a3",
"1a4da4",
"ae0dd8",
"b58be9",
"ea455d",
"f461b2",
"48f071",
"9eaf68",
"d41d8c",
"b99276",
"3d979b",
"e92687",
"876016",
"a207b1",
"21724f",
"6827e3",
"d95465",
"a4922e",
"6116ee",
"07e6a7",
"391a87",
"747c2a",
"91ee3d",
"bc5c0d",
"9d711d",
"e7a260",
"37ca28",
"725ff2",
"877310",
"8b488e"
]
},
{
"id":"mk19_a_np_q052",
"number":52,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 52",
"stimulus":[
{
"type":"p",
"hlId":"28bc6a",
"class":"invalid",
"children":[
"This question has been invalidated as a result of postpublication analysis and/or new data that are relevant to the question. CME credit and ABIM MOC points will be honored for this invalidated question."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"9fd8a8",
"children":[
"Please select option B for CME and MOC credit."
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Do not select"
}
},
{
"letter":"B",
"text":{
"__html":"Select this option"
}
},
{
"letter":"C",
"text":{
"__html":"Do not select"
}
},
{
"letter":"D",
"text":{
"__html":"Do not select"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2a2d0d",
"children":[
"Invalidated question"
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2a2d0d",
"children":[
"Invalidated question"
]
}
],
"invalidated":true,
"relatedSection":null,
"objective":{
"__html":"Invalidated question"
},
"references":[

],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":61,
"B":29,
"C":2,
"D":7,
"E":0
},
"hlIds":[
"28bc6a",
"9fd8a8",
"2a2d0d",
"2a2d0d"
]
},
{
"id":"mk19_a_np_q053",
"number":53,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 53",
"stimulus":[
{
"type":"p",
"hlId":"2f627b",
"children":[
"A 28-year-old woman seeks preconception counseling. She has a 3-year history of primary hypertension. Medical history is otherwise unremarkable, and her only medication is ramipril."
]
},
{
"type":"p",
"hlId":"8bb1e9",
"children":[
"On physical examination, blood pressure is 138/78 mm Hg. Average blood pressure with home blood pressure monitoring is 126/72 mm Hg. Other vital signs are normal. BMI is 30. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"328cab",
"children":[
"Previous evaluation revealed no evidence of retinopathy, left ventricular hypertrophy, or kidney disease."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discontinue ramipril"
}
},
{
"letter":"B",
"text":{
"__html":"Discontinue ramipril; start hydralazine"
}
},
{
"letter":"C",
"text":{
"__html":"Discontinue ramipril; start spironolactone"
}
},
{
"letter":"D",
"text":{
"__html":"No change in therapy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"43f798",
"children":[
"Renin-angiotensin system blocking agents (ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor antagonists) are contraindicated in pregnancy and should be discontinued before conception."
]
},
{
"type":"keypoint",
"hlId":"7fff31",
"children":[
"Chronic hypertension guidelines for pregnant women recommend a systolic blood pressure of 120 to <160 mm Hg and a diastolic pressure of 80 to <110 mm Hg."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"855a11",
"children":[
"The most appropriate management is to discontinue the ACE inhibitor ramipril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") in this patient who is planning pregnancy. Renin-angiotensin system blocking agents, such as ACE inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors, are contraindicated in pregnancy and should be discontinued before conception. Exposure during the second and third trimesters of pregnancy has been associated with neonatal kidney failure and death."
]
},
{
"type":"p",
"hlId":"3ea77a",
"children":[
"In pregnant patients with chronic hypertension, the 2019 American College of Obstetricians and Gynecologists (ACOG) guidelines recommend a systolic blood pressure during pregnancy of 120 to <160 mm Hg and a diastolic pressure of 80 to <110 mm Hg. In the setting of comorbidities or underlying impaired kidney function, treating at lower blood pressure thresholds may be appropriate. This patient's blood pressure is well within this range on treatment, and her blood pressure would be expected to decline during pregnancy. Therefore, monitoring her blood pressure after discontinuation of ramipril without the initiation of a replacement drug is a reasonable approach. If her blood pressure increases beyond the target range during pregnancy, initiation of a drug that is safe in pregnancy is recommended. In that event, first-line therapy includes methyldopa, labetalol, and nifedipine."
]
},
{
"type":"p",
"hlId":"da4c70",
"children":[
"Pregnant patients with acute and severe hypertension have been successfully and safely treated with parenteral hydralazine. There is less experience in its use as a routine oral antihypertensive drug in pregnant women with chronic hypertension. Hydralazine is an unlikely first-line drug (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") for pregnant women needing antihypertensive treatment because it causes reflex tachycardia, often necessitating combination with a β-blocking drug, and results in fluid retention, often requiring the addition of a diuretic."
]
},
{
"type":"p",
"hlId":"b6f743",
"children":[
"Mineralocorticoid receptor antagonists such as spironolactone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") and eplerenone also block the renin-angiotensin system. This class of drug is often used in patients with hyperaldosteronism and resistant hypertension, but it has not been shown to be safe in pregnancy."
]
},
{
"type":"p",
"hlId":"cc46f7",
"children":[
"Not discontinuing the ramipril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") in this patient at this point in time is unsafe. The safest approach is to discontinue any inhibitor of the renin-angiotensin system before conception."
]
}
],
"relatedSection":"mk19_a_np_s11_2_1",
"objective":{
"__html":"Manage chronic hypertension before conception."
},
"references":[
[
"ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133:e26-e50. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30575676",
"target":"_blank"
},
"children":[
"PMID: 30575676"
]
},
" doi:10.1097/AOG.0000000000003020"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":30,
"B":51,
"C":2,
"D":17,
"E":0
},
"hlIds":[
"2f627b",
"8bb1e9",
"328cab",
"cb2b54",
"43f798",
"7fff31",
"855a11",
"3ea77a",
"da4c70",
"b6f743",
"cc46f7"
]
},
{
"id":"mk19_a_np_q054",
"number":54,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 54",
"stimulus":[
{
"type":"p",
"hlId":"9a1d0c",
"children":[
"A 46-year-old man is evaluated in the emergency department for right flank and abdominal pain that began several hours ago. Medical history is significant for hypertension, type 2 diabetes mellitus, hyperlipidemia, and obesity. He has no history of kidney stones. Medications are losartan, rosuvastatin, and metformin."
]
},
{
"type":"p",
"hlId":"f36ccc",
"children":[
"On physical examination, vital signs are normal. BMI is 32. The patient appears uncomfortable. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d8afe5",
"class":"cell text l",
"children":[
"9.6 mg/dL (2.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d34d5",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9eaf68",
"class":"cell text l",
"children":[
"Electrolytes:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"db618e",
"class":"cell text l",
"children":[
"139 mEq/L (139 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"057980",
"class":"cell text l",
"children":[
"4.4 mEq/L (4.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5127b3",
"class":"cell text l",
"children":[
"Specific gravity 1.018; pH 5.0; 2+ blood; no leukocyte esterase; no nitrites; 10-20 erythrocytes/hpf; 1-3 leukocytes/hpf"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"6f4378",
"children":[
"Noncontrast helical CT scan of the abdomen shows a 5-mm stone at the right ureteropelvic junction. Hounsfield units are compatible with a uric acid stone."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Allopurinol"
}
},
{
"letter":"B",
"text":{
"__html":"Lithotripsy"
}
},
{
"letter":"C",
"text":{
"__html":"Potassium citrate"
}
},
{
"letter":"D",
"text":{
"__html":"Tamsulosin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"f8921a",
"children":[
"The most effective treatment to facilitate the passage of uric acid stones is urinary alkalinization with potassium citrate."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"9d9e3f",
"children":[
"The most appropriate treatment is potassium citrate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Acute management of symptomatic nephrolithiasis is aimed at pain management and facilitation of stone passage. Pain can be relieved by NSAIDs and opioids as needed. Stone passage decreases with increasing size. Only 50% of stones >6 mm will pass, and stones >10 mm are extremely unlikely to pass spontaneously. This patient most likely has a uric acid kidney stone. On helical CT scan, the density of the stone, as measured by Hounsfield units, is suggestive of uric acid. Patients with a uric acid kidney stone will have an acidic urine pH, as seen in this patient (pH 5.0). Uric acid stones are also more common in individuals with metabolic syndrome, as seen in this patient. The most effective treatment for uric acid stones is to alkalinize the urine, as uric acid is readily soluble in alkaline urine. If the urine pH is increased to 6.5 to 7.0, more than 90% of uric acid will be converted to soluble urate salts, dissolving the stone. Administration of potassium citrate at a dose of 40 to 80 mEq/d will effectively alkalinize the urine and reduce the size of the stone, allowing it to rapidly transit to the bladder."
]
},
{
"type":"p",
"hlId":"7ed551",
"children":[
"Allopurinol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") should be reserved to treat patients with gout and/or recurrent uric acid kidney stones that are unresponsive to alkalinization and increased fluid intake, neither of which applies to this patient."
]
},
{
"type":"p",
"hlId":"f9c8e7",
"children":[
"Lithotripsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is an appropriate treatment for kidney stones >6 mm that are unlikely to pass. However, for this patient, the 5-mm stone will likely pass, especially if the urine pH is increased to 6.5 to 7.0."
]
},
{
"type":"p",
"hlId":"f72c18",
"children":[
"The data concerning the use of tamsulosin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") to facilitate stone passage are controversial. But because there are few adverse effects attributed to this medication, many experts recommend its use. In the case of uric acid stones, urinary alkalinization with the use of potassium citrate is a more effective treatment."
]
}
],
"relatedSection":"mk19_a_np_s10_5",
"objective":{
"__html":"Treat uric acid kidney stones."
},
"references":[
[
"Heilberg IP. Treatment of patients with uric acid stones. Urolithiasis. 2016;44:57-63. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26645868",
"target":"_blank"
},
"children":[
"PMID: 26645868"
]
},
" doi:10.1007/s00240-015-0843-8"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":9,
"B":7,
"C":22,
"D":61,
"E":0
},
"hlIds":[
"9a1d0c",
"f36ccc",
"a462a3",
"1a4da4",
"d8afe5",
"f461b2",
"0d34d5",
"9eaf68",
"d41d8c",
"b99276",
"db618e",
"e92687",
"057980",
"a207b1",
"21724f",
"6827e3",
"075484",
"747c2a",
"5127b3",
"6f4378",
"1054f1",
"f8921a",
"9d9e3f",
"7ed551",
"f9c8e7",
"f72c18"
]
},
{
"id":"mk19_a_np_q055",
"number":55,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 55",
"stimulus":[
{
"type":"p",
"hlId":"2001bc",
"children":[
"A 49-year-old woman is evaluated during a routine follow-up visit. Medical history is significant for chronic kidney disease, hypertension, and HIV infection. She has been taking her current antihypertensive medications for 6 years. Her antiretroviral regimen was changed 6 weeks ago to a more convenient once-daily dosing regimen. Current medications are dolutegravir-abacavir-lamivudine and lisinopril-hydrochlorothiazide."
]
},
{
"type":"p",
"hlId":"6cbba7",
"children":[
"Findings on physical examination, including vital signs, are normal."
]
},
{
"type":"p",
"hlId":"1e316b",
"children":[
"Laboratory studies performed 2 weeks ago showed a continued suppressed viral load and a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level increase from her baseline of 1.2 mg/dL to 1.6 mg/dL (106.1-141.4 µmol/L)."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"01d588",
"children":[
"Today's laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"23df03",
"class":"cell text l",
"children":[
"No blood, protein, or erythrocytes"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6e652f",
"class":"cell text l",
"children":[
"100 mg/g (unchanged from baseline)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discontinue lisinopril-hydrochlorothiazide"
}
},
{
"letter":"B",
"text":{
"__html":"Measure 24-hour urine creatinine clearance"
}
},
{
"letter":"C",
"text":{
"__html":"Return to prior antiretroviral regimen"
}
},
{
"letter":"D",
"text":{
"__html":"No further management is indicated"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"96a1f1",
"hvc":true,
"children":[
"Some medications (such as cimetidine, trimethoprim, cobicistat, dolutegravir, and bictegravir) reduce proximal tubule secretion of creatinine, resulting in increases in serum creatinine."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"0dbc26",
"children":[
"No further management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is indicated for this patient. Some medications (such as cimetidine, trimethoprim, cobicistat, dolutegravir, and bictegravir) reduce proximal tubule secretion of creatinine, resulting in increases in serum creatinine that are nonprogressive; they do not affect glomerular filtration rate (GFR). This patient's antiretroviral regimen was changed to include dolutegravir 6 weeks earlier. Slight increases in serum creatinine of 0.2 mg/dL to 0.3 mg/dL (17.7-26.5 µmol/L) may occur. This is more pronounced in patients with chronic kidney disease (CKD), in which creatinine secretion contributes proportionately more to creatinine clearance. In patients with CKD who are taking the integrase inhibitors dolutegravir or bictegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine, or the pharmacokinetic enhancer (CYP3A inhibitor) cobicistat, serum creatinine elevations are nonprogressive and will remain stable within 1 to 2 weeks of initiation. Therefore, in the absence of other signs of kidney disease (hematuria, pyuria, or increasing proteinuria), and with a serum creatinine that has remained unchanged since the patient's 4-week assessment, no further evaluation is necessary. In this case, measuring the patient's serum cystatin C level could be a helpful confirmatory test, because the level is not affected by these medications."
]
},
{
"type":"p",
"hlId":"1ba881",
"children":[
"Discontinuation of combined lisinopril-hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not necessary. This patient has been taking her current antihypertensive combination for 6 years, and it is unlikely to have caused this acute increase in serum creatinine; the hemodynamic effects of ACE inhibitors on glomerular filtration occur within days of initiation."
]
},
{
"type":"p",
"hlId":"d6a8d4",
"children":[
"A 24-hour urine creatinine clearance (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") will be decreased in this case (due to drug-related lower creatinine secretion) and will not provide additional diagnostic information."
]
},
{
"type":"p",
"hlId":"b2bfef",
"children":[
"Returning to the prior antiretroviral regimen (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated, as the effects of dolutegravir on the patient's serum creatinine level does not indicate GFR decline."
]
}
],
"relatedSection":"mk19_a_np_s1_1_1_1",
"objective":{
"__html":"Identify drugs as a nonglomerular cause of an increase in serum creatinine level."
},
"references":[
[
"Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32:434-439. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27190354",
"target":"_blank"
},
"children":[
"PMID: 27190354"
]
},
" doi:10.1093/ndt/gfw064"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":12,
"B":14,
"C":20,
"D":53,
"E":0
},
"hlIds":[
"2001bc",
"6cbba7",
"1e316b",
"01d588",
"f461b2",
"3a34ea",
"747c2a",
"23df03",
"58e613",
"6e652f",
"cb2b54",
"96a1f1",
"0dbc26",
"1ba881",
"d6a8d4",
"b2bfef"
]
},
{
"id":"mk19_a_np_q056",
"number":56,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 56",
"stimulus":[
{
"type":"p",
"hlId":"f9a56f",
"children":[
"A 44-year-old woman is evaluated during a follow-up visit for chronic hypertension. Over the past month, her average blood pressure measured with home blood pressure monitoring was 150/90 mm Hg. There is no family history of hypertension. She has no other medical problems. The patient adheres to a low sodium diet. Medications are maximum doses of amlodipine, atenolol, and lisinopril."
]
},
{
"type":"p",
"hlId":"50c8b3",
"children":[
"On physical examination, blood pressure is 150/96 mm Hg, and pulse rate is 64/min; other vital signs are normal. BMI is 26. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"96f59d",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.8 mg/dL (70.7 µmol/L) and normal electrolyte levels. Urinalysis shows no blood, protein, or leukocyte esterase."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1a5dcc",
"children":[
"Which of the following is the most appropriate next step in management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add chlorthalidone"
}
},
{
"letter":"B",
"text":{
"__html":"Measure plasma aldosterone concentration/plasma renin activity ratio"
}
},
{
"letter":"C",
"text":{
"__html":"Measure plasma fractionated metanephrines"
}
},
{
"letter":"D",
"text":{
"__html":"Obtain renal artery imaging"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"27c638",
"hvc":true,
"children":[
"Resistant hypertension is blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes, or blood pressure at goal but requiring four or more medications; one of these medications must be a diuretic."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"02e67c",
"children":[
"The most appropriate next step in management is to add chlorthalidone, a thiazide diuretic (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Resistant hypertension is defined as blood pressure (BP) that remains above goal despite concurrent use of three antihypertensive agents of different classes, or BP at goal but requiring four or more medications. One of these medications must be a diuretic. Suboptimal antihypertensive therapy in patients with difficult-to-control hypertension is frequently the result of not including a diuretic agent, which ensures that extracellular volume expansion is prevented or treated. Therefore, before a diagnosis of resistant hypertension is made or evaluation is initiated for secondary causes of hypertension, the patient should be treated with an appropriate diuretic medication, with attention to effective dose and dosing frequency. Although hydrochlorothiazide is the most commonly used thiazide diuretic, chlorthalidone has a longer half-life, which allows once-daily dosing; some evidence from trials suggests efficacy in reducing cardiovascular events."
]
},
{
"type":"p",
"hlId":"b66b02",
"children":[
"Obtaining a plasma aldosterone concentration/plasma renin activity ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not indicated at this time, as there is no clinical suspicion for primary hyperaldosteronism such as resistant hypertension, hypokalemia, incidentally discovered adrenal mass, family history of early-onset hypertension, or stroke at age <40 years. This patient does not have hypokalemia or a metabolic alkalosis to raise suspicion for hyperaldosteronism."
]
},
{
"type":"p",
"hlId":"4205dd",
"children":[
"Testing for plasma fractionated metanephrines (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), which screens for a pheochromocytoma, is not indicated. The following characteristics raise clinical suspicion for pheochromocytoma: resistant hypertension; new-onset hypertension or onset at a young age; paroxysmal hypertension; episodic tachycardia, headaches, and sweating; history of familial syndromes; adrenal adenoma found incidentally on imaging with or without hypertension; or pressor response during invasive procedures or anesthesia. The patient has none of these indications for testing."
]
},
{
"type":"p",
"hlId":"422379",
"children":[
"Obtaining renal artery imaging (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not indicated, as there is no clinical suspicion for renal artery stenosis, which includes the onset of severe hypertension in patients >55 years of age, recurrent flash pulmonary edema, refractory heart failure, or acute kidney injury after initiation of an ACE inhibitor or angiotensin receptor blocker."
]
}
],
"relatedSection":"mk19_a_np_s4_10",
"objective":{
"__html":"Treat difficult-to-control hypertension by adding a diuretic."
},
"references":[
[
"Braam B, Taler SJ, Rahman M, et al. Recognition and management of resistant hypertension. Clin J Am Soc Nephrol. 2017;12:524-535. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27895136",
"target":"_blank"
},
"children":[
"PMID: 27895136"
]
},
" doi:10.2215/CJN.06180616"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":51,
"B":29,
"C":2,
"D":18,
"E":0
},
"hlIds":[
"f9a56f",
"50c8b3",
"96f59d",
"1a5dcc",
"27c638",
"02e67c",
"b66b02",
"4205dd",
"422379"
]
},
{
"id":"mk19_a_np_q057",
"number":57,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 57",
"stimulus":[
{
"type":"p",
"hlId":"c2afc1",
"children":[
"A 54-year-old woman is evaluated in the hospital for polyuria 3 days after undergoing resection of a glioblastoma multiforme. She is receiving 0.45% saline at 50 mL/h and nasogastric enteral nutrition because of difficulty swallowing. Medications are dexamethasone and levetiracetam."
]
},
{
"type":"p",
"hlId":"3d461b",
"children":[
"On physical examination, she is in no acute distress. Vital signs are normal. Muscle strength is 4/5 in her left upper extremity. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2dd192",
"class":"cell text l",
"children":[
"85 mg/dL (30.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d34d5",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b9b107",
"class":"cell text l",
"children":[
"152 mEq/L (152 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"687d76",
"class":"cell text l",
"children":[
"3.8 mEq/L (3.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e88973",
"class":"cell text l",
"children":[
"118 mEq/L (118 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5adbf9",
"class":"cell text l",
"children":[
"23 mEq/L (23 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a3cb56",
"class":"cell text l",
"children":[
"170 mg/dL (9.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b9fe11",
"class":"cell text l",
"children":[
"32 mEq/L (32 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a54671",
"class":"cell text l",
"children":[
"Urine potassium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"108437",
"class":"cell text l",
"children":[
"Urine osmolality"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d11bb",
"class":"cell text l",
"children":[
"560 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"0ea9e0",
"children":[
"Which of the following is the most likely cause of this patient's hypernatremia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Diabetes insipidus"
}
},
{
"letter":"B",
"text":{
"__html":"Electrolyte diuresis"
}
},
{
"letter":"C",
"text":{
"__html":"Glucose diuresis"
}
},
{
"letter":"D",
"text":{
"__html":"Urea diuresis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"8e645c",
"children":[
"Polyuria is caused by either a water diuresis (dilute urine) or a solute diuresis (urine osmolality, 300-600 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O)."
]
},
{
"type":"keypoint",
"hlId":"473699",
"children":[
"Polyuria caused by an osmotic diuresis is caused by either an electrolyte diuresis or a nonelectrolyte diuresis (e.g., urea, glucose)."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"11ce62",
"children":[
"The most likely cause of this patient's hypernatremia is urea diuresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient has polyuria, which can be categorized as a water diuresis or a solute diuresis based on the urine osmolality. In osmotic diuresis, urine osmolality is usually between 300 and 600 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O. This patent's urine osmolality is elevated (560 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O), likely indicating a solute diuresis. This can be further categorized as an electrolyte diuresis or a nonelectrolyte diuresis. Because the total electrolyte in her urine comprises <50% of the urine osmolality [2 × (Urine Sodium + Urine Potassium)], this patient is having a solute diuresis. She takes dexamethasone, which, due to its catabolic effect, has increased the blood urea nitrogen, resulting in a urea diuresis with subsequent loss of water. This can be confirmed by measuring the urine urea concentration. Treatment for this patient would be to either increase her water intake or decrease the dexamethasone dose."
]
},
{
"type":"p",
"hlId":"8f04e0",
"children":[
"Although diabetes insipidus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") may occur in patients who have undergone neurosurgery, this patient's increased urine osmolality is inconsistent with diabetes insipidus."
]
},
{
"type":"p",
"hlId":"a27056",
"children":[
"An electrolyte diuresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is typically caused by intravenous administration of a large volume of 0.9% saline or after relief of bilateral urinary tract obstruction, resulting in polyuria. When urine output increases, a common response is to increase the intravenous infusion rate, which further increases the sodium load and promotes urine output and causes an unending spiral; in this case, the urine electrolyte concentration cannot explain the ongoing diuresis. In addition, although an increase in sodium intake will cause polyuria, unless the sodium load is hypertonic, it will not result in hypernatremia."
]
},
{
"type":"p",
"hlId":"52a380",
"children":[
"Dexamethasone can increase serum glucose levels. Although this patient's serum glucose level is elevated, it is below the renal threshold (approximately 180 mg/dL [10 mmol/L]) for complete reabsorption. Therefore, a glucose diuresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not responsible for either the patient's polyuria or hypernatremia."
]
}
],
"relatedSection":"mk19_a_np_s2_2_2_1",
"objective":{
"__html":"Identify urea diuresis as the cause of hypernatremia."
},
"references":[
[
"Lindner G, Schwarz C, Funk GC. Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients. Nephrol Dial Transplant. 2012;27:962-967. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21810766",
"target":"_blank"
},
"children":[
"PMID: 21810766"
]
},
" doi:10.1093/ndt/gfr428"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":57,
"B":12,
"C":6,
"D":25,
"E":0
},
"hlIds":[
"c2afc1",
"3d461b",
"a462a3",
"29d161",
"2dd192",
"f461b2",
"0d34d5",
"89662a",
"d41d8c",
"b99276",
"b9b107",
"e92687",
"687d76",
"a207b1",
"e88973",
"6827e3",
"5adbf9",
"847136",
"a3cb56",
"e331de",
"b9fe11",
"a54671",
"075484",
"108437",
"0d11bb",
"0ea9e0",
"8e645c",
"473699",
"11ce62",
"8f04e0",
"a27056",
"52a380"
]
},
{
"id":"mk19_a_np_q058",
"number":58,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 58",
"stimulus":[
{
"type":"p",
"hlId":"4e3cc0",
"children":[
"A 61-year-old man is evaluated for bilateral action tremor of the hands and rarely the feet that began 7 days ago. The intensity of the tremor varies and is worse in the morning and late afternoon. He has no other symptoms. There is no family history of tremor or Parkinson disease. Four months ago, he underwent living-donor related kidney transplantation. Medical history is also significant for hypertension. Medications are atorvastatin, lisinopril, metoprolol, mycophenolate mofetil, nifedipine, prednisone, sulfamethoxazole-trimethoprim, tacrolimus, and valganciclovir."
]
},
{
"type":"p",
"hlId":"5d101c",
"children":[
"On physical examination, vital signs are normal. There is bilateral tremor of the hands present when the hands are resting in the lap, with outstretched arms, and with various actions. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"c0cc4e",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 1.2 mg/dL (106.1 µmol/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"899858",
"children":[
"Which of the following is the most likely medication responsible for this patient's tremor?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Metoprolol"
}
},
{
"letter":"B",
"text":{
"__html":"Mycophenolate mofetil"
}
},
{
"letter":"C",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"D",
"text":{
"__html":"Tacrolimus"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ef029f",
"children":[
"Calcineurin inhibitor side effects include tremor, new-onset type 2 diabetes mellitus, decreased glomerular filtration rate, hypertension, dyslipidemia, and gingival hyperplasia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b00e0a",
"children":[
"Tacrolimus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is the most likely medication responsible for this patient's tremor. Immunosuppressive medications allow successful kidney transplantation but have numerous side effects that should be considered when patients on these medications present with new symptoms. Long-term maintenance therapy for most kidney transplant recipients includes a combination of calcineurin inhibitors (tacrolimus or cyclosporine), antimetabolites (mycophenolate mofetil or azathioprine), and glucocorticoids. Tremor is an oscillatory movement of a body part that is classified based on its presence at rest or with action. Tremor is a side effect of calcineurin inhibitors and is most common with tacrolimus. Calcineurin-induced tremor is bilateral and may affect the hands and feet. Tacrolimus tremor is activated by action, but in about 50% of cases the tremor can be classified as both an action and resting tremor. The tremor is associated with elevated drug levels and may be most pronounced when drug levels peak following a dose. This patient's tacrolimus trough measurement should be checked, as treatment interventions include dose reduction if permissible, conversion to long-acting formulations, addition of a β-blocker, or conversion to an alternate agent if the tremor is debilitating and unresponsive to other interventions. These adjustments should be made in conjunction with the patient's nephrologist or transplant program. Other side effects of calcineurin inhibitors include new-onset type 2 diabetes mellitus, decreased glomerular filtration rate, hypertension, dyslipidemia, and gingival hyperplasia."
]
},
{
"type":"p",
"hlId":"a88804",
"children":[
"Metoprolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not causing, and may be useful in treating, this patient's tacrolimus-related tremor."
]
},
{
"type":"p",
"hlId":"9a46c2",
"children":[
"Side effects of mycophenolate mofetil (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") include nausea, vomiting, diarrhea, leukopenia, and anemia, but not tremor."
]
},
{
"type":"p",
"hlId":"1211d1",
"children":[
"Although glucocorticoids such as prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") cause a myriad of effects that may include psychological distress and jumpiness, they do not cause tremor. Other side effects associated with glucocorticoids include hypertension, edema, new-onset type 2 diabetes, osteoporosis, and osteonecrosis."
]
}
],
"relatedSection":"mk19_a_np_s12_9_2_2",
"objective":{
"__html":"Evaluate a kidney transplant recipient for side effects of immunosuppressive therapy."
},
"references":[
[
"Erro R, Bacchin R, Magrinelli F, et al. Tremor induced by calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients. J Neurol. 2018;265:1676-1683. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29777361",
"target":"_blank"
},
"children":[
"PMID: 29777361"
]
},
" doi:10.1007/s00415-018-8904-x"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":0,
"B":22,
"C":11,
"D":68,
"E":0
},
"hlIds":[
"4e3cc0",
"5d101c",
"c0cc4e",
"899858",
"ef029f",
"b00e0a",
"a88804",
"9a46c2",
"1211d1"
]
},
{
"id":"mk19_a_np_q059",
"number":59,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 59",
"stimulus":[
{
"type":"p",
"hlId":"801985",
"children":[
"A 63-year-old man is evaluated in the hospital for acute kidney injury following a motor vehicle accident 48 hours ago. He sustained pelvic and rib fractures and a splenic laceration requiring splenectomy. He received isotonic fluids (17 L) plus norepinephrine for blood pressure support. He is intubated and on mechanical ventilation. During the past 24 hours, urine output fluctuated from 10 to 15 mL/h, with a 24-hour urine output of 280 mL. Medications are vancomycin, ceftazidime, intravenous norepinephrine, and 150 mL/h of intravenous crystalloid fluids."
]
},
{
"type":"p",
"hlId":"f52f7b",
"children":[
"On physical examination, the patient is mechanically ventilated and sedated. Temperature is 38.3 °C (100.9 °F), blood pressure is 88/52 mm Hg, pulse rate is 96/min, and respiration rate is 16/min. ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"Oxygen saturation"
]
},
" is 95% with the patient breathing 0.40 F",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"IO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"2"
]
}
]
},
". Jugular venous pressure is elevated. Cardiac examination is normal, and lungs are clear to auscultation. The abdomen is distended and tense. A bladder catheter is draining small amounts of urine."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"78122d",
"class":"cell text l",
"children":[
"8.5 g/dL (85 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fea41d",
"class":"cell text l",
"children":[
"73 mg/dL (26.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"dd6850",
"class":"cell text l",
"children":[
"3.6 mg/dL (318.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7ea361",
"class":"cell text l",
"children":[
"Specific gravity 1.012; pH 5.5; 1+ blood; no protein; 1-3 erythrocytes/hpf; scattered hyaline casts"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bladder pressure measurement"
}
},
{
"letter":"B",
"text":{
"__html":"CT urography"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney biopsy"
}
},
{
"letter":"D",
"text":{
"__html":"Kidney ultrasonography"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a3c588",
"children":[
"Abdominal compartment syndrome is defined as a sustained intra-abdominal pressure >20 mm Hg that is associated with at least one organ dysfunction."
]
},
{
"type":"keypoint",
"hlId":"d7767c",
"children":[
"The diagnosis of abdominal compartment syndrome can be confirmed through measurement of bladder pressure via a bladder catheter as a surrogate for intra-abdominal pressure measurement."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2e2bdb",
"children":[
"The most appropriate diagnostic test to perform next is bladder pressure measurement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient may have abdominal compartment syndrome (ACS), which is defined as a sustained intra-abdominal pressure >20 mm Hg that is associated with at least one organ dysfunction. The diagnosis of ACS should be considered in the setting of abdominal surgery, trauma, intra-abdominal bleeding, ascites, bowel obstruction, ileus, or pancreatitis. It can also be caused by a capillary leak in the setting of sepsis and massive fluid resuscitation. The diagnosis of ACS can be confirmed through measurement of bladder pressure using an indwelling catheter as a surrogate for intra-abdominal pressure measurement. Appropriate treatment includes surgical decompression of the abdominal compartment."
]
},
{
"type":"p",
"hlId":"b08552",
"children":[
"CT urography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is the diagnostic test of choice for patients with unexplained hematuria and allows characterization of kidney tumors and cysts. MRI with contrast is an alternative for evaluation of kidney masses and cysts when CT cannot be performed. These imaging tests would not be useful in this patient with acute kidney injury."
]
},
{
"type":"p",
"hlId":"5eef02",
"children":[
"Indications for kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") include glomerular hematuria, severely increased albuminuria, acute or chronic kidney disease of unclear cause (in the absence of atrophic kidneys), and kidney transplant dysfunction or monitoring. Bladder pressure measurement is indicated as the next test because it is the most likely to provide a diagnosis, obviating the need for additional testing."
]
},
{
"type":"p",
"hlId":"fe2ac5",
"children":[
"Kidney ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is helpful to exclude obstruction, but new bilateral ureteral obstruction is not strongly suspected in this patient and the placement of a bladder catheter rules out acute urethral obstruction."
]
}
],
"relatedSection":"mk19_a_np_s9_6_5",
"objective":{
"__html":"Diagnose abdominal compartment syndrome."
},
"references":[
[
"Patel DM, Connor MJ Jr. Intra-abdominal hypertension and abdominal compartment syndrome: an underappreciated cause of acute kidney injury. Adv Chronic Kidney Dis. 2016;23:160-166. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27113692",
"target":"_blank"
},
"children":[
"PMID: 27113692"
]
},
" doi:10.1053/j.ackd.2016.03.002"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":63,
"B":7,
"C":2,
"D":28,
"E":0
},
"hlIds":[
"801985",
"f52f7b",
"a462a3",
"f9867c",
"78122d",
"29d161",
"fea41d",
"f461b2",
"dd6850",
"747c2a",
"7ea361",
"ab9d96",
"a3c588",
"d7767c",
"2e2bdb",
"b08552",
"5eef02",
"fe2ac5"
]
},
{
"id":"mk19_a_np_q060",
"number":60,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 60",
"stimulus":[
{
"type":"p",
"hlId":"b2fc95",
"children":[
"A 46-year-old man is evaluated in the hospital for hypernatremia. He was hospitalized 2 days ago with hyperglycemic hyperosmolar syndrome. He was obtunded and intubated to protect his airway. He was treated with 3 liters of 0.9% saline and insulin infusion. Medical history is significant for type 2 diabetes mellitus treated with metformin."
]
},
{
"type":"p",
"hlId":"d7ee84",
"children":[
"On hospital day 2, blood pressure is 155/96 mm Hg, and pulse rate is 76/min. Other vital signs and the remainder of the examination are normal."
]
},
{
"type":"p",
"hlId":"364b13",
"children":[
"The patient is extubated but his level of consciousness fluctuates and he cannot follow commands or eat or drink fluids without choking."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d12432",
"children":[
"Current laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b9b107",
"class":"cell text l",
"children":[
"152 mEq/L (152 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28b9c6",
"class":"cell text l",
"children":[
"3.2 mEq/L (3.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"50021b",
"class":"cell text l",
"children":[
"124 mEq/L (124 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d95465",
"class":"cell text l",
"children":[
"19 mEq/L (19 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a27737",
"class":"cell text l",
"children":[
"200 mg/dL (11.1 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"c775cc",
"children":[
"Which of the following is the most appropriate treatment for this patient's hypernatremia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Intravenous 5% dextrose"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous 0.45% saline"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous 0.9% saline"
}
},
{
"letter":"D",
"text":{
"__html":"Water via nasogastric tube"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"6a6501",
"children":[
"The treatment of isovolemic hypernatremia is water, preferably orally or by nasogastric tube if the patient is incapable of drinking."
]
},
{
"type":"keypoint",
"hlId":"eac43b",
"children":[
"The rate of correction of serum sodium for hypernatremia should be <10 mEq/L (10 mmol/L) daily."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ead464",
"children":[
"The most appropriate treatment for this patient's hypernatremia is administration of water via nasogastric tube (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Hyperglycemic hyperosmolar syndrome (HHS), an acute complication of type 2 diabetes mellitus, manifests as extreme hyperglycemia and must be treated early and aggressively to avoid life-threatening consequences from dehydration and electrolyte abnormalities. Extreme glucosuria causes an osmotic diuresis and severe volume depletion, which may be exacerbated by gastrointestinal losses of volume and electrolytes. The condition may progress to lethargy, obtundation, and death. Treatment includes vigorous hydration and insulin. This patient became hypernatremic because of water loss during glucose-induced osmotic diuresis. Treatment of his hyperglycemia with insulin caused a decrease in extracellular osmolality, causing water to move into cells. For every 100-mg/dL (5.6-mmol/L) decrease in serum glucose, serum sodium will increase by approximately 2.0 mEq/L (2.0 mmol/L). This patient's water deficit is approximately 4500 mL, making administration of water the most appropriate treatment. Because this patient is confused, administration of water through nasogastric tube is the best approach; otherwise, the patient could receive water orally. Although decreases of serum sodium up to 1.0 mEq/L (1.0 mmol/L) per hour do not appear to have adverse effects, most authorities recommend decreasing serum sodium by no more than 10 mEq/L (10 mmol/L) daily. Because of ongoing water losses, the calculated rate of correction will be somewhat lower than the actual rate."
]
},
{
"type":"p",
"hlId":"ca6ea3",
"children":[
"Administration of 5% dextrose (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is as effective as water in treating hypernatremia. However, this patient has hyperglycemia, and administration of a glucose-containing solution may worsen it as well as increase free water losses by inducing an osmotic diuresis."
]
},
{
"type":"p",
"hlId":"ae9893",
"children":[
"Although 0.45% normal saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is hypotonic and will correct this patient's elevated serum sodium, a minimum of 9 liters is necessary to decrease serum sodium into the normal range."
]
},
{
"type":"p",
"hlId":"50e0f8",
"children":[
"The use of 0.9% saline (sodium concentration = 154 mEq/L [154 mmol/L]) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") will not improve this patient's hypernatremia. Furthermore, it will worsen his already elevated blood pressure and further exacerbate his hyperchloremic metabolic acidosis."
]
}
],
"relatedSection":"mk19_a_np_s2_2_2_2",
"objective":{
"__html":"Treat isovolemic hypernatremia."
},
"references":[
[
"Overgaard-Steensen C, Ring T. Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients. Crit Care. 2013;17:206. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23672688",
"target":"_blank"
},
"children":[
"PMID: 23672688"
]
},
" doi:10.1186/cc11805"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":18,
"B":34,
"C":11,
"D":37,
"E":0
},
"hlIds":[
"b2fc95",
"d7ee84",
"364b13",
"d12432",
"89662a",
"d41d8c",
"b99276",
"b9b107",
"e92687",
"28b9c6",
"a207b1",
"50021b",
"6827e3",
"d95465",
"847136",
"a27737",
"c775cc",
"6a6501",
"eac43b",
"ead464",
"ca6ea3",
"ae9893",
"50e0f8"
]
},
{
"id":"mk19_a_np_q061",
"number":61,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 61",
"stimulus":[
{
"type":"p",
"hlId":"2957f1",
"children":[
"A 62-year-old woman is evaluated during a follow-up visit for hypertension and chronic kidney disease. Medical history is otherwise unremarkable. Medications are losartan and amlodipine. The patient is adherent to her medication regimen and low sodium diet."
]
},
{
"type":"p",
"hlId":"c1592d",
"children":[
"On physical examination, blood pressure is 148/94 mm Hg in both arms, pulse rate is 65/min, and respiration rate is 18/min. BMI is 30. Neck examination shows jugular venous distension. Cardiac examination reveals an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" gallop. Lungs are clear to auscultation. There is 1+ pitting edema over the pretibial lower extremities and ankles bilaterally. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f1e327",
"class":"cell text l",
"children":[
"22 mEq/L (22 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"34f471",
"class":"cell text l",
"children":[
"2.6 mg/dL (229.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"028d9b",
"class":"cell text l",
"children":[
"4.9 mEq/L (4.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1fd2c7",
"class":"cell text l",
"children":[
"136 mEq/L (136 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b8cacc",
"class":"cell text l",
"children":[
"1500 mg/g"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"20d29c",
"class":"cell text l",
"children":[
"24 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Carvedilol"
}
},
{
"letter":"B",
"text":{
"__html":"Furosemide"
}
},
{
"letter":"C",
"text":{
"__html":"Hydralazine"
}
},
{
"letter":"D",
"text":{
"__html":"Lisinopril"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"010c6b",
"children":[
"A loop diuretic such as furosemide is indicated for treating hypertension in patients with advanced chronic kidney disease."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"dba8ce",
"children":[
"The most appropriate additional treatment for this patient's antihypertensive medication regimen is furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). ACE inhibitors or angiotensin receptor blockers (ARBs) are first-line medications for patients with advanced chronic kidney disease (CKD) or proteinuric CKD. Calcium channel blockers reduce albuminuria and slow the decline in kidney function but should be combined with an ACE inhibitor or ARB. Diuretics are the backbone of hypertension management in patients with CKD because of increased extracellular volume. This patient has an elevated blood pressure not controlled to a target goal of <130/80 mm Hg in the setting of stage G4 CKD and evidence of a sodium-retentive state based on the presence of jugular venous distention and lower extremity edema. A thiazide diuretic will unlikely be effective, as her estimated glomerular filtration rate is <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Therefore, a loop diuretic, such as furosemide, two or three times daily, is indicated for management of this patient's hypertension. Suboptimal blood pressure control in patients with sodium-retentive, edematous conditions, such as advanced CKD, heart failure, and cirrhosis, is frequently the result of not including a diuretic, which ensures that extracellular volume expansion is prevented or treated."
]
},
{
"type":"p",
"hlId":"d85e45",
"children":[
"Without a compelling indication such as heart failure or recent myocardial infarction, the addition of a β-blocker such as carvedilol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") to this patient's treatment regimen is not appropriate. Additionally, a β-blocker will not reduce this patient's expanded extracellular volume, thus limiting its ability to reduce the blood pressure."
]
},
{
"type":"p",
"hlId":"165245",
"children":[
"Similarly, hydralazine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated at this time because it will likely increase the patient's already expanded extracellular volume, resulting in inadequate blood pressure control."
]
},
{
"type":"p",
"hlId":"35775b",
"children":[
"Although the patient has CKD and albuminuria, adding lisinopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), an ACE inhibitor, to the patient's antihypertensive medication regimen, which already includes losartan, an ARB, is not the appropriate treatment. Combination therapy with an ACE inhibitor and ARB may result in adverse events, such as acute kidney injury and hyperkalemia, and does not improve cardiovascular outcomes compared with treatment with an ACE inhibitor or ARB alone."
]
}
],
"relatedSection":"mk19_a_np_s4_7_2_3_1",
"objective":{
"__html":"Treat hypertension with a loop diuretic in advanced chronic kidney disease."
},
"references":[
[
"Kalaitzidis RG, Elisaf MS. Treatment of hypertension in chronic kidney disease. Curr Hypertens Rep. 2018;20:64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29892833",
"target":"_blank"
},
"children":[
"PMID: 29892833"
]
},
" doi:10.1007/s11906-018-0864-0"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":7,
"B":81,
"C":6,
"D":5,
"E":0
},
"hlIds":[
"2957f1",
"c1592d",
"a462a3",
"6827e3",
"f1e327",
"f461b2",
"34f471",
"e92687",
"028d9b",
"b99276",
"1fd2c7",
"58e613",
"b8cacc",
"77db81",
"20d29c",
"78ff87",
"010c6b",
"dba8ce",
"d85e45",
"165245",
"35775b"
]
},
{
"id":"mk19_a_np_q062",
"number":62,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 62",
"stimulus":[
{
"type":"p",
"hlId":"15c274",
"children":[
"A 36-year-old woman is evaluated during a routine follow-up visit for stage G4 chronic kidney disease. Her ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" is 22 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Medications are lisinopril, sevelamer, and sodium bicarbonate. She has selected hemodialysis for her renal replacement therapy, and an arteriovenous fistula will eventually be placed in her nondominant left arm."
]
},
{
"type":"p",
"hlId":"1a6316",
"children":[
"Three weeks later, the patient is hospitalized with septic shock secondary to community-acquired pneumonia. Venous access for the administration of fluids, vasopressors, and antibiotics is urgently needed."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"f5650a",
"children":[
"Which of the following is most appropriate method of venous access for this patient?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Internal jugular vein insertion of a central venous catheter"
}
},
{
"letter":"B",
"text":{
"__html":"Peripherally inserted central catheter in the left arm"
}
},
{
"letter":"C",
"text":{
"__html":"Peripherally inserted central catheter in the right arm"
}
},
{
"letter":"D",
"text":{
"__html":"Subclavian vein insertion of a central venous catheter"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"739954",
"children":[
"The American Society of Nephrology recommends that peripherally inserted central catheter line catheters should be avoided in patients with an estimated glomerular filtration rate <60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b38705",
"children":[
"Internal jugular vein insertion of a central venous catheter is the most appropriate method of venous access for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Patients with advanced chronic kidney disease (CKD) may ultimately require renal replacement therapy. Arteriovenous fistula (AVF) placement is the safest and most enduring option for vascular access. AVFs have superior clinical outcomes compared with arteriovenous grafts. Protecting the veins of the nondominant arm is of paramount importance for the future success of a functioning AVF and involves limiting phlebotomy and intravenous catheters in that arm."
]
},
{
"type":"p",
"hlId":"5f3da9",
"children":[
"Peripherally inserted central catheters (PICCs) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, C"
]
},
") are long catheters that are inserted peripherally and terminate in the central veins. PICCs are popular because of their ease of insertion and use. PICC lines can lead to significant trauma and venous stenosis in the veins that may be used for AVF creation. This could impair blood flow through the fistula, impair maturation, and even lead to primary nonfunctioning of the hemodialysis access. Data demonstrate that PICC lines in either arm, placed before or after initiation of hemodialysis, are independently associated with a 15% to 20% lower likelihood of transition to any working fistula or graft. The long-term use of PICC lines is also associated with an increased risk for death. The American Society of Nephrology recommends that PICC line catheters should be avoided in patients with an estimated glomerular filtration rate <60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"f8ed18",
"children":[
"Avoidance of subclavian venous catheters (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") helps limit subclavian stenosis, which can impair the proper functioning of an arteriovenous access used for dialysis. Although central lines inserted through the internal jugular vein are associated with central venous stenosis, a central line is a better alternative than a PICC or subclavian insertion of a central venous catheter; central lines are not inserted into a peripheral vein, which would be used for the creation of a hemodialysis site, and utilize a vessel not as prone to stenosis as the subclavian vein."
]
}
],
"relatedSection":"mk19_a_np_s12_8_3",
"objective":{
"__html":"Manage venous access for a patient with chronic kidney disease."
},
"references":[
[
"McGill RL, Ruthazer R, Meyer KB, et al. Peripherally inserted central catheters and hemodialysis outcomes. Clin J Am Soc Nephrol. 2016;11:1434-1440. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27340280",
"target":"_blank"
},
"children":[
"PMID: 27340280"
]
},
" doi:10.2215/CJN.01980216"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":61,
"B":2,
"C":21,
"D":16,
"E":0
},
"hlIds":[
"15c274",
"1a6316",
"f5650a",
"739954",
"b38705",
"5f3da9",
"f8ed18"
]
},
{
"id":"mk19_a_np_q063",
"number":63,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 63",
"stimulus":[
{
"type":"p",
"hlId":"c362ab",
"children":[
"A 25-year-old man is evaluated in the emergency department for a 1-week history of fatigue, dyspnea, and hemoptysis. He has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"2a200c",
"children":[
"On physical examination, blood pressure is 155/95 mm Hg, and respiration rate is 25/min; other vital signs are normal. No rash is noted. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"687cd3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C3, serum",
"children":[
"C3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a3d0ba",
"class":"cell text l",
"children":[
"95 mg/dL (950 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"dcfa5e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C4, serum",
"children":[
"C4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"312f97",
"class":"cell text l",
"children":[
"20 mg/dL (200 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e6438c",
"class":"cell text l",
"children":[
"2.3 mg/dL (203.3 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"25d6d7",
"class":"cell text l",
"children":[
"Antimyeloperoxidase antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8377f4",
"class":"cell text l",
"children":[
"Antiproteinase-3 antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"44fb07",
"class":"cell text l",
"children":[
"3+ blood; 3+ protein; numerous erythrocytes and erythrocyte casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"e4ab3b",
"children":[
"Kidney biopsy shows necrotizing and crescentic glomerulonephritis with linear staining for IgG on immunofluorescence."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"012885",
"children":[
"Which of the following is the most appropriate serologic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Anti–double-stranded DNA antibodies"
}
},
{
"letter":"B",
"text":{
"__html":"Anti–glomerular basement membrane antibodies"
}
},
{
"letter":"C",
"text":{
"__html":"Anti–phospholipase A2 receptor antibodies"
}
},
{
"letter":"D",
"text":{
"__html":"Circulating IgA levels"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"dc0737",
"children":[
"Anti–glomerular basement membrane antibody disease is characterized by necrotizing and crescentic glomerulonephritis with linear staining for IgG on immunofluorescence."
]
},
{
"type":"keypoint",
"hlId":"753cc8",
"children":[
"Measurement of anti–glomerular basement membrane (anti-GBM) antibodies confirm the diagnosis of anti-GBM antibody disease and are used to monitor response to treatment."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a0f2f5",
"children":[
"The most appropriate serologic test to perform next is measurement of anti–glomerular basement membrane (anti-GBM) antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient has rapidly progressive glomerulonephritis (RPGN), defined as an acute and steep rise in serum creatinine accompanied by hematuria and proteinuria. The differential diagnosis for RPGN is divided histologically into three patterns on immunofluorescence microscopy of the kidney biopsy: pauci-immune staining (ANCA-mediated glomerulonephritis), linear staining (anti-GBM glomerulonephritis), and granular staining (lupus nephritis). This patient has RPGN and a kidney biopsy showing linear staining, which is seen in anti-GBM antibody disease. Lung involvement (Goodpasture syndrome) occurs in >50% of patients with anti-GBM antibody disease; hemoptysis can be a presenting symptom, although shortness of breath or cough should also raise suspicion for a pulmonary-renal syndrome even in the absence of hemoptysis. Testing for anti-GBM antibodies is required as the next step in management to confirm diagnosis. For this patient, anti-GBM antibody titers would also be used to monitor treatment response. Up to one in three patients with anti-GBM antibody disease will have positive ANCA serologies, usually antimyeloperoxidase (MPO) antibodies, which can affect prognosis. Combined seropositivity is most commonly seen in patients with anti-GBM antibody disease who are older women. Therefore, it is appropriate to test for p-ANCA/anti-MPO and c-ANCA/antiproteinase 3 antibodies. Successful treatment, which typically includes glucocorticoids, plasmapheresis, and cyclophosphamide, will eradicate the patient's serum anti-GBM antibody titer."
]
},
{
"type":"p",
"hlId":"710104",
"children":[
"Testing for anti–double-stranded DNA antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not required in this patient, as his antinuclear antibody test is negative and his kidney biopsy shows no granular staining suggestive of lupus nephritis."
]
},
{
"type":"p",
"hlId":"dcb4e2",
"children":[
"Anti–phospholipase A2 receptor antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") can be checked in patients suspected of having primary membranous nephropathy, which typically presents with the nephrotic syndrome and preserved kidney function. The findings of erythrocytes and erythrocyte casts also argue against primary membranous nephropathy."
]
},
{
"type":"p",
"hlId":"ea6374",
"children":[
"IgA nephropathy (IgAN) can present with any of the manifestations of the nephritic syndrome. Diagnosis can only be made when kidney biopsy shows dominant mesangial immune deposits of IgA with C3, and occasionally IgG or IgM. Circulating IgA levels (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") are not diagnostically useful, nor can they be reliably correlated with disease activity and should not be obtained. This patient's kidney biopsy shows linear staining, which is not consistent with IgAN."
]
}
],
"relatedSection":"mk19_a_np_s6_4_2_3",
"objective":{
"__html":"Diagnose anti–glomerular basement membrane antibody disease."
},
"references":[
[
"Gulati K, McAdoo SP. Anti-glomerular basement membrane disease. Rheum Dis Clin North Am. 2018;44:651-673. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30274629",
"target":"_blank"
},
"children":[
"PMID: 30274629"
]
},
" doi:10.1016/j.rdc.2018.06.011"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":5,
"B":85,
"C":5,
"D":5,
"E":0
},
"hlIds":[
"c362ab",
"2a200c",
"a462a3",
"687cd3",
"a3d0ba",
"dcfa5e",
"312f97",
"f461b2",
"e6438c",
"b534b1",
"ffb935",
"25d6d7",
"ffb935",
"8377f4",
"ffb935",
"747c2a",
"44fb07",
"e4ab3b",
"012885",
"dc0737",
"753cc8",
"a0f2f5",
"710104",
"dcb4e2",
"ea6374"
]
},
{
"id":"mk19_a_np_q064",
"number":64,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 64",
"stimulus":[
{
"type":"p",
"hlId":"6463e3",
"children":[
"A 73-year-old man is evaluated during a follow-up visit for an unexplained worsening of chronic kidney disease. Recent laboratory studies showed a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 2.4 mg/dL (212.2 µmol/L); 9 months ago, ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" was 1.1 mg/dL (97.2 µmol/L). He has had two episodes of idiopathic acute pancreatitis in the past 3 years."
]
},
{
"type":"p",
"hlId":"9ce0f2",
"children":[
"The physical examination, including vital signs, is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"48490f",
"class":"cell text l",
"children":[
"2.4 mg/dL (212.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9eaf68",
"class":"cell text l",
"children":[
"Electrolytes:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"876016",
"class":"cell text l",
"children":[
"5.3 mEq/L (5.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4fb259",
"class":"cell text l",
"children":[
"108 mEq/L (108 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4634aa",
"class":"cell text l",
"children":[
"20 mEq/L (20 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e97ead",
"class":"cell text l",
"children":[
"Specific gravity 1.020; pH 5.0; no blood; 1+ protein; 1+ glucose; no leukocyte esterase; 0-2 erythrocytes/hpf; 3-5 leukocytes/hpf; moderate granular casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"75b691",
"children":[
"Kidney ultrasound shows a 12-cm right kidney and a 13-cm left kidney with a mild increase in cortical echogenicity."
]
},
{
"type":"p",
"hlId":"61079b",
"children":[
"Kidney biopsy shows chronic tubulointerstitial nephritis with dense lymphoplasmacytic infiltrates."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"IgG4-related disease"
}
},
{
"letter":"B",
"text":{
"__html":"Sarcoidosis"
}
},
{
"letter":"C",
"text":{
"__html":"Systemic lupus erythematosus"
}
},
{
"letter":"D",
"text":{
"__html":"Tubulointerstitial nephritis with uveitis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"86bb92",
"children":[
"Patients with IgG4-related disease commonly present with a sentinel organ enlargement and dysfunction, but careful evaluation often reveals more extensive disease."
]
},
{
"type":"keypoint",
"hlId":"9592a4",
"children":[
"Kidney involvement of IgG4-related disease typically manifests as chronic interstitial nephritis with fibrosis and dense lymphoplasmacytic infiltrate."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"afce59",
"children":[
"The most likely diagnosis is IgG4-related disease (IgG4-RD) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), which is typically characterized by infiltration and tumefaction of the affected tissue with resultant organ enlargement, fibrosis, and dysfunction. Patients commonly present with a sentinel organ enlargement, but careful evaluation often reveals more extensive disease. Some common presentations of IgG4-RD include idiopathic pancreatitis, sclerosing cholangitis, bilateral salivary and/or lacrimal gland enlargement, retroperitoneal fibrosis, orbital pseudotumor, or proptosis. Diagnosis is made by tissue biopsy, which demonstrates a dense lymphoplasmacytic infiltrate, CD4-positive T cells and plasma cells in germinal centers, IgG4-staining plasma cells, storiform fibrosis, obliterative phlebitis or arteritis, and tissue eosinophilia. IgG4 levels are elevated in the serum in 70% to 80% of patients; therefore, a normal serum IgG4 level does not rule out the disease. Initial treatment is prednisone. In this patient, clues to the underlying diagnosis are the presence of idiopathic pancreatitis and large kidney size for a patient with chronic kidney disease. Kidney involvement of IgG4-RD typically manifests as chronic interstitial nephritis (CIN) with fibrosis; plasma cells typically stain positive for IgG4."
]
},
{
"type":"p",
"hlId":"885709",
"children":[
"Sarcoidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is most commonly characterized by noncaseating granulomas and CIN changes on biopsy. Sarcoidosis does not explain this patient's episodes of idiopathic pancreatitis or the lymphoplasmacytic cell infiltrate on kidney biopsy."
]
},
{
"type":"p",
"hlId":"96b932",
"children":[
"Systemic lupus erythematosus (SLE) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may present with CIN. However, SLE more frequently manifests in the kidney as acute glomerular disease and is not associated with pancreatitis or lymphoplasmacytic cell infiltrate on kidney biopsy."
]
},
{
"type":"p",
"hlId":"451dc8",
"children":[
"Tubulointerstitial nephritis with uveitis (TINU) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a distinct syndrome of acute interstitial nephritis with features of uveitis and may be accompanied by various autoantibodies and hypocomplementemia. Most patients with TINU are adolescents and young women. This patient's clinical syndrome is not consistent with TINU."
]
}
],
"relatedSection":"mk19_a_np_s5_3_1_4",
"objective":{
"__html":"Diagnose IgG4-related disease."
},
"references":[
[
"Zhang P, Cornell LD. IgG4-related tubulointerstitial nephritis. Adv Chronic Kidney Dis. 2017;24:94-100. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28284385",
"target":"_blank"
},
"children":[
"PMID: 28284385"
]
},
" doi:10.1053/j.ackd.2016.12.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":78,
"B":7,
"C":5,
"D":9,
"E":0
},
"hlIds":[
"6463e3",
"9ce0f2",
"a462a3",
"f461b2",
"48490f",
"9eaf68",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"876016",
"a207b1",
"4fb259",
"6827e3",
"4634aa",
"747c2a",
"e97ead",
"75b691",
"61079b",
"413696",
"86bb92",
"9592a4",
"afce59",
"885709",
"96b932",
"451dc8"
]
},
{
"id":"mk19_a_np_q065",
"number":65,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 65",
"stimulus":[
{
"type":"p",
"hlId":"0c0bea",
"children":[
"A 65-year-old man is evaluated for a 7-week history of increasing fatigue and poor appetite. Medical history is otherwise unremarkable. He takes no medications."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f1fae6",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hematocrit",
"children":[
"Hematocrit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1b63b8",
"class":"cell text l",
"children":[
"28%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6d5102",
"class":"cell text l",
"children":[
"3.0 g/dL (30 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f1669c",
"class":"cell text l",
"children":[
"10.4 mg/dL (2.6 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9ad5f4",
"class":"cell text l",
"children":[
"130 mEq/L (130 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a0193e",
"class":"cell text l",
"children":[
"3.6 mEq/L (3.6 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5042b4",
"class":"cell text l",
"children":[
"99 mEq/L (99 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5adbf9",
"class":"cell text l",
"children":[
"23 mEq/L (23 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"948309",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Osmolality, serum",
"children":[
"Osmolality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d9d655",
"class":"cell text l",
"children":[
"290 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"386431",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Total, serum",
"children":[
"Total protein"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9d7832",
"class":"cell text l",
"children":[
"9.8 g/dL (98 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"108437",
"class":"cell text l",
"children":[
"Urine osmolality"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"216e35",
"class":"cell text l",
"children":[
"240 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9b00f9",
"class":"cell text l",
"children":[
"45 mEq/L (45 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"0016f3",
"children":[
"Which of the following is the most likely cause of this patient's hyponatremia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hypercalcemia"
}
},
{
"letter":"B",
"text":{
"__html":"Multiple myeloma"
}
},
{
"letter":"C",
"text":{
"__html":"Poor solute intake"
}
},
{
"letter":"D",
"text":{
"__html":"Psychogenic polydipsia"
}
},
{
"letter":"E",
"text":{
"__html":"Syndrome of inappropriate antidiuretic hormone secretion"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"c15ae6",
"children":[
"The first step in evaluating a patient with hyponatremia is to measure serum osmolality."
]
},
{
"type":"keypoint",
"hlId":"09acbd",
"children":[
"Isotonic hyponatremia is a laboratory artifact caused by increased plasma concentrations of lipids or proteins."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"1c9b6e",
"children":[
"The most likely cause of this patient's hyponatremia is multiple myeloma (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). Results of this patient's laboratory studies, including elevated serum calcium, anemia, and elevated total protein and low albumin suggesting an increased gamma globulin fraction, support the diagnosis of multiple myeloma. The key finding, however, is that the patient has a normal measured serum osmolality in the context of hyponatremia. When evaluating a patient with hyponatremia, the first step is to measure serum osmolality. In this patient, the serum osmolality is normal, and thus he has isotonic hyponatremia. Isotonic hyponatremia (serum osmolality, 275-295 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O) is a laboratory artifact caused by the method by which serum sodium is measured. Plasma is divided into a water phase (93%), in which the sodium is dissolved, and a solid phase (7%), which consists of lipids and proteins. If the solid phase is increased by an increase in proteins, such as those found in multiple myeloma or severe elevations in serum triglycerides, there is a decrease in the water phase (i.e., from 93% to 80%). Most laboratories use a diluting electrode in which there is a tenfold dilution of the specimen when measuring electrolytes. With a decrease in the aqueous phase, the dilution is no longer 1:10, but even greater, resulting in a spurious value for sodium."
]
},
{
"type":"p",
"hlId":"d58bc3",
"children":[
"Hypercalcemia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") can cause polyuria secondary to nephrogenic diabetes insipidus, which would increase the sodium concentration, not lower it, as seen in this patient."
]
},
{
"type":"p",
"hlId":"48b1d1",
"children":[
"Because the kidney requires solute to excrete water, a decrease in solute intake (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), which occurs in potomania (excessive beer drinking) or in individuals with starvation, the kidney's ability to excrete water is reduced and can result in hyponatremia without excessive water intake. In these cases, urine osmolality would be <100 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O."
]
},
{
"type":"p",
"hlId":"ff5328",
"children":[
"In psychogenic polydipsia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), excess water intake exceeds the kidney's ability to excrete water through the urine, and urine osmolality would likely be <100 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O."
]
},
{
"type":"p",
"hlId":"73d76f",
"children":[
"In the syndrome of inappropriate antidiuretic hormone (SIADH) secretion (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"), the measured serum osmolality is always low, unlike that seen in this patient. Furthermore, patients with SIADH have hypo-osmolar hyponatremia."
]
}
],
"relatedSection":"mk19_a_np_s2_2_1_1_2",
"objective":{
"__html":"Identify multiple myeloma as a cause of isotonic hyponatremia."
},
"references":[
[
"Katrangi W, Baumann NA, Nett RC, et al. Prevalence of clinically significant differences in sodium measurements due to abnormal protein concentrations using an indirect ion-selective electrode method. J Appl Lab Med. 2019;4:427-432. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31659081",
"target":"_blank"
},
"children":[
"PMID: 31659081"
]
},
" doi:10.1373/jalm.2018.028720"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":6,
"B":62,
"C":6,
"D":8,
"E":18
},
"hlIds":[
"0c0bea",
"f8786b",
"a462a3",
"f1fae6",
"1b63b8",
"4590ed",
"6d5102",
"1a4da4",
"f1669c",
"f461b2",
"3a34ea",
"89662a",
"d41d8c",
"b99276",
"9ad5f4",
"e92687",
"a0193e",
"a207b1",
"5042b4",
"6827e3",
"5adbf9",
"948309",
"d9d655",
"386431",
"9d7832",
"108437",
"216e35",
"e331de",
"9b00f9",
"0016f3",
"c15ae6",
"09acbd",
"1c9b6e",
"d58bc3",
"48b1d1",
"ff5328",
"73d76f"
]
},
{
"id":"mk19_a_np_q066",
"number":66,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 66",
"stimulus":[
{
"type":"p",
"hlId":"f7ab05",
"children":[
"A 25-year-old woman is evaluated in the emergency department for weakness and muscle cramps. During the past 3 months, she had a weight loss of 15 kg (33.1 lb). She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"dd0bc3",
"children":[
"On physical examination, blood pressure is 124/72 mm Hg, pulse rate is 100/min, and respiration rate is 18/min. BMI is 36. Muscle strength is 4/5 in the upper and lower extremities. Other than weakness, the remainder of the neurologic examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"38947c",
"class":"cell text l",
"children":[
"0.8 mg/dL (70.7 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0e7e50",
"class":"cell text l",
"children":[
"135 mEq/L (135 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d7a001",
"class":"cell text l",
"children":[
"2.4 mEq/L (2.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8465e1",
"class":"cell text l",
"children":[
"79 mEq/L (79 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"010c52",
"class":"cell text l",
"children":[
"44 mEq/L (44 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"18044b",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, arterial (ambient air)",
"children":[
"Arterial blood gases"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"397dff",
"class":"cell text li",
"children":[
"pH"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fccaac",
"class":"cell text l",
"children":[
"7.61"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"dd372e",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Pco2, arterial (ambient air)",
"children":[
"P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"059a6b",
"class":"cell text l",
"children":[
"45 mm Hg (6.0 kPa)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c1bef6",
"class":"cell text l",
"children":[
"Urine chloride"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"49cf02",
"class":"cell text l",
"children":[
"3 mEq/L (3 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bartter syndrome"
}
},
{
"letter":"B",
"text":{
"__html":"Cushing syndrome"
}
},
{
"letter":"C",
"text":{
"__html":"Primary hyperaldosteronism"
}
},
{
"letter":"D",
"text":{
"__html":"Surreptitious vomiting"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"101319",
"children":[
"Saline-responsive metabolic alkalosis presents with a low urine chloride of <15 mEq/L (15 mmol/L); the most common causes are vomiting, nasogastric suction, and diuretic use."
]
},
{
"type":"keypoint",
"hlId":"1086e5",
"children":[
"Patients with high urine chloride (>15 mEq/L [15 mmol/L]), hypertension, and hypokalemia who do not appear to be overtly volume overloaded should be evaluated for a mineralocorticoid excess disorder (saline-resistant metabolic alkalosis) such as Cushing syndrome and primary hyperaldosteronism."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2a83c4",
"children":[
"The most likely cause of this patient's metabolic alkalosis is surreptitious vomiting (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Metabolic alkalosis is diagnosed by an elevation in serum bicarbonate concentration and elevated serum pH. This disorder is caused by either a loss of acid or administration or retention of bicarbonate. Conditions that contribute to the maintenance of metabolic alkalosis include volume contraction, ineffective arterial blood volume, hypokalemia, chloride depletion, and decreased glomerular filtration. Laboratory evaluation of metabolic alkalosis is based on urine chloride concentration. Metabolic alkalosis is considered saline responsive when associated with true hypovolemia and responds to correction of the volume deficit with isotonic saline. Saline-responsive metabolic alkalosis presents with a low urine chloride of <15 mEq/L (15 mmol/L); the most common causes are vomiting, nasogastric suction, and diuretic use. Hypokalemia in these circumstances occur secondarily due to aldosterone elevation and cation loss as the kidney attempts to lose bicarbonate. Although these patients are usually hypovolemic or normovolemic (with normal or low blood pressures), patients with preexisting chronic hypertension may present with high to normal blood pressures."
]
},
{
"type":"p",
"hlId":"97acb2",
"children":[
"Bartter syndrome (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") and Gitelman syndrome are autosomal recessive genetic disorders of renal sodium and chloride transporters that clinically mimic loop diuretic and thiazide diuretic use, respectively. Both syndromes present with hypokalemic alkalosis with urine chloride (>15 mEq/L [15 mmol/L]); therefore, neither syndrome is the diagnosis in this case."
]
},
{
"type":"p",
"hlId":"8b8468",
"children":[
"The presence of hypertension, metabolic alkalosis, and hypokalemia suggests elevated aldosterone states such as Cushing syndrome and primary hyperaldosteronism (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, C"
]
},
"). However, the presence of a low urine chloride (<15 mEq/L [15 mmol/L]) in this patient rules out these diagnoses. Patients with high urine chloride (>15 mEq/L [15 mmol/L]), elevated blood pressure, and hypokalemia who do not appear to be overtly volume overloaded should be evaluated for a mineralocorticoid excess disorder (saline-resistant metabolic alkalosis) such as Cushing syndrome and primary hyperaldosteronism."
]
}
],
"relatedSection":"mk19_a_np_s3_3",
"objective":{
"__html":"Diagnose surreptitious vomiting as a cause of metabolic alkalosis."
},
"references":[
[
"Soifer JT, Kim HT. Approach to metabolic alkalosis. Emerg Med Clin North Am. 2014;32:453-63. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24766943",
"target":"_blank"
},
"children":[
"PMID: 24766943"
]
},
" doi:10.1016/j.emc.2014.01.005"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":12,
"B":1,
"C":6,
"D":80,
"E":0
},
"hlIds":[
"f7ab05",
"dd0bc3",
"a462a3",
"f461b2",
"38947c",
"89662a",
"d41d8c",
"b99276",
"0e7e50",
"e92687",
"d7a001",
"a207b1",
"8465e1",
"6827e3",
"010c52",
"18044b",
"d41d8c",
"397dff",
"fccaac",
"dd372e",
"059a6b",
"c1bef6",
"49cf02",
"413696",
"101319",
"1086e5",
"2a83c4",
"97acb2",
"8b8468"
]
},
{
"id":"mk19_a_np_q067",
"number":67,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 67",
"stimulus":[
{
"type":"p",
"hlId":"a60b7d",
"children":[
"A 37-year-old man is hospitalized for a 2-month history of anorexia, 4.5-kg (10-lb) weight loss, nocturia, morning nausea, and fatigue. He has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"3b950b",
"children":[
"On physical examination, blood pressure is 197/98 mm Hg, pulse rate is 80/min, and respiration rate is 18/min. BMI is 24. Funduscopic examination reveals hypertensive retinopathy. There is no papilledema. Cardiac examination reveals a sustained apical impulse and an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". The lungs are clear to auscultation. There is 1+ edema of the lower extremities."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b79185",
"class":"cell text l",
"children":[
"163 mg/dL (58.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"95c7e6",
"class":"cell text l",
"children":[
"14.2 mg/dL (1255.3 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"dbbe15",
"class":"cell text l",
"children":[
"134 mEq/L (134 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"028d9b",
"class":"cell text l",
"children":[
"4.9 mEq/L (4.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5f1b49",
"class":"cell text l",
"children":[
"103 mEq/L (103 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"432158",
"class":"cell text l",
"children":[
"11 mEq/L (11 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5ec0e5",
"class":"cell text l",
"children":[
"Specific gravity 1.010; pH 7; 1+ blood; 1+ protein; 2-5 erythrocytes/hpf; 1-3 leukocytes/hpf; scattered granular and hyaline casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"c9493f",
"children":[
"Kidney ultrasound shows a 7.3-cm right kidney and a 7.7-cm left kidney; there is marked cortical echogenicity and loss of corticomedullary distinction but no hydronephrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Dialysis"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous 0.9% saline"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous methylprednisolone"
}
},
{
"letter":"D",
"text":{
"__html":"Percutaneous kidney biopsy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"b82063",
"children":[
"When patients present with presumed acute kidney injury, a late presentation of end-stage kidney disease must be part of the differential diagnosis."
]
},
{
"type":"keypoint",
"hlId":"59a406",
"children":[
"History, physical examination, and laboratory indices often do not discriminate between acute and chronic kidney disease (CKD); however, small (<10 cm) echogenic kidneys on ultrasound is very consistent with advanced CKD."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"e31f8e",
"children":[
"The most appropriate management is to initiate dialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). The history and physical examination findings suggest that this patient has had long-standing uncontrolled hypertension. The small (<9 cm) echogenic kidneys seen on kidney ultrasound indicate that he has had advanced chronic kidney disease (CKD), likely for years. When patients present with “acute” kidney injury, a late presentation of end-stage kidney disease (ESKD) must be part of the differential diagnosis. History, physical examination, and laboratory indices may not be able to distinguish between acute and chronic disease. However, the ultrasound finding of small echogenic kidneys is very consistent with advanced CKD. Initiation of dialysis for symptoms of uremia and severe metabolic acidosis is the most appropriate next step for this patient, regardless of the cause or duration of his kidney disease."
]
},
{
"type":"p",
"hlId":"f05d6b",
"children":[
"A rapid volume challenge through intravenous 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is most appropriate for patients with acute prerenal kidney injury, but it may provoke heart failure in this patient with ESKD."
]
},
{
"type":"p",
"hlId":"f818bb",
"children":[
"Intravenous high-dose glucocorticoids such as methylprednisolone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") are initiated for patients with acute glomerulonephritis with rapid decline in kidney function; this therapy would not be efficacious in patients, such as this one, with advanced CKD."
]
},
{
"type":"p",
"hlId":"195bb4",
"children":[
"A percutaneous kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is indicated only if a reversible or treatable cause of kidney disease is suspected, but it is not helpful or practical in patients with small echogenic kidneys that indicate irreversible kidney disease. Finally, percutaneous kidney biopsy is relatively contraindicated in patients with small kidneys because of increased risk for bleeding."
]
}
],
"relatedSection":"mk19_a_np_s9_7_2",
"objective":{
"__html":"Manage end-stage kidney disease with dialysis."
},
"references":[
[
"Levey AS, James MT. Acute kidney injury. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201711070",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2017;167:ITC66-ITC80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29114754",
"target":"_blank"
},
"children":[
"PMID: 29114754"
]
}
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":75,
"B":7,
"C":3,
"D":16,
"E":0
},
"hlIds":[
"a60b7d",
"3b950b",
"a462a3",
"29d161",
"b79185",
"f461b2",
"95c7e6",
"89662a",
"d41d8c",
"b99276",
"dbbe15",
"e92687",
"028d9b",
"a207b1",
"5f1b49",
"6827e3",
"432158",
"747c2a",
"5ec0e5",
"c9493f",
"cb2b54",
"b82063",
"59a406",
"e31f8e",
"f05d6b",
"f818bb",
"195bb4"
]
},
{
"id":"mk19_a_np_q068",
"number":68,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 68",
"stimulus":[
{
"type":"p",
"hlId":"45d512",
"children":[
"A 52-year-old woman is evaluated during a follow-up visit for hypertension. Losartan and chlorthalidone were started 1 month ago. She adheres to her medication regimen and low sodium diet. She has no other medical problems and takes no other medications. Previous ECG and results of a comprehensive metabolic profile and urinalysis were normal."
]
},
{
"type":"p",
"hlId":"00e1ab",
"children":[
"On physical examination, blood pressure is 145/82 mm Hg, and pulse rate is 70/min; other vital signs are normal. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"294932",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.8 mg/dL (70.7 µmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"serum potassium"
]
},
" level of 3.6 mEq/L (3.6 mmol/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Aliskiren"
}
},
{
"letter":"B",
"text":{
"__html":"Amlodipine"
}
},
{
"letter":"C",
"text":{
"__html":"Hydralazine"
}
},
{
"letter":"D",
"text":{
"__html":"Hydrochlorothiazide"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a71fc2",
"children":[
"Two strategies can be used for antihypertensive dose adjustment in the treatment of hypertension: maximize medication dose before adding another agent or add another agent before maximizing the dose of the prior agents."
]
},
{
"type":"keypoint",
"hlId":"b2f507",
"children":[
"Two drugs from classes that target the same blood pressure control system are less effective and potentially harmful when used together."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"9232c1",
"children":[
"The most appropriate additional treatment is amlodipine, a calcium channel blocker (CCB) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient with hypertension requires escalation of her antihypertensive medication regimen because her blood pressure (BP) is not at target. The 2017 American College of Cardiology/American Heart Association BP guideline recommends a BP target of <130/80 mm Hg. Two strategies can be used: maximize medication dose before adding another agent or add another agent from a different class of medication before maximizing the dose of the prior agents. There are no randomized trials comparing these strategies. Generally, there is diminishing return in BP lowering if dose is titrated up from 50% to 100% of maximum. Also, it is unlikely that increasing the dose of a drug from 50% to 100% of maximum will result in a significant BP reduction. Finally, titration to maximum doses more commonly results in side effects and may reduce medication adherence. Therefore, adding a third drug to a two-drug regimen is a strategy recommended by many experts."
]
},
{
"type":"p",
"hlId":"a4e6f8",
"children":[
"Two drugs from classes that target the same BP control system are less effective and potentially harmful when used together. For example, administration of combination therapy with renin-angiotensin system blockers, such as an ACE inhibitor with an angiotensin receptor blocker (ARB) or an ACE inhibitor or ARB with the direct renin inhibitor aliskiren, increases cardiovascular and renal risk. Therefore, aliskiren should not be added (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"ee7b37",
"children":[
"Hydralazine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not the best option, because agents shown to reduce clinical events (such as thiazide diuretics, calcium channel blockers, ACE inhibitors, ARBs) should be used preferentially. Additionally, it is a thrice-daily medication. Use of longer-acting antihypertensive drugs that only require once-daily dosing and combination pills to reduce pill burden can increase adherence."
]
},
{
"type":"p",
"hlId":"3fc1f8",
"children":[
"Adding hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not the best option because two thiazide diuretics will not improve BP control in this patient and risks the development of hypokalemia. However, concomitant use of diuretics that have different mechanisms of action, such as a combination of a thiazide diuretic, potassium-sparing diuretic, and/or a loop diuretic, can effectively control extracellular volume and hypertension."
]
}
],
"relatedSection":"mk19_a_np_s4_7_2_3_4",
"objective":{
"__html":"Adjust an antihypertensive medication regimen using combination drug therapy."
},
"references":[
[
"Byrd JB, Brook RD. Hypertension. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201905070",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC65-ITC80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31060074",
"target":"_blank"
},
"children":[
"PMID: 31060074"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":5,
"B":90,
"C":1,
"D":4,
"E":0
},
"hlIds":[
"45d512",
"00e1ab",
"294932",
"78ff87",
"a71fc2",
"b2f507",
"9232c1",
"a4e6f8",
"ee7b37",
"3fc1f8"
]
},
{
"id":"mk19_a_np_q069",
"number":69,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 69",
"stimulus":[
{
"type":"p",
"hlId":"877f9d",
"children":[
"A 26-year-old woman is evaluated in the emergency department for acute flank pain and gross hematuria."
]
},
{
"type":"p",
"hlId":"d3ca7f",
"children":[
"On physical examination, the patient is afebrile. Pulse rate is 102/min; other vital signs are normal. Costovertebral angle tenderness is noted. The abdomen is soft and nontender."
]
},
{
"type":"p",
"hlId":"830f5f",
"children":[
"Urinalysis shows 3+ blood, trace protein, no nitrites or leukocyte esterase, 2-3 leukocytes/hpf, and too numerous to count erythrocytes. Pregnancy test is positive."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Abdominal MRI"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney ultrasonography"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney, ureter, and bladder plain radiography"
}
},
{
"letter":"D",
"text":{
"__html":"Noncontrast helical abdominal CT"
}
},
{
"letter":"E",
"text":{
"__html":"Ureteroscopy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"25acba",
"children":[
"Ultrasonography is readily available, inexpensive, and very safe and is a useful first study in evaluating nephrolithiasis."
]
},
{
"type":"keypoint",
"hlId":"772ab8",
"children":[
"Kidney ultrasonography is the preferred diagnostic test for suspected nephrolithiasis in pregnant women."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a65a29",
"children":[
"The most appropriate diagnostic test to perform next is kidney ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") for this pregnant patient with likely nephrolithiasis. Imaging is indicated for diagnosis and to guide management based on stone size and location. Ultrasonography is increasingly being used as an initial diagnostic study. Although less sensitive than CT for nephrolithiasis, particularly for detecting small stones and ureteral stones, ultrasonography does not expose patients to radiation and is typically more readily available and has a lower cost compared with CT; it is also the preferred modality during pregnancy. A positive ultrasound may therefore be adequate for initial diagnosis in patients with a typical presentation for kidney stones; more complex testing is indicated for those with a high clinical suspicion but a nondiagnostic ultrasound or a more complicated clinical presentation."
]
},
{
"type":"p",
"hlId":"b683b6",
"children":[
"Abdominal MRI (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") can be used during pregnancy, but it is not optimal for imaging kidney stones. Ultrasonography is preferred, although MRI may be a diagnostic option if additional imaging is required for diagnosis."
]
},
{
"type":"p",
"hlId":"ae16e4",
"children":[
"Plain abdominal radiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has limited utility due to its inability to detect radiolucent uric acid stones, and it does not provide as much anatomic information as other modalities; furthermore, it should be avoided during pregnancy. However, it may be useful in assessing stone burden in nonpregnant patients with known radiopaque stones."
]
},
{
"type":"p",
"hlId":"93732d",
"children":[
"Noncontrast helical abdominal CT (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") has traditionally been the most commonly used imaging technique because it detects most stones, provides anatomic information, and visualizes the entire urinary tract; it may also suggest stone composition and potentially provide alternative diagnoses if nephrolithiasis is not detected. Although CT is more sensitive and specific than ultrasonography, a randomized controlled trial demonstrated equivalent diagnostic accuracy within the emergency department. Finally, CT is associated with significant radiation exposure and is contraindicated in pregnant women."
]
},
{
"type":"p",
"hlId":"73ed0f",
"children":[
"Ureteroscopy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"), in which an endoscopic device is introduced in a retrograde fashion into the ureter through the bladder, is most commonly used in the management of mid-ureteral and distal ureteral stones, using a combination of catheter-based stone disintegration methods (such as laser lithotripsy), stone baskets, and ureteral stent placement. Although this procedure does not involve radiation, it is not a diagnostic procedure indicated for suspected kidney stones because it is unnecessarily invasive."
]
}
],
"relatedSection":"mk19_a_np_s1_3",
"objective":{
"__html":"Diagnose nephrolithiasis during pregnancy."
},
"references":[
[
"Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13:654-662. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27578040",
"target":"_blank"
},
"children":[
"PMID: 27578040"
]
},
" doi:10.1038/nrurol.2016.154"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":2,
"B":75,
"C":1,
"D":21,
"E":2
},
"hlIds":[
"877f9d",
"d3ca7f",
"830f5f",
"ab9d96",
"25acba",
"772ab8",
"a65a29",
"b683b6",
"ae16e4",
"93732d",
"73ed0f"
]
},
{
"id":"mk19_a_np_q070",
"number":70,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 70",
"stimulus":[
{
"type":"p",
"hlId":"4ae394",
"children":[
"A 17-year-old boy is evaluated in the hospital for acute kidney injury. He was hospitalized 24 hours ago for a bone marrow biopsy, which confirmed the presence of acute lymphoblastic leukemia. On admission, ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"blood urea nitrogen"
]
},
" level was 24 mg/dL (8.6 mmol/L) and ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level was 1.0 mg/dL (88.4 µmol/L). Intravenous 0.9% saline was started at 125 mL/h. This morning, his ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level is 1.9 mg/dL (168 µmol/L). His urine output diminished to less than 50 mL/h."
]
},
{
"type":"p",
"hlId":"93596f",
"children":[
"On physical examination, vital signs are normal. There are few scattered ecchymoses on the upper and lower extremities. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9837f1",
"children":[
"Laboratory studies (hospital day 2):"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9cda9a",
"class":"cell text l",
"children":[
"46 mg/dL (16.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d91d56",
"class":"cell text l",
"children":[
"6.3 mg/dL (1.6 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cb7c08",
"class":"cell text l",
"children":[
"1.9 mg/dL (168 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3d979b",
"class":"cell text l",
"children":[
"137 mEq/L (137 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"291b42",
"class":"cell text l",
"children":[
"6.1 mEq/L (6.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5f1b49",
"class":"cell text l",
"children":[
"103 mEq/L (103 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"93c4e0",
"class":"cell text l",
"children":[
"17 mEq/L (17 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4d358a",
"class":"cell text l",
"children":[
"9.6 mg/dL (3.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"07e6a7",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Urate, serum",
"children":[
"Urate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"10aa6e",
"class":"cell text l",
"children":[
"15.2 mg/dL (0.90 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"868ddc",
"class":"cell text l",
"children":[
"Specific gravity 1.010; pH 5.0; 1+ blood; trace protein; multiple uric acid crystals, scattered granular casts and hyaline casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"a79d01",
"children":[
"Intravenous 0.9% saline is increased to 200 mL/h."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Allopurinol"
}
},
{
"letter":"B",
"text":{
"__html":"Febuxostat"
}
},
{
"letter":"C",
"text":{
"__html":"Rasburicase"
}
},
{
"letter":"D",
"text":{
"__html":"Urinary alkalinization"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"e19027",
"children":[
"Tumor lysis syndrome may spontaneously occur in patients with acute leukemia or high-grade lymphoma and is characterized by acute kidney injury with severe hyperuricemia, hyperphosphatemia, and hypocalcemia."
]
},
{
"type":"keypoint",
"hlId":"0057cf",
"children":[
"Treatment of tumor lysis syndrome includes prompt initiation of isotonic volume expansion and rasburicase to rapidly reduce serum urate levels."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"0cd554",
"children":[
"The most appropriate additional treatment is rasburicase (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). This young patient exhibits spontaneous tumor lysis syndrome (TLS) before the initiation of chemotherapy. TLS is characterized by acute kidney injury with severe hyperuricemia, hyperphosphatemia, and hypocalcemia. These electrolyte abnormalities can lead to cardiac arrhythmias, seizures, and death. TLS is most frequently seen in highly proliferative hematologic malignancies such as acute leukemia and high-grade lymphomas but can develop in many other cancers. Appropriate therapy includes prompt initiation of isotonic volume expansion and an agent such as rasburicase. Rasburicase is a urate oxidase enzyme that metabolizes urate to allantoin, a significantly more water-soluble compound."
]
},
{
"type":"p",
"hlId":"8cebc9",
"children":[
"Allopurinol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is the most commonly used urate-lowering agent. It competitively inhibits the enzyme xanthine oxidase, blocking the conversion of hypoxanthine (a breakdown product of purines) to urate. Although allopurinol will prevent new urate formation, it will not rapidly lower this patient's existing serum urate level."
]
},
{
"type":"p",
"hlId":"5a8f3e",
"children":[
"Febuxostat (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is a noncompetitive xanthine oxidase inhibitor and, as with allopurinol, blocks the formation of urate. Febuxostat is often used in patients in whom allopurinol is contraindicated. However, it is less effective than rasburicase in rapidly lowering serum urate levels."
]
},
{
"type":"p",
"hlId":"0e47af",
"children":[
"The role of urinary alkalinization in TLS (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") with either acetazolamide and/or sodium bicarbonate is unclear and controversial. Alkalinization was recommended to increase promote uric acid solubility. However, alkalinization of the urine can also promote a favorable environment for precipitation of calcium phosphate. Therefore, isotonic saline and rasburicase are preferred to prevent or treat TLS."
]
}
],
"relatedSection":"mk19_a_np_s9_6_4",
"objective":{
"__html":"Treat acute kidney injury due to tumor lysis syndrome."
},
"references":[
[
"Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38:295-308. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31284363",
"target":"_blank"
},
"children":[
"PMID: 31284363"
]
},
" doi:10.23876/j.krcp.19.042"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":14,
"B":2,
"C":68,
"D":15,
"E":0
},
"hlIds":[
"4ae394",
"93596f",
"9837f1",
"29d161",
"9cda9a",
"1a4da4",
"d91d56",
"f461b2",
"cb7c08",
"89662a",
"d41d8c",
"b99276",
"3d979b",
"e92687",
"291b42",
"a207b1",
"5f1b49",
"6827e3",
"93c4e0",
"a4922e",
"4d358a",
"07e6a7",
"10aa6e",
"747c2a",
"868ddc",
"a79d01",
"78ff87",
"e19027",
"0057cf",
"0cd554",
"8cebc9",
"5a8f3e",
"0e47af"
]
},
{
"id":"mk19_a_np_q071",
"number":71,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 71",
"stimulus":[
{
"type":"p",
"hlId":"a6a54e",
"children":[
"A 24-year-old man is evaluated in the emergency department for a 3-hour history of right flank pain that radiates to the groin. He reports nausea and dysuria but no fever or chills. Medical history is otherwise unremarkable. He takes no medications. Intravenous ketorolac is initiated for pain."
]
},
{
"type":"p",
"hlId":"3a49e8",
"children":[
"On physical examination, pulse rate is 104/min; other vital signs are normal. The patient appears uncomfortable. Abdominal examination reveals right costovertebral tenderness. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"9acf9f",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, Serum",
"children":[
"serum calcium"
]
},
" level of 9.8 mg/dL (2.5 mmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.8 mg/dL (70.7 µmol/L). Urinalysis shows a specific gravity of 1.020; a pH of 5.0; 1+ blood; no leukocyte esterase; no nitrites; 20-30 erythrocytes/hpf; and 0-1 leukocytes/hpf."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"8e7f11",
"children":[
"Which of the following is the most sensitive imaging test to perform?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Intravenous pyelography"
}
},
{
"letter":"B",
"text":{
"__html":"Kidney and bladder ultrasonography"
}
},
{
"letter":"C",
"text":{
"__html":"Kidney, ureter, and bladder radiography"
}
},
{
"letter":"D",
"text":{
"__html":"Noncontrast helical abdomen and pelvis CT"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"01881d",
"children":[
"Noncontrast helical CT of the abdomen and pelvis is the gold standard for diagnosis of kidney stones because of its high sensitivity and specificity."
]
},
{
"type":"keypoint",
"hlId":"1be9c5",
"children":[
"Ultrasonography is the preferred imaging test for suspected nephrolithiasis in pregnant women and when CT imaging is not available."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"1c9746",
"children":[
"The most sensitive imaging test to perform is a noncontrast helical abdomen and pelvis CT (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), which has the highest sensitivity and specificity of all imaging options used in evaluating nephrolithiasis. The sensitivity of noncontrast helical abdominal CT for the diagnosis of nephrolithiasis is greater than 95%. Noncontrast helical CT can also detect stones independent of their composition, with the exception of stones composed of indinavir crystals. Furthermore, noncontrast helical CT may be able to predict the composition of the stone based on the Hounsfield units. However, this should not preempt stone analysis. Finally, noncontrast helical CT potentially provides alternative diagnoses if nephrolithiasis is not detected."
]
},
{
"type":"p",
"hlId":"631f20",
"children":[
"There is no role for the use of intravenous pyelography (IVP) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") in the evaluation of kidney stones. IVP has high sensitivity for the diagnosis of hydronephrosis that might be caused by a stone but lacks the sensitivity and specificity of noncontrast helical CT in the diagnosis of nephrolithiasis and potential diagnosis of stone type. When noncontrast helical CT is unavailable or contraindicated, kidney ultrasonography is preferred to IVP. Finally, IVP requires the use of intravenous contrast."
]
},
{
"type":"p",
"hlId":"18d262",
"children":[
"Kidney and bladder ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is less accurate than noncontrast helical CT in the diagnosis of nephrolithiasis. Sensitivity ranges from 50% to 90%. Small stones and stones within the ureter are frequently not detected on ultrasonography. Ultrasonography is also less able to determine stone size or location within the ureter. However, if noncontrast CT is unavailable or if the patient is pregnant, ultrasonography is the preferred method of evaluation."
]
},
{
"type":"p",
"hlId":"c433cc",
"children":[
"Radiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has little role in the evaluation of kidney stones due to poor sensitivity and specificity. This modality will not detect radiolucent uric acid stones and often cannot determine if the calcification visualized is within or external to the urinary system. Because of low cost and low amount of radiation, radiography is useful for following the movement and growth of a stone as well as monitoring total stone burden."
]
}
],
"relatedSection":"mk19_a_np_s10_3",
"objective":{
"__html":"Diagnose nephrolithiasis with noncontrast helical CT."
},
"references":[
[
"Mayans L. Nephrolithiasis. Prim Care. 2019;46:203-212. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31030821",
"target":"_blank"
},
"children":[
"PMID: 31030821"
]
},
" doi:10.1016/j.pop.2019.02.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":6,
"B":5,
"C":4,
"D":85,
"E":0
},
"hlIds":[
"a6a54e",
"3a49e8",
"9acf9f",
"8e7f11",
"01881d",
"1be9c5",
"1c9746",
"631f20",
"18d262",
"c433cc"
]
},
{
"id":"mk19_a_np_q072",
"number":72,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 72",
"stimulus":[
{
"type":"p",
"hlId":"0eaf80",
"children":[
"A 65-year-old man is evaluated during a follow-up visit for stage G4 chronic kidney disease. He has a reduced appetite but no other significant symptoms. Four months ago, anemia was discovered and confirmed to be related to his chronic kidney disease. Medical history is also significant for hypertension and type 2 diabetes mellitus. Medications are atenolol, atorvastatin, basal insulin, prandial insulin, metolazone, sevelamer, furosemide, hydralazine, and nifedipine."
]
},
{
"type":"p",
"hlId":"76948a",
"children":[
"On physical examination, vital signs are normal. There is a mature arteriovenous fistula with a thrill. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d6b70f",
"class":"cell text l",
"children":[
"10.1 g/dL (101 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6d756c",
"class":"cell text l",
"children":[
"3.3 mg/dL (291.7 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8153ca",
"class":"cell text l",
"children":[
"4.2 mEq/L (4.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d95465",
"class":"cell text l",
"children":[
"19 mEq/L (19 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"37b689",
"class":"cell text l",
"children":[
"20 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Erythropoietin-stimulating agent"
}
},
{
"letter":"B",
"text":{
"__html":"Hemodialysis"
}
},
{
"letter":"C",
"text":{
"__html":"High-protein diet"
}
},
{
"letter":"D",
"text":{
"__html":"Sodium bicarbonate supplement"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2b97b6",
"children":[
"Metabolic acidosis in patients with chronic kidney disease should be treated with alkali therapy when serum bicarbonate levels are <22 mEq/L (22 mmol/L)."
]
},
{
"type":"keypoint",
"hlId":"3fc274",
"children":[
"Repletion of bicarbonate into the normal range in patients with chronic kidney disease (CKD) attenuates the rate of CKD progression."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"abb625",
"children":[
"The most appropriate treatment is sodium bicarbonate supplement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") for this patient with a metabolic acidosis. There is a strong association between metabolic acidosis and increased progression of chronic kidney disease (CKD) and mortality. Data suggest that repletion of bicarbonate attenuates the rate of CKD progression. Bicarbonate can be given as sodium bicarbonate tablets, as a powder (including in the form of baking soda), or through a diet rich in fruit and vegetables that are endogenous alkali sources. Guidelines recommend initiation of bicarbonate when the serum bicarbonate level is <22 mEq/L (22 mmol/L), as seen in this patient. Bicarbonate therapy should be titrated to achieve a serum bicarbonate level within the normal range."
]
},
{
"type":"p",
"hlId":"17e7f0",
"children":[
"FDA black box warnings for use of erythropoietin-stimulating agents (ESAs) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") include the risk for increased mortality and/or tumor progression in patients with active malignancy; increased risk for thromboembolic events in postsurgical patients not receiving anticoagulant therapy; and increased risk for serious cardiovascular events when ESAs are administered to patients with hemoglobin values >11 g/dL (110 g/L) or with a history of stroke. Because of the potential harm caused by ESAs in patients with CKD, use of these agents should be restricted to patients with hemoglobin values <10 g/dL (100 g/L) and symptoms."
]
},
{
"type":"p",
"hlId":"b541fc",
"children":[
"Hemodialysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not an appropriate management, as this patient has stage G4 CKD. Medical management of metabolic acidosis is indicated for these patients until progression to advanced stage G5 CKD with an estimated glomerular filtration rate <10 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". For patients with advanced stage G5 CKD, data indicate that there is no mortality benefit to early initiation of renal replacement therapy. The decision to start hemodialysis should be based upon the development of uremic symptoms refractory to medical management."
]
},
{
"type":"p",
"hlId":"063f1e",
"children":[
"A high-protein diet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is a source of the daily acid load and would worsen rather than improve this patient's metabolic acidosis."
]
}
],
"relatedSection":"mk19_a_np_s12_6_4",
"objective":{
"__html":"Treat metabolic acidosis in chronic kidney disease."
},
"references":[
[
"Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377:1765-1776. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29091561",
"target":"_blank"
},
"children":[
"PMID: 29091561"
]
},
" doi:10.1056/NEJMra1700312"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":17,
"B":10,
"C":2,
"D":71,
"E":0
},
"hlIds":[
"0eaf80",
"76948a",
"a462a3",
"f9867c",
"d6b70f",
"f461b2",
"6d756c",
"e92687",
"8153ca",
"6827e3",
"d95465",
"77db81",
"37b689",
"1054f1",
"2b97b6",
"3fc274",
"abb625",
"17e7f0",
"b541fc",
"063f1e"
]
},
{
"id":"mk19_a_np_q073",
"number":73,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 73",
"stimulus":[
{
"type":"p",
"hlId":"37a561",
"children":[
"A 35-year-old woman is evaluated during a follow-up visit for recurrent microscopic hematuria without proteinuria. Family history is significant for microscopic hematuria in her brother and mother; her two other siblings have no urinary abnormalities. There is no family history of chronic kidney disease or end-stage kidney disease. Her medical history is otherwise unremarkable, and she takes no medications."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"p",
"hlId":"a3fa60",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.7 mg/dL (61.9 µmol/L); urinalysis shows 2+ blood, no protein, and 20-30 erythrocytes/hpf."
]
},
{
"type":"p",
"hlId":"7f682c",
"children":[
"Kidney ultrasound shows normal-sized kidneys with no masses or stones."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Autosomal dominant tubulointerstitial kidney disease"
}
},
{
"letter":"B",
"text":{
"__html":"Fabry disease"
}
},
{
"letter":"C",
"text":{
"__html":"Hereditary nephritis (Alport syndrome)"
}
},
{
"letter":"D",
"text":{
"__html":"Thin glomerular basement membrane disease"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"8220a0",
"children":[
"Thin glomerular basement membrane (GBM) disease is an autosomal dominant type IV collagen abnormality that causes thinning of the GBM, resulting in hematuria but usually without proteinuria or abnormal kidney function."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"d1a9a8",
"children":[
"Thin glomerular basement membrane (GBM) disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is the most likely diagnosis. Also known as benign familial hematuria, inheritance in this disease is autosomal dominant. The inherited type IV collagen abnormality causes thinning of the GBM, which results in hematuria but usually without proteinuria or abnormal kidney function. Thin GBM disease may affect up to 5% of the population, with up to 50% of patients who are diagnosed reporting a family history of hematuria without kidney failure. Both microscopic and macroscopic hematuria can be seen, first manifesting in young adulthood. Although diagnosis can be made by kidney biopsy, this is not usually required in the setting of a good clinical and family history. Genetic testing may also be used to make the diagnosis."
]
},
{
"type":"p",
"hlId":"d3a142",
"children":[
"Autosomal dominant tubulointerstitial kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") should be suspected in patients with slowly progressive chronic kidney disease, a bland urine sediment, small kidneys, and a family history of end-stage kidney disease. This patient has normal-sized kidneys, microscopic hematuria, and no family history of kidney dysfunction."
]
},
{
"type":"p",
"hlId":"c96b34",
"children":[
"Fabry disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") follows an X-linked pattern on inheritance. Patients are expected to have kidney dysfunction by adulthood alongside abnormalities in other organs such as the skin (telangiectasias and angiokeratomas), eyes, heart (premature coronary artery disease), brain, and/or peripheral nervous system (severe neuropathic pain). This patient has no kidney dysfunction or other organ abnormalities."
]
},
{
"type":"p",
"hlId":"9593fa",
"children":[
"Hereditary nephritis (Alport syndrome) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") follows an X-linked pattern on inheritance in 85% of cases; the remaining 15% of cases follow an autosomal recessive pattern of inheritance. In addition, hereditary nephritis is expected to have a family history of not only hematuria, but also proteinuria (unlike this patient), renal dysfunction (including end-stage kidney disease in most families), and both visual and hearing abnormalities."
]
}
],
"relatedSection":"mk19_a_np_s8_2_2_2",
"objective":{
"__html":"Diagnose thin glomerular basement membrane disease."
},
"references":[
[
"Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV a345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93:1045-1051. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29551517",
"target":"_blank"
},
"children":[
"PMID: 29551517"
]
},
" doi:10.1016/j.kint.2017.12.018"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":9,
"B":4,
"C":24,
"D":63,
"E":0
},
"hlIds":[
"37a561",
"f8786b",
"a3fa60",
"7f682c",
"413696",
"8220a0",
"d1a9a8",
"d3a142",
"c96b34",
"9593fa"
]
},
{
"id":"mk19_a_np_q074",
"number":74,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 74",
"stimulus":[
{
"type":"p",
"hlId":"e73e86",
"children":[
"A 70-year-old woman is evaluated during a follow-up visit. One month ago, lisinopril was initiated for confirmed hypertension. Pretreatment blood pressure was 152/78 mm Hg. Therapeutic lifestyle interventions and pharmacologic therapies were initiated. Medical history is also significant for peripheral vascular disease, hyperlipidemia, and type 2 diabetes mellitus. Other medications are glipizide, rosuvastatin, and low-dose aspirin. She lives independently in her own home."
]
},
{
"type":"p",
"hlId":"aab522",
"children":[
"On physical examination, blood pressure is 144/69 mm Hg, and pulse rate is 86/min. Cardiovascular examination reveals an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
" and diminished lower extremity pulses. There is no peripheral edema. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d34d5",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"057980",
"class":"cell text l",
"children":[
"4.4 mEq/L (4.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a1f179",
"class":"cell text l",
"children":[
"34 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c238e9",
"class":"cell text l",
"children":[
"15 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add chlorthalidone"
}
},
{
"letter":"B",
"text":{
"__html":"Add prazosin"
}
},
{
"letter":"C",
"text":{
"__html":"Switch lisinopril to ramipril"
}
},
{
"letter":"D",
"text":{
"__html":"Continue current medical therapy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7691eb",
"children":[
"Although guidelines differ in recommendations for systolic blood pressure (SBP) targets, the benefit of SBP reduction to <130-140 mm Hg in older patients at increased risk for stroke or cardiovascular events is likely to exceed harms."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"9e5476",
"children":[
"The most appropriate management is to add chlorthalidone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Guidelines differ in recommendations for systolic blood pressure (SBP) goals in older patients. The American College of Cardiology/American Heart Association recommend an SBP of <130 mm Hg in noninstitutionalized, ambulatory community-dwelling adults ≥65 years of age, whereas the American College of Physicians (ACP)/American Academy of Family Physicians (AAFP) recommend an SBP of <150 mm Hg in most patients >60 years of age to minimize treatment-related harms. However, ACP/AAFP also recommend considering initiating or intensifying treatment in some adults >60 years of age at high cardiovascular risk to an SBP <140 mm Hg to reduce the risk for stroke or cardiac events. Because this patient with diabetes mellitus, peripheral vascular disease, and hyperlipidemia is at high risk for stroke or cardiac events, initiation of a second first-line antihypertensive drug such as chlorthalidone or a calcium channel blocker is reasonable."
]
},
{
"type":"p",
"hlId":"a49b34",
"children":[
"The initiation of antihypertensive drug therapy with a single agent followed by the addition of other agents is reasonable in the very elderly or those at risk for drug interactions or side effects. Guidelines recommend that the second drug should work by a different mechanism and include a typical first-line agent such as a calcium channel blocker, thiazide diuretic, ACE inhibitor, or angiotensin receptor blocker (ARB); however, ACE inhibitor/ARB combinations are not recommended. α-Blockers such as prazosin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") are not used as first-line therapy for hypertension because they are less effective for prevention of cardiovascular disease than other first-line agents such as thiazide diuretics."
]
},
{
"type":"p",
"hlId":"8844f9",
"children":[
"Adults with hypertension and peripheral artery disease (PAD) should be treated similarly to patients with hypertension without PAD. There is also no evidence that any one class of antihypertensive medication or strategy is superior. Therefore, there is no indication to switch this patient from lisinopril to ramipril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
")."
]
},
{
"type":"p",
"hlId":"73058b",
"children":[
"Continuing current medical therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") may place this older patient at increased risk for cardiovascular events. Although guideline targets for SBP differ, the benefit of SBP reduction to <130-140 mm Hg in older patients at increased risk for stroke or cardiovascular events is likely to exceed harms."
]
}
],
"relatedSection":"mk19_a_np_s4_14_4",
"objective":{
"__html":"Treat hypertension in an older patient with cardiovascular disease."
},
"references":[
[
"Byrd JB, Brook RD. Hypertension. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201905070",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC65-ITC80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31060074",
"target":"_blank"
},
"children":[
"PMID: 31060074"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":65,
"B":3,
"C":2,
"D":29,
"E":0
},
"hlIds":[
"e73e86",
"aab522",
"a462a3",
"f461b2",
"0d34d5",
"e92687",
"057980",
"77db81",
"a1f179",
"58e613",
"c238e9",
"cb2b54",
"7691eb",
"9e5476",
"a49b34",
"8844f9",
"73058b"
]
},
{
"id":"mk19_a_np_q075",
"number":75,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 75",
"stimulus":[
{
"type":"p",
"hlId":"a21681",
"children":[
"A 48-year-old man is evaluated in the emergency department for sudden onset of dyspnea. He has a 2-week history of progressive leg edema and bilateral flank pain. He has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"e242b0",
"children":[
"On physical examination, respiratory rate is 26/min; other vital signs are normal. There is 2-mm pitting edema in the lower extremities to the mid-shin bilaterally. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3f2cc2",
"class":"cell text l",
"children":[
"2.0 g/dL (20 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7010db",
"class":"cell text l",
"children":[
"401 mg/dL (10.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"42bd12",
"class":"cell text l",
"children":[
"Complement levels"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0f19a0",
"class":"cell text l",
"children":[
"1.1 mg/dL (97.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"55b2c1",
"class":"cell text l",
"children":[
"No blood; 4+ protein; 0-1 erythrocytes/hpf; 0-1 leukocytes/hpf"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"291dc1",
"class":"cell text l",
"children":[
"8900 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"9652c4",
"children":[
"Hepatitis B and C, HIV, and syphilis testing results are negative."
]
},
{
"type":"p",
"hlId":"c91ab5",
"children":[
"CT of the chest shows segmental pulmonary embolism. CT of the abdomen and pelvis shows bilateral renal vein thromboses."
]
},
{
"type":"p",
"hlId":"827877",
"children":[
"Low-molecular-weight heparin is initiated."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"ANCA antibodies"
}
},
{
"letter":"B",
"text":{
"__html":"Anti–double-stranded DNA antibodies"
}
},
{
"letter":"C",
"text":{
"__html":"Anti-phospholipase A2 receptor antibodies"
}
},
{
"letter":"D",
"text":{
"__html":"Kidney biopsy following discontinuation of heparin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"b65263",
"hvc":true,
"children":[
"Serologic testing for anti-phospholipase A2 receptor antibodies is a noninvasive test that approaches 100% specificity for primary membranous nephropathy."
]
},
{
"type":"keypoint",
"hlId":"078cc9",
"hvc":true,
"children":[
"Serologic testing for anti-phospholipase A2 receptor antibodies can eliminate the need for kidney biopsy in patients with preserved kidney function and no evidence of secondary causes as well as in patients with a clear contraindication to kidney biopsy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c5a437",
"children":[
"Anti-phospholipase A2 receptor (PLA2R) antibody (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") testing is the most appropriate diagnostic test to perform next. This patient with the nephrotic syndrome and venous thromboembolism most likely has membranous nephropathy. Patients with membranous nephropathy are particularly prone to thrombotic complications. These clots include lower extremity, pulmonary, and renal vein thromboses; they can occur in up to 25% of patients and are most likely to occur within the first 6 months of diagnosis. The risk for clotting increases when serum albumin is <2.8 g/dL (28 g/L) and increases proportionally with decreasing serum albumin levels. The diagnosis of primary membranous nephropathy can be made noninvasively using serum anti-PLA2R antibody testing. Anti-PLA2R antibodies are nearly 100% specific for primary membranous nephropathy and can obviate the need for kidney biopsy in patients with preserved kidney function and no evidence of secondary causes as well as in patients with a clear contraindication to kidney biopsy."
]
},
{
"type":"p",
"hlId":"7a3463",
"children":[
"ANCA-associated vasculitis typically presents as a rapidly progressive glomerulonephritis characterized by a rapid decline in kidney function and erythrocytes and erythrocyte casts on urine microscopy. These findings are not present in this patient; therefore, ANCA antibody testing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not appropriate."
]
},
{
"type":"p",
"hlId":"841931",
"children":[
"Anti–double-stranded DNA antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") are highly specific in establishing the diagnosis of systemic lupus erythematosus. Although class V lupus nephritis is a cause of secondary membranous nephropathy, normal complement levels and negative antinuclear antibody testing rule out lupus nephritis."
]
},
{
"type":"p",
"hlId":"20ae77",
"children":[
"Stopping anticoagulation to perform a kidney biopsy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") in this patient with venous thromboembolism is high risk; therefore, the next step in management should be anti-PLA2R testing, which, if positive, is a definitive diagnosis of membranous nephropathy."
]
}
],
"relatedSection":"mk19_a_np_s6_3_3_3",
"objective":{
"__html":"Diagnose membranous nephropathy using noninvasive testing."
},
"references":[
[
"Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95:429-38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30665573",
"target":"_blank"
},
"children":[
"PMID: 30665573"
]
},
" doi:10.1016/j.kint.2018.10.021"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":4,
"B":4,
"C":60,
"D":32,
"E":0
},
"hlIds":[
"a21681",
"e242b0",
"a462a3",
"4590ed",
"3f2cc2",
"182194",
"7010db",
"42bd12",
"960b44",
"f461b2",
"0f19a0",
"b534b1",
"ffb935",
"747c2a",
"55b2c1",
"d17af8",
"291dc1",
"9652c4",
"c91ab5",
"827877",
"ab9d96",
"b65263",
"078cc9",
"c5a437",
"7a3463",
"841931",
"20ae77"
]
},
{
"id":"mk19_a_np_q076",
"number":76,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 76",
"stimulus":[
{
"type":"p",
"hlId":"9cf457",
"children":[
"A 58-year-old woman is evaluated during a follow-up visit for progressive stage G3 chronic kidney disease. Her average blood pressure using home blood pressure monitoring is 130/70 mm Hg. She walks three times weekly for exercise. Medical history is also significant for hypertension. Medications are chlorthalidone, cholecalciferol, furosemide, losartan, and metoprolol."
]
},
{
"type":"p",
"hlId":"00b55f",
"children":[
"On physical examination, vital signs are normal. There is no jugular venous distension. Lungs are clear to auscultation. There is trace bilateral leg edema."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"831d74",
"class":"cell text l",
"children":[
"178 mg/dL (4.61 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"48f071",
"class":"cell text l",
"children":[
"1.5 mg/dL (132.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"80febf",
"class":"cell text l",
"children":[
"44 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8c3bdf",
"class":"cell text l",
"children":[
"420 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"4c91ff",
"children":[
"Which of the following is the most likely expected cause of premature death in this patient?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Cardiovascular disease"
}
},
{
"letter":"B",
"text":{
"__html":"End-stage kidney disease"
}
},
{
"letter":"C",
"text":{
"__html":"Infection"
}
},
{
"letter":"D",
"text":{
"__html":"Renal cell carcinoma"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"5f00c8",
"children":[
"Cardiovascular disease is the leading cause of death among patients with chronic kidney disease, and management should address cardiovascular risk factors, such as blood pressure control, glycemic control, and treatment of hyperlipidemia."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"5a6d44",
"children":[
"The most likely expected cause of premature death in this patient is cardiovascular disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Patients with stage G3 chronic kidney disease (CKD) are more likely to die of a cardiovascular event than they are to progress to stage G4 CKD or to end-stage kidney disease (ESKD) that requires initiation of renal replacement therapy. Also, the risk for cardiovascular-related death in patients with stages G3 and G4 CKD is four to five times higher than the risk for progression to ESKD (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). CKD and albuminuria are both independent risk factors for cardiovascular disease. Mortality risk in these patients increases with a decreasing estimated glomerular filtration rate and increasing albuminuria. Therefore, management of CKD addresses traditional cardiovascular risk factors, such as blood pressure control, glycemic control for patients with diabetes mellitus, and treatment of hyperlipidemia."
]
},
{
"type":"p",
"hlId":"a0831b",
"children":[
"Infection is the second leading cause of death in ESKD (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Patients are at increased risk due to a relatively immunosuppressed state from chronic inflammation and frequent exposure to the health care environment, including long-term need for vascular access and related-risk of bacteremia and sepsis. Infecting organisms are usually common organisms such ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"as Staphylococcus aureus"
]
},
" acquired through hemodialysis."
]
},
{
"type":"p",
"hlId":"9ba3a7",
"children":[
"Acquired cystic kidney disease becomes more common and progresses during the course of ESKD, and some studies suggest that it may affect >50% of patients who have had ESKD for >3 years. The epithelial cells lining these cysts may undergo malignant transformation by poorly understood mechanisms. Patients with ESKD have a markedly increased risk for renal cell carcinoma (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"); however, malignancy is only the third leading cause of death in patients with ESKD, and renal cell carcinoma comprises only a portion of malignancy-related deaths. Routine screening is not recommended, but a high level of suspicion is warranted in patients with symptoms such as new-onset gross hematuria or unexplained flank pain."
]
}
],
"relatedSection":"mk19_a_np_s12_6_1",
"objective":{
"__html":"Recognize chronic kidney disease as an independent risk factor for cardiovascular disease."
},
"references":[
[
"Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518-2531. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24892770",
"target":"_blank"
},
"children":[
"PMID: 24892770"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":88,
"B":9,
"C":2,
"D":1,
"E":0
},
"hlIds":[
"9cf457",
"00b55f",
"a462a3",
"182194",
"831d74",
"f461b2",
"48f071",
"77db81",
"80febf",
"58e613",
"8c3bdf",
"4c91ff",
"5f00c8",
"5a6d44",
"a0831b",
"9ba3a7"
]
},
{
"id":"mk19_a_np_q077",
"number":77,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 77",
"stimulus":[
{
"type":"p",
"hlId":"3193ec",
"children":[
"A 62-year-old man is evaluated in the emergency department for increasing abdominal and bilateral flank pain. The pain began yesterday, 2 days after he took primaquine prescribed as antimalarial prophylaxis for planned travel."
]
},
{
"type":"p",
"hlId":"7a6f9f",
"children":[
"On physical examination, temperature is 38.1 °C (100.6 °F), blood pressure is 102/55 mm Hg, pulse rate is 110/min, and respiration rate is 22/min. Cardiac examination reveals tachycardia without extra sounds. There is no edema. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2f2316",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Haptoglobin, serum",
"children":[
"Haptoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f2dcf7",
"class":"cell text l",
"children":[
"10 mg/dL (100 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"41a9a7",
"class":"cell text l",
"children":[
"7.9 g/dL (79 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"7d8e6e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Reticulocyte count",
"children":[
"Reticulocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d7b422",
"class":"cell text l",
"children":[
"8%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c6e520",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Bilirubin, Total, serum",
"children":[
"Total bilirubin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2b3e34",
"class":"cell text l",
"children":[
"5.8 mg/dL (99.2 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"75c865",
"class":"cell text l",
"children":[
"32 mg/dL (11.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cb7c08",
"class":"cell text l",
"children":[
"1.9 mg/dL (168 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"564d2b",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Lactate dehydrogenase, serum",
"children":[
"Lactate dehydrogenase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a8caf3",
"class":"cell text l",
"children":[
"1250 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"74d38a",
"class":"cell text l",
"children":[
"Specific gravity 1.010; pH 5.0; 3+ heme; 1+ albumin; no erythrocytes, leukocytes, or leukocyte esterase; numerous pigmented granular casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"e36d1e",
"children":[
"Examination of peripheral blood smear shows bite cells."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acute interstitial nephritis"
}
},
{
"letter":"B",
"text":{
"__html":"Heme pigment nephropathy"
}
},
{
"letter":"C",
"text":{
"__html":"Prerenal acute kidney injury"
}
},
{
"letter":"D",
"text":{
"__html":"Rhabdomyolysis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"cb4cb8",
"children":[
"Myoglobin and hemoglobin are heme pigment–containing proteins that can cause acute kidney injury."
]
},
{
"type":"keypoint",
"hlId":"d49343",
"children":[
"Heme pigment nephropathy is associated with a positive urine dipstick for blood in the absence of erythrocytes and the presence of pigmented granular casts."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a1c41f",
"children":[
"The most likely diagnosis is heme pigment nephropathy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient likely has underlying glucose-6-phosphate dehydrogenase (G6PD) deficiency, and acute hemolytic anemia due to primaquine exposure. Primaquine can precipitate hemolytic anemia in such patients, as can other antimalarial agents, rasburicase, sulfonamides (e.g., sulfamethoxazole), some nonsulfa antibiotics (e.g., isoniazid), dapsone, and nitrofurantoin. Myoglobin and hemoglobin are heme pigment–containing proteins that can cause acute kidney injury (AKI). Heme pigment nephropathy occurs when large amounts of heme pigment are released into the circulation due to massive intravascular hemolysis. Pigment nephropathy can cause acute tubular necrosis as the result of volume depletion, renal vasoconstriction, direct heme protein–mediated cytotoxicity, and intraluminal cast formation. Laboratory findings include anemia, increased serum lactate dehydrogenase, decreased haptoglobin, and increased serum creatinine. The urine dipstick is positive for blood in the absence of erythrocytes. Other urinary findings include pigmented granular casts and hemoglobinuria. Both myoglobinuria and hemoglobinuria can cause tea-colored urine and urine dipstick positive for blood; however, hemoglobin produces a reddish-brown color in centrifuged serum and myoglobin does not discolor the serum. The treatment is expansion of the intravascular volume with 0.9% saline."
]
},
{
"type":"p",
"hlId":"fa82c5",
"children":[
"Although primaquine is a newly initiated medication, the short time course and absence of pyuria are not consistent with drug-induced acute interstitial nephritis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"129418",
"children":[
"In this patient, the presence of a urine dipstick positive for blood in the absence of erythrocytes and numerous pigmented granular casts supports the diagnosis of heme pigment nephropathy rather than prerenal AKI (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), which is associated with a benign urinalysis."
]
},
{
"type":"p",
"hlId":"917dec",
"children":[
"When exposed to an oxidative stress, patients with G6PD deficiency can develop acute hemolytic anemia. Rhabdomyolysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not part of the clinical syndrome. However, the clinical course of rhabdomyolysis is similar to that of pigment nephropathy due to hemolysis. Laboratory findings of rhabdomyolysis-induced AKI include hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, metabolic acidosis, elevated serum creatinine, and elevated muscle enzymes such as serum creatine kinase (typically >5000 U/L), lactate dehydrogenase, and aspartate and alanine aminotransferases."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_1_3",
"objective":{
"__html":"Diagnose heme pigment nephropathy."
},
"references":[
[
"Kirsch AH, Pollheimer MJ, Troppan K, Horina JH, Rosenkranz AR, Eller K. The Case | Acute kidney injury and hemolysis in a 58-year-old woman. Kidney Int. 2017;91(4):993-994. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28314587",
"target":"_blank"
},
"children":[
"PMID: 28314587"
]
},
" doi:10.1016/j.kint.2016.09.008"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":8,
"B":85,
"C":4,
"D":3,
"E":0
},
"hlIds":[
"3193ec",
"7a6f9f",
"a462a3",
"2f2316",
"f2dcf7",
"f9867c",
"41a9a7",
"7d8e6e",
"d7b422",
"c6e520",
"2b3e34",
"29d161",
"75c865",
"f461b2",
"cb7c08",
"564d2b",
"a8caf3",
"747c2a",
"74d38a",
"e36d1e",
"413696",
"cb4cb8",
"d49343",
"a1c41f",
"fa82c5",
"129418",
"917dec"
]
},
{
"id":"mk19_a_np_q078",
"number":78,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 78",
"stimulus":[
{
"type":"p",
"hlId":"1aa528",
"children":[
"A 28-year-old woman is evaluated for leg weakness and mild nausea several days after treatment with intravenous ferric carboxymaltose for severe iron deficiency anemia. She has Crohn disease. She reports that her appetite is good. Medications are prednisone, sulfasalazine, infliximab, calcium carbonate, and vitamin D."
]
},
{
"type":"p",
"hlId":"aa0488",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), pulse rate is 80/min, and respiration rate is 16/min. BMI is 18. Abdominal examination reveals tenderness. Motor strength is 4/5 in the hip flexors and extensors. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1fd2c7",
"class":"cell text l",
"children":[
"136 mEq/L (136 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"687d76",
"class":"cell text l",
"children":[
"3.8 mEq/L (3.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4fb259",
"class":"cell text l",
"children":[
"108 mEq/L (108 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9fc245",
"class":"cell text l",
"children":[
"21 mEq/L (21 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"be4aca",
"class":"cell text l",
"children":[
"1.2 mg/dL (0.39 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f212ab",
"class":"cell text l",
"children":[
"Fractional excretion of phosphorus"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ba9c07",
"class":"cell text l",
"children":[
"21%"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"6403ae",
"children":[
"Which of the following is the most likely cause of this patient's hypophosphatemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Ferric carboxymaltose"
}
},
{
"letter":"B",
"text":{
"__html":"Low phosphorus diet"
}
},
{
"letter":"C",
"text":{
"__html":"Metabolic acidosis"
}
},
{
"letter":"D",
"text":{
"__html":"Prednisone"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4734c0",
"children":[
"Ferric carboxymaltose, an intravenous iron preparation, has been associated with hypophosphatemia by causing renal phosphate wasting."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ddbbc0",
"children":[
"The most likely cause of this patient's hypophosphatemia is ferric carboxymaltose (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This parenteral iron solution can be administered in a single dose and thus has been increasingly used to treat individuals with severe iron deficiency that cannot be corrected with oral preparations. However, this medication can result in transient hypophosphatemia. Although most reported cases occur after a patient receives repeated doses, hypophosphatemia has occurred after a single dose. The decrease in serum phosphorus is typically not significant, but for patients with risk factors (e.g., vitamin D deficiency, malnutrition, gastrointestinal disease, or use of medications that bind phosphorus in the gut), severe symptomatic hypophosphatemia has occurred. The mechanism has shown to be secondary to increases in fibroblast growth factor 23 (FGF-23), which cause phosphaturia and a decrease in 1-hydroxylation of vitamin D. Other causes of hypophosphatemia include hungry bone syndrome following parathyroidectomy; refeeding of starved individuals; oncogenic osteomalacia associated with sarcomas that secrete FGF-23; and X-linked hypophosphatemic rickets due to a mutation that causes increased FGF-23. It can also occur following liver resection in a living liver donor."
]
},
{
"type":"p",
"hlId":"d9c6cc",
"children":[
"A low phosphorus diet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not the cause of this patient's hypophosphatemia. The kidney can reduce phosphorus excretion to very low levels, but only a severely phosphate-restricted diet will decrease the serum phosphorus levels (significantly more frequently in women). In addition, the high fractional excretion of phosphorus identifies renal wasting of phosphorus and excludes poor dietary intake as the cause of her hypophosphatemia."
]
},
{
"type":"p",
"hlId":"a71d82",
"children":[
"This patient's serum bicarbonate level is low, suggesting either metabolic acidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") or compensation for respiratory alkalosis. Because there is no evidence of an increased respiratory rate, the low serum bicarbonate level most likely represents a metabolic acidosis. Although metabolic acidosis and respiratory alkalosis can shift phosphorus into cells, metabolic acidosis has a minimal effect and thus would not be the cause of this patient's hypophosphatemia. Additionally, the elevated fractional excretion of phosphorus eliminates intracellular shift of phosphorus as the cause of her hypophosphatemia."
]
},
{
"type":"p",
"hlId":"0914a6",
"children":[
"Although prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") can cause muscle breakdown and interfere with vitamin D metabolism, it does not typically cause hypophosphatemia."
]
}
],
"relatedSection":"mk19_a_np_s2_4_1_1",
"objective":{
"__html":"Identify ferric carboxymaltose as the cause of hypophosphatemia."
},
"references":[
[
"Ifie E, Oyibo SO, Joshi H, et al. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31385673",
"target":"_blank"
},
"children":[
"PMID: 31385673"
]
},
" doi:10.1530/EDM-19-0065"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":75,
"B":10,
"C":10,
"D":5,
"E":0
},
"hlIds":[
"1aa528",
"aa0488",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"1fd2c7",
"e92687",
"687d76",
"a207b1",
"4fb259",
"6827e3",
"9fc245",
"a4922e",
"be4aca",
"f212ab",
"ba9c07",
"6403ae",
"4734c0",
"ddbbc0",
"d9c6cc",
"a71d82",
"0914a6"
]
},
{
"id":"mk19_a_np_q079",
"number":79,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 79",
"stimulus":[
{
"type":"p",
"hlId":"966a9b",
"children":[
"A 67-year-old man is evaluated during a follow-up visit for resistant hypertension. He was recently evaluated for primary hyperaldosteronism, and the screening plasma aldosterone concentration/plasma renin activity ratio was >20. A dedicated adrenal CT scan showed diffuse bilateral adrenal hyperplasia. The patient also has type 2 diabetes mellitus, hyperlipidemia, coronary artery disease, and activity-limiting COPD. He does not want surgery under any circumstances. Medications are rosuvastatin, metformin, canagliflozin, amlodipine, enalapril, metoprolol, chlorthalidone, low-dose aspirin, albuterol, and tiotropium."
]
},
{
"type":"p",
"hlId":"39633f",
"children":[
"On physical examination, blood pressure is 160/94 mm Hg in both arms, pulse rate is 76/min, and respiration rate is 18/min. BMI is 24. Cardiac examination is notable for an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". Pulmonary examination reveals occasional expiratory wheezing."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1a5dcc",
"children":[
"Which of the following is the most appropriate next step in management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Bilateral adrenal vein sampling"
}
},
{
"letter":"B",
"text":{
"__html":"Eplerenone therapy"
}
},
{
"letter":"C",
"text":{
"__html":"MRI of the adrenal glands"
}
},
{
"letter":"D",
"text":{
"__html":"Oral sodium loading test"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"e24808",
"children":[
"Primary hyperaldosteronism is the most common cause of secondary hypertension in middle-aged adults and an important cause of resistant hypertension."
]
},
{
"type":"keypoint",
"hlId":"3cd8f0",
"children":[
"Primary hyperaldosteronism is most commonly caused by bilateral adrenal hyperplasia and is managed by an aldosterone receptor antagonist."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"93f8a8",
"children":[
"Initiating eplerenone therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is the most appropriate next step in management. This patient with resistant hypertension was evaluated for secondary causes of hypertension. A plasma aldosterone concentration/plasma renin activity ratio >20 with a plasma aldosterone concentration of at least 15 ng/dL (414 pmol/L) is considered a positive result for primary aldosteronism and patients should be referred to an endocrinologist or nephrologist, who may perform additional testing to confirm inappropriate aldosterone secretion in a salt-replete state. Primary hyperaldosteronism is the most common cause of secondary hypertension in middle-aged adults and an important cause of resistant hypertension. In this patient, a dedicated adrenal CT scan shows diffuse bilateral adrenal hyperplasia, as seen in two thirds of patients with primary hyperaldosteronism. Diffuse bilateral hyperplasia is managed by an aldosterone receptor antagonist such as eplerenone."
]
},
{
"type":"p",
"hlId":"0573c9",
"children":[
"Bilateral adrenal vein sampling (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") for aldosterone is used to distinguish between unilateral adenoma and bilateral hyperplasia in patients who are surgical candidates and would like to pursue surgical management. Functioning adrenal adenomas can be very small and may not be detected with advanced imaging, but they can be implicated as a cause of primary hyperaldosteronism if aldosterone secretion lateralizes to one gland. This patient has multiple comorbid conditions and does not want to pursue any surgical procedures. Therefore, adrenal vein sampling is not indicated."
]
},
{
"type":"p",
"hlId":"512acd",
"children":[
"An MRI of the adrenal glands (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated because CT of the adrenal glands, which was already performed, has superior spatial resolution compared with MRI for the assessment of adrenal glands."
]
},
{
"type":"p",
"hlId":"d22114",
"children":[
"In most patients, the diagnosis of primary hyperaldosteronism is confirmed by additional testing following a positive screening test. The oral sodium loading test is performed to detect autonomous aldosterone secretion following sodium chloride loading, either orally or by intravenous infusion. However, this confirmatory test is only performed after the patient's blood pressure is controlled and hypokalemia corrected. Although oral sodium loading (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a possible confirmatory test, it should not be initiated in this patient at this time."
]
}
],
"relatedSection":"mk19_a_np_s4_11_3",
"objective":{
"__html":"Treat primary hyperaldosteronism."
},
"references":[
[
"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889-1916. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26934393",
"target":"_blank"
},
"children":[
"PMID: 26934393"
]
},
" doi:10.1210/jc.2015-4061"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":14,
"B":75,
"C":6,
"D":6,
"E":0
},
"hlIds":[
"966a9b",
"39633f",
"1a5dcc",
"e24808",
"3cd8f0",
"93f8a8",
"0573c9",
"512acd",
"d22114"
]
},
{
"id":"mk19_a_np_q080",
"number":80,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 80",
"stimulus":[
{
"type":"p",
"hlId":"b1385c",
"children":[
"A 45-year-old woman is evaluated in the emergency department for altered mental status."
]
},
{
"type":"p",
"hlId":"42809e",
"children":[
"On physical examination, the patient is tachypneic and obtunded. Temperature is normal, blood pressure is 94/64 mm Hg, pulse rate is 80/min, and respiration rate is 24/min."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a1affc",
"class":"cell text l",
"children":[
"133 mEq/L (133 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"841805",
"class":"cell text l",
"children":[
"3.9 mEq/L (3.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"80ce87",
"class":"cell text l",
"children":[
"110 mEq/L (110 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"311261",
"class":"cell text l",
"children":[
"16 mEq/L (16 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"18044b",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, arterial (ambient air)",
"children":[
"Arterial blood gases"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"397dff",
"class":"cell text li",
"children":[
"pH"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d0201c",
"class":"cell text l",
"children":[
"7.4"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"dd372e",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Pco2, arterial (ambient air)",
"children":[
"P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"2"
]
}
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"38e6e7",
"class":"cell text l",
"children":[
"27 mm Hg (3.6 kPa)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"8209a3",
"children":[
"Which of the following is the most likely acid-base disorder?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Respiratory alkalosis and increased anion gap metabolic acidosis"
}
},
{
"letter":"B",
"text":{
"__html":"Respiratory alkalosis and normal anion gap metabolic acidosis"
}
},
{
"letter":"C",
"text":{
"__html":"Respiratory alkalosis, normal gap metabolic acidosis, and metabolic alkalosis"
}
},
{
"letter":"D",
"text":{
"__html":"Respiratory alkalosis with chronic compensation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"3d8068",
"children":[
"The first step in the interpretation of acid-base disorders requires the identification of the likely dominant acid-base disorder, followed by an assessment of the compensatory response."
]
},
{
"type":"keypoint",
"hlId":"aa4efa",
"children":[
"In the interpretation of acid-base disorders, when measured values fall outside the expected compensatory range, a mixed acid-base disorder is present."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"235d28",
"children":[
"The most likely acid-base disorder is a respiratory alkalosis and normal gap metabolic acidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). The first step in the interpretation of acid-base disorders usually requires the identification of the likely dominant or primary acid-base disorder, followed by an assessment of the compensatory response. When measured values fall outside the expected compensatory range, a mixed acid-base disorder is considered present. The primary disorder is usually reflected by the blood pH. Appropriate compensation may result in near-normal pH but never a normal pH. In patients with an obvious acid-base disturbance (for example, an abnormal serum bicarbonate), a normal pH suggests the presence of a mixed acid-base disorder. In this case, the patient's pH of 7.4 does not allow for a clear assignment of the primary disorder and therefore indicates a mixed acid-base disorder. The patient has a P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"2"
]
}
]
},
" of 27 mm Hg (3.6 kPa), suggesting the presence of a respiratory alkalosis. The expected metabolic compensation for chronic respiratory alkalosis is a reduction in the serum bicarbonate of 4 to 5 mEq/L (4-5 mmol/L) for each 10 mm Hg (1.3 kPa) decrease in the P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"2"
]
}
]
},
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
". I"
]
},
"n this case, the decrease in P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"CO"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"2"
]
}
]
},
" is 13 mm Hg (1.7 kPa); thus, the serum bicarbonate is expected to be 5.2 to 6.5 mEq/L (5.2-6.5 mmol/L) lower than normal. Therefore, expected serum bicarbonate would be calculated as follows:"
]
},
{
"type":"p",
"hlId":"b10853",
"class":"equation",
"children":[
"Normal Bicarbonate − Expected Compensation"
]
},
{
"type":"p",
"hlId":"e84061",
"class":"equation",
"children":[
"24 − (5.2-6.5) mEq/L (mmol/L) = 17.5-18.8 mEq/L (17.5-18.8 mmol/L)"
]
},
{
"type":"p",
"hlId":"96fd4f",
"children":[
"The patient's serum bicarbonate of 16 mEq/L (16 mmol/L) is lower than expected, indicating the presence of a concurrent metabolic acidosis. The anion gap of 7 is normal, indicating a normal anion gap metabolic acidosis."
]
},
{
"type":"p",
"hlId":"41cf09",
"children":[
"Respiratory alkalosis with an increased anion gap metabolic acidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not correct because the anion gap is 7, and thus not exceeding the normal threshold of 8.0 to 10 mEq/L ± 2.0 mEq/L (8.0-10 mmol/L ± 2.0 mmol/L)."
]
},
{
"type":"p",
"hlId":"bb5da9",
"children":[
"Respiratory alkalosis, normal anion gap metabolic acidosis, and metabolic alkalosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not correct because the serum bicarbonate is lower, not higher, than the expected compensatory response."
]
},
{
"type":"p",
"hlId":"8d6e77",
"children":[
"Respiratory alkalosis with chronic compensation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is partially correct but does not account for the serum bicarbonate level being lower than the expected compensatory response, which indicates a concurrent metabolic acidosis."
]
}
],
"relatedSection":"mk19_a_np_s3_5",
"objective":{
"__html":"Diagnose a mixed acid-base disorder."
},
"references":[
[
"Seifter JL, Chang HY. Disorders of acid-base balance: new perspectives. Kidney Dis (Basel). 2017;2:170-186. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28232934",
"target":"_blank"
},
"children":[
"PMID: 28232934"
]
},
" doi:10.1159/000453028"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":9,
"B":64,
"C":20,
"D":6,
"E":0
},
"hlIds":[
"b1385c",
"42809e",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"a1affc",
"e92687",
"841805",
"a207b1",
"80ce87",
"6827e3",
"311261",
"18044b",
"d41d8c",
"397dff",
"d0201c",
"dd372e",
"38e6e7",
"8209a3",
"3d8068",
"aa4efa",
"235d28",
"b10853",
"e84061",
"96fd4f",
"41cf09",
"bb5da9",
"8d6e77"
]
},
{
"id":"mk19_a_np_q081",
"number":81,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 81",
"stimulus":[
{
"type":"p",
"hlId":"25d042",
"children":[
"A 31-year-old woman is evaluated for lower extremity edema, a rash over both legs, and fatigue that have worsened during the past 3 months. She has no other medical problems and takes no medications. The patient was born in Egypt and moved to the United States at 20 years of age."
]
},
{
"type":"p",
"hlId":"930fe3",
"children":[
"On physical examination, the patient is afebrile, and blood pressure is 147/96 mm Hg. There is 1-mm pitting edema through the mid-shins bilaterally."
]
},
{
"type":"p",
"hlId":"8d57df",
"children":[
"The rash is ",
{
"type":"figure-link",
"target":"mk19_a_np_mcq_f081",
"wrapId":"1",
"children":[
"shown"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_np_mcq_f081"
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f92335",
"class":"cell text l",
"children":[
"3.9 g/dL (39 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"687cd3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C3, serum",
"children":[
"C3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6c127e",
"class":"cell text l",
"children":[
"58 mg/dL (580 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"dcfa5e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C4, serum",
"children":[
"C4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8e1fdb",
"class":"cell text l",
"children":[
"5.0 mg/dL (50 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"34f471",
"class":"cell text l",
"children":[
"2.6 mg/dL (229.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a42252",
"class":"cell text l",
"children":[
"Cryoglobulins"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"154c82",
"class":"cell text l",
"children":[
"Rheumatoid factor"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3f2d30",
"class":"cell text l",
"children":[
"3+ blood; 3+ protein; erythrocytes and rare erythrocyte casts"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"07ce18",
"class":"cell text l",
"children":[
"2100 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"b4a6f9",
"children":[
"A kidney biopsy is scheduled."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"c98cf9",
"children":[
"Which of the following viral studies will support the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Fourth-generation HIV testing"
}
},
{
"letter":"B",
"text":{
"__html":"Hepatitis A virus antibody testing"
}
},
{
"letter":"C",
"text":{
"__html":"Hepatitis B virus surface antigen and surface antibody testing"
}
},
{
"letter":"D",
"text":{
"__html":"Hepatitis C virus antibody testing"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0ab3fc",
"children":[
"Hepatitis C virus infection is associated with cryoglobulinemic glomerulonephritis."
]
},
{
"type":"keypoint",
"hlId":"ed2e7d",
"children":[
"Treatment of hepatitis C–associated cryoglobulinemic glomerulonephritis is direct-acting antiviral drugs."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"245cb0",
"children":[
"The most appropriate viral study to perform is hepatitis C virus (HCV) antibody testing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), and if positive, viral load measurement and genotyping. This patient's clinical presentation (purpuric rash) and laboratory results (low complement levels, positive rheumatoid factor, and positive cryoglobulins) support the diagnosis of cryoglobulinemic glomerulonephritis; biopsy is most likely to reveal membranoproliferative glomerulonephritis (MPGN). Cryoglobulinemia denotes the presence of clonal or polyclonal immunoglobulins that precipitate in the serum at temperatures <37.0 °C (98.6 °F) and dissolve with rewarming. Cryoglobulinemia is classified as type I, II, or III based on the composition of the cryoglobulins. Type I cryoglobulinemia involves a monoclonal immunoglobulin, usually IgM, and is associated with plasma cell dyscrasias. Types II and III are called mixed cryoglobulinemia; they are composed of a mixture of polyclonal IgG and monoclonal or polyclonal IgM. Mixed cryoglobulinemia is usually seen in association with infections such as HCV, connective disorders, and, rarely, lymphoproliferative disorders. Cutaneous symptoms (palpable purpura, Raynaud phenomenon, ulcers, necrosis, and livedo reticularis) predominate in 70% to 90% of patients with mixed cryoglobulinemia. Peripheral neuropathy (60%), arthritis (40%), and glomerulonephritis (40%) are common. An estimated 2% to 3% of the world population has HCV, but higher prevalence rates are seen in certain geographic locations, such as Egypt, where >10% of the population has HCV. Treatment of cryoglobulinemic glomerulonephritis due to HCV infection is aimed at eradication of the virus using direct-acting antiviral drugs with or without concomitant immunosuppression based on severity of disease."
]
},
{
"type":"p",
"hlId":"200fed",
"children":[
"Hepatitis A virus (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") infection has not been associated with specific glomerular lesions. Although hepatitis B virus (HBV) infection and HIV infection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, C"
]
},
") have been linked to glomerular diseases, these have classically been nephrotic syndromes, specifically membranous nephropathy with HBV and focal segmental glomerulosclerosis with HIV. This patient has a nephritic syndrome not compatible with HBV- or HIV-associated glomerular diseases."
]
}
],
"relatedSection":"mk19_a_np_s7_7",
"objective":{
"__html":"Diagnose hepatitis C virus infection as the cause of cryoglobulinemic glomerulonephritis."
},
"references":[
[
"Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int. 2018;22(Suppl 1):S81-S96. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29694729",
"target":"_blank"
},
"children":[
"PMID: 29694729"
]
},
" doi:10.1111/hdi.12649"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":1,
"C":19,
"D":78,
"E":0
},
"figuresContent":{
"mk19_a_np_mcq_f081":{
"id":"mk19_a_np_mcq_f081",
"number":81,
"bookId":"np",
"legend":"",
"footnotes":[

],
"imageInfo":{
"hash":"f138cc5a59742499c3f82779c307dfb5",
"height":574,
"width":900,
"extension":"jpg"
}
}
},
"hlIds":[
"25d042",
"930fe3",
"8d57df",
"a462a3",
"4590ed",
"f92335",
"687cd3",
"6c127e",
"dcfa5e",
"8e1fdb",
"f461b2",
"34f471",
"a42252",
"328929",
"154c82",
"328929",
"747c2a",
"3f2d30",
"d17af8",
"07ce18",
"b4a6f9",
"c98cf9",
"0ab3fc",
"ed2e7d",
"245cb0",
"200fed"
]
},
{
"id":"mk19_a_np_q082",
"number":82,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 82",
"stimulus":[
{
"type":"p",
"hlId":"a244fc",
"children":[
"A 57-year-old man is evaluated during a follow-up visit after beginning hydrochlorothiazide 1 month ago. He has hypertension and chronic kidney disease. He has no other medical problems. Medications are lisinopril, 40 mg once daily; amlodipine, 10 mg once daily; and hydrochlorothiazide, 25 mg once daily. The patient maintains a low sodium diet."
]
},
{
"type":"p",
"hlId":"dc70d0",
"children":[
"On physical examination, blood pressure is 138/86 mm Hg; other vital signs are normal. There is 1+ pitting pretibial edema bilaterally. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f1e327",
"class":"cell text l",
"children":[
"22 mEq/L (22 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cd0076",
"class":"cell text l",
"children":[
"2.5 mg/dL (221 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"40d30c",
"class":"cell text l",
"children":[
"5.4 mEq/L (5.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0e7e50",
"class":"cell text l",
"children":[
"135 mEq/L (135 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"424740",
"class":"cell text l",
"children":[
"28 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7ef11f",
"class":"cell text l",
"children":[
"1800 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discontinue hydrochlorothiazide; begin eplerenone"
}
},
{
"letter":"B",
"text":{
"__html":"Discontinue hydrochlorothiazide; begin furosemide"
}
},
{
"letter":"C",
"text":{
"__html":"Increase hydrochlorothiazide dose"
}
},
{
"letter":"D",
"text":{
"__html":"Continue current management"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"493359",
"children":[
"Sodium retention and volume overload are major contributory factors in the hypertension of chronic kidney disease."
]
},
{
"type":"keypoint",
"hlId":"17cc3b",
"children":[
"Loop diuretics, dosed two or three times daily, are preferred to thiazide diuretics in patients with hypertension and an estimated glomerular filtration rate <20 to 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"b6854d",
"children":[
"The most appropriate treatment for this patient is to discontinue hydrochlorothiazide and begin furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). Because sodium retention and volume overload are major contributory factors in the hypertension of chronic kidney disease (CKD), dietary sodium restriction to <2000 mg/d and addition of a diuretic are both essential for control of blood pressure (BP), especially in advanced CKD. Higher doses of diuretics are required in patients with CKD due to decreased glomerular filtration rate (GFR). Hydrochlorothiazide is not an effective diuretic in this patient who has advanced CKD with an estimated GFR (eGFR) <20 to 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", as evidenced by his elevated BP, lower extremity edema, and hyperkalemia after 1 month of treatment. Loop diuretics, dosed two or three times daily, are more potent diuretics and preferred in patients who have advanced CKD with an eGFR <20 to 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"32eace",
"children":[
"Eplerenone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not appropriate treatment for this patient because of several factors. The addition of an aldosterone receptor blocker such as eplerenone to an ACE inhibitor such as lisinopril will result in dual renin-angiotensin system inhibition and will further increase the serum potassium level. Additionally, potassium-sparing diuretics, such as aldosterone receptor blockers (spironolactone or eplerenone) or epithelial sodium channel blockers (amiloride), are weaker diuretics. Although aldosterone receptor blockers are recommended for certain patients with resistant hypertension, they are not first-line diuretic agents for BP management in patients with CKD and eGFR <20 to 30 mL/min /1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"df5c45",
"children":[
"Increasing this patient's dose of hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") will not reduce this patient's BP or edema. Thiazide diuretics such as hydrochlorothiazide become increasingly ineffective as GFR decreases."
]
},
{
"type":"p",
"hlId":"f88305",
"children":[
"According the American College of Cardiology/American Heart Association, adults with hypertension and CKD should be treated to a BP goal of <130/80 mm Hg. Continuing the current management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is inappropriate, as the patient has not achieved the desired BP target, and has edema and hyperkalemia."
]
}
],
"relatedSection":"mk19_a_np_s4_11_1_4",
"objective":{
"__html":"Treat hypertension in a patient with chronic kidney disease and an estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup>."
},
"references":[
[
"Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017;956:307-325. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27873228",
"target":"_blank"
},
"children":[
"PMID: 27873228"
]
},
" doi:10.1007/5584_2016_84"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":4,
"B":75,
"C":12,
"D":10,
"E":0
},
"hlIds":[
"a244fc",
"dc70d0",
"a462a3",
"6827e3",
"f1e327",
"f461b2",
"cd0076",
"e92687",
"40d30c",
"b99276",
"0e7e50",
"77db81",
"424740",
"d17af8",
"7ef11f",
"1054f1",
"493359",
"17cc3b",
"b6854d",
"32eace",
"df5c45",
"f88305"
]
},
{
"id":"mk19_a_np_q083",
"number":83,
"bookId":"np",
"correctAnswer":"E",
"title":"Question 83",
"stimulus":[
{
"type":"p",
"hlId":"eb719b",
"children":[
"A 59-year-old man is evaluated for recently discovered normochromic, normocytic anemia and an elevated serum creatinine level. He is otherwise well and takes no medications."
]
},
{
"type":"p",
"hlId":"fe6d2b",
"children":[
"All physical examination findings, including vital signs and neurologic examination, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"72a07f",
"class":"cell text l",
"children":[
"9.2 g/dL (92 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"55d45f",
"class":"cell text l",
"children":[
"3.0 mg/dL (265.2 µmol/L); 1 year ago: 1.0 mg/dL (88.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"514851",
"class":"cell text l",
"children":[
"Trace protein; no blood, erythrocytes, leukocytes, leukocyte esterase, or nitrites"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4b421c",
"class":"cell text l",
"children":[
"2500 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"983777",
"children":[
"Which of the following is the most appropriate test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Repeat urinalysis"
}
},
{
"letter":"B",
"text":{
"__html":"24-Hour urine collection for total protein"
}
},
{
"letter":"C",
"text":{
"__html":"Sulfosalicylic acid test"
}
},
{
"letter":"D",
"text":{
"__html":"Urine albumin-creatinine ratio"
}
},
{
"letter":"E",
"text":{
"__html":"Urine protein electrophoresis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"779c49",
"children":[
"The presence of significant measured proteinuria via urine protein-creatinine ratio in the context of minimal proteinuria on urine dipstick suggests the presence nonalbumin proteinuria."
]
},
{
"type":"keypoint",
"hlId":"bb67f6",
"children":[
"Nonalbumin proteinuria may include kidney-derived low-molecular-weight proteins, monoclonal immunoglobulins and light chains, myoglobin, and hemoglobin."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"915c7a",
"children":[
"The most appropriate test to perform next is a urine protein electrophoresis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
"). This patient has an unexplained elevation of serum creatinine, indicating the presence of kidney disease. Assessment for urine protein is indicated in patients with any suspected kidney disease. Albumin is the predominant protein detected on urine dipstick. However, although proteinuria is most commonly comprised of albumin, other proteins, including kidney-derived low-molecular-weight proteins, monoclonal immunoglobulins and light chains, myoglobin, and hemoglobin, may be present. In this case, there was a discrepancy between the semiquantification of urine protein by dipstick and the urine protein-creatinine ratio, which raises concern for the excretion of protein other than albumin. In addition, the patient also has a normocytic, normochromic anemia. The combination of these findings strongly suggests the possibility of multiple myeloma. A urine electrophoresis and urine examination for light chains should be performed to help establish the diagnosis."
]
},
{
"type":"p",
"hlId":"0c6760",
"children":[
"A repeat urinalysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") will not clarify the discrepancy between the urine dipstick and urine protein-creatinine ratio. The urine protein-creatinine ratio has identified significant proteinuria, which now must be investigated."
]
},
{
"type":"p",
"hlId":"89c79f",
"children":[
"Quantification of proteinuria has traditionally been performed with a 24-hour urine collection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), which measures all proteins present in the urine. Due to challenges in feasibility, accuracy, and patient adherence, measurement of proteinuria is now typically performed by determining the ratio of protein or albumin to creatinine on random urine samples. These ratios are easily obtained and correlate well with timed collections."
]
},
{
"type":"p",
"hlId":"4e99b5",
"children":[
"The sulfosalicylic acid test (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") can be used to detect the presence of not only albumin but also other proteins that are not detected with the urine dipstick, such as urine light chains or immunoglobulins. However, this test will simply confirm that the urine contains nonalbumin proteins, which has already been determined by the urine protein-creatinine ratio, but will not specifically identify light chains or immunoglobulins."
]
},
{
"type":"p",
"hlId":"a660cc",
"children":[
"The urine albumin-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") measures only albumin in the urine. Although this test is helpful in evaluating for diabetic kidney disease, it will not determine the nature of the nonalbumin protein found in this patient's urine."
]
}
],
"relatedSection":"mk19_a_np_s1_2_3",
"objective":{
"__html":"Evaluate the cause of proteinuria."
},
"references":[
[
"Echeverry G, Hortin GL, Rai AJ. Introduction to urinalysis: historical perspectives and clinical application. Methods Mol Biol. 2010;641:1-12. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/20407938",
"target":"_blank"
},
"children":[
"PMID: 20407938"
]
},
" doi:10.1007/978-1-60761-711-2_1"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":15,
"C":6,
"D":4,
"E":74
},
"hlIds":[
"eb719b",
"fe6d2b",
"a462a3",
"f9867c",
"72a07f",
"f461b2",
"55d45f",
"747c2a",
"514851",
"d17af8",
"4b421c",
"983777",
"779c49",
"bb67f6",
"915c7a",
"0c6760",
"89c79f",
"4e99b5",
"a660cc"
]
},
{
"id":"mk19_a_np_q084",
"number":84,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 84",
"stimulus":[
{
"type":"p",
"hlId":"0372f3",
"children":[
"A 52-year-old man is evaluated for a 3-day history of diffuse muscle aches. He has type 2 diabetes mellitus, hypertension, and stage G3 chronic kidney disease. Medications are metformin, valsartan, atorvastatin, calcium, and vitamin D."
]
},
{
"type":"p",
"hlId":"846978",
"children":[
"On physical examination, vital signs are normal. There is significant tenderness over the thighs and arms. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b47e6a",
"class":"cell text l",
"children":[
"8.4 mg/dL (2.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b58be9",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatine kinase, serum",
"children":[
"Creatine kinase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7a19cb",
"class":"cell text l",
"children":[
"16,200 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3ea104",
"class":"cell text l",
"children":[
"1.8 mg/dL (159.1 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bec0a",
"class":"cell text l",
"children":[
"5.2 mEq/L (5.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"653d7c",
"class":"cell text l",
"children":[
"18 mEq/L (18 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"907473",
"class":"cell text l",
"children":[
"6.1 mg/dL (2.0 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"089634",
"children":[
"Which of the following is the most likely cause of this patient's hyperphosphatemia?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Chronic kidney disease"
}
},
{
"letter":"B",
"text":{
"__html":"Insulin deficiency"
}
},
{
"letter":"C",
"text":{
"__html":"Rhabdomyolysis"
}
},
{
"letter":"D",
"text":{
"__html":"Vitamin D"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"afba71",
"children":[
"The cause of hyperphosphatemia can often be determined from the clinical history and is most commonly due to chronic kidney disease or acute kidney injury."
]
},
{
"type":"keypoint",
"hlId":"37543e",
"children":[
"Rhabdomyolysis and tumor lysis syndrome increase serum phosphate levels acutely due to widespread cellular damage."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"154a67",
"children":[
"The most likely cause of this patient's hyperphosphatemia is atorvastatin-induced rhabdomyolysis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") and is evidenced by the patient's elevated serum creatine kinase level. The cause of hyperphosphatemia can often be determined from the clinical history and is most commonly due to chronic kidney disease (CKD) or acute kidney injury. Because phosphate is primarily an intracellular anion, widespread cellular damage as occurs in rhabdomyolysis and tumor lysis syndrome increases serum phosphate, especially if the glomerular filtration rate (GFR) is decreased. Hyperphosphatemia can also be associated with diabetic ketoacidosis and, less commonly, lactic acidosis. Excessive phosphate intake rarely causes hyperphosphatemia because the kidney rapidly excretes phosphate. However, phosphate-containing cathartics can cause acute elevations in serum phosphate, especially in patients with reduced GFR. The risk for statin-induced serious muscle injury, including rhabdomyolysis, is <0.1%. Discontinuation of the statin in a patient with statin-induced myopathy is typically followed by a decreasing creatine kinase and resolution of symptoms, but recovery can be prolonged in patients with more severe muscle injury."
]
},
{
"type":"p",
"hlId":"0dd6a0",
"children":[
"Although hyperphosphatemia is common in stage G4 or G5 CKD (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), it is unusual with the mild degree of kidney dysfunction seen in this patient. With decreasing GFR, there is an increase in fibroblast growth factor 23, which not only decreases the reabsorption of phosphorus in the renal proximal tubule but also inhibits 1-hydroxylation of vitamin D. This results in increased renal phosphorus excretion and decreased absorption of phosphorus from the gastrointestinal tract, thus maintaining serum phosphorus until late-stage CKD, at which time these homeostatic mechanisms are no longer able to counter the decrease in renal phosphorus excretion."
]
},
{
"type":"p",
"hlId":"079e83",
"children":[
"Because insulin stimulates the sodium-dependent phosphorus transporter, hyperphosphatemia may occur in patients with insulin deficiency (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") due to decreased cellular uptake of phosphate. However, these patients develop hyperphosphaturia and subsequent hypophosphatemia due to the effect of hyperglycosuric osmotic diuresis."
]
},
{
"type":"p",
"hlId":"f600b3",
"children":[
"Vitamin D toxicity (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") can cause hyperphosphatemia but typically in cases of ingestion of large quantities. In addition, vitamin D–induced hyperphosphatemia is associated with elevated serum calcium levels, which are not seen in this patient."
]
}
],
"relatedSection":"mk19_a_np_s2_4_2_1",
"objective":{
"__html":"Diagnose rhabdomyolysis as a cause of hyperphosphatemia."
},
"references":[
[
"Leung J, Crook M. Disorders of phosphate metabolism. J Clin Pathol. 2019;72:741-747. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31467040",
"target":"_blank"
},
"children":[
"PMID: 31467040"
]
},
" doi:10.1136/jclinpath-2018-205130"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":10,
"B":1,
"C":89,
"D":1,
"E":0
},
"hlIds":[
"0372f3",
"846978",
"a462a3",
"1a4da4",
"b47e6a",
"b58be9",
"7a19cb",
"f461b2",
"3ea104",
"89662a",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"9bec0a",
"a207b1",
"21724f",
"6827e3",
"653d7c",
"a4922e",
"907473",
"089634",
"afba71",
"37543e",
"154a67",
"0dd6a0",
"079e83",
"f600b3"
]
},
{
"id":"mk19_a_np_q085",
"number":85,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 85",
"stimulus":[
{
"type":"p",
"hlId":"7cb827",
"children":[
"A 54-year-old man is evaluated for the nephrotic syndrome 10 days after undergoing a kidney biopsy. He reports normal urine volume and no hematuria. He has noticed mild bilateral flank aches during the past 2 days. Prebiopsy ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level was 0.9 mg/dL (79.6 µmol/L). Medical history is also significant for hyperlipidemia. Medications are furosemide and atorvastatin."
]
},
{
"type":"p",
"hlId":"11831a",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), blood pressure is 148/88 mm Hg, and pulse rate is 72/min. Bilateral costovertebral angle tenderness is noted. There is 2+ lower extremity edema. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"a786e1",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 3.2 mg/dL (282.9 µmol/L). Urinalysis shows a specific gravity of 1.012; pH of 5.0; 3+ blood; 3+ protein; 1+ leukocytes; >100 erythrocytes/hpf; occasional leukocytes; and no casts."
]
},
{
"type":"p",
"hlId":"db29ea",
"children":[
"Kidney biopsy shows membranous nephropathy with minimal interstitial fibrosis and no glomerulosclerosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Anti–phospholipase receptor A2 antibody measurement"
}
},
{
"letter":"B",
"text":{
"__html":"Fractional excretion of sodium"
}
},
{
"letter":"C",
"text":{
"__html":"Radionuclide imaging"
}
},
{
"letter":"D",
"text":{
"__html":"Renal ultrasonography with Doppler"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"f16f24",
"children":[
"Renal vein thrombosis is a complication of the nephrotic syndrome and is most commonly associated with membranous nephropathy."
]
},
{
"type":"keypoint",
"hlId":"da0fb7",
"children":[
"Preferred imaging studies for suspected renal vein thrombosis in patients with acute kidney injury or an estimated glomerular filtration rate of <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" include renal ultrasonography with Doppler and renal venography."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"6fc052",
"children":[
"The most appropriate diagnostic test to perform next is renal ultrasonography with Doppler (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient most likely has renal vein thrombosis (RVT), a complication of the hypercoagulable state of the nephrotic syndrome. Of the nephrotic states, RVT appears more commonly with membranous nephropathy (MN) than with other pathologies. Hematuria and flank pain are suggestive in this patient, although RVT can be asymptomatic. The gold standard diagnostic test for RVT is selective renal venography. However, less invasive procedures are more typically used. In this patient with acute kidney injury (AKI) (or an estimated glomerular filtration rate of <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"), it is preferable to avoid contrast exposure. The imaging study of first choice is ultrasonography with Doppler. If the test is negative and a high index of suspicion persists, then renal venography could be considered."
]
},
{
"type":"p",
"hlId":"76fc1c",
"children":[
"Anti–phospholipase receptor A2 antibodies (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") are present in approximately 70% of patients with MN and are emerging as a diagnostic and prognostic tool to identify and monitor disease. However, this test has no role in defining the etiology of AKI when underlying MN is known or in advancing the diagnosis of RVT."
]
},
{
"type":"p",
"hlId":"d47172",
"children":[
"In patients with oliguria, the fractional excretion of sodium (FE",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"Na"
]
},
") (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") can help distinguish between prerenal AKI and acute tubular necrosis. In prerenal AKI the FE",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"Na"
]
},
" is <1%. However, FE",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"Na"
]
},
" <1% can occur in other conditions, including contrast nephropathy, pigment nephropathy, glomerulonephritis, and early obstruction. FE",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"Na"
]
},
" >2% is consistent with acute tubular necrosis. However, FE",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"Na"
]
},
" may be >2% in patients with prerenal AKI who have urinary sodium loss due to diuretics, have adrenal insufficiency, or from bicarbonaturia in severe metabolic alkalosis. This patient is not oliguric and the presence of AKI in a patient with MN, hematuria, and flank pain strongly suggests RVT."
]
},
{
"type":"p",
"hlId":"6d0ab2",
"children":[
"Although radionuclide imaging (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may help assess if there is arterial flow to the kidney as well as estimate the glomerular filtration rate, it will not identify RVT with specificity."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_4",
"objective":{
"__html":"Diagnose renal vein thrombosis."
},
"references":[
[
"Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190-195. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21918501",
"target":"_blank"
},
"children":[
"PMID: 21918501"
]
},
" doi:10.1038/ki.2011.312"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":32,
"B":6,
"C":2,
"D":60,
"E":0
},
"hlIds":[
"7cb827",
"11831a",
"a786e1",
"db29ea",
"ab9d96",
"f16f24",
"da0fb7",
"6fc052",
"76fc1c",
"d47172",
"6d0ab2"
]
},
{
"id":"mk19_a_np_q086",
"number":86,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 86",
"stimulus":[
{
"type":"p",
"hlId":"099370",
"children":[
"A 27-year-old man is evaluated in the ICU for septic shock. For the past 3 months, he has received dialysis for end-stage kidney disease with a tunneled catheter because his arteriovenous fistula has not matured for use. He reports a 1-day history of fever and malaise."
]
},
{
"type":"p",
"hlId":"77c59f",
"children":[
"On physical examination, temperature is 38.5 °C (101.3 °F), blood pressure is 90/50 mm Hg, pulse rate is 89/min, and respiration rate is 22/min. A right internal jugular tunneled hemodialysis catheter is in place with no erythema or discharge at the exit site. A normal-appearing and functioning left arteriovenous fistula is present. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"5c60c5",
"children":[
"Blood and urine cultures are obtained."
]
},
{
"type":"p",
"hlId":"671988",
"children":[
"Cefepime and vancomycin are initiated, repeated fluid boluses are administered, and intravenous norepinephrine is started."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1e31fb",
"children":[
"Which of the following is the most appropriate additional management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Antibiotic lock therapy"
}
},
{
"letter":"B",
"text":{
"__html":"Arteriovenous fistula excision"
}
},
{
"letter":"C",
"text":{
"__html":"Exchange the tunneled catheter"
}
},
{
"letter":"D",
"text":{
"__html":"Remove the tunneled catheter"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a5f421",
"children":[
"Tunneled catheters should be removed immediately for severe sepsis, evidence of metastatic infection, evidence of an exit-site or tunnel infection, persistent fever, or bacteremia despite administration of antibiotics."
]
},
{
"type":"keypoint",
"hlId":"248374",
"children":[
"Antibiotic lock therapy with vancomycin and/or ceftazidime is an alternative option to treat catheter-related bloodstream infections in stable patients with less virulent organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus epidermitis"
]
},
"."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"bb7a87",
"children":[
"The most appropriate additional management is to remove the tunneled hemodialysis catheter (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Infection is the second leading cause of death in patients with end-stage kidney disease (ESKD). Patients are at increased risk due to a relatively immunosuppressed state from chronic inflammation and frequent exposure to the health care environment. Tunneled dialysis catheters increase the risk for bacteremia, and empiric antibiotics should be administered while awaiting blood culture results in patients with suspected bacteremia. Tunneled catheters should be removed immediately for severe sepsis, evidence of metastatic infection, evidence of an exit-site or tunnel infection, persistent fever, or bacteremia despite administration of antibiotics."
]
},
{
"type":"p",
"hlId":"44eae4",
"children":[
"Antibiotic lock therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") consists of the instillation of a highly concentrated antibiotic solution into an intravascular catheter lumen to treat catheter-related bloodstream infections. Antibiotic lock therapy with vancomycin and/or ceftazidime is an alternative option for stable patients with less virulent organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus epidermitis"
]
},
", but catheter salvage should not be attempted for patients with severe sepsis, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" infections, and some gram-negative organisms."
]
},
{
"type":"p",
"hlId":"b82fd1",
"children":[
"Arteriovenous fistula (AVF) excision (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not indicated. Hemodialysis arm-access sites have a lower risk for infection than do catheters; AVFs have the lowest risk compared with arteriovenous grafts. This patient has no evidence of an AVF-related infection, nor is it expected, as his AVF has not yet been used for dialysis."
]
},
{
"type":"p",
"hlId":"3d25f5",
"children":[
"Exchange of the catheter over a guidewire (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may be an option for clinically stable patients without a tunnel infection or for patients who clear the bacteremia within 48 hours of antibiotic administration. This patient meets none of these indications for catheter exchange."
]
}
],
"relatedSection":"mk19_a_np_s12_9_3_2",
"objective":{
"__html":"Manage hemodialysis line–related sepsis."
},
"references":[
[
"Johns TS, Mokrzycki MH. Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia [Editorial]. Clin J Am Soc Nephrol. 2016;11:756-758. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27037273",
"target":"_blank"
},
"children":[
"PMID: 27037273"
]
},
" doi:10.2215/CJN.02910316"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":18,
"B":1,
"C":15,
"D":66,
"E":0
},
"hlIds":[
"099370",
"77c59f",
"5c60c5",
"671988",
"1e31fb",
"a5f421",
"248374",
"bb7a87",
"44eae4",
"b82fd1",
"3d25f5"
]
},
{
"id":"mk19_a_np_q087",
"number":87,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 87",
"stimulus":[
{
"type":"p",
"hlId":"bb313a",
"children":[
"A 24-year-old woman is evaluated during a follow-up visit for hypokalemia. She has occasional muscle cramps but no weakness, polyuria, or diarrhea. Medical history is unremarkable. Family history is unobtainable. She takes no medications."
]
},
{
"type":"p",
"hlId":"3c1f6d",
"children":[
"On physical examination, blood pressure is 98/68 mm Hg. Other vital signs and the remainder of the examination are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3e1a8a",
"class":"cell text l",
"children":[
"10.2 mg/dL (2.55 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfe04",
"class":"cell text l",
"children":[
"0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"115bcd",
"class":"cell text l",
"children":[
"3.1 mEq/L (3.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"658b18",
"class":"cell text l",
"children":[
"100 mEq/L (100 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cbdac5",
"class":"cell text l",
"children":[
"29 mEq/L (29 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fad908",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Magnesium, serum",
"children":[
"Magnesium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e2d2de",
"class":"cell text l",
"children":[
"1.4 mg/dL (0.58 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e331de",
"class":"cell text l",
"children":[
"Urine sodium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a9938f",
"class":"cell text l",
"children":[
"48 mEq/L (48 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a54671",
"class":"cell text l",
"children":[
"Urine potassium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b9fe11",
"class":"cell text l",
"children":[
"32 mEq/L (32 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c1bef6",
"class":"cell text l",
"children":[
"Urine chloride"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"69a93b",
"class":"cell text l",
"children":[
"54 mEq/L (54 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a645eb",
"class":"cell text l",
"children":[
"Urine diuretic screen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"76c9de",
"class":"cell text l",
"children":[
"Spot urine calcium-creatinine ratio"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28d0ed",
"class":"cell text l",
"children":[
"Low"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Gitelman syndrome"
}
},
{
"letter":"B",
"text":{
"__html":"Laxative abuse"
}
},
{
"letter":"C",
"text":{
"__html":"Primary hyperaldosteronism"
}
},
{
"letter":"D",
"text":{
"__html":"Surreptitious vomiting"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4f6072",
"children":[
"Patients with Gitelman syndrome typically present in late adolescence or early adulthood with low-normal blood pressure, hypokalemic metabolic alkalosis, and, frequently, hypomagnesemia and high-normal serum calcium levels."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"fc87fe",
"children":[
"The most likely diagnosis is Gitelman syndrome (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), an autosomal recessive disorder that causes decreased activity in the sodium chloride transporter in the distal tubule. This patient has a hypokalemic metabolic alkalosis with a low-normal blood pressure. The differential of this presentation includes surreptitious vomiting, diuretic abuse, Bartter syndrome, and Gitelman syndrome. These patients have findings similar to those in patients being treated with thiazide diuretics. Patients with Gitelman syndrome typically present in late adolescence or early adulthood with low-normal blood pressure and hypokalemic metabolic alkalosis. Frequently, they will have hypomagnesemia and a high-normal serum calcium level. They will have low urine calcium excretion, as seen in this patient, and their urine diuretic screen will be negative. Bartter syndrome, which affects transport in the loop of Henle, has a similar presentation to Gitelman syndrome. However, Bartter syndrome typically presents in early childhood and is far less common than Gitelman syndrome. Because of significant sodium wasting, these patients will often have episodes of kidney injury due to hypotension. If measured, they typically have a normal-to-increased urine calcium."
]
},
{
"type":"p",
"hlId":"763c7a",
"children":[
"Patients who abuse laxatives (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") typically have a low urine chloride and proportionally low sodium and potassium excretion and frequently have a normal anion gap metabolic acidosis. In this case, the urine anion gap will be positive, reflecting increase urinary excretion of hydrogen ions."
]
},
{
"type":"p",
"hlId":"3a2e16",
"class":"equation",
"children":[
"Urine Anion Gap = (Urine Sodium + Urine Potassium) – Urine Chloride"
]
},
{
"type":"p",
"hlId":"4658ac",
"children":[
"The presence of metabolic alkalosis excludes laxative abuse as the cause of hypokalemia in this patient."
]
},
{
"type":"p",
"hlId":"5a7d72",
"children":[
"Primary hyperaldosteronism (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") results from the autonomous secretion of excessive aldosterone. It is relatively common, occurring in approximately 10% of patients with hypertension. Additional signs of primary hyperaldosteronism include hypokalemia and metabolic alkalosis. The patient's low blood pressure excludes primary hyperaldosteronism as the cause of her hypokalemia and metabolic alkalosis."
]
},
{
"type":"p",
"hlId":"eb0d86",
"children":[
"Patients with surreptitious vomiting (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") will have a hypokalemic metabolic alkalosis and low-normal blood pressure similar to that seen in patients with Gitelman syndrome; however, urine chloride will be low and urine calcium excretion should not be low."
]
}
],
"relatedSection":"mk19_a_np_s2_3_1_1",
"objective":{
"__html":"Diagnose Gitelman syndrome."
},
"references":[
[
"Fulchiero R, Seo-Mayer P. Bartter syndrome and Gitelman syndrome. Pediatr Clin North Am. 2019;66:121-134. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30454738",
"target":"_blank"
},
"children":[
"PMID: 30454738"
]
},
" doi:10.1016/j.pcl.2018.08.010"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":63,
"B":20,
"C":2,
"D":14,
"E":0
},
"hlIds":[
"bb313a",
"3c1f6d",
"a462a3",
"1a4da4",
"3e1a8a",
"f461b2",
"9bfe04",
"89662a",
"d41d8c",
"b99276",
"731ef5",
"e92687",
"115bcd",
"a207b1",
"658b18",
"6827e3",
"cbdac5",
"fad908",
"e2d2de",
"e331de",
"a9938f",
"a54671",
"b9fe11",
"c1bef6",
"69a93b",
"a645eb",
"ffb935",
"76c9de",
"28d0ed",
"413696",
"4f6072",
"fc87fe",
"763c7a",
"3a2e16",
"4658ac",
"5a7d72",
"eb0d86"
]
},
{
"id":"mk19_a_np_q088",
"number":88,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 88",
"stimulus":[
{
"type":"p",
"hlId":"a4c80b",
"children":[
"A 45-year-old man is evaluated during a routine follow-up visit for stage G3 chronic kidney disease. He also has hypertension and type 2 diabetes mellitus. Medications are cholecalciferol, hydrochlorothiazide, metformin, canagliflozin, and valsartan."
]
},
{
"type":"p",
"hlId":"d86653",
"children":[
"On physical examination, blood pressure is 140/80 mm Hg; other vital signs are normal. The remainder of the examination is normal."
]
},
{
"type":"p",
"hlId":"0f2071",
"children":[
"His calculated 10-year risk of an atherosclerotic cardiovascular disease event is 7.5%."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"43dc3a",
"class":"cell text l",
"children":[
"186 mg/dL (4.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8a43cb",
"class":"cell text l",
"children":[
"HDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"82d326",
"class":"cell text l",
"children":[
"34 mg/dL (0.88 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"0c2f10",
"class":"cell text l",
"children":[
"LDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cc1f9b",
"class":"cell text l",
"children":[
"113 mg/dL (2.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2bfd48",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"33d604",
"class":"cell text l",
"children":[
"47 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"d9913d",
"children":[
"Which of the following is the most appropriate treatment to reduce this patient's risk for atherosclerotic cardiovascular disease?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Evolocumab"
}
},
{
"letter":"B",
"text":{
"__html":"Ezetimibe"
}
},
{
"letter":"C",
"text":{
"__html":"High-intensity rosuvastatin"
}
},
{
"letter":"D",
"text":{
"__html":"Moderate-intensity atorvastatin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9cfd9b",
"children":[
"The use of statins to treat dyslipidemia in patients with chronic kidney disease has been shown to reduce cardiovascular events."
]
},
{
"type":"keypoint",
"hlId":"251ac6",
"children":[
"Statins do not slow progression of chronic kidney disease."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a10e0b",
"children":[
"The most appropriate treatment to reduce this patient's risk of atherosclerotic cardiovascular disease (ASCVD) is moderate-intensity atorvastatin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). The American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol recommends moderate-intensity statin therapy for any patient aged 40 to 75 years with diabetes mellitus. In addition, this guideline recognizes chronic kidney disease (CKD) as a risk enhancer for ASCVD and recommends a moderate-intensity statin for adults aged 40 to 75 years with an LDL cholesterol of 70 to 189 mg/dL (1.81-4.89 mmol/L) who have a 10-year ASCVD risk ≥7.5% (excluding patients treated with dialysis or kidney transplantation). The Kidney Disease: Improving Global Outcomes guidelines recommend treatment with a statin in all patients aged ≥50 years with non-dialysis–dependent CKD and in adults aged 18 to 49 years with non-dialysis–dependent CKD and any one of the following: coronary disease, diabetes, prior ischemic stroke, or a >10% estimated risk for coronary death or nonfatal myocardial infarction. The use of statins to treat dyslipidemia in patients with CKD has been shown to reduce cardiovascular events. However, statins do not slow progression of CKD. When patients reach end-stage kidney disease, statins do not reduce cardiovascular events. Atorvastatin is frequently chosen for patients with CKD because it undergoes hepatic clearance and does not require renal dose adjustments. In addition, atorvastatin may have beneficial effects on proteinuria."
]
},
{
"type":"p",
"hlId":"ceff67",
"children":[
"There is no indication for either evolocumab or ezetimibe (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, B"
]
},
"). The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab, are monoclonal antibodies that bind to serine protease PCSK9, a liver enzyme that degrades hepatocyte LDL receptors. Adding a PCSK9 inhibitor can be considered for secondary prevention in very high-risk patients if the LDL cholesterol level remains ≥70 mg/dL (1.81 mmol/L) or the non-HDL cholesterol level is ≥100 mg/dL (2.59 mmol/L) despite maximally tolerated lipid-lowering therapy. Ezetimibe can be added to maximally tolerated statin therapy in very high-risk patients with clinically evident ASCVD when the LDL cholesterol level remains ≥70 mg/dL (1.81 mmol/L)."
]
},
{
"type":"p",
"hlId":"8997f6",
"children":[
"High-intensity statin therapy is not indicated in this patient, and atorvastatin is usually preferred to rosuvastatin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a renally excreted statin, in patients with CKD."
]
}
],
"relatedSection":"mk19_a_np_s12_6_1_2",
"objective":{
"__html":"Prevent cardiovascular events in a patient with chronic kidney disease."
},
"references":[
[
"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046-e1081. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30565953",
"target":"_blank"
},
"children":[
"PMID: 30565953"
]
},
" doi:10.1161/CIR.0000000000000624"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":0,
"B":2,
"C":40,
"D":58,
"E":0
},
"hlIds":[
"a4c80b",
"d86653",
"0f2071",
"a462a3",
"182194",
"43dc3a",
"8a43cb",
"82d326",
"0c2f10",
"cc1f9b",
"f461b2",
"2bfd48",
"77db81",
"33d604",
"d9913d",
"9cfd9b",
"251ac6",
"a10e0b",
"ceff67",
"8997f6"
]
},
{
"id":"mk19_a_np_q089",
"number":89,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 89",
"stimulus":[
{
"type":"p",
"hlId":"8e0b41",
"children":[
"A 33-year-old woman is evaluated in the hospital following a recent diagnosis of membranoproliferative glomerulonephritis. She engages in transactional sex. She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"18700c",
"children":[
"On physical examination, blood pressure is 142/90 mm Hg; other vital signs are normal. There is 1-mm pitting edema of the ankles bilaterally. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"687cd3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C3, serum",
"children":[
"C3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4148af",
"class":"cell text l",
"children":[
"69 mg/dL (690 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"dcfa5e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C4, serum",
"children":[
"C4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f4eafc",
"class":"cell text l",
"children":[
"5 mg/dL (50 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cd0076",
"class":"cell text l",
"children":[
"2.5 mg/dL (221 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"25d6d7",
"class":"cell text l",
"children":[
"Antimyeloperoxidase antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8377f4",
"class":"cell text l",
"children":[
"Antiproteinase-3 antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c9c254",
"class":"cell text l",
"children":[
"Fourth-generation HIV test"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"98ac4a",
"class":"cell text l",
"children":[
"3+ blood; 2+ protein"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"91d2fc",
"class":"cell text l",
"children":[
"1700 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"ca8e17",
"children":[
"Kidney biopsy showed membranoproliferative glomerulonephritis with positive immunofluorescence staining for IgG, IgM, C1q, and C3."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"47184f",
"children":[
"Which of the following is the most likely cause of this patient's glomerulonephritis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Genetic mutations of alternative complement pathway proteins"
}
},
{
"letter":"B",
"text":{
"__html":"Hepatitis B virus infection"
}
},
{
"letter":"C",
"text":{
"__html":"Hepatitis C virus infection"
}
},
{
"letter":"D",
"text":{
"__html":"Syphilis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ade01a",
"children":[
"The immune complex form of membranoproliferative glomerulonephritis is associated with infectious, autoimmune, or malignancy-associated etiologies."
]
},
{
"type":"keypoint",
"hlId":"54dca1",
"children":[
"The most common etiology of immune complex membranoproliferative glomerulonephritis is infectious, specifically hepatitis C virus infection."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"f3dfae",
"children":[
"The most likely cause of this patient's glomerulonephritis is hepatitis C virus (HCV) infection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). This patient has membranoproliferative glomerulonephritis (MPGN). Based on her history of transactional sex, she is at increased risk for HCV infection, which is a secondary cause of immune complex–mediated MPGN. If the patient tests positive for HCV, treatment of the lesion would involve anti-HCV antiviral therapy and consideration of immunosuppression (glucocorticoids plus rituximab). The approach to evaluating MPGN lesions on kidney biopsy is based on the pattern of staining on immunofluorescence microscopy. The more common pattern is immune complex deposition with both immunoglobulin (IgG, IgM, and/or IgA) and complement (C1q and/or C3) on immunofluorescence, which infers an inciting cause or event that generally falls into one of three major categories: infectious, autoimmune, or malignancy associated. The most common of these etiologies is infectious, specifically infection with HCV."
]
},
{
"type":"p",
"hlId":"f7cd01",
"children":[
"A test for genetic mutations of alternative complement pathway proteins (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not indicated. This extremely rare finding manifests as a MPGN lesion showing only C3 (without immunoglobulin or C1q staining) on immunofluorescence staining. This suggests an antibody-independent means of complement activation and points to hyperactivity of the alternative complement pathway. These C3 glomerulopathies, named for the isolated C3 staining pattern seen on immunofluorescence, should prompt screening for genetic abnormalities in alternative complement pathway proteins. This patient has immune complex deposition with the presence of both immunoglobulin and complement; therefore, testing for alternate pathway mutations is not indicated."
]
},
{
"type":"p",
"hlId":"051ac5",
"children":[
"Hepatitis B virus infection and syphilis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, D"
]
},
") have been linked to glomerular diseases, but these classically present with the nephrotic syndrome associated with membranous nephropathy."
]
}
],
"relatedSection":"mk19_a_np_s6_4_4_5_1",
"objective":{
"__html":"Diagnose hepatitis C virus infection as the cause of membranoproliferative glomerulonephritis."
},
"references":[
[
"Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis. 2015;22:343-351. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26311595",
"target":"_blank"
},
"children":[
"PMID: 26311595"
]
},
" doi:10.1053/j.ackd.2015.06.003"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":11,
"B":20,
"C":63,
"D":6,
"E":0
},
"hlIds":[
"8e0b41",
"18700c",
"a462a3",
"687cd3",
"4148af",
"dcfa5e",
"f4eafc",
"f461b2",
"cd0076",
"b534b1",
"ffb935",
"25d6d7",
"ffb935",
"8377f4",
"ffb935",
"c9c254",
"ffb935",
"747c2a",
"98ac4a",
"d17af8",
"91d2fc",
"ca8e17",
"47184f",
"ade01a",
"54dca1",
"f3dfae",
"f7cd01",
"051ac5"
]
},
{
"id":"mk19_a_np_q090",
"number":90,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 90",
"stimulus":[
{
"type":"p",
"hlId":"e73947",
"children":[
"A 44-year-old woman is evaluated in the emergency department for confusion. Previous history is unknown."
]
},
{
"type":"p",
"hlId":"608f59",
"children":[
"On physical examination, vital signs are normal. She is oriented to her name only. Pulmonary and cardiovascular examinations are normal. The patient has confusion, but the neurologic examination is otherwise unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e88973",
"class":"cell text l",
"children":[
"118 mEq/L (118 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"115bcd",
"class":"cell text l",
"children":[
"3.1 mEq/L (3.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6d29b3",
"class":"cell text l",
"children":[
"90 mEq/L (90 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f1e327",
"class":"cell text l",
"children":[
"22 mEq/L (22 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"948309",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Osmolality, serum",
"children":[
"Osmolality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1a2abc",
"class":"cell text l",
"children":[
"248 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Fluid restriction"
}
},
{
"letter":"B",
"text":{
"__html":"0.9% saline"
}
},
{
"letter":"C",
"text":{
"__html":"3% saline plus desmopressin"
}
},
{
"letter":"D",
"text":{
"__html":"Tolvaptan"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"21c452",
"children":[
"The initial treatment of symptomatic hyponatremia is acutely increasing the serum sodium by 3 to 4 mEq/L (3-4 mmol/L) with 3% saline infusion."
]
},
{
"type":"keypoint",
"hlId":"3acb49",
"children":[
"In the treatment of symptomatic hyponatremia, simultaneous administration of desmopressin with 3% saline infusion results in a more predictable and safer increase in serum sodium."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"70a372",
"children":[
"The most appropriate treatment is 3% saline plus desmopressin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). The first step when treating symptomatic hyponatremia is determining whether it is an acute (<48 hours) or a chronic (>48 hours) presentation. For this patient with confusion, it cannot be determined how long the serum sodium level has been low; in these cases, the hyponatremia should always be treated as chronic. It is important to prevent overly rapid correction of the serum sodium. To prevent swelling, the brain cell response to hyponatremia is to extrude osmotically active solutes. This volume regulatory response occurs over 48 hours. After 48 hours, rapid increase in the serum sodium concentration will cause brain cells to acutely shrink, which can lead to osmotic demyelination syndrome (ODS). In symptomatic individuals with hyponatremia, acutely increasing the serum sodium by 3 to 4 mEq/L (3-4 mmol/L) will usually improve symptoms; if the increase in serum sodium is ≤8 mEq/L (8 mmol/L) in 24 hours, the incidence of ODS can be markedly decreased and often avoided. Because of her symptoms, it is essential to increase the serum sodium 3 to 4 mEq/L (3-4 mmol/L) quickly by administering either a 100-mL bolus or 30 mL/h of hypertonic 3% saline and measuring the serum sodium every 2 hours. However, if the hyponatremia is due to volume depletion or excessive water intake, the serum sodium can rise rapidly as the kidney excretes the excess water. Simultaneous administration of desmopressin makes the rate of correction resulting from 3% saline infusion more predictable and safer for the patient because it prevents an unexpected water diuresis and rapid increases in the serum sodium."
]
},
{
"type":"p",
"hlId":"95a9b1",
"children":[
"In symptomatic hyponatremic patients, fluid restriction (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") alone is not an appropriate treatment. The goal is to improve symptoms and prevent further neurologic complication by rapidly increasing the serum sodium level by 3 to 4 mEq/L (3-4 mmol/L) with 3% saline and desmopressin administration."
]
},
{
"type":"p",
"hlId":"5c0911",
"children":[
"Administration of 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") may lower the serum sodium in patients with the syndrome of inappropriate antidiuretic hormone secretion, because the amount of sodium infused can be excreted in a smaller volume of urine leaving behind water."
]
},
{
"type":"p",
"hlId":"c889e8",
"children":[
"Tolvaptan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), an antidiuretic hormone antagonist, should not be used in patients with symptomatic hyponatremia, as the response is unpredictable."
]
}
],
"relatedSection":"mk19_a_np_s2_2_1_2",
"objective":{
"__html":"Treat hyponatremia in a symptomatic patient."
},
"references":[
[
"Sterns RH. Treatment of severe hyponatremia. Clin J Am Soc Nephrol. 2018;13:641-649. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29295830",
"target":"_blank"
},
"children":[
"PMID: 29295830"
]
},
" doi:10.2215/CJN.10440917"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":9,
"B":20,
"C":64,
"D":6,
"E":0
},
"hlIds":[
"e73947",
"608f59",
"a462a3",
"89662a",
"d41d8c",
"b99276",
"e88973",
"e92687",
"115bcd",
"a207b1",
"6d29b3",
"6827e3",
"f1e327",
"948309",
"1a2abc",
"1054f1",
"21c452",
"3acb49",
"70a372",
"95a9b1",
"5c0911",
"c889e8"
]
},
{
"id":"mk19_a_np_q091",
"number":91,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 91",
"stimulus":[
{
"type":"p",
"hlId":"b26345",
"children":[
"A 41-year-old woman is evaluated during a follow-up visit for stage 2 hypertension confirmed by daytime ambulatory blood pressure monitoring. She also has a 10-year history of type 2 diabetes mellitus and hyperlipidemia. Medications are atorvastatin, metformin, and empagliflozin."
]
},
{
"type":"p",
"hlId":"f3e63c",
"children":[
"On physical examination, blood pressure is 142/92 mm Hg, and pulse rate is 72/min; other vital signs are normal. BMI is 28. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"462c3c",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 0.9 mg/dL (79.6 µmol/L). Urine dipstick reveals no blood or protein."
]
},
{
"type":"p",
"hlId":"12021b",
"children":[
"The patient is instructed in lifestyle modifications for blood pressure control."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1e31fb",
"children":[
"Which of the following is the most appropriate additional management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Begin amlodipine"
}
},
{
"letter":"B",
"text":{
"__html":"Begin hydrochlorothiazide"
}
},
{
"letter":"C",
"text":{
"__html":"Continue nonpharmacologic therapy with blood pressure measurement in 3 months"
}
},
{
"letter":"D",
"text":{
"__html":"Obtain urine albumin-creatinine ratio"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"3f4796",
"children":[
"Because moderately increased albuminuria may go undetected by dipstick urinalysis, direct quantification is required in high-risk patients."
]
},
{
"type":"keypoint",
"hlId":"87069b",
"children":[
"The American Diabetes Association recommends an ACE inhibitor or angiotensin receptor blocker at the maximum tolerated dose as first-line treatment for hypertension in patients with diabetes mellitus and urine albumin-creatinine ratio >300 mg/g."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"4e1e54",
"children":[
"The most appropriate additional management is to obtain a urine albumin-creatinine ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Dipstick measurements of protein are dependent on urine concentration; false-negative results may be caused by dilute urine, and false-positive results may be caused by highly concentrated urine. Because moderately increased albuminuria may go undetected by dipstick urinalysis, direct quantification is required in high-risk patients. The American College of Cardiology/American Heart Association (ACC/AHA) blood pressure (BP) guideline recommends a BP goal of <130/80 mm Hg for patients with diabetes mellitus. The American Diabetes Association (ADA) recommends a BP target of <130/80 mm Hg for patients with diabetes and hypertension at higher cardiovascular risk (existing atherosclerotic cardiovascular disease [ASCVD] or 10-year ASCVD event risk ≥15%), if it can be safely attained. For patients who have diabetes and hypertension with a 10-year ASCVD <15%, the ADA recommends a target of 140/90 mm Hg. According to the ACC/AHA, ACE inhibitors or ARBs may be considered in the presence of albuminuria. For patients with hypertension, diabetes, and urine albumin-creatinine ratio >300 mg/g, the ADA recommends an ACE inhibitor or ARB at the maximum tolerated dose as first-line treatment; such treatment should also be considered if urine albumin-creatinine ratio ≥30 mg/g to 300 mg/g. Consequently, the next step in management of this patient is to measure her urine albumin-creatinine ratio to determine if an ACE inhibitor or ARB is indicated."
]
},
{
"type":"p",
"hlId":"fcad1e",
"children":[
"Selecting a specific antihypertensive drug, such as a CCB (amlodipine) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"), a thiazide diuretic (hydrochlorothiazide) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), an ACE inhibitor, or an ARB is not indicated until quantification of albuminuria is performed."
]
},
{
"type":"p",
"hlId":"5e9702",
"children":[
"Patients with stage 2 hypertension should be managed with both pharmacologic and nonpharmacologic therapy. Therefore, continuing nonpharmacologic therapy only is not sufficient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). After initiation of therapy, the patient's BP should be remeasured in 1 month, not 3 months."
]
}
],
"relatedSection":"mk19_a_np_s4_14_2",
"objective":{
"__html":"Screen for albuminuria to determine optimal treatment of hypertension."
},
"references":[
[
"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S125-S150. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298421",
"target":"_blank"
},
"children":[
"PMID: 33298421"
]
},
" doi:10.2337/dc21-S010"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":17,
"B":16,
"C":12,
"D":56,
"E":0
},
"hlIds":[
"b26345",
"f3e63c",
"462c3c",
"12021b",
"1e31fb",
"3f4796",
"87069b",
"4e1e54",
"fcad1e",
"5e9702"
]
},
{
"id":"mk19_a_np_q092",
"number":92,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 92",
"stimulus":[
{
"type":"p",
"hlId":"8a4bb7",
"children":[
"A 52-year-old woman is evaluated in the emergency department for abdominal pain and metabolic acidosis. The patient has been drinking alcohol steadily for 1 week and has been brought to the emergency department by friends. The patient also had episodes of nausea and vomiting and abdominal pain over the past 24 to 48 hours. The patient was hospitalized 1 year ago with isopropyl alcohol intoxication. She reports no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"ffd590",
"children":[
"On physical examination, blood pressure is 110/72 mm Hg, pulse rate is 110/min, and respiration rate is 20/min. BMI is 18. Abdominal examination reveals diffuse tenderness to palpation. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"29d161",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"Blood urea nitrogen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7aff01",
"class":"cell text l",
"children":[
"32 mg/ dL (11.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"db618e",
"class":"cell text l",
"children":[
"139 mEq/L (139 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"841805",
"class":"cell text l",
"children":[
"3.9 mEq/L (3.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"658b18",
"class":"cell text l",
"children":[
"100 mEq/L (100 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"432158",
"class":"cell text l",
"children":[
"11 mEq/L (11 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"927377",
"class":"cell text l",
"children":[
"Ethanol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b798cd",
"class":"cell text l",
"children":[
"40 mg/dL (8.64 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"847136",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glucose, plasma",
"children":[
"Glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6f766d",
"class":"cell text l",
"children":[
"72 mg/dL (4.0 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"5a64cc",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Osmolality, serum",
"children":[
"Plasma osmolality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d9d655",
"class":"cell text l",
"children":[
"290 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1c5528",
"class":"cell text l",
"children":[
"Specific gravity 1.030; pH 5.5; no blood; trace ketones"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Alcoholic ketoacidosis"
}
},
{
"letter":"B",
"text":{
"__html":"Ethylene glycol toxicity"
}
},
{
"letter":"C",
"text":{
"__html":"Isopropyl alcohol toxicity"
}
},
{
"letter":"D",
"text":{
"__html":"Methanol toxicity"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"9b5926",
"children":[
"Alcoholic ketoacidosis results in an increased anion gap metabolic acidosis and minimal ketones on urine dipstick analysis."
]
},
{
"type":"keypoint",
"hlId":"37c971",
"children":[
"Ethylene glycol, methanol, and isopropyl alcohol toxicities are associated with an increased osmolal gap."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2640b2",
"children":[
"The most likely diagnosis is alcoholic ketoacidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has an increased anion gap metabolic acidosis with an anion gap of 28, and ketoacidosis due to acute ethanol intoxication is the most likely cause. Alcoholic ketoacidosis occurs in patients following an episode of acute intoxication; however, by the time of clinical evaluation, the ingested ethanol may be extensively metabolized, leading to low or absent serum ethanol levels. Ethanol is oxidized to acetaldehyde and then to acetic acid, during which process the electron-carrier coenzyme nicotinamide adenine dinucleotide (NAD+) is reduced to NADH in increasing amounts. Simultaneously, decreased insulin secretion (as a result of starvation) and increased counter-regulatory hormones cause lipolysis and generation of ketones, such as acetoacetate and β-hydroxybutyrate, which result in the anion gap. The high ratio of NADH to NAD+ leads to increased reduction of acetoacetate to β-hydroxybutyrate. Because the nitroprusside reagent in the serum and urine ketone assays detects only acetoacetate, these tests may be falsely negative due to decreased acetoacetate levels despite the presence of increased levels of the ketone β-hydroxybutyrate, as in this case. Definitive diagnosis may require direct measurement of β-hydroxybutyrate levels in the serum, which is available at some laboratories."
]
},
{
"type":"p",
"hlId":"7db474",
"children":[
"Ethylene glycol and methanol toxicities (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, D"
]
},
") are associated with a plasma osmolal gap >10 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O. The plasma osmolal gap is calculated as the difference between the measured osmolality and calculated osmolality, which is determined as follows:"
]
},
{
"type":"p",
"hlId":"6a87e5",
"class":"equation",
"children":[
"2 × Serum Sodium (mEq/L) + Plasma Glucose (mg/dL)/18 + Blood Urea Nitrogen (mg/dL)/2.8"
]
},
{
"type":"p",
"hlId":"a1f4f2",
"children":[
"In this case, the difference between the calculated and measured osmolality is 3 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O (293 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O – 290 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O), making either ethylene glycol or methanol toxicity unlikely."
]
},
{
"type":"p",
"hlId":"d189f3",
"children":[
"Because isopropyl alcohol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is metabolized to acetone (a ketone), it will lead to ketosis but not to an acidosis. An osmolal gap, which is not present in this patient, will also develop with isopropyl alcohol intake."
]
}
],
"relatedSection":"mk19_a_np_s3_2_2",
"objective":{
"__html":"Diagnose alcoholic ketoacidosis."
},
"references":[
[
"Kraut JA, Mullins ME. Toxic alcohols. N Engl J Med. 2018;378:270-280. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29342392",
"target":"_blank"
},
"children":[
"PMID: 29342392"
]
},
" doi:10.1056/NEJMra1615295"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":55,
"B":18,
"C":14,
"D":13,
"E":0
},
"hlIds":[
"8a4bb7",
"ffd590",
"a462a3",
"29d161",
"7aff01",
"89662a",
"d41d8c",
"b99276",
"db618e",
"e92687",
"841805",
"a207b1",
"658b18",
"6827e3",
"432158",
"927377",
"b798cd",
"847136",
"6f766d",
"5a64cc",
"d9d655",
"747c2a",
"1c5528",
"413696",
"9b5926",
"37c971",
"2640b2",
"7db474",
"6a87e5",
"a1f4f2",
"d189f3"
]
},
{
"id":"mk19_a_np_q093",
"number":93,
"bookId":"np",
"correctAnswer":"E",
"title":"Question 93",
"stimulus":[
{
"type":"p",
"hlId":"e5248e",
"children":[
"A 32-year-old man is evaluated during a follow-up visit after passing his third calcium oxalate kidney stone in 4 years despite maintaining a high urine volume. He has no other medical problems. His only medication is potassium citrate, which was initiated after passing the most recent stone. He drinks 4 cups of coffee daily and typically eats meals at fast-food restaurants."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"0a500d",
"class":"cell text l",
"children":[
"24-Hour urine studies:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"bd7a97",
"class":"cell text li",
"children":[
"Volume"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"82be25",
"class":"cell text l",
"children":[
"2600 mL"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"397dff",
"class":"cell text li",
"children":[
"pH"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f884cc",
"class":"cell text l",
"children":[
"6.5"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a9640c",
"class":"cell text li",
"children":[
"Calcium"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9c5207",
"class":"cell text l",
"children":[
"295 mg (normal range, 50-300 mg)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"7e6003",
"class":"cell text li",
"children":[
"Citrate"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"eb2f9b",
"class":"cell text l",
"children":[
"850 mg (normal range, 100-300 mg)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"30f55d",
"class":"cell text li",
"children":[
"Oxalate"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8b9679",
"class":"cell text l",
"children":[
"35 mg (normal range, 10-40 mg)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"67ec1b",
"class":"cell text li",
"children":[
"Uric acid"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"aef82e",
"class":"cell text l",
"children":[
"640 mg (normal range, 250-750 mg)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"bd5972",
"children":[
"The patient is counseled to start a low sodium diet."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1e31fb",
"children":[
"Which of the following is the most appropriate additional management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Decrease calcium intake"
}
},
{
"letter":"B",
"text":{
"__html":"Decrease coffee intake"
}
},
{
"letter":"C",
"text":{
"__html":"Decrease oxalate intake"
}
},
{
"letter":"D",
"text":{
"__html":"Start allopurinol"
}
},
{
"letter":"E",
"text":{
"__html":"Start chlorthalidone"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ac95af",
"children":[
"Thiazide diuretics decrease calcium excretion by up to 50% and can be used to manage recurrent calcium oxalate kidney stones."
]
},
{
"type":"keypoint",
"hlId":"278d12",
"children":[
"In patients with recurrent calcium oxalate kidney stones, urinary calcium excretion can be reduced by limiting sodium and protein intake."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c68fcc",
"children":[
"The most appropriate additional management is to start chlorthalidone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") to decrease urinary calcium excretion to prevent recurrent calcium oxalate stones. This patient's urinary calcium excretion is in the high-normal range. The threshold that defines high urinary calcium excretion and when to initiate a thiazide diuretic for prevention of calcium oxalate stones is unclear. However, the underlying principle is that the risk for stone formation is continuous with increasing amounts of calcium in the urine. Patients with ongoing stone formation despite dietary and fluid management should be considered for medical therapy with a thiazide diuretic to decrease urinary calcium excretion. Thiazide diuretics can decrease calcium excretion by up to 50% and reduce the recurrence of calcium oxalate stones. Chlorthalidone is the preferred agent because of its long half-life. Chlorthalidone increases calcium reabsorption in the kidney primarily by causing mild volume depletion, which increases sodium and calcium reabsorption in the proximal tubule. When hydrochlorothiazide is used, twice-daily dosing is recommended. In addition to chlorthalidone, urinary calcium excretion can also be reduced by limiting sodium and protein intake."
]
},
{
"type":"p",
"hlId":"cd9c80",
"children":[
"Decreasing calcium intake (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not the most appropriate management. Because calcium complexes with oxalate in the gastrointestinal tract, decreasing calcium intake allows for increased oxalate absorption and increased risk for stone formation. Therefore, unless a person is on a high-calcium diet (>1500 mg/d), intake should not be limited."
]
},
{
"type":"p",
"hlId":"e18d77",
"children":[
"There is no evidence that excess coffee intake is associated with kidney stone disease, so reduction in coffee intake (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") would not be expected to be beneficial."
]
},
{
"type":"p",
"hlId":"36cf18",
"children":[
"Except in patients with hyperoxaluria, limiting oxalate intake (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has not been shown to decrease the incidence of stones, and thus the patient does not need to decrease intake."
]
},
{
"type":"p",
"hlId":"a8bb9a",
"children":[
"Because uric acid may serve as a nidus for stone formation, allopurinol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") has been used to reduce stone occurrence, especially in patients with high levels of uric acid in the urine, which is not present in this patient."
]
}
],
"relatedSection":"mk19_a_np_s10_5",
"objective":{
"__html":"Prevent recurrent calcium oxalate stone disease."
},
"references":[
[
"Zisman AL. Effectiveness of treatment modalities on kidney stone recurrence. Clin J Am Soc Nephrol. 2017;12:1699-1708. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28830863",
"target":"_blank"
},
"children":[
"PMID: 28830863"
]
},
" doi:10.2215/CJN.11201016"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":8,
"B":24,
"C":29,
"D":6,
"E":33
},
"hlIds":[
"e5248e",
"f8786b",
"a462a3",
"0a500d",
"d41d8c",
"bd7a97",
"82be25",
"397dff",
"f884cc",
"a9640c",
"9c5207",
"7e6003",
"eb2f9b",
"30f55d",
"8b9679",
"67ec1b",
"aef82e",
"bd5972",
"1e31fb",
"ac95af",
"278d12",
"c68fcc",
"cd9c80",
"e18d77",
"36cf18",
"a8bb9a"
]
},
{
"id":"mk19_a_np_q094",
"number":94,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 94",
"stimulus":[
{
"type":"p",
"hlId":"b60216",
"children":[
"An 84-year-old woman is evaluated during a follow-up visit for stage G4 chronic kidney disease. Her only symptom is lack of energy. She is independent in her activities of daily living. She has declined renal replacement therapy after attending a dialysis education class. She understands the process and purpose of dialysis and the consequence of non-treatment but prefers non-dialytic therapy. Medical history is also significant for diabetes mellitus, heart failure, hypertension, and stroke. Medications are furosemide, lisinopril, hydralazine, insulin aspart, insulin detemir, nifedipine, metoprolol, and aspirin, 81 mg."
]
},
{
"type":"p",
"hlId":"89f8b5",
"children":[
"On physical examination, blood pressure is 160/72 mm Hg, and pulse rate is 60/min; other vital signs are normal. Cardiac examination reveals an S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
},
". The remainder of the examination is noncontributory."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1c67e8",
"class":"cell text l",
"children":[
"9.4 mg/dL (2.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e6438c",
"class":"cell text l",
"children":[
"2.3 mg/dL (203.3 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fcabe9",
"class":"cell text l",
"children":[
"4.7 mEq/L (4.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"cf51f3",
"class":"cell text l",
"children":[
"4.4 mg/dL (1.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"662bd2",
"class":"cell text l",
"children":[
"26 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add a phosphate binder"
}
},
{
"letter":"B",
"text":{
"__html":"Discontinue all medications except insulin"
}
},
{
"letter":"C",
"text":{
"__html":"Intensify hypertension management"
}
},
{
"letter":"D",
"text":{
"__html":"Refer for hospice care"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"04b6c7",
"hvc":true,
"children":[
"The goal of non-dialytic palliative therapy in patients with end-stage kidney disease involves ongoing medical management of medical problems to prolong comfort and functioning."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c7a9aa",
"children":[
"The most appropriate management is to intensify hypertension management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Treatment options for patients with end-stage kidney disease (ESKD) include dialysis, transplantation, and the less aggressive option of non-dialytic medical management only. Shared decision-making is vital with these patients. This patient reached an informed decision to pursue non-dialytic medical management. This management is particularly appropriate for older patients with ESKD and comorbid conditions who may gain only minimal, if any, additional lifespan. Non-dialytic medical therapy avoids the burdens of dialysis and is associated with fewer hospitalizations compared with older patients who initiate hemodialysis. The goal of medical management is to prolong the comfort and functioning of a patient's life through ongoing medical management of medical problems. The appropriate intervention for this patient is to intensify her hypertension management, as she has a history of stroke and her blood pressure is 160/72 mm Hg. Blood pressure recommendations differ for older patients, but reduction of systolic blood pressure to <140 mm Hg in patients with stroke is generally supported."
]
},
{
"type":"p",
"hlId":"4dd0a6",
"children":[
"Adding a phosphate binder (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not appropriate management, as her serum phosphorus level is in the normal range."
]
},
{
"type":"p",
"hlId":"2d471f",
"children":[
"Discontinuing all medications other than insulin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") in not compatible with the philosophy of non-dialytic medical management, which includes ongoing medical management of medical problems."
]
},
{
"type":"p",
"hlId":"840bc3",
"children":[
"This patient functions well in her life and has no particular needs that will be met with hospice care. Hospice referral (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") may be indicated in the future as her chronic kidney disease progresses."
]
}
],
"relatedSection":"mk19_a_np_s12_9_1_3",
"objective":{
"__html":"Manage end-stage kidney disease with non-dialytic palliative therapy."
},
"references":[
[
"van Loon IN, Goto NA, Boereboom FTJ, et al. Quality of life after the initiation of dialysis or maximal conservative management in elderly patients: a longitudinal analysis of the Geriatric assessment in OLder patients starting Dialysis (GOLD) study. BMC Nephrol. 2019;20:108. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30922246",
"target":"_blank"
},
"children":[
"PMID: 30922246"
]
},
" doi:10.1186/s12882-019-1268-3"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":27,
"B":1,
"C":52,
"D":21,
"E":0
},
"hlIds":[
"b60216",
"89f8b5",
"a462a3",
"1a4da4",
"1c67e8",
"f461b2",
"e6438c",
"e92687",
"fcabe9",
"a4922e",
"cf51f3",
"77db81",
"662bd2",
"cb2b54",
"04b6c7",
"c7a9aa",
"4dd0a6",
"2d471f",
"840bc3"
]
},
{
"id":"mk19_a_np_q095",
"number":95,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 95",
"stimulus":[
{
"type":"p",
"hlId":"b4d5ff",
"children":[
"A 32-year-old woman is seen following evaluation for a single episode of painless hematuria that she noted last week. She has chronic kidney disease secondary to chronic tubulointerstitial nephritis confirmed by biopsy. She took Chinese herbal weight loss pills daily for 3 years. She took acetaminophen or ibuprofen for arthralgia three or four times monthly for 5 years. Since the kidney biopsy, she has discontinued all drugs and supplements. She has no other medical problems."
]
},
{
"type":"p",
"hlId":"9ce0f2",
"children":[
"The physical examination, including vital signs, is normal."
]
},
{
"type":"p",
"hlId":"02af44",
"children":[
"Urinalysis shows a specific gravity of 1.012, 3+ blood, 1+ protein, 1+ leukocytes, 25-50 nondysmorphic erythrocytes/hpf, 3-5 leukocytes/hpf, and no casts; urine culture is negative."
]
},
{
"type":"p",
"hlId":"018af4",
"children":[
"CT scan of the abdomen and pelvis shows normal kidneys and collecting system."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Cystoscopy with retrograde pyelography"
}
},
{
"letter":"B",
"text":{
"__html":"MRI of the kidneys"
}
},
{
"letter":"C",
"text":{
"__html":"Renal angiography"
}
},
{
"letter":"D",
"text":{
"__html":"Observation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"dba376",
"children":[
"Certain Chinese herbal medications have been associated with aristolochic acid nephropathy, which can cause chronic tubulointerstitial disease and is associated with urothelial cancer."
]
},
{
"type":"keypoint",
"hlId":"631cbd",
"children":[
"CT urography and cystoscopy with retrograde pyelography are the most appropriate tests for a patient with hematuria and risk factors for urothelial cancer."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"eb2952",
"children":[
"Cystoscopy with retrograde pyelography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is the most appropriate management for this patient to assess for evidence of urothelial tumor. Chronic tubulointerstitial nephritis (CTIN) in the setting of protracted use of herbal medications, particularly those of Chinese origin, suggests the possibility of aristolochic acid nephropathy. Consequently, this patient may be at increased risk for urothelial cancer despite her young age. CT of the abdomen and pelvis is not sufficiently sensitive to rule out neoplasia of the ureters or bladder."
]
},
{
"type":"p",
"hlId":"8fd0c5",
"children":[
"MRI of the kidneys (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not the most appropriate test for evaluating the lower urinary tract. Although an MRI may be ordered as an alternative imaging modality in evaluating for renal masses, CT remains the gold standard."
]
},
{
"type":"p",
"hlId":"718bfc",
"children":[
"Renal angiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may be considered for persistent gross hematuria of uncertain etiology when all other lower urinary tract imaging modalities have failed to identify a cause, but it would not be the most appropriate management in this case."
]
},
{
"type":"p",
"hlId":"4ca44f",
"children":[
"In a young patient without risk factors for urothelial cancer (such as smoking, occupational exposure, use of Chinese herbal medications), exclusion of stone, renal mass, and active urinary tract infections followed by expectant observation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is appropriate for a single episode of gross hematuria. This patient's analgesic use is relatively low to ascribe the CTIN to this etiology with confidence. There is no history of occupational or other environmental exposure, and there is no test available to identify aristolochic acid as the cause of this patient's CTIN. However, given the patient's history of protracted use of herbal medications, it would be prudent to rule out the associated risks of herbal medication use, such as urothelial tumor."
]
}
],
"relatedSection":"mk19_a_np_s5_3_8",
"objective":{
"__html":"Screen for urothelial cancer in a patient with hematuria and aristolochic acid nephropathy."
},
"references":[
[
"Jelakovic B, Dika Ž, Arlt VM, et al. Balkan endemic nephropathy and the causative role of aristolochic acid. Semin Nephrol. 2019;39:284-296. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31054628",
"target":"_blank"
},
"children":[
"PMID: 31054628"
]
},
" doi:10.1016/j.semnephrol.2019.02.007"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":49,
"B":2,
"C":1,
"D":48,
"E":0
},
"hlIds":[
"b4d5ff",
"9ce0f2",
"02af44",
"018af4",
"cb2b54",
"dba376",
"631cbd",
"eb2952",
"8fd0c5",
"718bfc",
"4ca44f"
]
},
{
"id":"mk19_a_np_q096",
"number":96,
"bookId":"np",
"correctAnswer":"C",
"title":"Question 96",
"stimulus":[
{
"type":"p",
"hlId":"84dd76",
"children":[
"A 69-year-old man is evaluated 7 days after starting nafcillin to treat a culture-proven methicillin-sensitive ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcal aureus"
]
},
" sternal wound infection. The infection was diagnosed 10 days after coronary artery bypass surgery. History is significant for diabetes mellitus. Other medications are aspirin, metformin, metoprolol, atorvastatin, and acetaminophen as needed."
]
},
{
"type":"p",
"hlId":"68ce9e",
"children":[
"On physical examination, vital signs are normal. The sternal wound appears to be healing, with minimal tenderness and redness and decreased drainage. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"687cd3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C3, serum",
"children":[
"C3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"27488b",
"class":"cell text l",
"children":[
"61 mg/dL (610 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"dcfa5e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Complement, C4, serum",
"children":[
"C4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c1c084",
"class":"cell text l",
"children":[
"13 mg/dL (130 mg/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3b91e2",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L); before hospital admission: 0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"75178a",
"class":"cell text l",
"children":[
"3+ blood; 2+ protein; 30-40 erythrocytes/hpf; 2-5 leukocytes/hpf; dysmorphic erythrocytes; rare erythrocyte casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"916554",
"children":[
"Kidney biopsy shows a mild proliferative glomerulonephritis with infiltrating neutrophils, granular C3, and IgG and IgM staining on immunofluorescence; hump-shaped subepithelial electron-dense deposits are seen on electron microscopy."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add lisinopril"
}
},
{
"letter":"B",
"text":{
"__html":"Add prednisone"
}
},
{
"letter":"C",
"text":{
"__html":"Continue nafcillin"
}
},
{
"letter":"D",
"text":{
"__html":"Initiate sodium restriction and furosemide"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"defe55",
"children":[
"Treatment of infection-related glomerulonephritis is typically supportive and aimed at the infectious etiology."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"9b511d",
"children":[
"Continuing nafcillin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is the most appropriate treatment for this patient with infection-related glomerulonephritis (IRGN). IRGN results from a recently resolved infection or an ongoing infection at the time of development of glomerulonephritis. Diabetes mellitus is the most common comorbidity, and older age (>65 years) is a key risk factor; both factors are present in this patient. Treatment of IRGN is typically supportive and aimed at the infectious etiology."
]
},
{
"type":"p",
"hlId":"02681e",
"children":[
"The prognosis for complete recovery from IRGN is excellent in children. However, in adults, the prognosis of the newly recognized forms of IRGN (e.g., due to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
" and gram-negative organisms) is less favorable, with more patients developing severe kidney dysfunction, progressing to chronic kidney disease (CKD) and sometimes to end-stage kidney disease. Initiation of an ACE inhibitor such as lisinopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") at the time of acute kidney injury is not recommended. However, in this patient's long-term follow-up, lisinopril therapy is a reasonable option if he develops proteinuric CKD as a residual of IRGN."
]
},
{
"type":"p",
"hlId":"81767d",
"children":[
"Adding a trial of glucocorticoid therapy such as prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") to antibiotic therapy for IRGN is considered only in rare cases in which a severe proliferative glomerulonephritis on biopsy is accompanied by a rapid progression toward kidney failure. In this patient, the glomerular lesion is not described as severe, and his serum creatinine levels during his hospitalization do not indicate rapidly progressive glomerulonephritis defined by at least a 50% decline in glomerular filtration rate over a short time period."
]
},
{
"type":"p",
"hlId":"93805f",
"children":[
"The indication for diuretics and sodium restriction is the presence of hypertension and edema secondary to fluid retention. In these cases, sodium restriction and a loop diuretic (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") are recommended first-line therapies. Because this patient does not have evidence of hypertension or edema, these therapies are not indicated."
]
}
],
"relatedSection":"mk19_a_np_s6_4_4_4_4",
"objective":{
"__html":"Treat infection-related glomerulonephritis."
},
"references":[
[
"Nasr SH, Radhakrishnan J, D’Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int. 2013;83:792-803. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23302723",
"target":"_blank"
},
"children":[
"PMID: 23302723"
]
},
" doi:10.1038/ki.2012.407"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":7,
"B":56,
"C":32,
"D":5,
"E":0
},
"hlIds":[
"84dd76",
"68ce9e",
"a462a3",
"687cd3",
"27488b",
"dcfa5e",
"c1c084",
"f461b2",
"3b91e2",
"747c2a",
"75178a",
"916554",
"1054f1",
"defe55",
"9b511d",
"02681e",
"81767d",
"93805f"
]
},
{
"id":"mk19_a_np_q097",
"number":97,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 97",
"stimulus":[
{
"type":"p",
"hlId":"1a5e19",
"children":[
"A 37-year-old woman is evaluated for a new-onset headache. She describes the headache as a steady pain located in the front of her head, bilaterally, and not associated with any other symptoms. The headache has been present for more than 24 hours. She is in the third trimester of her first pregnancy. Until now, her pregnancy has been unremarkable and she has otherwise been healthy."
]
},
{
"type":"p",
"hlId":"870a90",
"children":[
"On physical examination, blood pressure is 145/95 mm Hg; other vital signs are normal. There is no papilledema. On abdominal examination, the patient has a gravid uterus consistent with her stage of pregnancy, and there is no abdominal tenderness. Neurologic examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"03f787",
"class":"cell text l",
"children":[
"12.3 g/dL (123 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5b89d5",
"class":"cell text l",
"children":[
"156,000/µL (156 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"155b0c",
"class":"cell text l",
"children":[
"Alanine aminotransferase"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"603465",
"class":"cell text l",
"children":[
"Aspartate aminotransferase"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"0d34d5",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b0c5a3",
"class":"cell text l",
"children":[
"Random ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c853bc",
"class":"cell text l",
"children":[
"125 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acute fatty liver of pregnancy"
}
},
{
"letter":"B",
"text":{
"__html":"Migraine headache"
}
},
{
"letter":"C",
"text":{
"__html":"Pheochromocytoma"
}
},
{
"letter":"D",
"text":{
"__html":"Preeclampsia"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"f7ce82",
"children":[
"Preeclampsia is defined as new-onset hypertension with proteinuria (≥300 mg/24 h or a urine protein-creatinine ratio ≥300 mg/g) after 20 weeks of pregnancy."
]
},
{
"type":"keypoint",
"hlId":"3bc2ec",
"children":[
"Preeclampsia can be diagnosed in pregnant patients without proteinuria if hypertension is accompanied by evidence of other end-organ damage (thrombocytopenia, kidney dysfunction, liver dysfunction, pulmonary edema, cerebral or visual symptoms)."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"cdf459",
"children":[
"The most likely diagnosis is preeclampsia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Preeclampsia is defined as new-onset hypertension with proteinuria (≥300 mg/24 h or a urine protein-creatinine ratio ≥300 mg/g) after 20 weeks of pregnancy. Preeclampsia can also be diagnosed in patients without proteinuria if the hypertension is accompanied by evidence of other end-organ damage. End-organ involvement that meet the diagnostic criteria for preeclampsia includes thrombocytopenia (platelet count <100,000/µL [100 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L]); kidney dysfunction (serum creatinine >1.1 mg/dL [97.2 µmol/L]) or a doubling of the serum creatinine concentration); impaired liver function (elevated aminotransaminases levels to ≥2 times the upper limit of normal); pulmonary edema; and cerebral or visual symptoms such new-onset headache unresponsive to medication and not accounted for by alternative diagnoses. In this patient, hypertension, kidney dysfunction, and new-onset headache are present."
]
},
{
"type":"p",
"hlId":"2349d4",
"children":[
"Acute fatty liver of pregnancy (AFP) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is a rare but serious condition that also occurs late in pregnancy. It presents with symptoms similar to those of HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Indicators of liver failure, including hypoglycemia and coagulopathy, are often worse in AFP than in HELLP syndrome. This patient has no manifestations of AFP."
]
},
{
"type":"p",
"hlId":"56d147",
"children":[
"International Headache Society criteria for migraine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") without aura include at least five headache attacks lasting 4 to 72 hours; at least four migraine characteristics (unilateral location, pulsating quality, inhibits or prohibits daily activities, aggravation by walking up or down stairs or similar routine physical activity); and at least one associated symptom (nausea/vomiting, photophobia/phonophobia). In addition, the headache cannot be better accounted for by another diagnosis. Preeclampsia is a better explanation for this patient's headache."
]
},
{
"type":"p",
"hlId":"b43c32",
"children":[
"Hypertension associated with pheochromocytoma (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") can show a sustained pattern, with or without paroxysms, or occur as paroxysms only. Pheochromocytoma is rare and typically associated with additional findings (tachycardia, nervousness, diaphoresis). Proteinuria and acute elevation of serum creatinine are not typical manifestations."
]
}
],
"relatedSection":"mk19_a_np_s11_2_4",
"objective":{
"__html":"Diagnose preeclampsia."
},
"references":[
[
"American College of Obstetricians and Gynecologists. Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133:e1-e25. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30575675",
"target":"_blank"
},
"children":[
"PMID: 30575675"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":11,
"C":1,
"D":88,
"E":0
},
"hlIds":[
"1a5e19",
"870a90",
"a462a3",
"f9867c",
"03f787",
"fcac73",
"5b89d5",
"155b0c",
"960b44",
"603465",
"960b44",
"f461b2",
"0d34d5",
"b0c5a3",
"c853bc",
"413696",
"f7ce82",
"3bc2ec",
"cdf459",
"2349d4",
"56d147",
"b43c32"
]
},
{
"id":"mk19_a_np_q098",
"number":98,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 98",
"stimulus":[
{
"type":"p",
"hlId":"e4e8b1",
"children":[
"A 26-year-old man is referred for an elevated ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 1.4 mg/dL (123.8 µmol/L) that was measured when he presented to an urgent care center for flank pain. The flank pain was determined to be musculoskeletal and caused by a weight-lifting injury. A subsequent urinalysis was normal, and a random urine ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"albumin-creatinine ratio"
]
},
" was 10 mg/g. He reports that he takes no creatine supplements but is evasive when questioned about anabolic steroid use. His medical history is otherwise unremarkable, and he takes no prescribed medications."
]
},
{
"type":"p",
"hlId":"6514c9",
"children":[
"On physical examination, vital signs are normal. BMI is 29. The patient is muscular, with no evidence of subcutaneous fat. He has mild muscle tenderness in the right lower back. The remainder of the examination is unremarkable."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"983777",
"children":[
"Which of the following is the most appropriate test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Blood urea nitrogen measurement"
}
},
{
"letter":"B",
"text":{
"__html":"Creatinine clearance"
}
},
{
"letter":"C",
"text":{
"__html":"Radionuclide imaging"
}
},
{
"letter":"D",
"text":{
"__html":"Serum cystatin C measurement"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2ca034",
"children":[
"Increased or decreased muscle mass can alter the serum creatinine level in the absence of kidney disease."
]
},
{
"type":"keypoint",
"hlId":"bde935",
"children":[
"Serum cystatin C is more sensitive in identifying milder decrements in kidney function than serum creatinine."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"9cc741",
"children":[
"The most appropriate test is serum cystatin C measurement (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Reduction of muscle mass, as seen in amputees and those with malnutrition or muscle wasting, can result in a lower serum creatinine concentration without a change in glomerular filtration rate (GFR). Because of decreased muscle mass, serum creatinine overestimates kidney function in older persons, especially women. Young persons and men often have higher muscle mass and higher serum creatinine concentration at a given GFR compared with older persons and thus underestimates kidney function in this population. This patient's elevated serum creatinine level is likely the result of increased muscle mass. Serum cystatin C is an alternative marker of GFR that is less influenced than serum creatinine by age, sex, muscle mass, and body weight. Cystatin C is produced by all nucleated cells, completely filtered by glomeruli, and then metabolized by renal tubules; serum levels thus provide an index of GFR. Serum cystatin C is more sensitive in identifying milder decrements in kidney function than serum creatinine."
]
},
{
"type":"p",
"hlId":"53b33b",
"children":[
"Blood urea nitrogen (BUN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is derived from the metabolism of proteins. BUN concentration is a poor marker of kidney function because it is not produced at a constant rate and is reabsorbed along the tubules; furthermore, alterations in renal blood flow markedly influence tubular reabsorption and excretion."
]
},
{
"type":"p",
"hlId":"828a01",
"children":[
"Because of the secretion of creatinine in the proximal tubule, the direct measurement of creatinine clearance (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") with a 24-hour urine collection tends to overestimate GFR. Nonetheless, with an adequate collection, the 24-hour urine collection can be used to estimate GFR; however, this test is prone to collection errors and would be unnecessarily burdensome for this patient."
]
},
{
"type":"p",
"hlId":"5bf34b",
"children":[
"Radionuclide imaging (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") provides the most accurate measurement of GFR and is the gold standard in research. It is useful for accurate determination of GFR during evaluation of kidney donors, evaluation of recipients for other organs, or assessment of the differential GFR of each kidney before nephrectomy. However, for this patient, the availability of serum cystatin C measurement makes radionuclide imaging unnecessary."
]
}
],
"relatedSection":"mk19_a_np_s1_1_1_2",
"objective":{
"__html":"Evaluate kidney function with serum cystatin C measurement."
},
"references":[
[
"Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008;3:348-354. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/18235143",
"target":"_blank"
},
"children":[
"PMID: 18235143"
]
},
" doi:10.2215/CJN.02870707"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":11,
"B":25,
"C":1,
"D":63,
"E":0
},
"hlIds":[
"e4e8b1",
"6514c9",
"983777",
"2ca034",
"bde935",
"9cc741",
"53b33b",
"828a01",
"5bf34b"
]
},
{
"id":"mk19_a_np_q099",
"number":99,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 99",
"stimulus":[
{
"type":"p",
"hlId":"1b8518",
"children":[
"A 67-year-old man is evaluated during a follow-up visit 4 weeks after being diagnosed with the nephrotic syndrome. He has a 7-year history of well-controlled type 2 diabetes mellitus with no retinopathy, neuropathy, or clinically evident vascular disease. He has no other medical problems, and his only medication is metformin."
]
},
{
"type":"p",
"hlId":"0b614b",
"children":[
"On physical examination, blood pressure is 110/60 mm Hg; other vital signs are normal. No rash is noted. There is 2-mm pitting edema in the lower extremities to the knees bilaterally."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"780602",
"class":"cell text l",
"children":[
"2.1 g/dL (21 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d91465",
"class":"cell text l",
"children":[
"330 mg/dL (8.5 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"38b22c",
"class":"cell text l",
"children":[
"1.4 mg/dL (123.8 µmol/L) (4 months ago, 1.0 mg/dL [88.4 µmol/L])"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"5d87c8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin A1c, blood",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"540e48",
"class":"cell text l",
"children":[
"6.9%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"bc64ac",
"class":"cell text l",
"children":[
"Serum protein electrophoresis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b01639",
"class":"cell text l",
"children":[
"24-Hour urine protein excretion"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1a1734",
"class":"cell text l",
"children":[
"12,000 mg/24 h"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"591572",
"children":[
"Kidney biopsy shows expansion of the mesangial areas by deposits of homogenous, pale eosinophilic material that are positive with Congo red staining and demonstrate apple-green birefringence when viewed under polarized light."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Diabetic kidney disease"
}
},
{
"letter":"B",
"text":{
"__html":"IgA nephropathy"
}
},
{
"letter":"C",
"text":{
"__html":"Membranous nephropathy"
}
},
{
"letter":"D",
"text":{
"__html":"Renal AL amyloidosis"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a63094",
"children":[
"The gold standard for pathologic diagnosis of amyloidosis is the characteristic apple-green birefringence with Congo red stain when examined under polarized light."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"392eea",
"children":[
"Renal AL amyloidosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is the most likely diagnosis in this patient. Amyloidosis is characterized by extracellular tissue deposition of fibrillary protein. The gold standard for pathologic diagnosis is the characteristic apple-green birefringence with Congo red stain when kidney biopsy specimens are examined under polarized light. The most common form of renal amyloidosis, occurring in 60% to 65% of patients, is derived from monoclonal immunoglobulin light chains (AL amyloid, as in this case). Amyloidosis may be confined to one organ or affect multiple organs; kidney involvement is common in systemic amyloidosis. AL amyloidosis typically affects patients >50 years of age, predominantly men. When kidney involvement occurs, patients typically present with nephrotic-range proteinuria (with the full nephrotic syndrome seen in 25% to 50% of patients) as well as some degree of renal insufficiency. Serum and urine protein electrophoresis with immunofixation can identify the monoclonal protein, but quantification of serum free light chains (κ, λ) provides a more sensitive assay. In practice, all three testing modalities are usually checked simultaneously."
]
},
{
"type":"p",
"hlId":"0242e1",
"children":[
"Diabetic kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") typically occurs after long-standing type 2 diabetes mellitus (typically >10 years' duration) in patients with other evidence of microvascular or macrovascular complications of disease, most notably diabetic retinopathy, which this patient did not have. In the absence of these characteristic findings, a kidney biopsy should be performed to establish a diagnosis."
]
},
{
"type":"p",
"hlId":"eb0044",
"children":[
"IgA nephropathy (IgAN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is the most common primary glomerular disease worldwide, usually diagnosed in youth or early adulthood. IgAN can present with any of the manifestations of the nephritic syndrome. Diagnosis may be suspected clinically but can only be made by kidney biopsy showing dominant mesangial immune deposits of IgA with C3, and occasionally IgG or IgM. This older patient presenting with the nephrotic syndrome is not compatible with the diagnosis of IgAN."
]
},
{
"type":"p",
"hlId":"0dbd95",
"children":[
"Patients with membranous nephropathy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") typically describe slowly progressive edema, and laboratory testing reveals proteinuria, hypoalbuminemia, and hyperlipidemia, most often with preserved kidney function. Diagnosis is traditionally made by kidney biopsy, although serologic testing for anti-phospholipase A2 receptor antibodies allows for the possibility of diagnosing the disease noninvasively. The hallmark biopsy finding is the presence of subepithelial immune deposits."
]
}
],
"relatedSection":"mk19_a_np_s7_6",
"objective":{
"__html":"Diagnose renal AL amyloidosis."
},
"references":[
[
"Hogan JJ, Alexander MP, Leung N. Dysproteinemia and the kidney: core curriculum 2019. Am J Kidney Dis. 2019;74:822-836. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31331759",
"target":"_blank"
},
"children":[
"PMID: 31331759"
]
},
" doi:10.1053/j.ajkd.2019.04.029"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":3,
"B":3,
"C":7,
"D":87,
"E":0
},
"hlIds":[
"1b8518",
"0b614b",
"a462a3",
"4590ed",
"780602",
"182194",
"d91465",
"f461b2",
"38b22c",
"5d87c8",
"540e48",
"bc64ac",
"ffb935",
"b01639",
"1a1734",
"591572",
"413696",
"a63094",
"392eea",
"0242e1",
"eb0044",
"0dbd95"
]
},
{
"id":"mk19_a_np_q100",
"number":100,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 100",
"stimulus":[
{
"type":"p",
"hlId":"ec469f",
"children":[
"An 81-year-old woman is evaluated in the emergency department for abrupt onset of lower extremity edema that began 2 weeks ago and has progressed to generalized edema. Medical history is significant for hypertension. Her only medication is amlodipine."
]
},
{
"type":"p",
"hlId":"d6f46f",
"children":[
"On physical examination, vital signs are normal. There is periorbital edema, ascites, and pitting edema of the forearms and lower extremities to the thighs. The remainder of the examination, including cardiovascular and pulmonary examinations, is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fea02d",
"class":"cell text l",
"children":[
"1.6 g/dL (16 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"8186ab",
"class":"cell text l",
"children":[
"364 mg/dL (9.4 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c6ce55",
"class":"cell text l",
"children":[
"2.8 mg/dL (248 µmol/L); 2 months ago: 0.7 mg/dL (61.9 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ec9779",
"class":"cell text l",
"children":[
"No blood; 4+ protein"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"f88f05",
"children":[
"Kidney ultrasound with Doppler shows normal-sized echogenic kidneys with no hydronephrosis; there are no abnormalities on Doppler flow."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"413696",
"children":[
"Which of the following is the most likely diagnosis?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"ANCA-associated glomerulonephritis"
}
},
{
"letter":"B",
"text":{
"__html":"Anti–glomerular basement membrane antibody disease"
}
},
{
"letter":"C",
"text":{
"__html":"Membranous nephropathy"
}
},
{
"letter":"D",
"text":{
"__html":"Minimal change glomerulopathy"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bf826e",
"children":[
"The classic presentation of minimal change glomerulopathy is sudden-onset nephrotic syndrome with abrupt appearance of edema and, eventually, anasarca."
]
},
{
"type":"keypoint",
"hlId":"56db45",
"children":[
"Up to 25% of adults with minimal change glomerulopathy may have acute kidney injury, with a particular risk in older patients with hypertension, low serum albumin levels, and heavy proteinuria."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"bf76cc",
"children":[
"The most likely diagnosis is minimal change glomerulopathy (MCG; also known as minimal change disease) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") in this older patient who has the nephrotic syndrome with acute kidney injury (AKI). MCG is the most common cause of the nephrotic syndrome in children (>90% of cases), but it is also responsible for 10% to 15% of cases of the nephrotic syndrome in adults, especially older patients (≥65 years of age) and elderly patients (≥80 years of age). The classic presentation of MCG is sudden-onset nephrotic syndrome with abrupt appearance of edema and, eventually, anasarca. Up to 25% of adults with MCG may also have AKI, with an increased risk in older patients with hypertension, low serum albumin levels, and heavy proteinuria. Another cause of the nephrotic syndrome with AKI includes MCG with concomitant interstitial nephritis in the setting of NSAID use and collapsing forms of focal segmental glomerulosclerosis."
]
},
{
"type":"p",
"hlId":"fcc511",
"children":[
"Both ANCA-associated glomerulonephritis and anti–glomerular basement membrane antibody disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options A, B"
]
},
") can cause severe AKI in an elderly patient, but the urinary findings in these rapidly progressive glomerulonephritides show both hematuria and subnephrotic-range proteinuria. This patient's findings on urinalysis are typical of the nephrotic syndrome, not glomerulonephritis."
]
},
{
"type":"p",
"hlId":"14e584",
"children":[
"Membranous nephropathy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") can also cause the nephrotic syndrome and AKI. However, AKI seen in membranous nephropathy is usually due to renal vein thrombosis, which was not seen on this patient's Doppler ultrasound. Membranous nephropathy is most commonly diagnosed in middle-aged adults, with a slight male predominance, and is an unusual etiology of the nephrotic syndrome in patients >75 years of age unless there is an underlying malignancy. Furthermore, the onset of edema in membranous nephropathy is usually slower than in MCG."
]
}
],
"relatedSection":"mk19_a_np_s6_3_4",
"objective":{
"__html":"Diagnose minimal change glomerulopathy with acute kidney injury."
},
"references":[
[
"Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94:861-869. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29980292",
"target":"_blank"
},
"children":[
"PMID: 29980292"
]
},
" doi:10.1016/j.kint.2018.04.024"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":2,
"B":6,
"C":59,
"D":33,
"E":0
},
"hlIds":[
"ec469f",
"d6f46f",
"a462a3",
"4590ed",
"fea02d",
"182194",
"8186ab",
"f461b2",
"c6ce55",
"747c2a",
"ec9779",
"f88f05",
"413696",
"bf826e",
"56db45",
"bf76cc",
"fcc511",
"14e584"
]
},
{
"id":"mk19_a_np_q101",
"number":101,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 101",
"stimulus":[
{
"type":"p",
"hlId":"490df5",
"children":[
"An 87-year-old man is hospitalized for the inability to void. He has a 4-year history of urinary hesitancy and dribbling. He lives alone with the assistance of a nephew but finds it increasingly difficult to live independently. He has no other medical history and takes no medications."
]
},
{
"type":"p",
"hlId":"fdb446",
"children":[
"On physical examination, he is thin and frail appearing. Blood pressure is 158/64 mm Hg, and pulse rate is 78/min without orthostatic changes. BMI is 22. The prostate is diffusely enlarged. There is 1+ lower extremity edema. Generalized weakness is noted. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"38edb4",
"children":[
"A bladder catheter drains 850 mL of urine."
]
},
{
"type":"p",
"hlId":"e0ebce",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Blood urea nitrogen",
"children":[
"blood urea nitrogen"
]
},
" level of 133 mg/dL (47.5 mmol/L) and a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 8.9 mg/dL (786.8 µmol/L)."
]
},
{
"type":"p",
"hlId":"316bac",
"children":[
"Kidney ultrasound shows an 8.3-cm right kidney and a 7.9-cm left kidney, marked cortical echogenicity and thinning, and moderate-severe hydronephrosis."
]
},
{
"type":"p",
"hlId":"21efcc",
"children":[
"During the first 24 hours, urine output with the bladder catheter in place is 1240 mL. Follow-up bladder ultrasound shows less than 50 mL of residual urine. On hospital day 2 the urine output is 340 mL."
]
},
{
"type":"p",
"hlId":"f0fc88",
"children":[
"On hospital day 3, the ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level is 8.2 mg/dL (724.8 µmol/L). Repeat kidney ultrasound shows persistent hydronephrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1a5dcc",
"children":[
"Which of the following is the most appropriate next step in management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discuss goals of care"
}
},
{
"letter":"B",
"text":{
"__html":"Initiate intravenous 0.9% saline"
}
},
{
"letter":"C",
"text":{
"__html":"Obtain noncontrast CT of abdomen and pelvis"
}
},
{
"letter":"D",
"text":{
"__html":"Place bilateral ureteral stents"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"51c3e2",
"hvc":true,
"children":[
"Long-standing obstructive uropathy may lead to end-stage kidney disease even if the source of obstruction is corrected."
]
},
{
"type":"keypoint",
"hlId":"e58ac9",
"hvc":true,
"children":[
"Patients with end-stage kidney disease and advanced age or multiple comorbidities may not want renal replacement therapy and will benefit from a discussion focused on overall goals of care."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ddf1cb",
"children":[
"The most appropriate next step in management is to discuss goals of care (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has end-stage kidney disease (ESKD) due to long-standing urinary retention from prostatic hyperplasia. There is no significant diuresis during the 48 hours since bladder catheter placement, and the decrease in his serum creatinine level is insignificant. The small kidney sizes with severe cortical echogenicity and thinning suggest advanced chronic kidney disease. Patients with ESKD and advanced age or multiple comorbidities may not want renal replacement therapy. For these patients, palliative care aimed at improving the quality of life may be a better option. Such care aligns treatment with a patient's goals through culturally sensitive shared decision-making and advance care planning, along with treating symptoms resulting from uremia, hypervolemia, hyperkalemia, and/or acidosis. Therefore, a discussion of overall goals of care is the most appropriate next step."
]
},
{
"type":"p",
"hlId":"601394",
"children":[
"Initiating intravenous 0.9% saline (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is not an appropriate management step. The patient does not appear hypovolemic, and volume expansion will not help."
]
},
{
"type":"p",
"hlId":"87efbb",
"children":[
"In patients with obstructive uropathy, noncontrast CT of the abdomen and pelvis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is indicated for suspected nephrolithiasis. The patient's finding of persistent hydronephrosis on repeat kidney ultrasound is not unusual in patients a few days following relief of long-standing obstruction and does not indicate the presence of bilateral ureteral obstruction. Similarly, there is no indication that ureteral stents will further improve kidney function (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
")."
]
}
],
"relatedSection":"mk19_a_np_s12_9_1_3",
"objective":{
"__html":"Manage end-stage kidney disease."
},
"references":[
[
"Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77:643-650. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/18350762",
"target":"_blank"
},
"children":[
"PMID: 18350762"
]
}
]
],
"hospitalist":true,
"hvc":true,
"peerComparison":{
"A":53,
"B":8,
"C":22,
"D":17,
"E":0
},
"hlIds":[
"490df5",
"fdb446",
"38edb4",
"e0ebce",
"316bac",
"21efcc",
"f0fc88",
"1a5dcc",
"51c3e2",
"e58ac9",
"ddf1cb",
"601394",
"87efbb"
]
},
{
"id":"mk19_a_np_q102",
"number":102,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 102",
"stimulus":[
{
"type":"p",
"hlId":"b8c16b",
"children":[
"A 31-year-old woman is evaluated during a follow-up visit for progressive autosomal dominant polycystic kidney disease. She has a recent history of an infected kidney cyst. She also has hypertension. Family history is significant for end-stage kidney disease in her father at 50 years of age due to autosomal dominant polycystic kidney disease. Her only medication is lisinopril."
]
},
{
"type":"p",
"hlId":"2bf91b",
"children":[
"On physical examination, vital signs are normal. Abdominal examination reveals a palpable kidney on the right side. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"1226d4",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level of 1.3 mg/dL (114.9 µmol/L), representing a decrease in ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"estimated glomerular filtration rate"
]
},
" of >5 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" from 1 year ago. Liver chemistry tests are normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discontinue lisinopril; start telmisartan"
}
},
{
"letter":"B",
"text":{
"__html":"Obtain ultrasonography of the kidneys"
}
},
{
"letter":"C",
"text":{
"__html":"Start octreotide"
}
},
{
"letter":"D",
"text":{
"__html":"Start tolvaptan"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0625e0",
"children":[
"Tolvaptan can slow kidney function decline in adults at risk for progressive autosomal dominant polycystic kidney disease."
]
},
{
"type":"keypoint",
"hlId":"904741",
"children":[
"Blockade of the renin-aldosterone system is a staple of treating patients with autosomal dominant polycystic kidney disease, including those on tolvaptan."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"ce945e",
"children":[
"The most appropriate treatment for this patient is tolvaptan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). In 2018, tolvaptan was approved by the FDA to slow kidney function decline in adults at risk for progressive autosomal dominant polycystic kidney disease (ADPKD). This patient has four known risk factors associated with progression to end-stage kidney disease (ESKD): onset of hypertension before 35 years of age; urologic events (gross hematuria, cyst infection, and/or flank pain) before 35 years of age; an estimated glomerular filtration rate decrease >5 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" within 1 year; and a family history of ESKD at or before 58 years of age. Other risk factors associated with progression to ESKD include male sex, total kidney volume greater than expected for age, and truncating ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"PKD1"
]
},
" variant."
]
},
{
"type":"p",
"hlId":"e2ea44",
"children":[
"Before the availability of tolvaptan, blood pressure control using blockade of the renin-aldosterone system was the only validated therapeutic strategy for management of ADPKD. This conservative therapy should still be a staple of treating patients with ADPKD, including those on tolvaptan. This patient is already taking an ACE inhibitor with blood pressure at goal; she would not be expected to have any benefit from switching to an angiotensin receptor blocker such as telmisartan at this point (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"d55df3",
"children":[
"Measurement of total kidney volume can be important in assessing risk for ESKD in patients with ADPKD; volume can be compared to expected volume for age, and changes in volume over time can also be assessed. Ultrasonography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is an acceptable modality for kidney size and cyst burden but is inferior to MRI for measurement of total kidney volume. This patient, however, does not require a measurement of total kidney volume to be considered high risk given her confluence of other risk factors; she can proceed directly to tolvaptan therapy without a kidney volume measurement."
]
},
{
"type":"p",
"hlId":"f3738f",
"children":[
"Octreotide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") has been shown to reduce kidney cyst fluid accumulation in selected patients with ADPKD but has not been shown to slow the decline in kidney function as seen with tolvaptan."
]
}
],
"relatedSection":"mk19_a_np_s8_1_1_3",
"objective":{
"__html":"Treat autosomal dominant polycystic kidney disease with tolvaptan."
},
"references":[
[
"Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29:2458-2470. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30228150",
"target":"_blank"
},
"children":[
"PMID: 30228150"
]
},
" doi:10.1681/ASN.2018060590"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":1,
"B":63,
"C":2,
"D":34,
"E":0
},
"hlIds":[
"b8c16b",
"2bf91b",
"1226d4",
"cb2b54",
"0625e0",
"904741",
"ce945e",
"e2ea44",
"d55df3",
"f3738f"
]
},
{
"id":"mk19_a_np_q103",
"number":103,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 103",
"stimulus":[
{
"type":"p",
"hlId":"c4a3e6",
"children":[
"A 45-year-old woman is evaluated during a follow-up visit for newly diagnosed severe hypertension. She began low-dose hydrochlorothiazide and amlodipine therapy 1 month ago. There is no family history of hypertension. She has no other medical problems and takes no other medications."
]
},
{
"type":"p",
"hlId":"dfc333",
"children":[
"On physical examination, blood pressure is 164/100 mm Hg in both arms, pulse rate is 76/min, and respiration rate is 18/min. BMI is 24. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7e774e",
"class":"cell text l",
"children":[
"30 mEq/L (30 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9bfe04",
"class":"cell text l",
"children":[
"0.9 mg/dL (79.6 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"844eb8",
"class":"cell text l",
"children":[
"2.9 mEq/L (2.9 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"731ef5",
"class":"cell text l",
"children":[
"138 mEq/L (138 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ad4a56",
"class":"cell text l",
"children":[
"No blood or protein"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"ab9d96",
"children":[
"Which of the following is the most appropriate diagnostic test to perform next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Plasma aldosterone concentration/plasma renin activity ratio"
}
},
{
"letter":"B",
"text":{
"__html":"Plasma fractionated metanephrines measurement"
}
},
{
"letter":"C",
"text":{
"__html":"Renal artery CT angiography"
}
},
{
"letter":"D",
"text":{
"__html":"24-Hour urine free cortisol measurement"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"444c1c",
"children":[
"Primary hyperaldosteronism is the most common cause of secondary hypertension and should be suspected in patients with resistant hypertension, hypokalemia, family history of early-onset hypertension, blood pressure >160/100 mm Hg, or stroke at age <40 years."
]
},
{
"type":"keypoint",
"hlId":"465809",
"children":[
"The plasma aldosterone concentration/plasma renin activity ratio is the recommended screening test for primary hyperaldosteronism."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"981b09",
"children":[
"The most appropriate diagnostic test to perform next is the plasma aldosterone concentration/plasma renin activity ratio (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Primary hyperaldosteronism, in which aldosterone production cannot be suppressed with sodium loading, is the most common cause of secondary hypertension in middle-aged adults and an important cause of resistant hypertension. A triad of resistant hypertension, metabolic alkalosis, and hypokalemia (including in patients treated with low-dose thiazide diuretics) should raise suspicion. Screening is recommended if any of the following are present: resistant hypertension; hypokalemia (spontaneous or substantial, if diuretic induced); incidentally discovered adrenal mass; family history of early-onset hypertension; moderately severe hypertension (>160/100 mm Hg); or stroke at age <40 years. It is common for patients with primary hyperaldosteronism to have normal serum potassium levels; a high index of suspicion is therefore required. This patient has substantial hypokalemia (serum potassium level of 2.9 mEq/L [2.9 mmol/L]) with initiation of low-dose hydrochlorothiazide and persistent, moderately severe hypertension. The patient also has a metabolic alkalosis."
]
},
{
"type":"p",
"hlId":"ef2f2a",
"children":[
"Plasma fractionated metanephrines (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") are obtained to screen for a pheochromocytoma. The absence of episodic palpitations, headaches, and tachycardia and the presence of metabolic alkalosis and hypokalemia make pheochromocytoma a less likely diagnosis for this patient."
]
},
{
"type":"p",
"hlId":"94bc96",
"children":[
"Renal artery CT angiography (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is an appropriate screening test for renovascular disease, including fibromuscular dysplasia. Older patients with renovascular hypertension often have other manifestations of atherosclerosis, including the presence of coronary artery, cerebrovascular, or peripheral vascular disease. Lateralizing abdominal bruits may be auscultated. Abrupt onset of hypertension in patients <35 years of age suggests fibromuscular dysplasia. None of these clinical findings is present to suggest the diagnosis of renovascular disease."
]
},
{
"type":"p",
"hlId":"f85670",
"children":[
"The 24-hour urine free cortisol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a frequently used screening test for hypercortisolism. In adults, hypercortisolism may manifest as hypertension and hypokalemia, but it is relatively rare compared with primary hyperaldosteronism. In the absence of Cushingoid facies, central obesity, proximal muscle weakness, and ecchymosis, Cushing syndrome is a very unlikely cause of this patient's hypertension."
]
}
],
"relatedSection":"mk19_a_np_s4_11_3",
"objective":{
"__html":"Diagnose primary hyperaldosteronism as a secondary cause of hypertension."
},
"references":[
[
"Lee FT, Elaraj D. Evaluation and management of primary hyperaldosteronism. Surg Clin North Am. 2019;99:731-745. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31255203",
"target":"_blank"
},
"children":[
"PMID: 31255203"
]
},
" doi:10.1016/j.suc.2019.04.010"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":90,
"B":2,
"C":2,
"D":5,
"E":0
},
"hlIds":[
"c4a3e6",
"dfc333",
"a462a3",
"6827e3",
"7e774e",
"f461b2",
"9bfe04",
"e92687",
"844eb8",
"b99276",
"731ef5",
"747c2a",
"ad4a56",
"ab9d96",
"444c1c",
"465809",
"981b09",
"ef2f2a",
"94bc96",
"f85670"
]
},
{
"id":"mk19_a_np_q104",
"number":104,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 104",
"stimulus":[
{
"type":"p",
"hlId":"89131a",
"children":[
"A 23-year-old woman is evaluated during a follow-up visit for focal segmental glomerulosclerosis that was diagnosed 3 weeks ago. The edema in her lower extremities has not improved on her current regimen of prednisone, losartan, atorvastatin, and maximal doses of oral furosemide."
]
},
{
"type":"p",
"hlId":"915358",
"children":[
"On physical examination, vital signs are normal. The patient weighs 72 kg (158.7 lb). There is 3-mm pitting edema of the lower extremities through the mid-thigh, equal on both sides. The remainder of the examination is unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4590ed",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein, Albumin, serum",
"children":[
"Albumin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3f2cc2",
"class":"cell text l",
"children":[
"2.0 g/dL (20 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"913c33",
"class":"cell text l",
"children":[
"303 mg/dL (7.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"848a67",
"class":"cell text l",
"children":[
"0.6 mg/dL (53 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d17af8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"Urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6b4254",
"class":"cell text l",
"children":[
"9150 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"806767",
"children":[
"CT of the chest is normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add metolazone"
}
},
{
"letter":"B",
"text":{
"__html":"Administer furosemide by continuous intravenous infusion"
}
},
{
"letter":"C",
"text":{
"__html":"Administer furosemide by intravenous bolus"
}
},
{
"letter":"D",
"text":{
"__html":"Discontinue prednisone; add cyclosporine"
}
},
{
"letter":"E",
"text":{
"__html":"Hemodialysis with ultrafiltration"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"c243f3",
"hvc":true,
"children":[
"In patients with the nephrotic syndrome and refractory edema despite high-dose loop diuretics, adding a thiazide diuretic and/or a potassium-sparing diuretic is the appropriate next step in management."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"228486",
"children":[
"The most appropriate management is to add metolazone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient with the nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) has refractory edema despite therapy with maximal doses of oral furosemide and therefore needs additional diuretic therapy. Addition of a second diuretic that works distal to the loop of Henle, such as a thiazide diuretic and/or a potassium-sparing diuretic, is the appropriate next step in management. In patients taking high-dose loop diuretics, increased delivery of salt and water to the distal portions of the nephron can lead to hypertrophy of these segments and overabsorption of sodium, undermining the effects of the loop diuretic."
]
},
{
"type":"p",
"hlId":"13eda9",
"children":[
"Factors that warrant admission for intravenous (IV) diuretics include lack of response after addition of a thiazide and/or potassium-sparing diuretic to a loop diuretic; acute respiratory symptoms secondary to pulmonary edema; or significant ascites that raise concern for gut edema and malabsorption of oral diuretics. These factors are not present in this patient. A number of randomized clinical trials have evaluated the efficacy of a continuous IV infusion of loop diuretics compared with IV bolus therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Options B, C"
]
},
"). Findings indicated that continuous IV infusion is associated with less ototoxicity than bolus injections of loop diuretics, but clear evidence of its diuretic superiority is lacking, at the minimum in heart failure patients."
]
},
{
"type":"p",
"hlId":"5315da",
"children":[
"This patient's significant edema alongside persistent nephrotic-range proteinuria and hypoalbuminemia does not warrant discontinuation of prednisone (first-line therapy for FSGS) for the addition of cyclosporine (second-line therapy for FSGS) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), as the patient has received glucocorticoid therapy for only 3 weeks. In adults with FSGS, therapeutic response can take up to 12 to 16 weeks. Therefore, it would be premature to consider this patient refractory to glucocorticoid therapy."
]
},
{
"type":"p",
"hlId":"5208b8",
"children":[
"Hemodialysis with ultrafiltration (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") for edema is reserved for patients with anasarca, significant kidney dysfunction, and an inability to diurese on maximal doses of IV diuretics."
]
}
],
"relatedSection":"mk19_a_np_s6_2_1",
"objective":{
"__html":"Manage edema associated with the nephrotic syndrome."
},
"references":[
[
"Gupta S, Pepper RJ, Ashman N, et al. Nephrotic syndrome: oedema formation and its treatment with diuretics. Front Physiol. 2018;9:1868. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30697163",
"target":"_blank"
},
"children":[
"PMID: 30697163"
]
},
" doi:10.3389/fphys.2018.01868"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":47,
"B":7,
"C":15,
"D":27,
"E":3
},
"hlIds":[
"89131a",
"915358",
"a462a3",
"4590ed",
"3f2cc2",
"182194",
"913c33",
"f461b2",
"848a67",
"d17af8",
"6b4254",
"806767",
"cb2b54",
"c243f3",
"228486",
"13eda9",
"5315da",
"5208b8"
]
},
{
"id":"mk19_a_np_q105",
"number":105,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 105",
"stimulus":[
{
"type":"p",
"hlId":"4a3d1e",
"children":[
"A 33-year-old man is evaluated for acute kidney injury 48 hours after being hospitalized for herpes simplex virus encephalitis. Diagnosis was confirmed with polymerase chain reaction testing of the cerebrospinal fluid. He is being treated with intravenous high-dose acyclovir. Empiric therapy with ceftriaxone plus vancomycin was initiated and then discontinued after the results of the cerebrospinal fluid analysis became available. Medical history is significant for chronic kidney disease due to hereditary nephritis and hypertension. Outpatient medications are lisinopril and hydrochlorothiazide, both held since admission."
]
},
{
"type":"p",
"hlId":"fffc2b",
"children":[
"On physical examination, vital signs are normal. The patient has some difficulty with attention and orientation to time but is otherwise neurologically intact. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d12432",
"children":[
"Current laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2f759e",
"class":"cell text l",
"children":[
"2.3 mg/dL (203.3 µmol/L); baseline: 1.8 mg/dL (159.1 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9eaf68",
"class":"cell text l",
"children":[
"Electrolytes:"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3d979b",
"class":"cell text l",
"children":[
"137 mEq/L (137 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"187e57",
"class":"cell text l",
"children":[
"5.6 mEq/L (5.6 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"c83256",
"class":"cell text l",
"children":[
"102 mEq/L (102 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6ddb6c",
"class":"cell text l",
"children":[
"26 mEq/L (26 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5f211a",
"class":"cell text l",
"children":[
"Specific gravity 1.010; pH 7.5; 1+ blood; 2+ protein; 1+ leukocytes; 1-3 leukocytes/hpf; 3-5 erythrocytes/hpf; fine-needle crystals"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"9da045",
"children":[
"Kidney ultrasound shows an 11-cm right kidney and an 11.8-cm left kidney with normal cortical appearance and without hydronephrosis."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"7e0aa5",
"children":[
"Which of the following is the most likely cause of this patient's acute kidney injury?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acute glomerulonephritis"
}
},
{
"letter":"B",
"text":{
"__html":"Acute interstitial nephritis"
}
},
{
"letter":"C",
"text":{
"__html":"Acute tubular necrosis"
}
},
{
"letter":"D",
"text":{
"__html":"Intratubular obstruction"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"a6d1d9",
"children":[
"Intravenous acyclovir can cause acute kidney injury due to intratubular obstruction from acyclovir crystal precipitation."
]
},
{
"type":"keypoint",
"hlId":"20b063",
"children":[
"Correction of volume depletion is critical for the prevention and treatment of crystal-induced acute kidney injury."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"2b23ef",
"children":[
"The most likely cause of this patient's acute kidney injury (AKI) is intratubular obstruction (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Intratubular obstruction can cause AKI through precipitation of crystals within the tubular lumen. Urinary findings include hematuria, pyuria, and crystals. This patient received intravenous high-dose acyclovir, which can cause acute AKI due to intratubular obstruction from acyclovir crystal precipitation. Predisposing factors for crystal-induced AKI include chronic kidney disease and volume depletion. Aggressive volume expansion is recommended during high-dose acyclovir therapy for these patients. Correction of volume depletion is also critical for the treatment of crystal-induced AKI as well as discontinuation of the drug if possible."
]
},
{
"type":"p",
"hlId":"6d5805",
"children":[
"Acute glomerulonephritis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not a likely cause of this patient's AKI. This patient has hereditary nephritis, which can lead to chronic glomerular basement membrane changes but not acute glomerulonephritis. Furthermore, neither acute viral encephalitis nor acyclovir is associated with acute glomerulonephritis."
]
},
{
"type":"p",
"hlId":"7acebb",
"children":[
"Acute interstitial nephritis (AIN) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is a common cause of AKI and is characterized by inflammation and edema of the interstitium. The classic clinical presentation of fever, rash, and peripheral eosinophilia occurs in only 10% to 30% of patients with AIN. Drug-induced AIN, especially due to antibiotics, is the most common cause of AIN and should be considered in any patient with AKI, a characteristic urinalysis, and history of any drug exposure. Drug-induced AIN typically takes 7 to 10 days to develop and is characterized by substantial pyuria and leukocyte casts, which is not seen in this patient's urinalysis results."
]
},
{
"type":"p",
"hlId":"2f83a9",
"children":[
"Acute tubular necrosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is usually suggested by urine sediment that shows pigmented brown casts and debris, which are not seen in this patient's urinalysis results."
]
}
],
"relatedSection":"mk19_a_np_s9_5_2_5",
"objective":{
"__html":"Diagnose crystal-induced acute kidney injury in patients receiving intravenous acyclovir."
},
"references":[
[
"Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol. 2017;13:226-240. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28218266",
"target":"_blank"
},
"children":[
"PMID: 28218266"
]
},
" doi:10.1038/nrneph.2017.10"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":2,
"B":35,
"C":9,
"D":53,
"E":0
},
"hlIds":[
"4a3d1e",
"fffc2b",
"d12432",
"f461b2",
"2f759e",
"9eaf68",
"d41d8c",
"b99276",
"3d979b",
"e92687",
"187e57",
"a207b1",
"c83256",
"6827e3",
"6ddb6c",
"747c2a",
"5f211a",
"9da045",
"7e0aa5",
"a6d1d9",
"20b063",
"2b23ef",
"6d5805",
"7acebb",
"2f83a9"
]
},
{
"id":"mk19_a_np_q106",
"number":106,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 106",
"stimulus":[
{
"type":"p",
"hlId":"c9d37e",
"children":[
"A 46-year-old woman is evaluated during a follow-up visit for hypertension, type 2 diabetes mellitus, and stage G3 chronic kidney disease. She reports no symptoms. Medications are losartan, amlodipine, metformin, canagliflozin, and rosuvastatin."
]
},
{
"type":"p",
"hlId":"d31091",
"children":[
"On physical examination, blood pressure is 124/72 mm Hg. Other vital signs and the remainder of the examination are unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d5fe2",
"children":[
"Laboratory studies: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1fd2c7",
"class":"cell text l",
"children":[
"136 mEq/L (136 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"af343e",
"class":"cell text l",
"children":[
"5.6 mEq/L (5.5 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d7acf9",
"class":"cell text l",
"children":[
"320 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"96ef5f",
"children":[
"ECG is normal."
]
},
{
"type":"p",
"hlId":"d867a5",
"children":[
"The patient is counseled to start a low potassium diet."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add hydrochlorothiazide"
}
},
{
"letter":"B",
"text":{
"__html":"Add patiromer"
}
},
{
"letter":"C",
"text":{
"__html":"Administer intravenous calcium gluconate"
}
},
{
"letter":"D",
"text":{
"__html":"No further treatment"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bdb9e7",
"children":[
"Potassium binders such as patiromer and sodium zirconium cyclosilicate can be used to treat hyperkalemia in patients with chronic kidney disease."
]
},
{
"type":"keypoint",
"hlId":"8a0137",
"children":[
"Use of potassium binders in patients with chronic kidney disease may allow continuation of essential medications, such as inhibitors of the renin-angiotensin system."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"187509",
"children":[
"The most appropriate management is to add patiromer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), a potassium binder, to treat this patient's moderate hyperkalemia. Initial evaluation of hyperkalemia requires a review of all medications, assessment of kidney function, and an ECG. Initial ECG manifestations include peaked precordial T waves and a shortened QT interval. Hyperkalemia frequently occurs in chronic kidney disease with an estimated glomerular filtration rate <20 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Hypoaldosteronism caused by inhibitors of the renin-angiotensin system, heparin, type 4 (hyperkalemic distal) renal tubular acidosis, or primary adrenal insufficiency also cause hyperkalemia. All potentially causative medications should be discontinued if possible. Although angiotensin receptor blockers (ARBs) such as losartan frequently cause hyperkalemia by decreasing aldosterone levels, guidelines recommend their use to slow the progression of kidney disease and provide cardiovascular protection. This patient has severely increased albuminuria, which puts her at increased risk for both progressing to end-stage kidney disease and a cardiovascular event. Routine discontinuation of ARBs has been associated with worsening outcomes; with the addition of effective potassium binders, discontinuation of ARBs is discouraged. Therefore, because of the beneficial cardiovascular and renal effects of blocking angiotensin, if serum potassium is only mildly elevated (as in this patient), the use of potassium binders may allow the patient to continue use of losartan. Patiromer and sodium zirconium cyclosilicate are two FDA-approved potassium binders. The choice of binder is determined by patient and physician preference, as each agent has its advantages and disadvantages. Sodium polystyrene sulfonate is no longer recommended as a potassium binder due to its poor efficacy in lowering potassium and numerous reported adverse effects."
]
},
{
"type":"p",
"hlId":"a35251",
"children":[
"Adding a thiazide diuretic such as hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") may improve this patient's hyperkalemia. However, it could result in volume depletion with decreased delivery of sodium to the potassium secretory sites, resulting in worsening hyperkalemia. In addition, this patient's blood pressure is at goal and there is no indication to further lower it."
]
},
{
"type":"p",
"hlId":"b6f917",
"children":[
"When hyperkalemia is associated with changes on ECG, intravenous calcium gluconate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") should be administered to stabilize the cardiac membrane by raising threshold potential. Because this patient's serum potassium was only moderately elevated and her ECG was normal, calcium gluconate is not indicated."
]
},
{
"type":"p",
"hlId":"80d1be",
"children":[
"Providing this patient with no treatment is inappropriate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Although her serum potassium is only moderately elevated, serum potassium levels >5 mEq/L (5 mmol/L) are associated with increased morbidity and mortality."
]
}
],
"relatedSection":"mk19_a_np_s2_3_2_2",
"objective":{
"__html":"Treat hyperkalemia."
},
"references":[
[
"Evans M, Palaka E, Furuland H, et al. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol. 2019;20:31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30704421",
"target":"_blank"
},
"children":[
"PMID: 30704421"
]
},
" doi:10.1186/s12882-019-1228-y"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":14,
"B":29,
"C":4,
"D":53,
"E":0
},
"hlIds":[
"c9d37e",
"d31091",
"9d5fe2",
"f461b2",
"3a34ea",
"89662a",
"d41d8c",
"b99276",
"1fd2c7",
"e92687",
"af343e",
"a207b1",
"21724f",
"6827e3",
"075484",
"58e613",
"d7acf9",
"96ef5f",
"d867a5",
"cb2b54",
"bdb9e7",
"8a0137",
"187509",
"a35251",
"b6f917",
"80d1be"
]
},
{
"id":"mk19_a_np_q107",
"number":107,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 107",
"stimulus":[
{
"type":"p",
"hlId":"d8b585",
"children":[
"A 31-year-old woman seeks preconception counseling. She has systemic lupus erythematosus and lupus nephritis, both of which have been stable for the past year; she has had no proteinuria for more than 12 months. She currently feels well. Medications are mycophenolate mofetil, hydroxychloroquine, and low-dose prednisone."
]
},
{
"type":"p",
"hlId":"f8786b",
"children":[
"Physical examination findings, including vital signs, are normal."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cd0f4f",
"children":[
"Which of the following medications should be discontinued in this patient before conception?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Hydroxychloroquine"
}
},
{
"letter":"B",
"text":{
"__html":"Mycophenolate mofetil"
}
},
{
"letter":"C",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"D",
"text":{
"__html":"No change in medication is required"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"d0cb56",
"children":[
"Mycophenolate mofetil is teratogenic and is contraindicated in pregnancy."
]
},
{
"type":"keypoint",
"hlId":"0196ea",
"children":[
"In diseases in which mycophenolate mofetil is used, patients should show stable disease for 3 to 6 months following discontinuation of the agent before proceeding with pregnancy."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"05316a",
"children":[
"Mycophenolate mofetil (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") should be discontinued in this patient before conception. Before discontinuation of mycophenolate and attempted conception, steps should be taken to ensure disease stability in this patient. Pregnancy planning is essential for ensuring positive outcomes and includes adjusting medications and optimizing clinical status. This patient is taking mycophenolate mofetil, a teratogenic agent that is contraindicated in pregnancy. Documented risks with mycophenolate mofetil use include first-trimester pregnancy loss and fetal malformations of the distal limbs, heart, esophagus, kidneys, and cleft lip and palate. Mycophenolate mofetil is also contraindicated in women who are breastfeeding because the drug is excreted into breast milk. This patient should discontinue this agent and, if continued immunosuppression is required, be switched to azathioprine, which is generally safer and well tolerated in pregnancy. In diseases such as systemic lupus erythematosus (SLE) in which mycophenolate mofetil is commonly used, patients should show stable disease for 3 to 6 months following discontinuation of the agent before proceeding with pregnancy."
]
},
{
"type":"p",
"hlId":"82699b",
"children":[
"Hydroxychloroquine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") has been used safely in pregnancy. This patient who is planning a pregnancy would be recommended to continue taking this drug. Hydroxychloroquine is initiated in every patient with SLE who can tolerate it, because evidence suggests it reduces disease-associated damage, prevents disease flares, and improves kidney and overall survival. In addition, hydroxychloroquine may reduce the risk for thrombosis, liver disease, and myocardial infarction; improve lipid profiles; and improve outcomes in high-risk pregnancies."
]
},
{
"type":"p",
"hlId":"4a9c3f",
"children":[
"Glucocorticoids such as prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") increase the risk for pregnancy-induced hypertension and diabetes mellitus but can be continued during pregnancy when the benefits outweigh the risks to the patient and fetus. Steps can be taken to reduce the risk of glucocorticoid therapy during pregnancy, including using the lowest dose possible for the shortest period of time; carefully managing preexisting medical conditions that may be exacerbated by glucocorticoid therapy (for example, osteoporosis, diabetes, and hypertension); and carefully monitoring for treatment adverse effects and providing early intervention should they arise."
]
},
{
"type":"p",
"hlId":"20ed3b",
"children":[
"Making no changes to this patient's medication regimen (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") would not be appropriate because mycophenolate mofetil is teratogenic and is contraindicated during pregnancy."
]
}
],
"relatedSection":"mk19_a_np_s11_3",
"objective":{
"__html":"Discontinue mycophenolate mofetil in a patient who is planning pregnancy."
},
"references":[
[
"ACOG Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133:e287-e295. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30913201",
"target":"_blank"
},
"children":[
"PMID: 30913201"
]
},
" doi:10.1097/AOG.0000000000003176"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":11,
"B":71,
"C":6,
"D":12,
"E":0
},
"hlIds":[
"d8b585",
"f8786b",
"cd0f4f",
"d0cb56",
"0196ea",
"05316a",
"82699b",
"4a9c3f",
"20ed3b"
]
},
{
"id":"mk19_a_np_q108",
"number":108,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 108",
"stimulus":[
{
"type":"p",
"hlId":"06830c",
"children":[
"A 60-year-old woman is evaluated during a follow-up visit for stage G3 proteinuric chronic kidney disease due to type 2 diabetes mellitus. Medications are lisinopril and metformin."
]
},
{
"type":"p",
"hlId":"2e285e",
"children":[
"On physical examination, blood pressure is 137/80 mm Hg, and pulse rate is 83/min; other vital signs are normal. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"5d87c8",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin A1c, blood",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1569f4",
"class":"cell text l",
"children":[
"8.3%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"28ecb5",
"class":"cell text l",
"children":[
"1.3 mg/dL (114.9 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f7434e",
"class":"cell text l",
"children":[
"4.3 mEq/L (4.3 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"83dfd7",
"class":"cell text l",
"children":[
"45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"48b103",
"class":"cell text l",
"children":[
"Spot ",
{
"type":"reference-range-link",
"referenceRange":"Protein-creatinine ratio, urine",
"children":[
"urine protein-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"44b277",
"class":"cell text l",
"children":[
"3680 mg/g"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Canagliflozin"
}
},
{
"letter":"B",
"text":{
"__html":"Glyburide"
}
},
{
"letter":"C",
"text":{
"__html":"Losartan"
}
},
{
"letter":"D",
"text":{
"__html":"Pioglitazone"
}
},
{
"letter":"E",
"text":{
"__html":"Sitagliptin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"0ea959",
"children":[
"Sodium-glucose cotransporter 2 inhibitors slow the progression of chronic kidney disease and reduce the risk for death from kidney or cardiovascular complications in patients with diabetic kidney disease."
]
},
{
"type":"keypoint",
"hlId":"5a18e9",
"children":[
"Glucagon-like peptide-1 receptor agonists reduce the risks for cardiovascular events and hypoglycemia and appear to possibly slow chronic kidney disease progression."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"1d7aa7",
"children":[
"The most appropriate treatment is to add canagliflozin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). There are a limited number of interventions proven to slow the decline of kidney function in patients with chronic kidney disease (CKD). Proven interventions include glycemic control, blood pressure control, renin-angiotensin system (RAS) blockers, and avoidance of renal toxins. For patients with diabetic kidney disease, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors slows the progression of CKD and reduces the risk for death from kidney or cardiovascular complications. For this patient with stage G3 CKD with nephrotic-range proteinuria due to type 2 diabetes mellitus, the SGLT2 inhibitor canagliflozin should be added to her medication regimen. Glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide are also suggested by the American Diabetes Association because they reduce the risks for cardiovascular events and hypoglycemia and appear to possibly slow CKD progression."
]
},
{
"type":"p",
"hlId":"8aa960",
"children":[
"Glyburide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is a second-generation sulfonylurea; pioglitazone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a thiazolidinedione; and sitagliptin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") is a dipeptidyl peptidase 4 inhibitor. Drugs from these classes have a neutral effect on the progression of CKD. The use of glyburide in patients with CKD is generally avoided because of the risk for hypoglycemia. Thiazolidinediones are used with caution in patients with CKD due to the potential for fluid retention."
]
},
{
"type":"p",
"hlId":"75ef3d",
"children":[
"Adding losartan (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), an angiotensin receptor blocker (ARB), is contraindicated for this patient, as she is currently receiving lisinopril, an ACE inhibitor. Blockade of the RAS has been shown to slow the rate of progression for proteinuric CKD and is indicated for all patients who can tolerate this medication class. However, dual blockade with an ACE inhibitor and an ARB results in more adverse events without additional kidney benefit."
]
}
],
"relatedSection":"mk19_a_np_s12_7_3",
"objective":{
"__html":"Treat a patient with diabetic kidney disease using a sodium-glucose cotransporter 2 inhibitor."
},
"references":[
[
"Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30990260",
"target":"_blank"
},
"children":[
"PMID: 30990260"
]
},
" doi:10.1056/NEJMoa1811744"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":75,
"B":4,
"C":10,
"D":5,
"E":6
},
"hlIds":[
"06830c",
"2e285e",
"a462a3",
"5d87c8",
"1569f4",
"f461b2",
"28ecb5",
"e92687",
"f7434e",
"77db81",
"83dfd7",
"48b103",
"44b277",
"78ff87",
"0ea959",
"5a18e9",
"1d7aa7",
"8aa960",
"75ef3d"
]
}
]